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Foreword
The Committee on Problems of Drug Dependence, Inc. (CPDD) is a
uniquely valuable independent organization of internationally
recognized experts in a variety of disciplines. From its early
years, it has fulfilled two functions that are not duplicated by
any other group: organizing and conducting the most prestigious
annual scientific meeting in the drug dependence field, and
coordinating a national system for assessment of the pharmacologic
efficacy and abuse potential of opiate drugs. For the current
year, the results of both can be seen in this volume.
The proceedings in this monograph include in condensed form the
papers presented at the 45th Annual Scientific Meeting of the CPDD,
held in Lexington, Kentucky, June 12-15, 1983, and the annual
reports of the CPDD drug testing program. Progress reports of
dependence liability studies supported by the National Institute on
Drug Abuse and summaries of NIDA's intramural research programs are
included as well.
Members of the scientific community and other interested readers
will find they can use this volume as a "state of-the-art" summary
of the latest developments in biological and chemical drug abuse
research. For the fifth year, the National Institute on Drug Abuse
is pleased to publish the proceedings of the CPDD Annual Scientific
Meeting as a NIDA Research Monograph.
William Pollin, M.D.
Director
National Institute on Drug Abuse
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In Memoriam: H. Frank Fraser, M.D.
Dr. Frank Fraser, Former Asssociate Director of the Addiction
Research Center in lexington, Kentucky, died in Louisville on
November 6, 1982. He is survived by his wife, Dorothy, two
sons,Robert and Thomas, and one daughter, Jane Fraser Carpenter.
Frank had a distinguished career in medical research ranging
over many fields. He graduated from Cornell University in 1932
and immediately entered the U.S Public Health Service. After a
tour of duty at the U.S. Penitentiary at Atlanta,he was
assigned to the Laboratory of Nutrition in the National Institutes
of Health. While in that laboratory, Dr. Fraser discovered
that cozymase (coenzyme 1) would cure blacktongue in dogs, the
canine analog of human pellegra. This discovery provided the 
clue to nicotonic acid being the pellegra preventive vitamin as 
was soon proved at the University of Wisconsin. He then was
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assigned to the Tennessee valley Authority where he studied the
bioavailability of phosphate in fertilizer made from TVA rocks.
During the war he worked in the Laboratory of Industrial Hygeine
at NIH where he studied the ability of different types of cloth-
ing to maintain body temperature under conditions of extreme cold.
After a tour of duty in Germany, he came to the Addiction
Research Center in Lexington in 1949 and remained in that labora-
tory until his retirement from the Public health Service in
1963, when he became a research advisor to the Eli Lilly Company
until 1971. In 1971, he returned to the ARC and to NIDA as a
consultant. Even after many illnesses had taken a toll, he con-
tinued to work and at the time of his death he was writing a
book setting forth his theories of drug dependence.
Frank's contributions to the study of drug dependence were
many. He evaluated many opioid analgesics for dependence lia-
bility and he was especially interested in the addictiveness of the 
active optical isomers of opioids and in the dependence liabil-
ity of the demethylated derivatives of opioids. He also made
many contributions to the evaluation of opioid antagonists, par-
ticularly pentazocine and cyclazocine. Frank was equally at 
home in research in the clinical wards and in the animal labora-
tory. He had a great interest in studying the subjective re-
sponses to opioids and other drugs of dependence. He developed
quantitative methodology for this purpose which is still in
use. Thus, he was a pioneer in psychopharmacology.
frank was a veritable idea mill, producing new hypotheses as
such a fantastic rate that the experimental resources he had
available could not keep up. Many of his ideas provided bases
for important and productive collaborations. He contributed
over 40 papers to the scientific literature. His enthusiasm for
science, pharmacology and drug dependence was infectious and
provided inspiration to his colleagues.
Frank served on the Expert Panel on Drug Dependence of the World
Health Organization and also served for a time as Chairman of
the Committee on Problems of Drug Dependence.
Frank was a very outgoing person who loved jokes. Often he
could not finish a story he was trying to tell because he would
start to laugh so hard as he approached the "punch line" that he
could not continue but had to hold his sides and roll on the 
floor."
Frank was also an ardent fisherman and for years maintained a
trailer and a boat on Lake Cumberland. He was an enthusiastic
bridge player, regularly participating in duplicate bridge tour- 
naments in which he earned many master points.
He will be sorely missed by his family, his many colleagues and
friends.
Harris Isbell, M.D.
Department of Pharmacology
University of Kentucky Medical Center
Lexington, Kentucky
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Introduction of Nathan B. Eddy
Memorial Award Recipient
Sydney Archer
I was pleased and honored to have been asked by the winner of
the Nathan B. Eddy Memorial Award to introduce him to this
audience. Eric J. Simon, who was born in Wiesbaden, Germany,
received his early education in that city, but after emigrating
to the United States he received his B.S. in Chemistry at Case
Institute of Technology in 1944. After a stint in the U.S. Army
from 1944-46, he returned to the University of Chicago where he
received his Ph.D. in organic chemistry with Professor Kharasch
in 1951. Shortly thereafter, he deserted his field for bio-
chemistry. After a short interlude as a postdoctoral fellow
with Professor Shemin at Columbia College of Physicians and
Surgeons, Eric accepted a position as a Research Associate in
Biochemistry at Cornell from 1952 to 1959. He became an
Assistant Professor of Medicine at NYU School of Medicine in
1959 and has been associated with that institution ever since,
where he is now a Professor of Psychiatry and Pharmacology.
His early research activities did not deal with opiates, but in
1963 he published a paper in Nature entitled "Inhibition of RNA
synthesis of E. coli by the narcotic drug levorphanol." As far as
I can determine, this was his first exposure to opiates. If one
continues to read his bibliography, it is easy to discern early
signs of dependence and, as we all know, he is now a confirmed ad-
dict. He is the current Secretary of the INRC or, as Eddy Way SO
quaintly calls it, the Junkie Club. His investigations in this
field culminated with the discovery of the opiate receptor in
1973, which was also found independently in the laboratories of
Snyder in Baltimore and Terenius in Uppsala. Since that time,
Professor Simon has made numerous contributions in this field
and he is clearly recognized as one of the leaders in the field
of opiate research. He was the recipient of the Research Pace-
setter Award presented by the National Institute on Drug Abuse
in 1977. In 1980, he was the recipient of the Louis and Bert
Freedman Award of the New York Academy of Sciences and, most
recently, received an Honorary Doctorate degree from the
University Rene Descartes in Paris. He has served on several
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Study Sections and is the current Secretary of the International
Narcotics Research Conference. He has served on the editorial
board of several important journals in the biomedical field.
Yet, the most important thing about Eric is not his accomplish-
ments in science and the honors that have followed, but the fact
that he is a warm, modest, considerate and gentle human being
who is loved by his family, friends and colleagues. I know of
no more deserving recipient of the Nathan B. Eddy Memorial Award
than Eric J. Simon, and I want to take this opportunity to thank
the anonymous Awards Committee for selecting him to be the 1983
recipient of this honor.
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Recent Studies on Opioid
Receptors: Heterogeneity and
Isolation (The Nathan B. Eddy
Memorial Award Lecture)
Eric J. Simon
INTRODUCTION
I want to thank Dr. Sydney Archer for his very kind and flatter-
ing presentation. I am deeply honored and very grateful to CPDD
for having chosen me to receive the 1983 Nathan B. Eddy Memorial
Award. It is a great honor to receive an award in the memory of
Dr. Eddy. He was one of the founders of CPDD and for 50 years he
was a leader of this organization and a strong force in drug
abuse research. Though trained as a physician he made his most
important contributions in the chemistry and pharmacology of the
opiates. His laboratory contributed many important papers on the
structure-activity relationship of natural and synthetic analge-
sics. His account of the first 42 years of the Committee is out-
standing for its accuracy and completeness. Nathan B. Eddy was
a great man to whose memory it is a privilege to contribute.
This award is also a great honor because of the outstanding
recipients who preceded me and because of the many excellent and
deserving scientists who have not yet been so honored.
I would not be here today without the outstanding work done by my
collaborators and students. I am deeply grateful to them and I
wish to single out for special mention Prof. Jacob M. Hiller who
has been my coworker and friend throughout all of our work on
opioid receptors.
I also want to thank my wife, Irene, for her understanding, patience
and love throughout many years. Her willingness to take much
responsibility off my shoulders made possible whatever success I
have been able to achieve in my profession.
This paper will present a summary of our recent studies on opioid
receptor multiplicity and our efforts to solubilize and purify
the opioid binding sites. At the end, I will make some comments
regarding the relationship of these studies to drug dependence.
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OPIOID RECEPTOR MULTIPLICITY
Three types of opioid receptors were suggested by Martin (Martin
et al. 1978, Gilbert and Martin 1978) based on his pharmacologi-
cal studies in chronic spinal dogs. He named them after their
prototypic ligands, mu for morphine, kappa for ketocyclazocine
and sigma for SKF 10,047. These 3 receptor types have stood the
test of time extremely well and they have also been postulated
based on in vitro bioassay and binding studies. Work in Hans
Kosterlitz's laboratory (Lord et al. 1977) has suggested the ex-
istence of yet another receptor type, which binds enkephalins
with high affinity and has been designated delta.
Recent work in our laboratory (Bonnet et al. 1981) has revealed
that heterogeneity similar to that found in rat or guinea pig
can also be seen in human brain. Competition binding data for
several regions of human brain are presented in Table 1.
TABLE 1
Binding competition experiments in human brain regions
n = no. of experiments. Results are expressed as the mean IC50
± standard error of the mean. From Bonnet et al. 1981.
Copyright 1981. Elsevier Biomedical Press.
3H-naloxone 3H-DADL
Brain
region n Naloxone DADL Naloxone DADL
Thalamus 5 2.7±O.3 49±4.9 1.4±O.l 13±2.2
Amygdala 3 2.8±0.2 63±24 14 ±2.9 3.3±O.7
Frontal
cortex 4 2.7±0.3 57±4.9 12 ±5.4 2.2±O.5
Striatum 5 2.6±O.4 58±15 31 ±5.2 3.8±0.6
Naloxone generally competes more effectively against labeled
naloxone than against 3H-enkephalin, while the opposite is true
for Dala2-Dleu5enkephalin. An exception to this can be seen in
the thalamus where naloxone competes somewhat better-against
3H-DADL than against itself. This finding, similar to results
in rat brain (Chang et al. 1979) is best explained by the presence
in the thalamus of a large preponderance of mu sites. The pres-
ence of mu and delta sites is suggested by the above study. More
recent results from our laboratory, suggest the presence of kappa
and sigma sites in human brain also (Itzhak et al. 1982).
One problem that plagued studies on opiate receptor heterogeneity
for some years was the inability to inhibit or inactivate one or
another class selectively by agents that are not ligands of the
receptors. This led Robson and Kosterlitz (1979) and J. Smith
in my laboratory (Smith and Simon 1972) to do selective protec-
tion experiments. In these studies it was shown that a given
type of binding site could be selectively protected while all
others were inactivated by irreversible agents (N-ethylmaleimide
was used by us, phenoxybenzamine by Robson and Kosterlitz).
This approach provided strong evidence for the existence of
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different receptor types and provided a method for enriching a
tissue in a given type of opioid binding site.
More recently our laboratory (Hiller et al. 1981) has reported
that ethanol and other aliphatic alcohols inhibit binding to
delta sites selectively (Fig. 1) This inhibition is reversible
and much evidence was accumulated to demonstrate that the effect
of the alcohol is on the binding site and not on the ligand.
Fig. 1. Effects of ethanol on the binding of 3H-labeled opioids
to opioid receptors in rat brain membrane preparations. Duplicate
2 ml samples (0.9 to 1.1 mg of protein per milliliter) in 0.05M
Tris HCl (pH 7.4) containing 1 mM dipotassium EDTA were incubated
with 1 nM 3H-dihydromorphine (specific activity, 73.2 Ci/mmole),
3H-naltrexone (8.5 Ci/mmole), and 3H-DADL (31.O Ci/mmole) . To
assess specific binding, samples were incubated in the presence
or absence of 1 µM unlabeled ligand. From Hiller et al. 1981.
(Copyright 1981 by AAAS).
The mechanism of the alcohol effect is not understood. We have
suggested that the alcohol increases membrane fluidity (a well
known action of alcohols) and that the delta sites are more sen-
sitive than mu and kappa sites to this change in their membrane
environment. Further work is required to prove or disprove this
hypothesis. The intriguing possibility that there may be a re-
lationship between alcohol and the endogenous opioid system is
also worthy of further investigation.
In order to indicate that our laboratory also carried out research
which does not involve "grinding and binding." I will present one
in vivo study which bears on the heterogeneity of opioid recep-
tors. Dr. Kenneth Carr in my laboratory has been producing
aversive reactions in rats by stimulation of the pain-related
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nucleus reticularis gigantocellularis. (NGC) with indwelling elec-
trodes. The rats are trained to press a lever to escape from the
stimulation. In a recent study (Carr et al. 1982) he showed that
both systemic morphine and ethylketazocine (EKC) will effectively
reduce escape attempts, which is interpreted to represent anal-
gesia. However, the effect of morphine is readily blocked by low
doses of naloxone while the effect of EKC is only partially
blocked even at 10 times higher doses of naloxone. This result
suggests that the two drugs act via different opioid receptors.
It is also the first instance in which a supraspinally elicited
aversion is reduced by a kappa analgesic.
The molecular basis of receptor heterogeneity is not known. There
are a number of possible explanations. For example, there could
be a single receptor which can exist in several different confor-
mations. There could also be separate receptor molecules for
many or all of the types described. These could represent dif-
ferent gene products (polypeptide chains) or different post-
translational modifications of the same polypeptide chain (differ-
ent carbohydrates, lipids, disulfide bridges, etc.). Which of
these (and other) possibilities are the correct ones will only be
known when it becomes possible to isolate and try to separate
different opioid receptor types. My laboratory is working active-
ly in this direction and I will describe some of our recent
findings.
ISOLATION OF OPIOID BINDING SITES
I have already indicated one reason for undertaking the difficult
work of isolating and purifying opioid receptors. In addition to
trying to establish the molecular basis of receptor heterogeneity
there are other important possibilities. Antibodies against the
receptor can be produced and aid in the study of receptor function
and distribution. The receptors can be reconstituted into mem-
branes to study their effects on ion fluxes. The chemical compo-
sition and subunit structure of the binding site and of coupled
enzymes can be elucidated. Finally it will become possible to
study the amino acid sequence of the receptor proteins and to
learn about the structure of genes coding for them.
Our attempts to isolate opioid receptors began early after their
discovery. It was quickly found that they are tightly attached
to cell membranes and that the first step, their removal from
the membrane and solubilization, may prove to be a difficult one.
In 1975 we reported that we were able to solubilize a macromole-
cular complex of 3H-etorphine from rat brain (Simon et al. 1975).
This complex had all the properties of an etorphine linked to an
opioid binding site. The molecular weight was about 400,000.
The solubilization of a receptor molecule that retained its
ability to bind opiates in solution did not meet with success
until 1980. That year we found in collaboration with Dr. Urs
Ruegg at the University of Geneva that we could solubilize active
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opioid receptors from the brain of toads (Bufo marinus) using
digitonin (Ruegg et al. 1980).
The reason why we tried toad was our realization that it had been
possible to. solubilize active ß-adrenergic receptors from non-
mammalian tissues, while only prebound ligand-receptor complex
could be solubilized from mammals. This did work for us and
appears to be due to a decreased sensitivity of receptors from
non-mammals to the deleterious effects of detergents.
At about the time we reported successful extraction of opioid
receptors from toad brain, success in receptor solubilization
was also reported by others. Bidlack and Abood (1980) reported
that they were able to solubilize opioid binding sites from rat
brain using the detergent Triton X-100. Simonds et al. (1980)
had success extracting receptors from neuroblastoma x glioma hy-
brid cells in culture and also from rat brain using a new deter-
gent called CHAPS.
More recently we (Howells et al. 1982) have learned how to solu-
bilize active opioid binding sites in good yield (20-40%) from
mammalian brain (rat, cow, human). The detergents digitonin and
glycodeoxycholate worked very well, provided a high concentration
(0.5-l M) of sodium chloride was present during the extraction
process. The soluble binding sites had very similar properties
to those of membrane-bound sites. An example of this similarity
is shown in Fig. 2. Correlation of affinities of widely varying
ligands is excellent.
Fig. 2. Correlation of the affinities of various opioid ligands
for membrane-bound and soluble binding sites from bovine striatum.
Affinities were determined by Scatchard analysis or by competition
studies. The line of best fit was determined by linear regression
analysis (r=0.99). From Howells et al. 1982. Copyright 1982,
The American Society for Pharmacology and Experimental Therapeu-
tics.
9
We have already been able to obtain results with solubilized bind-
ing sites that were not possible with membrane-bound receptors.
Thus, we have studied the retention of solubilized receptors on
columns of agarose-bound lectins (Gioannini et al. 1982). Lectins
are plant (and sometimes animal) proteins that bind sugars speci-
fically. Out of eight lectins used, only one was found to bind
opioid receptors. This was wheat germ agglutinin (WGA), a lectin
that specifically binds N-acetylglucosamine. The receptors were
specifically eluted from the WGA column by solutions containing
N-acetylglucosamine. This result was found for soluble opioid
receptors isolated from the brains of five species. It was the
first evidence that opioid receptors contain sugar moieties and
are, therefore, glycoproteins. In addition to this important
information a single pass through a WGA column gave 30-50 fold
purification of solubilized opioid binding sites.
Dr. T. Gioannini in our laboratory has recently constructed a
number of ligand affinity chromatography columns (unpublished
results). One column, in particular, in which naltrexone is link-
ed via its 6 position to a side chain attached to agarose, has
proved very useful for receptor purification. A combination of
lectin and ligand affinity chromatography results in a purifica-
tion of several hundred fold for soluble opioid receptors. Par-
tial purification has also been achieved recently in the labora-
tories of Abood, Klee, Loh, and Zukin.
In a very exciting recent study by Dr. Y. Itzhak (Itzhak et al.
1983) in our laboratory we have obtained evidence for a physical
separation of kappa sites from mu and delta sites. This was done
y sedimentation of digitonin-solubilized receptors from guinea
pig brain on a sucrose density gradient. A typical result of such
an experiment is shown in Fig. 3, The kappa sites sediment with
Fig. 3. Sucrose density gradient
centrifugation of solubilized
opioid binding sites from guinea
pig brain membranes. Fractions
were assayed for binding of 3H-
bremazocine (3.5 nM) in the pres-
ence of DAGO and DADL (100 nM
each) and for the binding of
3H-DAGO (7 nM) and 3H-DADL
(7 nMI Protein markers for
the estimation of molecular weight
are as follows: a) catalase,
b)thyroglobulin (monomer), c)
thyroglubulin(dimer). Each point
represents the mean ± SEM of at
least three determinations.
From Itzhak et al. 1983.
Copyright 1983. Pergamon Press,
Ltd.
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a velocity equivalent to a molecular weight of ca. 400,000 (as-
suming a globular protein), whereas mu and delta sites seem to
have a molecular weight of about 7110,000. This suggests that some
slight difference in the structure of the latter causes them to
dimerize in the low digitonin concentration present in the sucrose.
Whatever the reason for the separation it represents the first
direct evidence for a molecular difference between receptor types.
RELATIONSHIP OF THE ENDOGENOUS OPIOID SYSTEM TO DRUG DEPENDENCE
The fact that laboratories involved in this type of research have
received several Nathan B. Eddy Awards from CPPD and many grants
from NIDA reflects the conviction of these distinguished organi-
zations that knowledge of the endogenous opioid system will aid
us in our understanding of drug dependence. Nevertheless, it is
appropriate for me to address the question why 8-10 years after
the major discoveries we do not have definitive answers concern-
ing the biochemical mechanism of drug dependence.
There are basically two questions one can ask. During the devel-
opment of tolerance and dependence 1) are there changes in opioid
receptors? 2) are there changes in endogenous opioid peptides?
Rather careful studies on opioid receptors have led to negative
results. Neither the number of binding sites nor the binding
affinity seems to be altered during chronic treatment of rats with
morphine. These studies  were done in whole brain by Klee and
Streaty (1974) and in three brain regions by our laboratory
(Bonnet et al. 1976). It is therefore still possible that the
appropriate brain regions have not yet been examined.
Even more important is the fact that these studies were done prior
to our knowledge of receptor heterogeneity. Are there changes in
one of the types of opioid receptors? Recent work in several
laboratories has shown that selective tolerance can develop to a
particular opioid receptor type (for example, Schulz et al. 1980).
It is therefore essential to determine whether reduction of a
receptor type due to tolerance leads to decreased binding to that
type of receptor. The answer to this question is not yet known.
If it turns out to be negative, which is entirely possible, the
effect of tolerance must be on a step subsequent to binding. Such
a mechanism is suggested by the cell culture model of Klee and
collaborators in which chronic morphine affects adenylate cyclase
and not the binding sites.
A number of reports on changes in levels of opioid peptides have
also appeared. However, these results are still controversial
and sometimes contradictory. In one report the plasma ß-endorphin
levels of normal subjectswere 5-10 times higher than reported by
other laboratories, suggesting non-specificity of the antisera
used. In another report the effects were observed only after four
weeks of morphine pellet implantation, when three days sufficed to
render the animal fully tolerant and dependent.
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There are, in my view, a number of reasons why these previous
studies have been inconclusive. One is the fact that many of the
assays were done on opioid peptides in the blood. It is very
unlikely that blood levels in any way reflect the situation in
the central nervous system. Recent studies done in cerebrospinal
fluid from lumbar punctures would seem more promising in this
regard. Another reason is the fact that to date people have only
measured the levels of ß-endorphin and the enkephalins. We now
know that there are several other opioid peptides that may play a
role in chronic opiate treatment. Finally, it may become neces-
sary to study the biosynthesis and turnover of the peptides rather
than their levels in order to detect significant differences.
My feeling is, therefore, one of considerable optimism. Once we
learn more about the fundamental nature and function of the endo-
genous opioid system it is very probable that we will understand
the biochemical basis of the physiological aspects of drug depend-
ence such as tolerance and physical dependence and, perhaps some-
what later, of such behavioral aspects as euphoria and drug-seek-
ing behavior. It is for me impossible to imagine that an endo-
genous opioid system, already implicated in many acute effects of
opiates, would not have an important role in the chronic actions
of exogenous opiate drugs. I am even willing to stick my neck
out to suggest that once we understand opiate abuse we will also
begin to understand other forms of drug abuse and compulsive
behavior.
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In Memoriam: Abraham Wikler and
H. Frank Fraser--lntroductory
Remarks
Jerome H. Jaffe
This plenary session of the 45th Annual Meeting of the CPDD is
dedicated to the memory of two pioneers in the field of research
on addictive disorders, Abraham Wikler and H. Frank Fraser. It is
altogether proper that we make such a dedication at this meeting
and in this place- Lexington, Kentucky. For it was in Lexington,
Kentucky that they lived for most of their professional lives and
in Lexington where for 15 years they were colleagues and key fig-
ures on a remarkable research team. To appreciate their accom-
plishments, one must put these accomplishments in the context of
the times: The time was 1940.
Himmelsbach had begun an effort to measure the intensity of opiate
withdrawal, but apart from this step, little was known of the
addictive processes. The way opiates relieved pain was unknown.
It was still not certain whether opiate withdrawal was physical or
largely psychological. Dalirium tremers was widely believed to be
a toxic reaction to the actions of alcohol. There were no narcotic
antagonists. Most of the opioids in use today were unknown; the
notion of quantifying the subjective effects of drugs was in its
perinatal period and the word psychopharmacology had not yet been
invented.
Today, when young medical scientists wish to enter a field of
research, they seek positions at an established laboratory, already
doing work on a problem. Today, 30 years into the golden age of
federal funding, there are usually several well-equipped labora-
tories from which to choose.
In 1940, when Abraham Wikler began his residency in psychiatry at
the USPHS Hospital here in Lexington, there was no laboratory for
the study of addictions. There was only the barest beginning;
the concept was still a gleam in the eye of Harris Isbell. The
men whose memories we honor today built the very tools with which
they worked and with which we continue to work. Every time we use
a questionnaire to measure the effects of an opioid or a
euphorigenic drug, we are building on a foundation laid down by
Frank Fraser. Every time we invoke notions of conditioning and
14
reinfor cement to account for drug-seeking behavior, we are using
conceptual tools handed to us by Abe Wikler.
Today's plenary session includes four papers that build on work
by Abe Wikler or Frank Fraser. Dr. William Martin will speak
about opioid agonists and antagonists - the Lexington team was the
first to show that nalorphine could precipitate opioid withdrawal
giving impetus to the notion of the opioid receptor. Dr. conan
Kornetshy will talk about environmental factors influencing pain.
The paper by Hill, Kornetsky and Wikler, showing that at the
usual dosage, morphine affects anticipatory anxiety associated
with painful shock is still a classic. The next two papers touch
cm the issue of learning factors - both classic conditioning and
operant conditioning - in the addictive process. The first is on
conditioning factors in opioid dependence by Charles O'Brien and
Joseph Ternes. The second is on conditioned responses to alcohol
cues by Ronald Kadden, Ovide Pamerleau, and Roger Meyer. This
emphasis cm learning in the development of the addictive process
may emerge as Abe's most important contribution.
Dr. Eric Simon, this year's Eddy Award, is honored for his role
in the discovery of opioid receptors which, in turn, has helped
to open a major frontier in neurobiology. We in the field of
drug dependence have much to be proud of. This session dedicated
to the memory of Abe Wikler and Frank Fraser should prompt us to
recall the words of Robert Burton who said, "a dwarf standing on
the shoulders of a giant may see further than a giant himself."
Let us then do honor to two of the Lexington giants who have left
us.
15
A Steric Theory of Opioid Agonists,
Antagonists, Agonist-Antagonists,
and Partial Agonists
William R. Martin
I am pleased and honored to participate in this symposium honoring
Abraham Wikler and Frank Fraser. When I first joined the staff
of the Addiction Research Center in 1957, Harris Isbell and Frank
Fraser were among the great pioneers in clinical psychopharmacology.
Frank invited me to collaborate with him in a comparative study of
the subjective and physiologic effects of morphine and heroin. I
entered these experiments skeptical of the methods that had been
developed for measuring subjective effects and states through the
cooperative efforts of Harris Hill, Richard Belleville, Harris
Isbell, Frank Fraser, and Abe Wikler. I learned that these methods
were valid, yielded reproducible experimental results, and were
remarkably sensitive and discriminating instruments for measuring
drug effects. Despite Abe’s involvement in the development of these
instruments, he had little faith in them. He didn’t trust what
people said, only what they did. Of all the wonderful associations
at the Addiction Research Center, my interactions with Abe were
the longest and most deep. Abe had a profound and tenacious in-
tellect. He had just finished writing his arbeit “The Relation
of Psychiatry to Pharmacology” and his interests encompassed all of
neuropsychopharmacology. He was only then starting his experiment
dealing with conditioned abstinence and drug-seeking behavior, phe-
nomena which came to occupy his interest. Abe, however, retained
his interests in opioid antagonists. He and George Acheson invited
me to prepare a review of the narcotic antagonists for Pharmaco-
logical Reviews. Abe, with Chuck Gorodetzky and Don Jasinski, were
the first to recognize the significance of the concepts of multiple
opioid receptors and receptor dualism first formulated in this
review.
Those who have been involved in the development of strong anal-
gesics have recognized the complexity of the opioid receptor
(Beckett et al. 1956; Bentley and Lewis 1972; Archer and Michne
1976). Over the last several years I have been extending these
models. The method employed has been to construct clay models of
receptors whose surfaces are complementary to Framework Molecular
Models of prototypic opioids. These clay models are then used
to form plaster shells. These plaster shells which consists of
hills and valleys are surveyed and the reactive moieties are placed
in rectangular coordinates (Figure 1). The reactive sites are
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FIGURE 1
The schematic three dimensional oblique representation of the
opioid receptor and the structural formula of a general opioid
molecule.
then coded to indicate the approximate bond strength between the
reactive sites on the receptor and the complementary sites of
the opioid molecule. A more detailed description of this model
has been presented (Martin, in preparation). The structure of the
molecule used to construct the model and the three dimensional
receptor map is illustrated in Figure 1. The X-Y plane of the
coordinate system is the flat site (Beckett et al. 1956). This is
labelled site A. The X axis goes through the center of the flat
site to a point which is the vertical projection of site B to the
X-Y plane. Site B is the anionic site of the Beckett et al. (1956)
model. Site B’ is located approximately l Angstrom counterclock-
wise from site B and is the anionic site of the K receptor. Site
C is closely associated with site B and is one of the sites with
which substitutions on the nitrogen can interact. Site D inter-
acts with the ketonic oxygen of ethylketocyclazocine and with
certain substitutions on nitrogen. The E site interacts with the
3-OH moiety. The F site has two parts: The F site which interacts
with the 14-OH group and the F’ site which can interact with highly
reactive substitutions on the 14 position to form covalent bonds.
The E site interacts with the 3-OH group. The G site interacts
with the 6-OH group. The closely related G’ site interacts with
highly reactive substitution on the 6 position. The H position
interacts with large hydrophobic substitution on the 7 position
(Bentley and Lewis 1972).
µ AND K RECEPTORS
Sites A and B of the µ receptor (Figure 2) are called nuclear
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FIGURE 2
Figure 2 illustrates the A and B sites on the structural formula
and opioid receptor. The positioning of the µ agonist is sche-
matically illustrated with the filled circles and heavy connecting
line.
sites for their occupation is necessary for µ type agonistic
effects. Sites C, D, E, possibly F, G, and H are called satellite
sites and serve two roles: (1) To enhance the binding of the
drug to the receptor and (2) to orient the drug on the receptor.
Sites B', A and possibly D are nuclear sites for the K receptor
while sites E, F, G, and H are satellite sites.
FIGURE 3
The orienting effect of the N-methylcyclopropyl substitution to
put it on A, D position at the µ receptor and in the A, B', D
position on the K receptor. The drug on the receptor is sche-
matized with the filled figures.
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AGONIST-ANTAGONISTS
Figure 3 illustrates a specific type of pharmacologic redundancy
in which the drug acts as a competitive antagonist at the µ
receptor and as an agonist at the K receptor. At the µ receptor
the N-methylcyclopropyl group interacts with the D site which
rotates the drug around the Z-axis off of the B site. Since it
no longer occupies the B site it does not exert an agonistic
effect; however it still covers the receptor and will compete with
a µ agonist. At the K receptor the interaction of the methyl-
cyclopropyl substitution on the nitrogen at the D site will
position the nitrogen over the B’ site giving it K activity.
FIGURE 4
The orienting effect of the 14-OH group in conjunction with an
N-methylcyclopropyl group which places the drug in the A, high D, G
position.
PURE ANTAGONISTS
In the context of this paper, a pure opioid antagonist is defined
as a drug which is a competitive antagonist at both the µ and K
receptors. The steric formulation of the pure antagonist is pre-
sented in Figure 4. The 14-OH group which conveys antagonistic
activity to both N-allyl and methylcyclopropyl-noroxymorphone is
postulated to interact with the G site which in turn constrains the
rotation of the drug around the Z-axis. For the substitution on
nitrogen (allyl or methylcyclopropyl) to interact with the D site
the drug must rotate around the A-G axis allowing the substitution
on nitrogen to interact at a higher location on the D site, thus
shortening the D-G distance. This, however, lifts the nitrogen
above both the B and B’ sites, thus precluding both µ and K agonistic
activity. Since the drug still covers both the µ and K receptors,
it acts as a competitive antagonist at both receptors.
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FIGURE 5
The orienting effect of 7 position substitutions interacting with
the H site. Buprenorphine is shown occupying the receptor in an
agonist and antagonist position.
PARTIAL AGONISTS
Three partial µ opioid agonists have been identified: Buprenorphine
in the chronic spinal dog; profadol and propiram in man. The basic
idea underlying the steric theory of partial agonism is that because
of the complexity of the receptor, the drug can not only occupy the
receptor's nuclear positions but can also occupy it in satellite
positions. This principle is illustrated in Figures 5, 6, and 7.
Buprenorphine (Figure 5) is postulated to occupy the µ receptor
at the A, B, and F sites and thus exert an agonistic effect. How-
ever, it can also occupy the receptor in the B, F, and H positions
which would not exert an agonistic effect but would cover the
receptor and thus act as a competitive antagonist in this position.
It is suggested that profadol (Figure 6) can also occupy the
receptor in two positions: In the A-B position it would have a
µ agonistic property while an interaction between the phenolic
OH group and the E site would rotate the propiram molecule around
the Z-axis lifting it off of the B site. Thus, it would not exert
an agonistic action but would cover part of the receptor and act
as an antagonist in this position. Propiram (Figure 7) could also
occupy the µ receptor in two positions: The A-B agonist position
and the A-E antagonist position. In position 1 (antagonist) the
E site is presumed to be occupied by the ethereal oxygen which
orients the propiram molecule such that the nitrogen is oriented
in a position slightly counterclockwise to the E site and away
from the B site.
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FIGURE 6
Profadol occupies the µ receptor in two position as a consequence
of the phenolic hydroxyl group interacting with the E position.
Figure 7
The postulated orienting effect of the ethereal oxygen of
propiram.
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According to this formulation, the intrinsic activity of an agonist
is directly related to its affinity in the agonist position and
inversely to its affinity in the antagonist position. This
relationship can also be expressed as follows. The intrinsic
activity (a) of the partial agonist is defined by equation 4,
where K' is the dissociation constant for the drug occupying the
receptor in the agonist configuration and K" for the antagonist
configuration.
[DR]' Active Agonist Receptor Complex
[DR]" Inactive Agonist Receptor Complex
CONCLUSION
The unique virtue of this steric theory of the opioid receptor
is that it provides an explanation for the diverse properties of
opioids acting as agonists at different receptors, as agonists at
one receptor and antagonists at others (agonist-antagonists), as
antagonists and as partial agonists. The postulated principles
that are presumed to confer these diverse properties to opioids
are three in number: (1) The large number of reactive sites.
There is evidence of eleven at this time. The reactive sites
play two roles: (2) Their occupancy initiates pharmacologic
actions and (3) They orient the drug in the receptor. This model
does not necessitate either the postulation of alternative con-
figurations of a receptor (agonist or antagonist) (Belleau 1964;
Feinberg et al. 1976) or that the receptor undergoes allosteric
changes (Archer and Michne 1976; Portoghese and Takemori, personal
communication).
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Environmental Influences in the
Perception of Pain
Conan Kornetsky
INTRODUCTION
My presentation will describe some of the early experiments by
Abraham Wikler, Harris Hill, Harold Flanary, and myself on the
effects of environmental variables on the perception of pain. I
will try to relate these early experiments to current research
findings and place them in the Zeitgeist of the period, circa
1950. An appropriate sub-title for my topic would be "Old wine
in new bottles and new wine in old bottles."
I will not elaborate how Abraham Wikler, Harris Hill, Harold
Flanary and I got together except to say that for the most part
our roles were complementary. Each of us brought something uni-
que to the collaboration. Wikler brought a sophistication of
thought, ideas and experience from many fields. Hill, who had
just received his Ph.D. from the University of Indiana, brought
a broad base of psychological methodology, the ability to design
an idea into an experiment and also a quiet confidence. Flanary
brought to the group the ability of designing and putting together
the apparatus to fit any crazy idea. As a second year graduate
student I brought to the group an attribute not present in any of
the staff, a highly developed degree of naivete.
The topic, environmental influences on the perception of pain,
with specific reference to stress-induced analgesia (SIA) has
received a great deal of attention in the last few years. However,
the issue was not lost in the work of the research group at the
USPHS Hospital in Lexington, Kentucky over 30 years ago. Wikler,
in a review paper published in 1950 wrote,
It appears reasonable to postulate that the recognition
of the pain threshold in man is a discriminative func-
tion for which an optimum cortical excitatory state (CES)
is required. Emotional disturbances, pain, etc. may
raise pain threshold by elevating CES while analgesics
may raise threshold by lowering CES, in both cases away
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from the optimum level required for most precise
discrimination. Therefore the net effects of
analgesics or other drugs on pain threshold in any
individual under a given set of circumstances (e.g.,
tranquil, in pain, emotionally disturbed, etc.) may
be in the direction of increase or decrease in
discriminative ability and hence the pain threshold
may be elevated or lowered by the drug or drug
combinations used. (Wikler 1950)
Wikler then downgraded the importance of his own statement,
Such a concept, while only a restatement of the fact
that mental factors modify the effects of drugs on
'pain threshold,' may be useful in planning further
investigations. (Wikler 1950)
The concept that pain or other competing factors could alter the
perception of pain was, as Wikler indicated not an entirely new
idea, but was expressed very early in the history of medicine.
In the 5th century BC one of the Aphorisms of Hippocrates (Chadwick
and Mann 1950, Section II, #46, page 154) stated, "If a patient
be subject to two pains arising in different parts of the body
simultaneously, the stronger blunts the other."
In 1940 Hardy, Wolff, and Goodell, using thermal radiation to produce
pain, reported that pain in one part of the body raises the thres-
hold to nociceptive stimulation to another part of the body. Many
examples of such phenomena are given in the later comprehensive
review by Beecher in his 1959 book, Measurement of Subjective
Responses.
Kelly, more recently (1982), argues that if such phenomena are not
simply distraction, then the analgesia must last beyond the duration
of the induced pain experience. A 1945 experiment by Parsons and
Goetzl clearly met the demands of Kelly. These investigators
used electrical stimulation of a tooth pulp to produce pain. The
threshold was defined as the voltage at which the subjects first
experienced painful sensations. The external painful stimulus
used to cause changes in the tooth stimulation threshold was in-
duced by spraying ethylchloride on a small area of the subject's
tibiae. Not only was the pain threshold elevated, but it was
clearly elevated long after the cessation of the ethylchloride
spraying. Unfortunately, these investigators did not have naloxone
available to see if it would block the observed threshold-raising
effect of the induced pain.
The role of culturally determined environmental factors in percep-
tion of pain was also known during the 1940s. Molone (1949) had
observed during World War II that Okinawan children showed rela-
tively little response to pain in the presence of major tissue
damage. This lack of response was not seen in the Okinawan children
living in close proximity to Westerners. Isbell at the Lexington
Hospital was very much aware of the differences in response to
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clinical pain between the Oriental patient reared in Asia and
those reared in the United States. Beecher (1946) had already
published his classic description of the wounded soldiers at Anzio
during World War II. He observed that badly wounded men, not in
shock, with clear sensorium showed little evidence that they were
in pain. Even earlier was the report of William McDougall, who, as
a member of a Cambridge University Anthropological expedition to
British New Guinea (Murray Island), measured the pain threshold in
47 Murray Islanders. He used a weighted pointed object and reported
the threshold in terms of kilograms of pressure. He stimulated
the thumbnail, forefinger, and forehand. Subjects were asked to
cry "stop" when they felt pain. However, he stated "I found that
in nearly all cases it was possible to detect the moment of onset
of pain by observing the slight flinching which is commonly caused
in expectant subjects."
He compared the thresholds of Murray Island boys and men with those
of English boys and men. These results are shown in the Table.
As can be seen the threshold was higher in the Islanders although
the younger subjects had thresholds not different from those of
the adult Englishmen.
TABLE
Sensibility to Pain (x)
(in kilograms of pressure)
Subjects (N) Thumb Nail Forefinger Forehand
Murray Island
Men (47) 6.7 5.5 6.2
Murray Island
Boys (18) 3.8 3.0
(10-14 yrs)
English Men (23)
English Boys (5)
(13-14 yrs)
3.8
2.9
3.6 3.8
2.4
(From McDougall, 1901)
In order to determine the specificity of the finding, McDougall
also measured the threshold for two-point discrimination and
discrimination of differences between weights. For this type of
sensory stimulation the Islanders had lower thresholds than the
English subjects. Of interest is that after the study by McDougall
there were, as far as I could find, no experimental studies that
compared pain threshold in various cultural groups until a 1965
report by Sternbach and Tursky. It is not surprising that investi-
gators were aware that environmental factors could influence the
perception of pain, for during this period and even earlier many
investigators were studying the influence of past experience on
perception in modalities other than pain (Braly 1933; Bruner and
Goodman 1947; Bruner and Postman 1948). These investigations
were often referred to as the "new look in perception."
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During the period of the 1940's and 50's many of the studies that
experimentally tested the analgesic actions of the narcotic drugs
in man yielded conflicting results despite the well accepted
analgesic action of these drugs in the clinic. Although many
investigators reported consistent rises in the threshold for pain
after morphine, most investigators obtained variable results.
Wolff, Hardy, and Goodell (1940) found consistent rises in the pain
threshold for thermal radiation stimulation following morphine
administration, using the same procedure; however, Andrews (1943),
Denton and Beecher (1949), Chapman and Jones (1944), and Isbell
(unpublished data) found that the pain threshold might be elevated,
lowered, or unchanged following morphine. Wikler believed that
these discrepancies were a function of the large variability in
emotional response by subjects to experimental pain and that much
of this could be attributed to a class of responses which he called
"anticipatory."
THE LEXINGTON EXPERIMENTS
In order to study these anticipatory responses we embarked on a
series of experiments specifically designed to manipulate the degree
of anticipatory fear or anxiety in the subjects. In the first of
these experiments (Hill et al. 1952a), former narcotic addicts
(patients at the USPHS Hospital, Lexington, KY, with a history of
narcotic addiction) were used as subjects. In this experiment
simple reaction time (RT) was tested under four conditions. 1)
Electric shock penalties delivered to the hand for "slow" RT's,
2) shock penalties for slow RT's after morphine, 3) knowledge of
RT no shock control, and 4) morphine-control. Subjects were seated
in front of an opaque screen in which the response key and neon
bulbs were mounted. The subjects were told that the bulbs would
light in an "on your mark," "get set?" "go" sequence. The lowest
light indicated that a trial was beginning ("on your mark"). The
second bulb from the top flashed two sec later and indicated that
a trial was beginning ("get set"). The other two lights were
stimulus lights; one was above and one below the "get set" light.
Only one of these was lit for any one trial, the subject responding
to either by quickly moving the key to the left. The preparatory
interval between the warning and the "go" light was variable, a
pre-determined random order of 1, 2, or 3 seconds. For all pre-
conditions the two "go" lights had identical meaning for the
subjects and these appeared an equal number of times. After the
pre period each of the two "go" lights had different meanings to
the subject. If the first was lit, it would indicate that the
previous response was fast; if the second was lit, it would indicate
that the previous response was slow. RT was determined with know-
ledge of performance with and without morphine.
The same procedure was also used with the subject receiving elec-
tric shock for slow RT. Thus, if in the previous trial the response
was slow, the top light came on and at the completion of the response
the subject received the electric shock. The dose of morphine was
15 mg delivered intramuscularly. Figure 1 shows the results of
this experiment. Whether or not the subject's RT was considered
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Figure 1. Effects of morphine [MS] on RT as a function of
aversive electric shock. (Adapted  from hill et al.
1952a)
slow or fast was based on the median of the series. What is clear
is that anticipation of the shock certainly slowed RT and morphine
clearly ameliorated this disruption in RT. It is not clear from
the experiment whether or not the anticipation of the shock made
the shock feel worse than it really was. The verbal report of the
subjects suggest that the shock itself was not the disturbing
factor but it was the anticipation of the shock. This experiment
led to two additional experiments, one using electrical shock and
one using thermal radiation as the nociceptive stimulus.
In order to test the hypothesis that the stress or anxiety level
of the subject could alter the threshold for pain, the following
experiment was carried out (Hill et al. 1952b). Volunteer subjects
were randomly assigned to one of two groups and prior to the
determination of the threshold they were treated quite differently.
In one group everything was done to decrease any fear the subject
might have regarding the anticipated painful stimuli. This was
called the "Informal" group. Subjects in the other group were
given no reassurance and nothing was done to decrease their putative
apprehension. This group was called the "Formal" group. Both
groups were studied with and without 15 mg of morphine. Except
for the difference in the formality of the experiment the procedure
was identical for all subjects.
The subjects were first trained in the procedure and then received
two suprathreshold stimuli that were called the "standard." Sub-
sequent stimuli would be rated by the subject as either "stronger"
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or “weaker” than the standard. If drug were to be given, it was
then administered. One hour later the threshold was determined
by means of the psychophysical method of limits. Figure 2 shows
the percent of “stronger” responses as a function of shock intensity
in watts. The upper graph shows the subjects in the “Formal”
group and the lower graph the subjects in the “Informal” group.
Of most interest is that morphine significantly raised the thres-
hold only in the “Formal” group of subjects and that the informal
procedure alone had almost as much effect as morphine in raising
the threshold. Note that the threshold after morphine was almost
Figure 2. The percent "stronger" responses of subjects with and
without morphine as a function of intensity of elec-
trical stimulation under “Formal” and “Informal”
experimental conditions. (Adapted from Hill et al. 1952b)
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identical in the “Formal” and “Informal” conditions. Further, the
more anxiety-provoking formal treatment of the subjects resulted
in an overestimation of the intensity of the previously delivered
“standard” stimulus, and morphine resulted in a more accurate
estimate of the intensity of the “standard.”
This experiment was repeated using thermal radiation to the fore-
head of the subjects as the nociceptive stimulus (Kornetsky, 1954).
In this experiment a number of additional variables were added in
order to determine the role of the anticipation of the stimulus
in the pain experience. These were the amplitude of the galvanic
skin response (GSR) expressed as conductance, latency of the GSR,
anticipatory GSR’s and time from onset of the stimulus to when the
subject thought he felt pain. The dose of morphine was as in the
previous study 15 mg, administered intramuscularly 60 min before
the test. The results of this study are summarized in figure 3.
The verbal report results completely replicated the previous study
in which electric shock was the stimulus. In this study the mean
number of times the subjects stated that the stimulus was “strong-
er” than the previously delivered “standard” is shown in the lower
right chart. As can be seen morphine only caused a significant
decrease in the number of reported “stronger” stimulations in the
“Formal” group of subjects.
Figure 3 The effects of morphine (M) compared to control (C) on
latency of response (motor response), GSR latency,
amplitude of GSR to thermal radiation stimuli, and
percent stimuli judged as "stronger" than a pre-
treatment standard under "Formal" and "Informal"
experimental conditions. Based on data from
Kornetsky, 1954)
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In each case illustrated morphine was only effective in the more
anxiety-provoking paradigm. Although latency of GSR and number
of anticipatory conditioned GSR’s were significantly altered by
morphine, the actual amplitude of the GSR was not affected, indi-
cating the importance of the anticipatory state in the percep-
tion of the painful stimulus.
DISCUSSION
These studies raise some important questions regarding current
experiments in which stress or pain are used to induce analgesia.
These early Lexington experiments suggest that pain threshold can
also be raised by decreasing the stress of the painful encounter,
certainly a maneuver not foreign to the clinician. Stress or
pain or simply decreasing the anticipation of a painful experience
are probably not the only maneuvers that will produce analgesia.
Pleasurable experiences such as sex (Beecher 1959, p. 153),
listening to music, watching the Superbowl, etc., will also de-
crease pain and often the pain does not return immediately after
the cessation of the behavior.
Experimental evidence that it need not be a painful stimulus that
induces analgesia is given by the 1965 report of Cox and Valenstein.
These investigators demonstrated that rewarding electrical stimula-
tion to the hypothalamus attenuated the aversive properties of
foot shock in the rat.
Of interest is that Mayer et al. (1971) in their paper on brain
stimulation-induced analgesia reported that there was a point-
biserial correlation of 0.83 between rewarding self-stimulation
rates of response and whether or-not these sites produced analgesia.
Although analgesia produced by intracranial stimulation is con-
sidered a discovery of the 1970’s, the Cox and Valenstein experi-
ment was done in 1965 and as early as 1954 Heath reported that
stimulation of the septal area resulted in immediate relief from
intractable pain. Lilly in 1960 reported that rewarding brain
stimulation raises the threshold for aversive central stimulation.
In the 1970’s numerous studies were published demonstrating that
various stressors would raise the threshold to pain (e.g., Akil
et al. 1976). An important question is the specificity of this
stress-induced analgesia. Kelly stated in a 1982 publication,
“It has never been proven that the sensory deficit induced by
stress is limited to the modality of pain.” Although some in-
vestigators have stated that responses to other sensory modalities
are not affected, there are no published experiments in which the
threshold for stimulation to other modalities was done with the
same care that these investigators used in measuring the threshold
for pain stimulation.
Evidence, however, that other aspects of behavior can be
altered by the stress of inescapable shock is given by the learned
helplessness model (Ovennier and Seligman 1967; Seligman and
Maier 1967) in which animals given inescapable electric shock
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showed subsequent performance deficits. The argument often given
for stress-induced effects being specific for perception of
pain stimulation alone is based on the reports that the in-
duced analgesia can be blocked by naloxone. Since naloxone itself
causes increases in sensitivity to nociceptive stimulation (e.g.,
Buchsbaum et al. 1977 in man; Carmody et al. 1979 in rats and
mice; and Sasson and Kornetsky 1983 in rats), simply increasing
the animal’s sensitivity to the pain stimulus under test may result
in apparent block of the induced analgesia.
The discrepancy between earlier work by Wikler and his colleagues
in which stress seemed to lower the threshold for pain and current
work in which stress raises the threshold may be a function of
where one’s attention is directed. In the Lexington studies the
stress (the “Formal” procedure) directed the subject’s attention
toward the stimulus. In the stress-induced analgesia studies the
stress is directing the subjects attention away from the nocicep-
tive stimuli.
In conclusion alteration in pain thresholds by stress or pain is
not a new phenomenon and the attempts to relate the phenomonon
to an analgesic endorphin-like action may result in losing sight of
a more general role of the endorphins in stress and their possible
role in modulating the attentional components of perceptions.
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Classical Conditioning in Opiate
Dependence
Charles P. O’Brien, Ronald N. Ehrman, and
Joseph W. Ternes
INTRODUCTION
Opioid use provides an excellent opportunity for classical
conditioning. The opiate drug is a Pavlovian unconditioned
stimulus (US) which is reliably and consistently followed by an
unconditioned response (UCR) which involves several efferent
systems. Whether in animals or in humans, drug administration
usually involves a set of complex procedures and several sensory
systems, which can function as a conditioning stimulus (CS).
Dr. Wikler, one of the pioneers we are honoring today, often
pointed out that repeated drug use could produce conditioned
effects. According to his analysis, the CS should initially
acquire the power to elicit a conditional response (CR) which
resembles the UCR. In an opiate-dependent individual another
possible conditioning situation can occur. As the last dose of
drug is metabolized a withdrawal syndrome occurs and in this
instance environmental stimuli or rituals may be paired with the
withdrawal symptoms. After repeated pairings, the CS alone may
acquire the ability to evoke a conditioned response which
resembles withdrawal effects. In Wikler's terms, the individual
has acquired an additional disease, a disease sui generis as he
called it.
Despite vastly improved addiction treatment programs in the
1980's we still have no available treatment modality which
directly deals with the conditioning aspects of addiction. Why
is this? Part of the problem relates to the confusion about
which type of conditioned effects to treat, conditioned opioid-
like effects, or conditioned withdrawal-like effects.
Additionally there is confusion about which systems to measure:
analgesia, temperature, salivation or euphoria. Do these
effects occur commonly or do they only occur in a few unusual
patients? Are these phenomena lawful and orderly? What about
the apparent contradictions in the literature? Definitive
answers to these questions are elusive. The goal of this paper
is to clarify some of the issues. We will begin by describing
three categories of opioid-conditioned phenomena: conditioned
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opioid like effects, conditioned withdrawal-like effects and
conditioned tolerance. Then we will attempt to put some of the
sources of conflict into perspective and discuss their clinical
implications.
OPIOID-LIKE CONDITIONING
Historically, the first observed conditioned opioid responses
were reported by Pavlov and colleagues. They found that
morphine injections caused profuse salivation, vomiting and
sleep in dogs. After several trials, the mere sight of the
technician who gave the injection was enough to produce the same
effects as morphine: salivation, vomiting and sleep. This was
such a reliable effect in Pavlov's lab that it was used as a
demonstration for students. It was reported by other labs in
the early literature and seemed to be a well-established
response.
However, more recently Lynch (1976) had difficulty producing a
morphine conditioned response in dogs. After several failures,
he consulted Dr. W. Horsley Gantt, who had been a student of
Pavlov in Leningrad. Gantt pointed out that Lynch was
administering four conditioning trials in a one-hour session.
Following Gantt's advice, he began limiting the trials to one
or two per session with no other protocol Changes. After a few
more sessions, Lynch began to observe behavioral, salivary,
heart rate and respiratory responses to the conditional
stimulus. He found morphine-like conditioned responses to be
robust and parts of the response were very resistant to
extinction.
Similar results have been reported in humans and in rats.
These are summarized in Table I. While these responses can be
reliably produced, they require specific conditions as
illustrated in the anecdote from  Lynch's lab. The human
results (Meyer and Mirin 1979) were obtained in selected
hospitalized patients who self-injected sterile coded saline
solution which might have contained opioid. The more
naturalistic the setting, the greater the likelihood of
opioid like or "placebo" effects. Injections of saline given
by a nurse were less likely to produce euphoria or
physiological charges than those self-administered after a
"cook--up" ritual in a simulated "shooting gallery' (O'Brien et
al. 1975). Most subjects showed mild opioid-like effects which
extinguished after one to three unreinforced trials (saline
injections). A few, however, persisted in opioid-like
responses after many saline self-injections. Such subjects
have been clinically described as needle-freaks (Levine 1972).
WITHDRAWAL-LIKE CONDITIONING
A quite different type of opioid conditioned response has also
been described. These are conditioned withdrawal-like responses
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TABLE 1. Opioid-Like Conditioning1
and they were first described by Dr. Wikler. He noted the
appearance of withdrawal symptoms (yawns, tearing, rhinorrhea)
in post-addicts in response to verbal stimuli. These former
addicts were in the Addiction Research Center at Lexington
during the 1940's and 50's. Dr. Wikler noted the appearance of
withdrawal symptoms during group therapy sessions when drug-
taking was discussed. He also heard fascinating anecdotes from
patients who told of feeling well after months or years of
incarceration and then returning to their home, usually New
York City. As soon as they caught sight of their former drug-
using environment, however, withdrawal symptoms occurred and
relapse to drug use ensued.
Wikler interpreted these reports as classical. conditioning of
withdrawal signs and symptoms. In the laboratory, this
interpretation of the anecdotal reports has been supported by
experimentally producing conditioned withdrawal in animals and
in humans. A summary of the reports is given in Table II, Our
group has demonstrated that withdrawal symptoms can be
conditioned in human subjects (O'Brien, Testa, O'Brien, Brady,
and Wells, 1977). Naloxone, a narcotic antagonist, was used as
the US to produce mild dysphoria and physiological and
behavioral signs of withdrawal, the UCR. After patients in
methadone maintenance were given training injections of small
doses of naloxone paired with a compound (tone and odor) CS
test trials in which the CSs were paired with placebo
injections also produced similar withdrawal signs. It should
be noted that the CR which is described in this section is a
withdrawal response which resembles the UCR to naloxone. This
type of conditioning does not occur until after physical
dependence upon the opiate has developed and occurs only in
those instances where a CS is correllated with the onset of the
withdrawal syndrome. An addict who maintains his habit so as to
avoid withdrawal sickness would have little or no opportunity to
acquire the conditioned withdrawal reaction. Hence, the
directly conditioned withdrawal CR may not provide an adequate
explanation of relapse to narcotics use.
CONDITIONED TOLERANCE EFFECTS
There appears to be a third type of conditioning in which
compensatory mechanisms become conditioned during the addictive
cycle. In such cases, the conditioned stimulus comes to elicit
a CR which is opposite or antagonistic to the unconditioned
response. Unlike the two previous CRs, the conditioned
compensatory response is an atypical result of a Pavlovian
conditioning paradigm because the CR and the drug-elicited
response tend to cancel each other (see Siegel 1977 for a
review of compensatary CRs).
Wikler (1973) first pointed out that reactions to direct drug
effects could be conditioned. He described this as
conditioning of adaptive responses to drugs and these
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TABLE II. Experimentally Conditioned Withdrawal Studiesl
adaptations would be opposite to the direct drug effect.
Perhaps the clearest example of this is with atropine. One
unconditioned effect is an inhibition of salivary secretions.
After several trials, however, both dogs and cats begin to show
increased salivation prior to the injection of atropine. This
is presumably an adaptive response to the anticipated dry mouth.
Perhaps the most compelling evidence in favor of conditioned
compensatory mechanisms has been reported by Shepard Siegel
(1975, 1976). He has shown that the stimuli associated with
morphine injection come to elicit a reaction which reduces the
analgesic effect of morphine, thus demonstrating conditioned
tolerance. Siegel assessed morphine effects by measuring
analgesia on a hot plate. In one experiment, separate groups
of rats were given repeated morphine injections in one of two
environments: their home cages or the test situation (the hot
plate). When both groups were subsequently tested on the hot
plate after morphine injection, only those rats which received
morphine in their home cage showed evidence of analgesia to
pain. The other rats were tolerant to the effects of morphine,
that is, showed no analgesia. In addition, these tolerant rats
were hyperalgesic when given a placebo injection of physio-
logical saline instead of their regular morphine. Siegel
(1975) also reported that repeated placebo injections following
the development of tolerance were effective in extinguishing
the conditioned compensatory reaction of hyperalgesia. He
argues that morphine tolerance can be accounted for in terms of
a conditioning theory which posits the acquisition of timely
compensatory responses in anticipation of central drug effects.
His data (Siegel 1975) suggest that the compensatory response
is elicited by the stimuli which have been paired with drug.
Although Siegel has only measured the analgesic (1975) and
pyretic (1976) components of morphine effects, it would be
interesting to determine whether Other physiological
concomitants of the drug state act in the same manner. Siegel
proposed that the hyperalgesia he observed is a conditioned
compensatory CR. If Siegel's rat data can be extrapolated to
humans, they support our speculation that the incidence of
relapse to narcotic use among detoxified addicts is due to the
fact that cues associated with the drug come to produce
compensatory CRs. However, the procedures which produce
compensatory CRs instead of drug-like CRs are uncertain. Even
in controlled animal experiments, similar protocols can produce
dissimilar results. Thus, Sherman's (1979) attempts at
replication of Siegel's experiments were only partially
successful (see note added in proof, Sherman 1979).
There is evidence that most drug-associated cues produce
compensatory effects in humans (See Table III). When the
subject is in a drug-associated environment and performing
rituals which reliably predict the onset of drug effect, the
subject exhibits behavioral and physiological responses opposite
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TABLE III. Conditioned Response Opposite to Opioid Effect1
to opioid effects. These responses would tend to diminish
observed opioid effects and thus they may mediate conditioned
tolerance. In fact, there is preliminary evidence (Ternes
1981) that recently detoxified addicts receiving unsignalled
(unexpected) opioid infusions show relatively non-tolerant drug
effects whereas the same dose produces a more tolerant reaction
when it is self-injected.
An obvious source of confusion is that conditioned withdrawal
and conditioned compensatory responses appear to be similar.
Although they can arise by different mechanisms, their typo-
graphy is identical. In the event that a compensatory CR such
as hypothermia is attributed to a lack of narcotic in the
system by the addict, the effect may be mislabeled as with-
drawal symptoms. Perhaps this is why so many drug-associated
stimuli appear to produce withdrawal-like reactions in addicts
and why these responses are so difficult to extinguish (O'Brien
et al. 1979).
SOURCES OF CONFLICT
While we have not reviewed each type of conditioning in depth,
it is evident that there are enormous complexities and numerous
sources of conflicts which help to explain the discrepant
studies in the literature. First we should ask why sane
conditioned effects resemble opioid effects and others oppose
them. A major issue is the identity of the drug UCR in a given
situation. Recently, Eikelboom and Stewart (1982) in a
comprehensive review of this issue proposed that drug-like CR'S
occur when the drug acts on the afferent arm of a reflex arc so
that the observed effect or UCR is actually a homeostatic
response to this afferent stimulation. According to this model,
compensatory CR's occur when the drug acts on the efferent limb
of a reflex arc. In this case, the drug-elicited response in
the efferent arm is the US and the CNS-mediated response in the
efferent arm which opposes the drug effect is the UCR. The CR
mimics the UCR and in this instance, since it opposes the drug
effect, it is a compensatory CR.
The model described by Eikelboom and Stewart is appealing, but
there are difficulties in a simple use of the afferent and
efferent categories. This is particularly problematic for an
opioid because of recent advances in determining the opioids'
site of action. In the dorsal horn of the spinal cord, for
example, opioids apparently produce analgesia by mimicking the
effects of endogenous opiates released from enkephalinergic
nerve fibers which synapse onto the afferent pain fiber. The
result of the opioids: activity on the pain fiber is a
reduction in the release of substance P, a transmitter of
pain-related impulses. This is a case of neuromodulation which
fits poorly into an afferent-efferent integrator model. Also,
there is no postulated mechanism for a compensatory response to
this neuromodulation.
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We have observed an interesting pattern of behavioral and
physiological response when drug addicts are allowed to go
through their drug preparation rituals, followed by injection
under double blind conditions of either saline or opioid drug.
Prior to injection physiological changes occur such as
temperature decrease. These may be characterized as signs of
withdrawal. After the injection of saline, some warming of the
skin temperature and other behavioral high-like symptoms occur.
These can be characterized as opioid-like CR's. However, over
repeated injection trials, the opioid-like CR's disappear and
the pre-injection withdrawal-like CR's increase in strength and
duration. Typically, these withdrawal-like CR'S are
particularly resistant to extinction. Although it is easy to
characterize these conditioned responses as withdrawal-like or
drug-like, the specific conditions controlling their
development and the degree of interdependence in establishment
of these responses in the human opiate abuser is still obscure.
One study which observed morphine-dependent rats in both pre-
injection and post-injection environments (Eikelboom and
Stewart 1979) reported findings similar to those observed in
opioid-dependent humans: conditioned hypothermia in the
pre-injection environment and conditioned hyperthermia in the
post-injection environment. In a subsequent study, these
investigators (Eikelboom and Stewart 1981) found that temporal
cues, not environmental cues, were the salient CRs for the
pre-injection hypothermia. But they confirmed the finding that
the preinjection CR was withdrawal-like and the post-injection
CR was opioid-like. This pattern is similar to what we found in
human addicts (O'Brien 1975).
Another source of confusion about the form of the conditioned
response may result from deficiencies in the designs of
experiments which do not use continuous measurements in the
same subjects. Also, complex conditioning environments in
laboratory or clinical settings make it difficult to readily
identify the appropriate conditioned stimuli.
There is evidence in the animal literature pertaining to the
uncertainty about what stimuli associated with drug use will be
the most salient and thus most likely to acquire control over
conditioned responding. For example, even in the simplified
experimental situation where a bell or a distinctive cage is
used as the CS, there are multiple stimulus components competing
for control. As suggested above, this competition potentially
is greater in the clinical situation where "natural"
conditioning presumably is taking place. If a subject has drug
effects paired with complex environmental stimuli (for example,
sounds, smells, sights), conditoning to one CS may overshadow
that of another stimulus. If in the test situation a less
salient stimulus is evaluated, the elicited CR may be weaker or
perhaps different. The phenomenon of "overshadowing" was
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recently studied by Walter and Riccio (1983). These authors
have also pointed cut that internal stimuli produced by the
early effects. of the opioid may themselves serve as CS's
eliciting a CR. Internal cues may well be part of a complex
CS, but since they require the injection of the day, they are
always linked to a UCR and thus a test trial with CS but no UCR
is not possible.
Interestingly, at another level, we have evidence that the
cognitive expectations of the human subject, that is whether he
expects to receive drug or saline drug during a particular
self-injection, can affect his subjective evaluation of the
experience. For example, if the individual expects to receive
drugs and does not, although he may report feeling high, his
physiology and behavior do not suggest a drug effect. Such an
individual may represent the so-called "needle freak."
Alternatively, other individuals may not report getting high on
these saline self-injections even though their physiology and
behavior support the notion. In addition, the emotional state
of an addict at the time of his exposure to drug-related
stimuli can markedly affect the incidence and magnitude of a CR
to a drug-related CS.
As the above examples indicate, the conditioning phenomena are
truly multifaceted and exceedingly complex. We believe that
some increased resolution to these problems could be obtained
by studies designed to repeatedly and continuously assess these
conditioning phenomena in the same subjects. Furthermore, the
state of the organism at the time of conditioning: drug free.
methadone maintained, or withdrawn should also be studied to
determine whether it has any systematic effect on the type of
conditioned response observed.
CLINICAL APPLICATIONS
Classically conditioned responses to opioid drugs have been
experimentally reproduced in several animal species and in human
subjects. Clinical anecdotes and studies of addicts in
treatment suggest that conditioning occurs naturally during the
development of human opioid dependence. These studies in
patients have shown responses to drug-related stimuli or rituals
that can be interpreted as conditioned responses. However, it
is not yet clear what role if any these conditioned responses
play in the maintenance of the opioid-dependent state.
Although there are many aspects of drug-related conditioning
which remain unclear, our group is trying to determine whether
it is time for direct clinical applications. Elsewhere in the
volume, Childress et al. (1984) report the preliminary results
of a new controlled study in which systematic extinction is
integrated into a comprehensive treatment program for opioid
dependence. The data so far indicate that significant
conditioned responses are detectable in at least 30-40% of
patient volunteers: that the responses do not diminish with the
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passage of time and delivery of excellent standard therapy; and
that the responses do diminish with many extinction trials
although, as previously reported (O'Brien et al. 1979) they are
quite resistant to extinction. The results so far also indicate
a very important aspect of the experimental treatment: it is
acceptable to patients. Many patients spontaneously report the
value of systematic exposure to imagery, slides, video tapes and
rituals related to drug use. They have been keeping appoint-
ments and remaining involved in the treatment. Some have noted
the occurrence of apparently conditioned responses when they are
exposed to certain situations outside of the clinic. Thus
patients are seeing the relevance of this unusual addition to
their treatment program.
At this time we don't know whether the broad set of stimuli
composing the extinction paradigm will add anything to standard
treatments. Only long-term follow-up using objective outcome
criteria can determine that. However this is the direction in
which we are led by Dr. Wikler and other pioneers who have
demonstrated the conditioning effects of opioids. It may be
that conditioning plays a role in alcoholism and other forms of
drug dependence as well, but it is with opioids that the data
are the most comprehensive and clear. We hope that other
clinical researchers will not be dissuaded by the complexity of
the conditioned responses described here. The addiction
syndrome is a complex process, and there is ample evidence that
conditioning plays a role, at least with some addicts. We now
need new experimental treatment approches to determine whether
we can influence this portion of the illness and whether this
mskesanydifferencein treatment outcome.
REFERENCES
Eikelboom, R., Stewart, J. Conditioned temperature effects
using morphine as the unconditioned stimulus.
Psychopharmacology, 61:31-38, 1979.
Eikelboom, R., Stewart, J. Conditioning of drug-induced
physiological responses. Psychological Review, 89:597-528,
1982.
Levine, D.G. Needle freaks: Compulsive self-injection by drug
abusers. American Journal of Psychiatry, 131:297-300, 1974.
Lynch, J.J., Stein, E.A., Fertsiger, A.P. An analysis of 70
years of morphine classical conditioning: Implication for
clinical treatment of narcotic addiction. The Journal of
Nervous & Mental Disease. 163:147-158, 1976.
Meyer, R.E. and Mirin, S.M. The Heroin of Stimulus: Implications
for a Theory of Addiction. New York: Plenum Medical Book
company, 1979.
O'Brien, C.P. Experimental analysis of conditioning factors in
human narcotic addiction. Pharmacological Reviews,
27:533-543, 1975.
O'Brien, C.P., Testa, T., O'Brien, T.J., Brady, J.P. and Wells,
B. Conditioned narcotic withdrawal of humans. Science,
195:1000-1002, 1977.
45
Sherman, J.E. The effects of conditioning and novelty on the
rat's analgesic and pyretic responses to morphine.
learning and Motivation, 10:383-418, 1979.
Siegel, S. Evidence from rats that morphine tolerance is a
learned response. Journal of Comparative and Physiological
Psychology, 89:498-506, 1972.
Siegel, S. Morphine analgesic tolerance: Its situation
specificity supports a Pavlovian conditioning model.
Science, 193: 323-325, 1976.
Siegel, S. The role of conditioning in drug tolerance and
addiction. In M.E. Jarvik (Ed.) Psychopharmacology in the
Practice of Medicine. New York: Appleton-Century Crofts,
1977.
Siegel, S. Classical conditioning, drug tolerance and drug
dependence. In Y. Israel, F.B. Glaser, H. Kalant, R.E.
Popham, W. Schmidt and R.G. Smart (Eds.) Research Advances
in Alcohol and Drug Problems (Vo1.7). New York: Plenum,
1983.
Ternes, J.W. An opponent process view of tolerance in human
narcotic addicts. Paper presented in the symposium Social
Psychological Applicatiins of Opponent Process Theory:
Addiction, attachment, altruism and beating boredom.
Annual Convention of the Eastern Psychological Association,
New York, 1981.
Walter, T.A., and Riccio, D.C. Overshadowing effects in the
stimulus control of morphine analgesic tolerance.
Behavioral Neuroscience, 97:658-662, 1983.
ACKNOWLEDGEMENT
supported by the Veterans Administration Medical Research
Service and National Institute on Drug Abuse Grant DA 3008.
AUTHORS
Charles P. O'Brien, M.D., Ph.D., Chief, Psychiatry Service,
Philadelphia VA Medical Center and Professor, Department of
Psychiatry, University of Pennsylvania School of Medicine,
Philadelphia, PA 19104
Joseph W. Ternes, Ph.D., Chief Psychologist, Drug Dependence
Treatment Unit, Philadelphia VA Medical Center and Clinical
Associate Professor of Psychology in Psychiatry, University of
Pennsylvania School of Medicine, Philadelphia, PA 19104
Ronald  N. Ehrman, Ph.D., Research Psychologist, Drug Dependence
Treatment Unit, Philadelphia VA Medical Center and Clinical
Assistant Professor of Psychology in Psychiatry, University of
Pennsylvania School of Medicine, Philadelphia, PA 19104
46
On the Stimulus Control of
Drinking in Alcoholics
Ronald M. Kadden, Ovide F. Pomerleau, and
Roger E. Meyer
Habitual use of beverage alcohol in such a way as to cause
serious health and psychosocial problems has been the subject of
considerable investigation in behavioral research laboratories
for some time. Our objective in this presentation is to review
this work as it relates to the persistence of drink-seeking
behavior and high rates of relapse following treatment,
phenomena so frequently observed that they have been
incorporated as part of the “alcohol dependence syndrome”
(Edwards and Gross 1976).
Behavioral analysis of alcohol dependence has viewed drinking as
a discriminated operant whose stimulus antecedents and
reinforcing consequences maintain the behavior at high strength
(Miller and Mastria 1977). Much theoretical and research
attention have been devoted to the operant--alcohol
drinking--and its consequences, through investigations of the
reinforcing potency of alcohol and the role of schedules of
reinforcement (see review by Falk et al. 1983). Relatively less
attention has been paid to the antecedent stimulus factors which
play an important role in the control of drinking, despite
widespread recognition of their relevance to the problem (e.g.,
Keller 1972; Warlatt and Gordon 1980; Mathew et al. 1979; Nathan
and Lisman 1976; Stricklet et al. 1979).
The work that has been done to examine the role of stimulus cues
for drinking has focused for the most part on Pavlovian
conditioning phenomena, with emphasis, on the effect of
environmental stimuli in the elicitation of conditioned
physiological responses. After sufficient pairings of
particular environmental stimuli with alcohol ingestion or
withdrawal, these cues become conditional stimuli (CSs) capable
of eliciting physiological responses that are experienced by the
alcoholic as a distinct subjective state. These elicited
responses can in turn serve as discriminative stimuli (SDs,)
that set the occasion for the operant behavior of drinking
(Pomerleau 1981; Pomerleau et al. 1983). This two-factor
conditioning model (e.g., Bescorla and Solomon 1967) may help to
account for the perseverative nature of alcoholic behavior. by
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virtue of its inclusion of involuntary elicited responding,
which often occurs without awareness on the part of the
individual. The drive state that is thus aroused is thought to
be highly compelling.
Adoption of a Pavlovian conditioning model to account for the
action of antecedent stimuli raises a number of experimental
questions, such as the reactivity of alcoholics to various
environmental cues, the relationship of physiological reactions
to cognitive factors such as “craving;’ and the degree to which
reactivity to environmental cues may predict treatment outcome.
One of the earliest contributions to this line of investigation
was the seminal work of Abraham Wikler who explored the role of
conditioned respondents, or what he called “conditioned
withdrawal.” This work and its implications for opiate
addiction have already been described in the preceding paper by
O’Brien and Ternes (this volume).
Extension of this approach to the problems of alcohol dependence
and relapse was first described in detail by Ludwig and Wikler
(1974). Reasoning from a Pavlovian conditioning model, they
speculated on possible roles for both exteroceptive
(environmental) and interoceptive (arising from “visceral and
cerebral neuronal receptors,” p. 116) stimuli in reinstituting
drinking in abstinent alcoholics. These stimuli, they
suggested, become conditioned by repeated association, in close
temporal contiguity, with heavy drinking or with the
psychophysiological effects of alcohol-withdrawal. When the
newly abstinent alcoholic finds himself/herself in the presence
of these conditioned stimuli, he/she is likely to experience
physiological responses that are preceived and labeled as
"craving." The alcoholic is more likely to resume drinking in
such a situation (Ludwig and Wikler 1974).
Preliminary data supported this interpretation. In one study,
abstinent alcoholic subjects were more likely to agree to
perform an operant task that would be reinforced with alcohol if
they had received a priming dose of their favorite liquor and
mixer, and if a quart of their preferred liquor was placed in
view. Alcoholics receiving a non-preferred alcohol mixture,
regardless of quantity, and without a liquor bottle in view,
refused to perform the operant task (Ludwig et al. 1974). The
presence of customary alcohol cues was more effective than the
priming dose of alcohol.
In a subsequent study, the alcohol-related cues were enhanced by
providing a barroom simulation in the laboratory. The subjects
in that study were alcoholics who had been either binge or’
steady drinkers. The object was to test the hypothesis that
steady drinkers, having presumably had more frequent pairings of
alcohol-related cues with heavy drinking and withdrawal, would
show stronger conditioned responses. The data confirmed the
hypothesis, showing a higher degree of self-reported craving,
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higher rates of operant responding for alcohol, and some
indications of greater physiological arousal in former steady
drinkers when in the presence of alcohol-related cues, as
compared with former binge drinkers, or in the absence of
drinking cues (Ludwig et al. 1977). Statistical analyses showed
that most of the variance in operant responding in the barroom
situation could be accounted for by changes in craving, alpha
EEG activity, respiratory rate, and blood pressure. Although
the results of these studies were not definitive, they are
consistent with the hypothesis that elicited interoceptive cues
set the occasion for subsequent alcohol consumption.
These findings have been extended by our own work (Kaplan et al.
1983). As part of a larger study, 16 detoxified alcoholics in
treatment were given two drinks of either real (alcoholic) or
placebo (nonalcoholic) beer, served in a frosted mug on a tray
with an empty beer can, while physiological and subjective
responses were recorded. There was a significant correlation
between skin conductance to the initial presentation of the
beverage (before consumption) and increased desire to drink in
the alcoholic subjects, but not in the control subjects. After
consuming the drinks, the alcoholics who received placebo
thought they had received real beer, whereas the control
subjects were less likely to make this error. This suggests a
significant cueing function, for the alcoholic subjects, by
alcohol-related discriminative stimuli (beer can, frosted mug,
physical aspects of the “near-beer” beverage), and possibly a
conditioned reinforcing effect as well.
Subjects were then asked to select a reward, in the form of a
third drink or a lottery ticket, for completion of a subsequent
operant task. Among the alcoholic subjects (but not among the
controls) there was a significant correlation between subjects’
reporting thinking that the preceding drinks had contained real
beer and their choice of the drink as the reward. To further
examine the variables affecting the choice of the drink as a
reward, a stepwise multiple regression was computed. For the
alcoholic subjects, increased desire to drink, a high degree of
alcohol dependence, and cardiac acceleration at the presentation
of the drink all contributed significantly in predicting the
choice of the drink as a reward, accounting for 57% of the total
variance. The actual alcohol content of the beverage they had
consumed was not a significant predictor of reward choice. For
the non-alcoholic control subjects, only desire to drink
contributed significantly as a predictor of reward choice
(Kaplan et al. 1983).
Further evidence for the role of associative processes in the
control of alcohol-related behavior has been developed using the
laboratory rat. The unconditioned response of rodents to an
injection of ethanol is a dose-related hypothermia. If given
repeated ethanol injections in a consistent environment, rats
develop tolerance to the hypothermic effects of the ethanol.
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Le. Poulos, and Cappell (1979) determined that this tolerance
could be explained, at least in part, on the basis of Pavlovian
conditioning. Ethanol and saline injections were given on
alternate days in two distinctive environments. When ethanol
was then given in the environment formerly reserved for the
saline injections, previously developed tolerance was partially
reversed. This result has been replicated by Mansfield and
Cunningham (1980).
Siegel has suggested that the development of tolerance in a
distinctive stimulus situation may be due to the conditioning of
a response which is opposite in direction to the unconditioned
effects of the alcohol. When elicited by the conditioned
stimuli, the response serves to prepare the organism to modulate
the anticipated effects of the alcohol (Hinson and Siegel
1980). The conditioned response (CR) can be observed by
providing a placebo injection in the distinctive environment
previously reserved for ethanol injections. This procedure
does, in fact, result in a hyperthermic response (Crowell et al.
1981; Le et al. 1979; Mansfield and Cunningham 1980), of
sufficient magnitude to account for the previously observed
tolerance.
Having demonstrated that the thermic response can be conditioned
to environmental stimuli, and having clarified the nature of the
elicited conditioned response, a further step was to determine
whether this response, like a true CR, could be extinguished by
repeated exposures to CS (alcohol-related cues) without
reinforcement (by ethanol). The hyperthermic response to
placebo injections did in fact decline over the course of
extinction sessions, and, upon retest with an ethanol injection,
the extinction procedure was found to have reversed the
previously developed tolerance (Crowell et al. 1981; Mansfield
and Cunningham 1980).
These studies are of importance in understanding alcohol
dependence, because acquired tolerance is a critical factor in
controlling the quantity of alcohol consumed by an alcoholic
(Cappell and LeBlanc 1983; Maisto et al. 1978). The role of
conditioning that has been demonstrated with respect to the
alcohol-induced thermal response may also apply to responses
having more obvious motivational significance (Donegan et al.
1983).
Encouraged by research supporting the conditionability of
alcohol-related stimuli, and by studies showing conditioned
salivation to palatable food cues in people with a history of
obesity (Wooley et al. 1975, 1979; Rodin 1978), Pomerleau et al.
(1983) initiated a series of systematic investigations on
conditioning in alcoholics. An attempt was made to maximize the
effectiveness of the eliciting stimuli by having each subject
smell his favorite alcoholic beverage in an open, labelled
bottle, thus utilizing the alcohol-related cues that constitute
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the “final common pathway” for drinking. As a control
condition, subjects were asked to sniff cedar chips. Subjects
included 8 alcoholics in treatment, 10 control subjects who
reported no history of problem drinking nor parental alcoholism,
and two recovering alcoholics who claimed 2-3 years of
sobriety. Both heart rate and skin conductance responses were
elevated during alcohol sniff trials for the alcoholic subjects,
consistent with the findings of Kaplan et al. (1983), but the
elevations in the present instance were not statistically
significant. Swallowing rate (shown to be proportional to the
amount of salivation) and craving (selection of a number from
0-10 in response to the question, “How badly do you want to
drink alcohol?”) showed significant elevations for alcoholic
subjects on alcohol-sniffing trials. Control subjects were
relatively unresponsive. The two recovering alcoholics
resembled those in treatment on the swallowing measure. These
data strengthen the idea that conditioned respondents are
elicited by alcohol-related cues in people with a history of
frequent heavy drinking.
Although both swallowing rate (salivation) and craving were
significantly elevated, the changes in the swallowing measure
were more pronounced and may have provided a more accurate
indicator of conditioning and/or desire to drink. The craving
measure, like other subjective/cognitive measures, is a verbal
operant subject to the influence of the same complex variables
as the statement, “I’ll never drink again.” The theoretical
question of whether conditioned respondents such as those
observed here are an essential part of the discriminative
stimulus complex for drinking behavior, or whether they are
simply an interesting epiphenomenon, remains to be resolved.
Even if the conditioned responses to alcohol cues are merely
correlated with drinking, determination of their magnitude may
provide a useful technique for estimating the probability of
subsequent drinking in alcoholics (Pomerleau et al. 1983).
We next questioned whether the salivary response is associated
with cognitive processes that might facilitate the decision to
drink (Cooney, Baker, Pomerleau, & Josephy, in press). Subjects
were 15 inpatients in an alcohol rehabilitation program, tested
in the same setting and with a procedure similar to that used in
the preceding experiment. They were asked to rate their craving
for alcohol and their anticipation of its taste. They also
completed a 37-item questionnaire (Southwick et al. 1981)
designed to assess expectations about the effects of alcohol
(e.g., anticipated pleasant effects or impairment from
drinking). These assessments were made following three 5-minute
trials in which subjects viewed, held, and sniffed a pint bottle
of their favorite alcoholic beverage. Salivation was greater
while sniffing alcohol and was significantly correlated with
several indicators of positive expectations regarding the
effects of alcohol, but not with self-rated desire to drink nor
with expectations regarding behavioral impairment. The failure
51
to find a correlation with desire to drink suggests the role of
cognitive distortions (denial) in patients engaged in an
abstinence-oriented rehabilitation program. Nevertheless, the
significant correlations that were obtained do provide some
basis for inferring a relationship between a cue-elicited
respondent (salivation) and at least some of the cognitive
aspects of craving.
This series of studies supports earlier indications of
respondent conditioning to alcohol-related cues, and reaffirms
the relationship between elicited responses and the decision to
drink. The studies have begun to elucidate some of the response
variables involved in the conditioning process, and have so far
produced findings that are consistent with a two-factor
conditioning model.
If, indeed, the two-factor model is valid, then it should
provide some predictive power regarding treatment outcome.
Those patients who retain respondent activity in the presence of
alcohol-related cues might be expected to have a higher
probability of relapse than those who do not. We have put this’
question to an experimental test with 50 alcoholic subjects.
The basic design uses the sniff-test procedure described
previously and seeks to correlate measures of physiological
reactivity to alcohol-related cues with a number of indicators
of outcome six months after treatment. The treatment outcome
data are now being collected. The finding of a significant
relationship between physiological reactivity and treatment
outcome would be an important step toward providing an objective
means of identifying high-risk patients.
Should this study validate the role of conditioned respondents
as a factor in treatment outcome, then the logical next step
would be to study the effect of extinguishing the respondents.
This should reduce the probability of relapse if, as postulated
by the two factor model, respondents serve as SDs that set the
occasion for drinking. Repeated presentations of the sight and
smell of an alcoholic beverage without permitting consumption
should eventually result in a decrement in the conditioned
respondents (Cooney, Baker & Pomerleau, in press) and therefore
diminish their ability to precipitate drinking.
If this procedure were adopted clinically, a careful analysis of
each patient’s drinking history would be necessary to identify
the major stimuli requiring extinction (Poulos et al. 19811.
This approach to treatment was in fact undertaken in a study of
six cases by Blakey and Baker (1980). Patients were given
graded exposure to the “triggers” that set off their drinking,
but were not allowed to drink. Five of the patients attained
abstinence and reported a lack of desire to drink.
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FINAL CONSIDERATIONS
This review has examined a number of clinical and experimental
findings that implicate conditioned respondents as a factor in
the stimulus control of problem drinking. At this writing, the
case is far from being definitively established, and additional.
controlled experimental studies are called for. As the work
proceeds, other issues are sure to come to the fore. It may be
possible at this time to anticipate some of them.
One area of further research will undoubtedly focus on the
process by which environmental stimuli become conditioned as
alcoholism develops, and whether alcohol drinking cues are
conditioned to the intoxicating effects of alcohol, the
withdrawal effects, or both. Further interest may also be
devoted to the question of whether the elicited responses
resemble the unconditional response to alcohol, are opposite in
direction to the alcohol response, or are in some other way
preparatory for ethanol ingestion. The specific answer to this
question will undoubtedly vary, depending on the response
systems involved (Lynch et al. 1973).
A variable that has received but scant attention to date is the
difficulty of extinguishing certain conditioned respondents
(Lynch et al. 1973). This phenomenon may prove to be an
important element of the treatment-resistance of addictive
behavior, and may impose a formidable obstacle to improving the
effectiveness of treatment. Other means of behavior change may
therefore have to be considered, such as response suppression
through the use of aversive contingencies, or the
counterconditioning of alternative responses (preferably ones
incompatible with the undesirable response). perhaps through the
use of biofeedback techniques. Relapse prevention training
(Chaney et al. 1978), although emphasizing cognitions, could
also be used to teach patients to cope with recurrent
conditioned respondents.
Another issue relates to differences in types of alcoholics. It
may be found that patient variables, such as severity of
dependence, psychiatric diagnosis, or cognitive functioning,
interact with conditioning phenomena. For example, patients
diagnosed as having anti-social personality disorder have been
found to respond in a unique fashion to pre-aversive stimuli,
tending to reduce their impact more than “normals” (Hare 1978).
If these people were also alcoholic, they might respond
differently to alcohol-related cues or prove to be more
resistant to extinction procedures, a possibility with
far-reaching clinical implications since this subtype
constitutes a large, treatment-resistant group of alcoholics
(Hesselbrock et al. in press).
The possibility that certain environmental events can prompt
substance abuse without prior conditioning will also need to be
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considered. For several decades researchers have observed that
intermittent presentation of biologically important events such
as food or powerful electric shocks can induce a variety of
behaviors having no contingent relationship with the scheduled
event (see reviews by Falk 1981; Wetherington 1982). These
“adjunctive” behaviors are highly persistent and resistant to
extinction; examples include schedule-induced water consumption,
attack, hoarding, and pica. Translated to the particulars of
substance abuse, the suggestion is that various events in daily
life occurring on an intermittent basis, in the presence of 
adequate motivation, can provide “conditions for the initial
capture of the stream of behavior” (Falk et al. 1983, p. 72).
Drug consummatory behaviors such as cigarette smoking, alcohol
drinking, or the self-administration of other psychoactive
substances may be sustained past the initial “priming” period
because, in the circumstances in which adjunctive behavior is
induced, the consequences of substance use may produce
neurochemical alterations that affect performance and/or mood
(Pomerleau and Pomerleau 1983).
As more data are gathered, modifications of the basic two-factor
model may become necessary. Studies of the antecedents to
abusive drinking have tended to emphasize the role of Pavlovian
conditioning factors. One reason for the appeal of this
theoretical approach is that physiological respondents are not
as susceptible to voluntary manipulation as are operants. Even
if the supposed conditioned respondent turns
out to be an epiphenomenon, the physiological reactions may
nevertheless accurately reflect the alcoholic’s current
motivation to drink and, thus, may predict future drinking and
relapse. Alternatively, in view of the multiple, concurrent
roles that stimuli play, it may be found that greater weight
will have to be given to the contribution of environmental
events (such as the setting, and substance availability) as
discriminative stimuli which set the occasion for abusive
drinking. Only systematic experimentation can settle these
issues.
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Progress Report on the
Stimulant-Depressant Abuse
Liability Evaluation Project
James H. Woods
The Committee on Problems of Drug Dependence has initiated a provi-
sional program for the assessment of abuse liability of compounds
with depressant or stimulant profiles. Currently, the program is
evaluating a set of methods that may be applied in the future to
the open assessment of compounds in animals. The Committee has
agreed to proceed with this provisional program to evaluate its
feasibility for open evaluation of compounds. The compounds that
have been evaluated so far have bean solicited by the stimulant-
depressant committee. The initial pair of compounds was selected
to provide an assessment of reliability of result and to charac-
terize a new agent with the procedures used in the laboratories.
The laboratories currently engaged in this effort are situated at
the Addiction Research Center, Lexington, (Drs. Gorodetzky, Cone,
Risner, Shannon, and Vaupel), University of Chicago (Drs. Johanson
and Schuster), Johns Hopkins (Drs. Brady, Ator, Griffiths, and
Lamb), and Medical College of Virginia (Drs. Harris and Aceto).
These laboratories use a set of procedures that may provide a
general assessment of these agents in a variety of species. The
initial approach was to submit two compounds under blind procedures
(designated CPDD 1 and 2); the laboratories would use procedures
that they considered relevant to abuse liability assessment of the
compounds. The overall objective to be met at some point in the
future is the selection of an optimal set of procedures that will
complement each other in providing the appropriate preclinical
assessment of abuse liability of unknown compounds in animals.
To accomplish blind assessment, compounds were solicited by Dr.
Jacobson, and sent to individual laboratories under code labels.
Each compound was assessed under blind conditions and reports on
the findings described and discussed at two meetings of the groups.
The compounds were identified for the laboratories and for the
purposes of reporting preliminary results at the CPDD scientific
meeting in Lexington.
A brief review of the procedures used by the laboratories and their
results with the two compounds will now be presented by individual
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laboratories. The compounds will be described as CPDD 1 (diazepam)
and CPDD 2 (bromazepam).
Addiction Research Center
Both compounds were examined in the intact rat (1.0-10.0 mg/kg);
both decreased body temperature, produced ataxia and sedation.
CPDD 2 produced a loss of the righting reflex. It was concluded
that both were likely sedative agents. In the sling dog
preparation, a set of beagles were used to compare pentobarbital,
diazepam, CPDD 1, and CPDD 2. Each of the compounds was given
intravenously using a cumulative dose procedure. Pentobarbital was
examined in 0.5 log unit increments from 0.3-30.0 mg/kg, diazepam
and CPDD 2 in a similar fashion in a dose range of 0.1-10.0 q/kg,
and CPDD 1 in a dose range of 0.03-3.0 mg/kg. Observations were
made under blind conditions by two observers. Each drug reduced
body temperature, had only slight effects upon respiration, pulse,
pupil size, and the nictitating membrane. Pentobarbital produced a
marked effect on the skin twitch at 30.0 q/kg. Neither diazepam
nor CPDD 1 or CPDD 2 produced comparable sedation to 30.0 mg/kg
pentobarbital.
In rats trained to discriminate diazepam from saline, CPDD 1 (i.p.)
was compared to diazepam (s.c.) and pentobarbital (S.C.). CPDD 1
substituted completely for diazepam and was as potent as diazepam
and more potent than pentobarbital. CPDD 2 was not examined, but
bromazepam has been evaluated by Dr. Shannon; it too substitutes
for diazepam in this procedure. The CGS-8216 antagonist reversed
the discriminative effects of CPDD 1 and diazepam, but not
pentobarbital.
In the dog, CPDD 1 and 2 were examined and compared to CGS-8216,
diazepam, pentobarbital, and methaqualone upon food-reinforced
performances in a multiple schedule of fixed-interval and fixed-
ratio components. All drugs ware administered orally except
CGS-8216 which was given i.v. CPDD 1 and 2 produced 50% increases
in fixed-interval responding at some doses (1.0-10.0 mg/kg) as did
diazepam over the same range of doses. Pentobarbital increased
responding at 10.0 mg/kg. Methaqualone and CGS-8216 failed to
increase fixed-interval responding over the range of doses
examined. Each of the drugs, except CGS-8216 (0.01-3.0 mg/kg),
reduced fixed-ratio rate of responding. CGS8216 antagonized the
rate-increasing effects of diazepam (CGS-8216; 1.0 q/kg) but
failed to antagonize the actions of pentobarbital on either
component of the schedule (CGS-8216; 3.0 mg/kg) or the
rate-reducing effects of methaqualone (0.1 mg/kg; CGS-8216).
University of Chicago
CPDD l and 2 were examined in groups of pigeons trained to discrim-
inate oxazepam (4.0 mg/kg) from saline or d-amphetamine (2.0 q/kg)
from saline. Both CPDD 1 and 2 substituted completely for
oxazepam; CPDD 2 suppressed rates of responding to a greater extent
than CPDD 1 though they were equipotent in substituting for
oxazepam as cues. In the amphetamine-trained pigeons, CPDD l and 2
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substituted for amphetamine in two of five pigeons. The
discriminative effects of CPDD 1 and 2 were antagonized by
pretreatments of Ro 15-1788 (0.03 mg/kg).
In modestly food-deprived rhesus monkeys, CPDD 1 and 2 increased
food intake. CPDD 2 was more potent than CPDD 1; both effects were
antagonized by RO 15-1788 (1.0 q/kg).
In rhesus monkeys trained to self-inject cocaine or pentobarbital
on fixed-ratio 10 schedules, CPDD 1 and 2 were studied over a
series of doses in a substitution procedure. CPDD 1 failed to
maintain rates of self-injection responding above vehicle in a
cocaine-trained monkey but did so in a pentobarbital-trained
monkey. This is in keeping with the individual differences in
self-injection behavior of diazepam in this procedure. Historical
controls with diazepam suggest that it will maintain self-injection
responding in less than a majority of monkeys whereas most monkeys
that self-inject pentobarbital also self-inject diazepam. The
range of doses of CPDD 1 studied were 0.02-0.4 q/kg/injection.
CPDD 2 has been studied more extensively; it has failed to be
self-injected in two cocaine monkeys, but was self-injected at
rates above vehicle in 3 of 4 pentobarbital-trained monkeys. The
doses of CPDD 2 studied were 0.001-0.03 mg/kg/injection.
Johns Hopkins University
This laboratory has made extensive use of the baboon in both drug
self-injection and drug-discrimination studies. They first carried
out dose-ranging studies of the effects of CPDD 1 and 2 in baboons
performing on a food-reinforced fixed-ratio schedule; observational
effects were also noted. CPDD 2 was more potent than CPDD 1 in
this procedure; both produced similar signs of ataxia. CPDD 1 was
similar in potency to diazepam and much less potent than triazolam.
In their self-injection procedure, cocaine was the maintenance drug
and various doses of CPDD 1 (0.01-1.0 mg/kg/injection) and 2 (0.l-
1.0 q/kg/injection) were studied. Dose-effect curves were flat
and neither compound was self-injected considerably more than
saline.
CPDD 2 produced overt behavioral effects not readily' apparent at
the doses of CPDD 1 studied. After a single injection of 1.0 mg/kg
of CPDD 2, clear ataxia was seen and the baboon almost fell off the
bench. Shortly thereafter, the baboon began lever pressing
steadily for food pellets (available 24 hr/day under an fixed-ratio
10 schedule of reinforcement). In fact, food pellet intake became
unusually high for both baboons studied under CPDD 2.
In the drug discrimination procedure,. the baboons were trained to
discriminate lorazepam (1.0 mg/kg) from the no-drug condition in a
two-lever procedure similar to those described above. In each of
three baboons, CPDD 1 and 2 produced complete drug-appropriate
responses at 3.2 mg/kg. Lorazepam was at least three times more
potent, and diazepam was equivalent in potency to CPDD 1 and 2.
CPDD 2 reduced rates of responding at the largest dose evaluated
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(3.2 mg/kg) whereas CPDD 1 failed to reduce rates even at 5.6
mg/kg. Ro 15-1788 (1.0 mg/kg) antagonized completely the
discriminative effects of lorazepam, CPDD 1, and CPDD 2.
Medical College of Virginia
The research at this laboratory is to be directed to assessment of
physiological dependence development. Their participation in the
program was agreed upon later in the history of the project, and
they have not yet had the opportunity to complete a set of studies
on these compounds.
Summary
The laboratories reported data on CPDD 1 that was indeed very
similar to that of their direct or historical controls for
diazepam. It is clear that the antagonists used in the program
will reverse only a benzodiazepine-induced behavioral effect. The
data on bromazepam suggest a very similar pattern and potency for
this benzodiazepine compared to diazepam.
Plans
Additional compounds have been submitted to the research groups
including compounds with stimulant profiles. When agreement among
research groups has been arrived at with respect to the composition
of a complete battery of assessment procedures and sufficient
background material has been obtained with a variety of known
effort.  If they deem it worthwhile, the group will seek the
compounds, the group will attempt a thorough evaluation of the
.
support of the Committee on Problems of Drug Dependence for the
establishment of an open drug evaluation program.
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Progress Report From the NIDA
Addiction Research Center
(Preclinical Laboratory), Lexington,
Kentucky
C.W. Gorodetzky, E. J. Cone, R.E. Johnson,
M. E. Risner, T.-P. Su, and S. Y. Yeh
As last year, I will begin with a brief administrative update.
At this time, all appears progressing on schedule for a total
relocation of the ARC from Lexington to Baltimore in the summer
of 1984. We are looking forward to the possibility of again
co-hosting this meeting in 1985 with Johns Hopkins University
in conjunction with an ARC 50th anniversary symposium and the
dedication of our new facility.
In my progress report this year, I will briefly highlight three
areas of research in the preclinical laboratory particularly
related to abuse liability and urine screening.
MARIJUANA VALIDITY STUDY
Several years ago the Syva Company marketed reagents for their
EMIT drug abuse urine assay (or EMIT-DAD) for detection of
cannabinoids in human urine. More recently similar reagents
have become available for the portable EMIT single test system
(or EMIT-ST). Most recently the Roche Company has produced a
cannabinoid radioimmunoassay in their Abuscreen series. Only
scarce data are currently available on the time course of detect-
ability of marijuana cigarette smoking using these assays or for
direct comparison of the tests. Most data which do exist are
anecdotal or come from outpatient studies, where control of drug
intake is less than optimal. Because of the interest in these
screening assays, and their increased use (for example, by the
Department of Defense), we decided to undertake a controlled
clinical validity study under inpatient conditions in collabo-
ration with our colleagues in Baltimore.
Subjects for this study were male volunteers, between the ages
of 25 and 55, who gave informed consent for participation in a
protocol reviewed and approved by the Institutional Review Board
of the Baltimore City Hospitals. All gave a history of light to
moderate marijuana use and cigarette smoking. All were judged to
be in good health by pretest history, physical examination, labo-
ratory and psychological screens. Prior to initiating the
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protocol, each subject was required to have seven consecutive
days of urine negative for cannabinoids and other drugs of abuse
(by the EMIT-DAU screening procedure). The protocol provided for
administration to each subject of four drug conditions as follows:
1) One THC cigarette and one placebo THC cigarette; 2) two
THC cigarettes; 3) two
regular cigarettes.
placebo THC cigarettes; and 4) two
The THC cigarettes were the standard 10 mg.
cigarettes provided by the Research Technology Branch of NIDA’s
Preclinical Research Division. Cigarettes were required to be
smoked between 0800 and 0830 of the test day using a puff monitor-
ing system. Drug conditions were administered double-blind in
random order; each subject’s urine was required to be negative
for THC metabolites for not less than three consecutive days
prior to administration of the next drug condition. Following
drug administration various physiological signs were measured and
mood questionnaires administered at timed intervals for 24 hr.;
the results of this part of the study will be the subject of a
subsequent report. All urine samples were collected individually
for each subject from time of admission to the research ward (at
least 3 days prior to initiation of the protocol) to completion
of the protocol. Each subject urinated ad lib (that is, whenever
he felt the need to do so) and, in addition, was asked to urinate
at 0800, 1600, and 2400, to complete 8-hr. collection periods.
After recording volume, pH, and specific gravity, an aliquot of
each sample was put aside for immediate EMIT-DAU analysis and a
larger aliquot was frozen and shipped to Lexington for further
analysis.
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All samples were analyzed in random order under blind conditions
by EMIT-DAU, EMIT-ST, and the Abuscreen RIA according to the
methods described by the manufacturers. All three immunoassays
are designed to detect with greatest sensitivity the major metabo-
lite of THC, 11-nor THC-9-carboxylic acid. All are cali-
brated using as a standard the more readily available synthetic
analog. In each assay an unknown sample is considered positive
if its reading is greater than that of a cut-off standard, 20 ng./
ml. for EMIT-DAU, and 100 ng./ml. for both EMIT-ST and RIA.
Five subjects have now completed the protocol, producing a total
of 742 urine samples for analysis. Data were analyzed as percent
of urine samples positive by 8 hr. periods. The RIA and EMIT-ST,
both with 100 ng./ml. cut-offs, showed close agreement. There
were greater than 50% positive urines for approximately 16 hr.
following one marijuana cigarette and 24 to 32 hr. following
two cigarettes. The more sensitive EMIT-DAU showed greater than
50% positives for 40 hr. following one cigarette and 64 hr.
following two cigarettes. Based on analysis of 282 urine samples
from the placebo cigarette, regular tobacco cigarette, and pre-
test conditions, there were no false positives by EMIT-ST or RIA,
and .7% false positive by EMIT-DAU.
In order to examine between-subjects variability, the time to the
last positive urine sample was determined for each subject under
each drug condition. Time to last positive is defined as the
first positive sample succeeded by at least three consecutive
negative samples. Considerable variability between subjects was
seen. Subjects A and B showed a relatively short time course of
detectability, while Subjects D and E remained positive for
considerably longer time periods. Subject C appeared to be inter-
mediate following one cigarette and detectable for a long period
following two cigarettes. Mean time of detectability by this
analysis was in the same range as the previous analysis. Exam-
ining concordance of results by the three screening tests, there
was a very high concordance between RIA and EMIT-ST, with only
18 of 742 analyses discordant. Both of these tests compared to
the EMIT-DAU showed a greater discordance, reflective of the
greater sensitivity of the EMIT-DALI test.
Tentative conclusions after completion of approximately one-half
of this study are: 1) Marijuana cigarette smoking is detectable
in greater than 50% of urine samples by EMIT-ST and RIA for
approximately 16 hr. after one marijuana cigarette and 24 to
32 hr. following two marijuana cigarettes. By EMIT-DAU time
course of detectability is approximately 40 hr. after one ciga-
rette and 64 hr. after two cigarettes; 2) EMIT-ST and RIA give
quite comparable results; 3) there appears to be a large amount
of between-subjects variability in time course of detection.
We currently plan, in addition to completion of the second five
subjects, to examine possible correlations of patient history
with time course of detection, and to analyze immunoassay positive
samples by confirmatory methods, based on HPLC, and possibly, GC.
REINFORCING PROPERTIES OF FENCAMFAMINE
Fencamfamine is a sympathomimetic central stimulant which has
recently appeared in the illicit drug market of the U.S., being
identified in samples from drug seizures in several states. It
is marketed as one ingredient of the multi-vitamin preparation
Reactivan, which is sold in the United Kingdom for fatigue. It
is not presently under control by the DEA and is available from
at least one chemical company catalog in the U. S. The abuse of
fencamfamine by athletes was described in 1969; and the influence
of alkalinization of its urinary detection has been studied. It
was concluded that alkalinization procedures did suppress fencam-
famine excretion and might make detection in the urine more
difficult. Fencamfamine is N-ethyl-3-phenyl-2-norbornanamine.
Although, like cocaine, it contains a bridged ring, the overall
molecule bears little relationship to that of cocaine. However,
fencamfamine has the beta-phenylethylamine structure character-
istic of amphetamine and may elicit pharmacological activity as
a rigid phenylethylamine analog. It might be noted that fencam-
famine has four asymmetric carbons and can exist as a variety of
endo- and exo- isomers.
The subjects for this study were two purebred beagle dogs pur-
chased from a commercial supplier. Between experimental sessions,
each dog was individually housed in a pen and given free access
to drinking water and dry food.
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Following recovery from surgery for implantation of a venous
catheter, the dogs were given access to response-contingent drug
injections under a fixed-ratio with limited hold schedule of rein-
forcement. Daily experimental sessions were conducted Monday
through Friday in operant conditioning chambers equipped with a
response pedal (positioned on the floor) and several stimulus
lights. Each session consisted of 11 trials, each trial lasting
a maximum of 4 min. During each trial, the 15th pedal-pressing
response produced a 15-sec. i.v. injection of drug (i.e., an
FR-15 schedule). Following acquisition of stable responding
(with either 30 or 100 µg./kg./injection cocaine as the rein-
forcer), the dogs were tested with five doses of fencamfamine
HCl (ranging from 10 to 560 µg./kg./injection) and five doses of
cocaine HCl (ranging from 10 to 1000 µg./kg./injection). Each
dose was tested for five consecutive sessions, with treatment
order arbitrarily determined for each dog. Saline (0.1 ml./kg./
injection) was also included in the test series and was tested
for five consecutive sessions at least twice during the experi-
ments.
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Both fencamfamine and cocaine were self-administered above saline
levels. Across several doses of both drugs, the dogs self-
administered the maximum number of injections available each
session. Generally, there was an inverted U-shaped relationship
between the number of injections per session and dose per injec-
tion. local rates of responding also varied systematically as a
function of injection dose. At least one dose of fencamfamine
maintained higher local rates than did any dose of cocaine.
Finally, overall rates of responding were systematically related
to dose per injection, first increasing, then decreasing with
increasing doses. As with local response rates, at least one
dose of fencamfamine maintained higher overall rates of respond-
ing than did any dose of cocaine,
In summary, response-contingent i.v. injections of fencamfamine,
like cocaine, can maintain responding under a fixed-ratio schedule
of reinforcement. Dose-effect curves for both fencamfamine and
cocaine were similar; both the number of injections self-
administered per session and the rates of responding were
systematically related to amount of drug delivered per injec-
tion. Cocaine appeared to be slightly more potent than
fencamfamine, but the differences were not large. Taken
together, these data suggest that fencamfamine, like cocaine,
is a reinforcing drug and may have a potential for abuse.
OPIOID/ANTIHISTAMINE INTERACTIONS
Although the abuse of tripelennamine with paregoric was described
as early as 1964, the use of antihistamines and opioids by drug
abusers has been reported with increasing frequency only in
recent years. Tripelennamine and pentazocine appears to be the
most common combination, being known in the vernacular as “T’s
and Blues.” In this report, I will briefly summarize two sets
of studies presently underway in our laboratories on the opioid/
antihistamine interaction.
One study has been examining the interaction of pentazocine with
both tripelennamine and other antihistamines using the rat hot-
plate method. Drug was administered subcutaneously or intra-
peritoneally, and analgesic activity was measured with a low
temperature hot plate maintained at 51.5° C. with cut-off time
at 45 sec.
Examining the time course of subcutaneously administered penta-
zocine analgesia, at doses of 5 to .30 mg./kg., peak effects were
seen between 15 and 30 min., with significant effects often
lasting to 75 min. A lesser degree of analgesia was also seen
with tripelennamine alone in doses of 5 to 20 mg./kg. using i.p.
administration.
When 20 mg of tripelennamine (i.p.) was administered simulta-
neously with 5 or 10 mg. of pentazocine (s.c.), tripelennamine
appeared to potentiate both doses of‘ pentazocine. Lower doses
of tripelennamine did not potentiate these doses of pentazocine.
The areas under the time action curve for several other anti-
histamines alone and in combination with 5 or 10 mg. of pentazocine
showed that pentazocine analgesia appeared to be potentiated by
diphenhydramine, chlorpheniramine, promethazine, and cyclizine,
but not chlorcyclizine.
These data appear to indicate that tripelennamine can potentiate
the analgesic effect of pentazocine in rats under some dose
combinations, and this potentiating effect does not appear to be
limited to tripelennamine alone, but is also common to some other
antihistamines.
Earlier studies in our laboratory with the discriminative stimulus
model showed that pentazocine partially generalized to SKF-10047
in rats trained to discriminate the SKF compound from saline.
Tripelennamine under some dose conditions was found to antagonize
these discriminative stimulus effects of pentazocine. Therefore,
it was hypothesized that tripelennamine might antagonize dysphoric
sigma opioid receptor effects of pentazocine, thereby enhancing
its euphorigenic potential. Following from this study, the
present study has examined pentazocin.e and several antihistamines
in a sigma opioid receptor binding assay. This assay has been
previously described and utilizes specific 3H-SKF-10047 binding
to sites in a guinea pig brain homogenate which are inaccessible
to 1-etorphine. These binding sites are saturable with respect
to the presence of increasing concentrations of labeled SKF-10047.
Ligand selectivities of these etorphine-inaccessible sites indi-
cate that these sites may represent sigma opioid receptors, since
psychotomimetic opioids were among the most potent in the assay.
In the present study, the sigma receptor binding assay was per-
formed using a 1% guinea pig brain suspension of the particulate
fraction. One nM. of 3H-SKF-10047 was incubated with the suspen-
sion in the presence of 100 nM. of etorphine. The specific
binding was defined by that portion of 3H-SKF-10047 inhibited
by 0.1 mM. of unlabeled SKF-10047. Two ml. of the brain
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suspension was incubated with inhibitors in the presence of
100 nM. 1-etorphine for 5 min. Then 1 nM. of tritiated SKF-
10047 was added to the reaction mixture and the reaction was
allowed to proceed at 22° for another 15 min. After sitting
on ice for 10 min. the samples were filtered through GF/C filters
which had been presoaked in tertiary amyl alcohol-saturated water
before use. Samples were then counted in a liquid scintillation
counter.
Pentazocine is one of the most potent inhibitors in this assay,
with IC50 of 85 nM. Tripelennamine was also examined in this
assay and found to be one-fifth as potent as SKF-10047 as an
inhibitor of specific SKF binding. The dose response curves of
these two drugs also appear to be parallel to each other. The
Hill coefficients of both curves were close to unity.
The affinities of various other antihistamines for the sigma
opioid receptors showed that in addition to tripelennamine,
many other HI-antihistamines were also potent ligands for the
psychotomimetic sigma opioid receptors, The most potent one
was promethazone with a KI of about 170 nM. Additionally,
choropheniramine, pyrilamine, and chlorcyclizine appeared to
be slightly more potent than tripelennamine.
The results so far appear to be consistent with a possible sigma
opioid receptor interaction of pentazocine and tripelennamine.
Also, consistent with the results of other investigators, this
potential opioid/antihistamine interaction does not appear to be
limited only to tripelennamine. Further studies with other
opioids and other types of antihistamines are presently being
pursued.
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Progress Report From the NIDA
Addiction Research Center,
Baltimore, Maryland
Donald R. Jasinski, John J. Boren, Jack E. Henningfield,
Rolley E. Johnson, W. Robert Lange, and Scott E. Lukas
This progress report summarizes four ARC studies that are of
interest to the Committee and its activities. These are: 1)
The abuse potential of T’s and Blues (pentazocine and tripel-
ennamine ) , 2) The abuse potential of THC and nabilone; 3) Stud-
ies on the use of buprenorphine in treating opioid dependence;
and 4) The effects of mecamylamine and nicotine chewing gum on
cigarette smoking and subjective response.
ABUSE POTENTIAL OF T’S AND BLUES
Within recent years, there has been concern over abuse of il-
licitly obtained mixtures of tripelennamine and pentazocine.
In the pattern of abuse reported, usually two tablets of pen-
tazocine (50 mg each) and one of pyribenzamine (50 mg) are
crushed and injected intravenously. The resulting effects are
described anecdotally as highly euphorigenic. The effects of
this mixture had been attributed to pentazocine: however, the
contribution of the tripelennamine being uncertain.
The present studies were done 1) to learn if tripelennamine
itself is a euphoriant and 2) to learn if tripelennamine en-
hances the euphorigenic activity of pentazocine or antagonizes
the dysphoric effect of higher pentazocine doses. This was
conducted as a crossover study in nine (9) volunteer opiate
abusers who were non-dependent at the time of the study. Drugs
were given in single doses intramuscularly under double-blind
conditions. Subjects participated at twice weekly drug inter-
vals with drug administrations according to a latin square
design. The nine drug treatments given to each subjects were:
1) placebo, 2) pentazocine 40 mg, 3) pentazocine 80 mg, 4)
tripelennamine 50 mg, 5) tripelennamine 100 mg, 6) pentazocine
40 mg and tripelennamine 50 mg, 7) pentazocine 40 mg and tri-
pelennamine 100 mg, 8) pentazocine 80 mg and tripelennamine 50
mg, and 9) pentazocine 80 mg and tripalennamine 100 mg. Stand-
ard measures for opioid-like effects including changes in pu-
pillary diameter, blood pressure, pulse, temperature and res-
piratory rate, the single dose opiate questionnaires and
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items from the MGB, PCAG and LSD scales (Jasinski, 1977) were
used to evaluate drug effects.
Subjects correctly identified placebo and discriminated the
various drug conditions from placebo. They identified penta-
zocine alone as well as tripelennamine alone predominantly as
an opioid. The mixtures were also identified as an opioid but
at a greater frequency than either of the drugs alone. The
onset, time to peak and duration of pentazocine and tripelenna-
mine were similar across all measures. Pentazocine alone and
tripelennamine alone produced significant responses on sub-
jects’ liking, MBG, PCAG and LSD scale scores. In addition,
both drugs raise systolic and diastolic pressure. Pentazocine,
but not tripelennamine, constricted pupils. On all measures
except pupils, the effects of tripelennamine and pentazocine
were additive . There was no evidence of synergistic activity.
The tripelennamine appeared to antagonize the miotic effects of
pentazocine.
From this data, it is concluded:
1.
2.
3.
4.
5.
Tripellennamine was identified as an opiate and induced
euphoria in experienced substance abusers.
The combination of tripelennamine and pentazocine produced
greater subject liking and euphoria than that seen for
either drug administered alone.
Both tripelennamine and pentazocine raised the systolic and
diastolic blood pressure, the combination produced a great-
er hypertensive response, and this increase was at least
additive.
Pentazocine constricted pupils, tripelennamine did not;
however, in combination, pupillary constriction was slight-
ly antagonized.
Low doses of tripelemamine increased the euphoric effects of
pentazocine and decreased the dysphoric effects seen at the
higher dose. High doses of tripelennamine did not! appre-
ciably further increase the euphoria and did not attenuate
the dysphoria of high doses of pentazocine. The combina-
tion producing the greatest liking most closely approached
the mixture popular in the street (2:1, pentazocine to
tripelennamine).
ABUSE POTENTIAL OF DELTA-9-TETRAHYDROCANNABINOL (THC) AND
NABILONE
Delta-9-THC is held to be the active ingredient of cannabis.
Oral preparations of THC and nabilone (a chemically related
cannabinoid) will be introduced into therapeutics as drugs for
eliminating the nausea and vomiting associated with cancer
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chemotherapy (Lemberger 1980). Although the abuse potential
of cannabis is well recognized, there is less evidence demon-
strating an abuse potential for THC. First, THC is generally
not a reinforcer in operant paradigms (Harris et al. 1974).
Secondly, there is little epidemiologic evidence of abuse of THC
since it has not been widely available either illicitly or
licitly in pure form. The purpose of the present studies was
to develop and validate clinical pharmacologic methods to as-
sess the abuse potential of cannabinoids, THC and nabilone.
The methods used in this study were essentially similar to
those used in other single dose studies and were derived from
the methods for studying opioids. This investigation was con-
ducted in subjects with histories of multiple drug abuse in-
cluding cannabis smoking. It was conducted as a crossover
study under double-blind conditions in ten (10) volunteers.
The nine drug conditions were given according to a latin square
design. The drugs given at twice weekly intervals were: 1)
placebo, 2) morphine 15 and 30 mg subcutaneously, 3) THC 5, 10
and 20 mg orally, and 4) nabilone 2, 4 and 8 mg orally. These
drugs were given both double blind and double dummy. Cm one
occasion subjects smoked a standard NIDA marijuana cigarette
(1.5%) and completed the observations in a manner similar to
the other conditions. The non-blinded marijuana smoking condi-
tion was administered as one of the ten treatments in the latin
square. The physiologic measures included changes in pupil
size, standing and supine blood pressure and pulse and respira-
tory rate. The subjects also completed single dose opiate
questionnaires, the MBG, PCAG and LSD scales (Jasinski 1977),
and a new questionnaire inquiring of strength in terms of the
number of joints which they would have to smoke on the street
to provide an equal effect. Finally observers completed the
observers’ single dose opiate questionnaire.
Abuse Potential of THC
In these studies subjects correctly discriminated THC from
placebo and morphine and identified THC as marijuana. THC and
the marijuana cigarette both produced tachycardia and similar
types of subjective effects as indicated by drug identifica-
tions and patterns of signs and symptoms. The onset, time to
peak, and duration effects of THC were longer than effects
after the marijuana cigarette. Both THC and the marijuana
cigarette produced morphine-like euphoria as evidenced by in-
creased liking scores, and MBG scale scores. The peak euphoric
effect of THC and the marijuana cigarette were at maximum no
greater than that of 15 mg of morphine.
On the basis of these studies it is concluded that THC has an
abuse potential; however, the abuse potential may be less than
that of the marijuana cigarette because of the slower onset
after orally administered THC. Further, it is concluded that
valid clinical pharmacologic methods were developed to assess
the abuse potential of cannabinoids. This data further sug-
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gests that the major effects of smoking marijuana are probably
due to the action of THC.
Abuse Potential of Nabilone
The subjects did not discriminate between nabilone and THC.
All doses of nabilone produced tachycardia, in contrast to THC
in which only the large dose produced tachycardia in the supine
position. Nabilone and THC produced similar subjective effects
including euphoria. The onset and time to peak effects were
similar for nabilone and THC. The duration of effects after
nabilone was. significantly longer than after THC. Both nabi-
lone and THC elevated supine, systolic and diastolic blood
pressure. Nabilone is seven (7) times more potent than THC in
producing subjective effects as determined from valid relative
potency calculations; however, valid relative potencies could
not be obtained for the physiologic effects. On the basis of
these studies it is concluded that nabilone has an abuse poten-
tial of the cannabinoid type.
STUDIES ON THE USE OF BUPRENORPHINE IN TREATING OPIOID
DEPENDENCE
Studies were conducted to demonstrate the efficacy of sub-
lingually and parenterally administered buprenorphine in sub-
stituting for’ methadone and heroin and subsequently reducing
the intensity of withdrawal. Subjects were admitted to the
research ward and the transition from the maintenance methadone
or heroin to buprenorphine was done under double-blind, double-
dummy conditions. After a period of buprenorphine maintenance,
placebo was substituted for buprenorphine again under double
blind conditions. Throughout the study subjects were observed
for self-reported symptoms and measured signs of opioid absti-
nence (Jasinski 1977).
Sublingual Buprenorphine in Methadone Dependence
Six volunteer methadone maintenance patients were transferred
to a daily 2 mg sublingual dose of buprenorphine. The daily
maintenance doses of methadone for these subjects were 45, 45,
40, 30, 25 and 25 mg of methadone daily for a mean dose of 35
mg. Abrupt substitution of buprenorphine for methadone was
followed by abstinence signs and symptoms of mild intensity
that appeared to peak about the third or fourth day and gradu-
ally diminish. When compared to untreated methadone with-
drawal, it was clear that suppression of abstinence occurred
with the substitution of huprenorphine. Thus, buprenorphine
administered sublingually substituted for and partially sup
pressed methadone withdrawal. The substituted buprenorphine
was administered for 28 days, and abruptly discontinued by
substitution of placebo. The abrupt substitution of placebo
for buprenorphine was followed by emergence of a mild with-
drawal syndrome which reached its peak in the third or
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fourth day and gradually receded. The comparison with the
control data from untreated methadone withdrawal indicates a
significantly attenuated withdrawal syndrome. However, when
compared with untreated buprenorphine withdrawal, the with-
drawal syndrome from substituted buprenorphine was significant-
ly greater.
Subcutaneously Administered Buprenorphine in Methadone
Dependence
Eleven methadone maintenance patients were abruptly transferred
to buprenorphine subcutaneously administered in doses of 2 n-g
daily. The daily maintenance doses of methadone were 60, 60,
60, 58, 55, 51, 50, 40, 30, 30 and 25 mg daily for a mean daily
dose of 47 mg. Abrupt substitution of subcutaneously given
buprenorphine for methadone is followed by abstinence signs and
symptoms of mild intensity that appeared to peak about the
third or fourth day and then gradually diminish and resembles
those seen after the substitution of buprenorphine by the sub-
lingual route.
Eight of these eleven subjects completed the protocol of double
blind buprenorphine administration. These eight subjects were
divided into two groups. Buprenorphine 2 mg subcutaneously
daily was administered to Group I and Group II for two and six
weeks respectively. Group I included three subjects maintained
on 60, 55 and 51 mg of methadone daily for a mean daily dose of
55 mg. Group II included five subjects previously maintained
on 50, 60, 58, 30, 30 and 25 mg of methadone daily for a mean
daily dose of 42 mg of methadone in these. The purpose of
these experiments was to test a hypothesis that the emergence
of abstinence in methadone maintenance patients after the dis-
continuation of substituted buprenorphine was due to the re-
emergence of methadone abstinence and to learn if a longer
period of buprenorphine administration was followed by a lesser
abstinence syndrome. The abstinence syndrome with both groups
was significantly less than untreated methadone withdrawal;
however, no significant difference could be demonstrated be-
tween the two groups suggesting that the withdrawal syndrome
was not merely the reemergence of methadone withdrawal.
Transition and Withdrawal Studies in Heroin-Dependent Patients
Fifteen (15) heroin-dependent. subjects were admitted to the
research ward and stabilized on 60 mg of morphine daily, admin-
istered as 15 mg subcutaneously at 6 a.m., 10 a.m., 4 p.m. and
10 p.m. After stabilization they were abruptly transferred to
buprenorphine under double dummy, double blind conditions.
Nine subjects were given sublingual buprenorphine in doses of 2
mg once daily for two weeks. Six other subjects were given
subcutaneous buprenorphine 2 mg daily for two weeks. Following
two and six weeks of buprenorphine administration there was
abrupt termination by the substitution of placebo. By both
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routes of administration, buprenorphine substituted for and
suppressed the abstinence during the transition from morphine
to buprenorphine although there were mild signs of abstinence
which were transitory and were diminished by the first week of
abstinence. The abrupt withdrawal of the buprenorphine after
two weeks of administration was followed by the onset of a mild
abstinence syndrome which emerged on the second day of with-
drawal and reached its peak on the third and fourth day of
withdrawal. The syndrome diminished such that by 7 to 10 days
after withdrawal patients were back to baseline in terms of
self-report and subjective measures of abstinence. On the
basis of these studies as well as the previous data reported to
the Committee (Jasinski et al. 1982) it is concluded that
buprenorphine is a safe and effective agent to be used as a
detoxification and maintenance drug in opioid dependence.
THE EFFECTS OF MECAMYLAMINE AND NICOTINE CHEWING GUM ON
CIGARETTE SMOKING AND SUBJECTIVE RESPONSE
As reported previously, studies have revealed that nicotine is
a dependence-producing substance and shares characteristics
with prototypic substances of abuse. On the basis of these
observations, it was decided to pursue studies to determine the
feasibility of chemotherapy for treatment of tobacco dependence
using the paradigm for treating opioid dependence as a model.
In addition, we reported that mecamylamine attenuates the re-
sponses to intravenous nicotine. This observation suggests
that mecamylamine can be used as a form of antagonist therapy
similar to naltrexone in opioid dependence. In these same
studies we found the intravenous self-administration of nico-
tine is dose-related, suggesting that pretreatment with nico-
tine suppresses subsequent nicotine self-injections in a manner
similar to methadone’s suppression of opioid self-injections in
maintained individuals. As a result, the current experiments
were conducted to assess the effects of mecamylamine and the
effects of nicotine-containing chewing gum (Nicorette) on
cigarette smoking behavior.
Effects of Mecamylamine
In accord with its action to attenuate the effects of nicotine,
it was hypothesized that acute mecamylamine pretreatment would
increase the rate of smoking. This was a collaborative study
with Maxine Stitzer, Johns Hopkins University. The subjects
were five female hospital employees without substance abuse
histories who participated five days weekly. Under double
blind conditions subjects were given mecamylamine 25, 5 and 10
mg or placebo at the start of each workshift. Each dose of
mecamylamine and placebo was administered four, times according
to a latin square sequence. Several measures of effects were
taken prior to the administration of mecamylamine or eight
hours after administration of mecamylamine; otherwise, the sub-
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jects performed their normal duties and were allowed to smoke
ad lib.
In accord with the hypothesis, the doses of mecamylamine in-
creased the number of cigarettes smoked, increased carbon mon-
oxide levels and increased verbal reports of less satisfaction
with the cigarettes. The conclusion of this study is that
mecamylamine pretreatment increased smoking behavior and that
mecamylamine in doses to 10 mg once daily is safe and tolerable
with minimal side effects.
Effects of Nicotine Chewing Gum
The experimental paradigm was similar to that for the mecamyla-
mine studies; however, these studies were conducted with post-
addict volunteers admitted to the research unit. A total of
six subjects were studied; however, data are presented from
only three of the six subjects. The Nicorette gum contained
0, 2 or 4 mg nicotine per piece of gum. The hypothesis was
that nicotine administered by this route should substitute for
and decrease cigarette smoking behavior. The nicotine
chewing gum in the two doses and placebo were administered
throughout the day according to a latin square design across
days. Within each day there were seven doses administered at
two-hour intervals. Several measures of cigarette smoking
behavior and subjective response were taken from 8:30 a.m. to
bedtime, which was approximately 16 hours. Data from these
three subjects clearly shows that the nicotine gum decreased
the number of cigarettes smoked, lowered expired air CO levels,
decreased the number of puffs and lessened verbal reports of
desire to smoke. On the basis of these studies it is concluded
that Nicorette chewing gum is an efficacious and safe means
of suppressing cigarette smoking behavior.
EEG Correlates of Nicotine-Induced Euphoria
We previously have reported that acute intravenous injections
of nicotine increased liking scores and produce euphoria.
Further, these effects have a rapid onset and short duration
(one to three minutes) to which acute tolerance develops. A
series of studies have been done in which EEG recordings have
been made from subjects during the i.v. injection of various
doses of nicotine (0.5, 1.5 and 3 mg) and placebo. During the
experiment the subject moved a lever with his finger in one of
two directions to indicate when he felt euphoric or dysphoric,
respectively. Movement of the pen produced a deflection of an
event pen directly beneath the EEG tracings. The EEG activity
was quantified using computerized power spectral analysis. The
results of this study indicate that there is a dose-related
decrease in the EEG power and a shift to a faster alpha fre-
quency during euphoric episodes. It is suggested that this
phenonema may provide a basis for the development and assess-
ment of animal models of euphoria.
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Antitussive Potencies of I- and
d-Opiates and Their Inhibition of
Codeine Binding
Thuy T. Chau and Louis S. Harris
Introduction
We have previously reported that l-codeine was 6 times more
potent than d-codeine in suppressing the cough reflex in the
anesthetized cat (Chau and Harris, 1980). At the doses tested,
the 2 isomers did not cause any significant respiratory effect.
The blood pressure and heart rate were not affected by l-codeine
but were decreased by the d-isomer. The antitussive effects of
d- and l-isomers of codeine were not antagonized by doses of
naloxone ranging from 1 to 10 mg/kg i.v. Naloxone by itself did
not affect the cough reflex. The lack of naloxone antagonism
was also shown in the guinea pig. l-Codeine given S.C. (20-60
mg/kg) produced a dose-related antitussive effect. A very high
dose of naloxone (10 mg/kg s.c.) was required to partially block
the effect of l-codeine in this series of preliminary studies.
We also showed the antinociceptive effect of l-codeine in mice
in the tail-flick and hot-plate tests. d-codeine on the con-
trary caused hyperalgesia, convulsions and death at high doses
(100 mg/kg S.C. or p.0.). The analgesic effect of l-codeine was
antagonized by naloxone. l-Codeine also inhibited The stereo-
specific binding of dihydromorphine although its inhibitory
potency was rather weak. It is known that codeine has only a
weak affinity for the mu receptors (Chaw-Pham et al., 1978).
The d-isomer was completely inactive up to 10-4 M.
Based upon those preliminary studies, we hypothesized that the
antitussive effect of opiates might be mediated by a subtype of
receptor which appeared to be non-stereoselective and less
naloxone sensitive than the already established opiate recep-
tors. We are now reporting the antitussive effects of the
optical isomers of some mu, kappa and sigma opiates and their in
vitro inhibitory potencies of 3H-codeine binding in the guinea
pig medulla.
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Methods
1. Effects on cough reflex, blood pressure, and heart rate
Cats weighing 3 to 4 kg were anesthetized with sodium
pentobarbital 35 mg/kg i.p. The cough reflex was initiated by
manual stimulation of the pharynx or lower part of the trachea
with a probe through a small slit made in the trachea. The
respiration rate, normal amplitude and the amplitude produced by
the cough reflex were measured by a pneumograph and recorded on
a polygraph. The control cough amplitude was initiated several
times prior to the i.v. injection of the drug into the femoral
vein. A decrease of the cough amplitude upon drug administra-
tion at different time points was defined as percent inhibition
of the cough reflex. Different doses of each isomer were given
and 3 cats were used for each dose. The Litchfield-Wilcoxon
method gave the ED50 expressed as base and the 95% confidence
limits.
In other experiments 1 mg/kg of naloxone HCl was given i.v. to
the cat 3-5 min prior to an ED84 dose of each drug. Two or
three cats were used to investigate the antagonistic effect of
naloxone upon each antitussive compound. The possible
antagonism of l-codeine hydrochloride (1 mg/kg) or 1-morphine
sulfate (1mg/kg) by l-SKF 10,047 (3 mg/kg), d-SKF 10,047 (3
mg/kg), by the ED16 dose of l- or d-cyclazocine, and by the ED16
dose of (±) ketocyclazocine in the-anesthetized cats was also
investigated using 2 cats per drug combination.
2. Inhibition of the saturable binding of (-)-3H-codeine in
the guinea pig medulla
The method was essentially that previously described (Chau
et al., 1982). Several final concentrations of l- or d-opiates
ranging from 10-10 to 10-4 M were tested for their inhibitory
effect on (-)-3H-codeine saturable binding. The saturable
binding is defined as the difference between (-)-3H-codeine
binding in the presence or absence of cold (-)-codeine. The
protein content in the homogenate was determined by the method
of Lowry et al. (1951) and the results of (-)-3H-codeine
saturable binding expressed as pmoles/mg protein. The ICso of
each drug, concentration which inhibited the saturable binding
of (-)-3H-codeine by 50%, was determined by log probit analysis.
Each IC50 was repeated 3 times for reproducibility.
Results and Discussion
1. Antitussive effects of the optical isomers of mu, kappa and
sigma agonists
The results are presented in Table 1.
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Table I
Antitussive Potencies of l- and d-Opiates
in the Cat-
Drugs
l-Codeine
d-Codeine
l-Morphine
d-Morphine
l-Methadone
d-Methadone
Levomethorphan
Dextromethorphan
l-Cyclazocine
d-Cyclazocine
(±)-Ketocyclazocine
l-SKF 10,047
d-SKF 10,047
EDso (95% C.L.)
mg/kg i.v., base
0.27 (0.14 - 0.47)
1.61 (0.98 - 2.65)
0.24 (0.13 - 0.43)
0.18 (0.08 - 0.40)
0.058 (0.035 - 0.098)
0.84 (0.40 - 1.73)
0.51 (0.21 - 1.25)
1.21 (0.61 - 2.4)
0.32 (0.20 - 0.50)
1.57 (0.79 - 3.12)
0.30 (0.16 - 0.50)
Inactive up to lethal dose
Inactive up to 5 mg/kg
a) N + 3 to 4 cats per dose
b) The cats were anesthetized with pentobarbital 35 mg/kg
i.p
c) The cough reflex was induced by manual stimulation of
the trachea with a blunt probe.
In our study, we found that, in general, except for mor-
phine, the l-opiates were more potent than the d-isomers but
that these differences were much smaller than those found for
the other opiate-like pharmacological actions. The optical
isomers of the mu and kappa type of opiates exhibit strong cough
suppressant effect, whereas the isomers of the purported sigma
opiate SKF 10-047 are inactive up to high doses for the d-isomer
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and up to lethal doses for the l-isomer. This suggests, at
first, that the antitussive effects of opiates may involve both
the mu and kappa types of opiate receptors. The fact that both
optical isomers have cough suppressant effects suggests that
another type of receptor yet may be involved in this effect and
exhibit a lesser degree of stereoselectivity than the analgesic
receptors as evidenced by the low potency ratio between the l-
and the d-isomers. Furthermore, the differences in naloxone
sensitivity of the opiates with respect to their antitussive
effects as shown in Table II also suggest that the antitussive
receptor(s) may be distinct from the analgesic receptors. It is
indeed puzzling that naloxone (1 mg/kg i.v.), in our studies,
antagonizes the cough suppressant effect of the optical isomers
of all the mu agonists except d- and l-codeine. Smaller doses
of naloxone also completely antagonize l-morphine while much
larger doses of the antagonist fail to block d- or l-codeine.
It is very conceivable that there is more than one mechanism by
which opiates exert their antitussive effects. The different
degrees of naloxone sensitivity are also evidenced by the
optical isomers of cyclazocine and the racemic mixture of keto-
cyclazocine which are only partially antagonized by naloxone.
2. Interaction between mu, kappa, and sigma agonists in the
suppression of the cough reflex in the cat.
(±)-Ketocyclazocine has been postulated to be a kappa
agonist (Martin et al., 1976) and cyclazocine, a mu antagonist
and mixed kappa and sigma agonist (Gilbert and Martin, 1976).
In our studies, l-cyclazocine does not antagonize the anti-
tussive effects of l-codeine but blocks that of morphine, be-
having like naloxone (Table III). (±)-Ketocycazocine on the
contrary partially blocks codeine but not morphine. The in-
volvement of the kappa and mu types of opiate receptors needs
further investigation. The sigma receptors do not appear to be
involved in the cough suppressant effect of opiates as evidenced
by the inactivity of the optical isomers of SKF 10,047. It is
interesting, however, that l-SKF 10,047 behaves like naloxone in
our antitussive model in agreement with suggestion from other
investigators that l-SKF 10,047 may be the mu antagonist whereas
d-SKF 10,047 may be the sigma agonist (Brady et al., 1982).
The hypothesis that opiates or at least codeine exert their
antitussive effects via non-stereoselective and less naloxone-
sensitive receptor(s) is verified by our in vitro studies. Both
opitical isomers of the mu opiates tested in these studies
inhibit the saturable binding of (-)-codeine in crude guinea pig
medulla homogenates. A good correlation exists between their in
vivo antitussive potencies and their in vitro inhibitory effect
on codeine binding. This suggests that the codeine binding
sites in our studies may be one of the antitussive sites but a
solid evidence of the latter remains to be established. The lack
of stereoselectivity of the hypothetical antitussive sites is
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also demonstrated by the isomers of kappa opiates, in both in
vivo and in vitro studies. It is, however, interesting to note
that the kappa opiates are more potent than the mu opiates in
displacing (-)-codeine from its binding sites, suggesting a
strong involvement of the kappa sites for which ketocyclazocine
and cyclazocine have a greater affinity.
Table II
Effects of Naloxone HCl on the Antitussive
Potencies of d- and l-Opiates in the Anesthetized Cat(a)
Dose ED84, % Inhibition of the Cough
Drug mg/kg i.v. base WD/Naloxone W/Naloxone(b)
l-Codeine 0.67 84
d-Codeine 2.5 84
l-Morphine 0.43 90
d-Morphine 0.43 89
l-Methadone 0.18 94
d-Methadone 1.8 74
Levomethorphan 1.0 78
Dextromethorphan 2.1 82
Ketocyclazocine 0.5 80
l-Cyclazocine 0.5 82
d-Cyclazocine 3.0 92
84 (d)
80 (d)
0
0 (c)
0 (c)
0 (c)
0 (c)
13
7
48 (c)
54 (c)
44
a) N = 2 t o 3
b) Naloxone HCl 1 mg/kg i.v. given to 3.6 min prior to the
antitussive opiate.
c) With Naloxone HCl 0.2 mg/kg.
d) Naloxone 10 and 20 mg/kg i.v. did not antagonize l- or
d-codeine.
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Table III
Interaction Between Mu, Kappa, and Sigma Agonists in the
Inhibition of the Cough Reflex in the Anesthetized Cats N=2
First Drug
(mg/kg i.v. base),
Second Drug
(mg/kg i.v. base)
l-SKF 10,047 (3.0) l-Codeine (0.75)
l-SKF 10,047 (3.0) l-Morphine (0.43)
d-SKF 10,047 (3.0) l-Codeine (0.75)
d-SKF 10,047 (3.0) l-Morphine (0.43)
Ketocyclazocine (0.1) l-Codeine (0.75)
Ketocyclazocine (0.1) l-Morphine (0.43)
l-Cyclazocine (0.2) l-Codeine (0.75)
l-Cyclazocine (0.2) l-Morphine (0.43)
d-Cyclazocine (1.0) l-Codeine (0.75)
d-Cyclazocine (1.0) l-Morphine (0.43)
% Inhibition of
the Cough Reflex
80
10
80
100
47
88
86
34
94
88
The two drugs in each combination were given 3-6 min apart.
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Drugs
l-Methadone
d-Morphine
l-Morphine
l-Codeine
Ketocyclazocine
l-Cyclazocine
Levomethorphan
d-Methadone
Dextromethorphan
d-Cyclazocine
d-Codeine
Naloxone
Table IV
In Vivo and In Vitro Studies
ED50(a) IC50(b)
(mg/kg i.v. base) (-)Codeine (nM)
0.06 1.2
0.18 6.7
0.24 8.4
0.27 5.3
0.30 1.17
0.32 1.08
0.51 5.4
0.84 24.0
1.21 25.0
1.57 6.7
1.61 40.5
---- 8% at 10-6 M
a) Antitussive effects in the anesthetized cats.
b) Inhibition of (-)-
3H-Codeine binding in the crude
homogenate of the guinea pig lower brain stem (1 x 10-8 M).
rl = 0.65 at 5% level (all opiates included).
r2 = 0.87 at 1% level (kappa opiates not included).
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Inhibition by Adenosine Analogs
of Opiate Withdrawal Effects
John F. Tucker, Neil T. Plant, Alexa von Uexküll, and
Harry O. J. Collier
SUMMARY
The stable derivatives of adenosine, 2-chloroadenosine and N6 -
cyclohexyladenosine, with high affinity for the A, (Ri) adenosine
receptor, suppress the naloxone-precipitated withdrawal contrac-
ture of the opiate-dependent guinea-pig ileum in vitro. These
adenosine derivatives also inhibit naloxone-precipitated jumping,
diarrhea and weight-loss in morphine-dependent mice. This effect
was not due to sedation, since (i) 2-chloroadenosine was effec-
tive at a non-sedative dose and (ii) sedative doses of chlordiaze-
poxide were ineffective.
INTRODUCTION
The final cholinergic motoneurone of the myenteric plexus of
guinea-pig ileum possesses specific receptors for adenosine
(Paton, 1981; Moody and Burnstock, 1982), whose activation in-
hibits the release of acetylcholine from the terminal (Vizi
and Knoll, 1976; Gustafsson et al. 1978; Hayashi et al. 1978).
Since adenosine thus resembles'opiates and alpha-adrenoceptor
agonists, it may be expected in the ileal model also (i) to
induce dependence, as do normorphine (Collier et al. 1981b) and
clonidine (Collier et al. 1981a) and (ii) to inhibit the opiate
withdrawal effect, as does clonidine (Collier et al. 1981a). We
have recently reported that adenosine and 2-chloroadenosine (2-
CA) induce dependence in the isolated ileum (Collier and Tucker,
1983). We report below that 2-CA and N6-cyclohexyladenosine
(CHA), which resist the rapid enzymatic destruction to which
adenosine is subject, readily inhibit opiate withdrawal effects,
both in vitro and in vivo.
METHODS
Guinea-pig ileum in vitro
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Dependence was induced by incubating pieces of ileum with 10-6M
normorphine in Krebs solution containing 7 x 10 5M hexamethonium
for 18-24h at 4°C, as previously described (Collier et al, 1981b;
Collier & Tucker, 1983). Test and control preparations from the
same animal were then set up in pairs at 37°C in a solution of
the same composition as used for incubation at 4°C and aerated
with 5% CO, in O2, for isometric recording of contraction of the
longitudinal muscle. Withdrawal was precipitated 25-30 min after
setting up at 37°C by challenge with 3 x 10 7M naloxone. Test
preparations were treated with 10-7M 2-CA, 1 min before challenge
or with 10 -7M CHA, 2-3 min after challenge. After the response
to naloxone had been recorded, responses to electrical stimula-
tion (supramaximal voltage; 0.5 ms pulse width; 0.1 Hz) and to
acetylcholine were recorded. The withdrawal contracture was ex-
pressed as a percentage of the maximal response to acetylcholine.
Mouse in vivo
Using male LACA mice, one 35 mg pellet of morphine was implanted
subcutaneously into each mouse, anesthetized with ether. Three
days later, mice were treated i.p. with 2-CA, CHA, chlordiaze-
poxide (CO) or saline, and 25 min later, they were challenged with
1 mg/kg i.p. naloxone. The number of jumps was recorded for 15
min after challenge and the presence or absence of diarrhea re-
corded at 30 min. Before challenge, and 20 min later, the mice
were weighed. In other experiments, 30 min after treatment with
2-CA or CD, opiate-naive mice were run on a conical rota-rod with
spiral walls, and their performance measured by the lateral dis-
tance that they, travelled before they fell. Treatments were coded;
and the animals' responses were recorded by an observer who did
not know what treatment each mouse had received.
Materials
The drugs used were: acethylcholine chloride (BDA), adenosine
(Sigma), chlordiazepoxide (Roche), 2-chloroadenosine (Sigma),
N6-cyclohexyladenosine (Calbiochem), hexamethonium bromide (Koch-
Light), morphine (May & Baker), naloxone hydrochloride (Endo) and
normorphine (Wellcome).
RESULTS
Ileum in vitro
Using preparations not previously incubated at 4°C, we obtained
the following mean values ± s.e.m. for the concentration required
to inhibit by 50% the electrically evoked contraction (acute 1C
50): adenosine 1.7 ± 0.3 x 10 6M; 2-CA, 5.4 ± 0.7 x 10 8M; CHA,
7.2 ± 0.8 x 10-8M.
In normorphine-dependent preparations, 2-CA, given before naloxone
challenge, almost completely prevented the occurrence of a with-
drawal contracture (Fig. 1). After 2-CA, as expected, responses
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to electrical stimulation were depressed, but those to acetylcho-
line were unchanged. Figure 2 shows that CHA, given 3 min after
naloxone challenge, largely suppressed an existing withdrawal
contracture.
FIGURE 1. Prevention by 2-Chloroadenosine (2-CA) of Withdrawal
Contracture Precipitated with Naloxone (Nx) in Guinea-pig Ileum
in vitro.
Pieces of ileum were incubated in 10-6 M normorphine for 18-24 h
at 4°C and for 30-40 min at 37°C. ES, electrical stimulation
with 0.5 ms pulses at 0.1 Hz; ACh, acethylcholine; *p<O.O1 for
differences between mean responses of test and control prepara-
tions (n=lO pairs).
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FIGURE 2. Suppression by N6-Cyclohexyladenosine (CHA) of With-
drawal Contracture Precipitated with Naloxone in Guinea-pig
Ileum in vitro. Details as in Fig. 1
Mouse in vivo
In total, 137 morphine-dependent mice were used in experiments
with 2-CA, CHA and CD., Table 1 shows that 2-CA and CHA at low
doses significantly inhibited withdrawal jumping, diarrhea and
weight-loss; whereas CD was ineffective. In about half the de-
pendent mice treated with CD, and in a few mice treated with 2-
CA, CHA or saline, the jumping response to naloxone was replaced
by a writhing response, with associated suppression of jumping.
These animals were excluded from the counts of jumping in Table 1.
The lowest dose of 2-CA effective in inhibiting withdrawal re-
sponses in dependent mice (0.2 mg/kg i.p.) did not significantly
worsen the rota-rod performance of opiate-naive mice (Figure 3).
It may be noted that all doses of CHA completely suppressed with-
drawal diarrhea. In general, the effects of the adenosine deri-
vatives were dose-related, but a kink in the lower part of the
dose-response lines consistently occurred.
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TABLE 1. Inhibition with 2-Chloroadenosine (2-CA) and N6-Cyclo-
hexyladenosine (CHA) of Withdrawal Effects Precipitated with
Naloxone in Morphine-Dependent Mice.
Drug Dose n No. of jumps/ Incidence of Weight-loss
(mg/kg i.p.) 15 min ± SE diarrhea (%) (mg±SE)
Control 25-27 214 ± 17 85.2 750 ± 67
2-CA 0.2 14 106 ± 29** 28.6* 441 ± 62*
0.5 22 113 ± 9** 50.0* 641 ± 94
1.25 9-10 70 ± 12** 10.0* 286 ± 72 **
3.125 14 32 ± 7** 21.4* 191 ± 45**
CHA 0.5 6 77 ± 25** 143 ± 76**
1.25 8 84 ± 10**
0*
0* 341 ± 79**
3.125 6-7 35 ± 12** 0* 63 ± 32**
CD 5 8-14 285 ± 42 57.1 601 ± 94
12.5 8.15 210 ± 15 80.0 789 ± 130
* P<O.O1; ** P<O.OO1: for significance of difference from
control value.
DISCUSSION
These experiments show that 2-CA and CHA potently inhibit opiate
withdrawal effects both in vitro and in vivo. The effect in vivo
was not due to sedation, since (i) 2-CA was effective at a non-
sedative dose and (ii) sedative doses of CO did not inhibit
withdrawal responses. If opiate dependence develops in vivo, as
it probably does in vitro, in neurones bearing opioid receptors
(Collier, 1980), this finding suggests that the neurones in-
volved also bear receptors for adenosine, the activation of
which would produce effects comparable to those of activating
their opioid receptors.
That 2-CA and CHA potently and effectively inhibit opiate with-
drawal effects raises the question: would these or other adeno-
sine derivatives be useful in the clinical management of opioid
withdrawal? This question generates a need for further experi-
ments on these two compounds in dependent mice to determine
(i) their side-effects and therapeutic ratios and (ii) their
efficacy relative to clonidine. A second question also arises:
would these adenosine derivatives themselves produce dependence
in vivo, as 2-CA is known to do in vitro (Collier and Tucker,
1983). If so, would this be accompanied by drug-seeking be-
haviour? It seems unlikely, however, that the adenosine
derivatives would produce drug-seeking behaviour, because the
adenosine antagonist, caffeine, is euphorigenic.
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That, in some mice, treatment with CD converted a precipitated
withdrawal response of jumping to one of writhing is remini-
scent of the observation that these two withdrawal effects
appear to be mutually exclusive in morphine-dependent rats
(Blasig et al. 1973).
FIGURE 3. Dose/Response Lines of 2-CA and CD for Performance on
the Rota-rod. Thirty minutes after drug treatment, mice were
run on a spiral rota-rod. Performance was measured by the
lateral distance that the mice traveled along the rota-rod
before they fell off.
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Abuse Liability and Behavioral
Toxicity Assessment:
Progress Report From the Behavioral Biology
Laboratories of the Johns Hopkins University
School of Medicine
J. V. Brady, R. R. Griffiths, R. D. Hienz,
G. E. Bigelow, H. H. Emurian, S. E. Lukas, N. A. Ator,
M. J. Nellis, R. L. Ray, G. D. Pearlson, I. A. Liebson,
F. Funderburk, D. R. Jasinski, J. Henningfield, and
R. E. Johnson
A. Introduction
The initial report on the Johns Hopkins program presented at the
44th Annual Scientific Meeting of the Committee on Problems of Drug
Dependence in Toronto, Canada, in June, 1982 summarized over a
decade of progress in drug abuse liability assessment with
laboratory baboons focused upon both drug self-administration
procedures and sensory-motor psychophysical methodologies to
evaluate the reinforcing properties and behavioral toxicology of
chemical agents (Brady and Griffiths 1983). Against this back-
ground emphasizing the relationship between the reinforcing
properties of drugs, on the one hand, and their behavioral effects,
on the other, the present report will focus upon the progress made
over the past year in such animal and human laboratory assessments
with PCP analogues, both short- and long-acting benzodiazepines, and
the somewhat "softer" drugs of abuse, caffeine, nicotine, and
marijuana. Additional studies described in other sections of this
volume (Stitzer et al., this volume; McCaul et al., this volume;
Ensminger et al., this volume; Griffiths et al., this volume;
Preston et al., this volume) augment this report of progress from
the Johns Hopkins and Baltimore City Hospital drug abuse research
programs in areas related to the sedative/anxiolytics and opiate
agonist/antagonist compounds.
B. Phencyclidine Analogue Self-Administration in Laboratory
Baboons
Consistent with the substantial body of knowledge demonstrating
that animals will self-administer drugs that are abused by humans
(Griffiths et al. 1979, 1980; Johanson and Balster 1978), PCP has
been shown to be self-injected by monkeys (Balster et al. 1973;
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Pickens et al. 1973), dogs (Jasinski et al. 1979), and rats
(Carroll et al. 1981). In addition, studies on the structure-
activity relationships of PCP analogues have demonstrated a good
correlation between receptor binding potencies and pharmacological
effects (Kalir et al. 1969, 1978; Vincent et al. 1979). The
present study was undertaken in order to assess the reinforcing
properties of PCP and four analogues in baboons under relatively
larye fixed-ratio schedules (i.e., fixed ratio 160) and during 24
hr access to the drugs. In addition, the effects on food intake,
as a possible measure of anorexia and/or behavioral toxicity, were
characterized.
Eight male baboons (Papio anubis) weighing 18-28 kg served as
subjects, using a harness-tether restraint system (Lukas et al.
1982) to protect surgically implanted venous silastic catheters
(Lukas 1983). Drug injection was available upon completion of a
160 response fixed ratio requirement on a Lindsley lever with a
3-hr time out period following each injection, permitting a maximum
of 8 injections per day. Self-injection performance was first
established with cocaine at a dose of 0.32 mg/kg. After 3
consecutive days of cocaine availability during which six or more
injections were taken each day, a dose of test drug or vehicle was
substituted for the cocaine for a period of 15 days. Cocaine was
then reinstated, and when the criterion of 3 consecutive days of
six or more injections per day had been met (typically 3-5 days),
another dose of a test drug was substituted.
The following drug doses expressed as mg/kg/injection of the salt
were studied: cocaine hydrochloride (0.32), phencyclidine
hydrochloride (0.01, 0.032, 0.1, 0.32), ketamine hydrochloride
(0.01, 0.032, 0.1, 0.32, 1.O), N-methyl-1-phenylcyclohexylamine
hydrochloride or NMPCA (0.0032, 0.01, 0.032, 0.1, 0.32). 1-(n-
butyl)-1-phenylcyclohexylamine hydrochloride or NNBPCA (0.01,
0.032,0.1, 0.32, 1.0), and 1-(1-(2-thienyl) cyclohexyl)
pyrrolidine hydrochloride or TCPY (0-01, 0.032, 0.1, 0.32). The
vehicle for NNBPCA was 0.5% ethanol in 0.9% NaCl; the vehicle for
all other drugs was 0.9% NaCl.
Figure 1 shows the mean number of injections during the last 5 days
for PCP, ketamine, NMPCA, NNBPCA, and TCPY. Cocaine generally
maintained self-injection levels of 7-8 injections per day while
values for vehicle were in the range of O-3 per day. Low doses of
all drugs were associated with self-injection levels similar to
vehicle control; increasing doses were generally associated with
increasing numbers of injections per day. These relationships
observed with number of injections per day also generally held true
for response rates. Response rates for vehicle and low doses of
all drugs were typically in the 0.003-0.006 res/sec range.
Response rates increased to 0.25-0.45 res/sec as the dose was
increased for all compounds except TCPY which were approximately
0.07 res/sec. The maximal rates of responding maintained by PCP
and its analogues were similar to those maintained by cocaine (0.32
mg/kg). As measured by the number of injections per day, PCP was
1.3 to 1.4 times more potent than TCPY and NMPCA, 3 times more
potent than NNBPCA, and 15 times more potent than ketamine.
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FIGURE 1. Mean number of injections per day main-
tained by PCP, ketamine, NNBPCA, NMPCA, and TCPY.
Y-axis: injections per day; X-axis: dose (mg/kg/
injection, log scale. C indicates mean of all 3-day
periods with cocaine that immediately preceded every
substitution of a drug dose or vehicle. V indicates
mean of the last 5 days after substitution of the
drug vehicle. Drug data points indicate mean of the
last 5 days after substitution of a drug dose.
Lines connect means at indicated doses of drug.
C. Sensory/Motor Effects of Chronic Diazepam Administration
Previous reports of a procedure for determining behavioral toxicity
using a reaction time (RT) methodology with laboratory baboons
(Brady et al. 1979; Hienz and Brady 1981; Hienz et al. 1981; Brady
and Griffiths 1983) have focused upon sensory and motor effects
following acute administration of a range of drugs. Dose-dependent
elevations in both visual and auditory thresholds as well as
increases in response latencies following single doses of diazepam
have been described, and studies conducted over the past year have
provided an extended analysis of chronic diazepam administration in
relationship to such psychophysical effects. The procedures for
determining such sensory/motor toxicity involved training baboons
to press and hold a lever until presentation of a sound burst or
light flash signalled availability of food delivery contingent upon
lever release (e.g., reaction time paradigm). Auditory and visual
thresholds were determined in separate sessions by randomly varying
the intensity of the test stimuli from trial to trial in accordance
with the method of constant stimuli, and examining detection
frequencies at each intensity. Drugs were administered intra-
muscularly (i.m.) immediately before each experimental session,
followed by 15 minutes of dark adaptation and 15 minutes of
"warm-up" on the reaction time task before threshold determination
was begun.
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Figure 2 presents changes in visual thresholds (top) and median
reaction times for visual stimuli (bottom) over 21 consecutive days
of daily i.m. administration of 0.32 mg/kg diazepam, and for the
following days of saline administration. Successive within-session
estimates of visual thresholds and median reaction times are
plotted for each session, and these within -session points are
connected with solid lines for drug days, and with dotted lines for
saline days. Thus each series of two to five connected data points
represents one day's data for changes in visual threshold (top
graph) and changes in visual reaction time (bottom graph). Day 1
shows the acute effects of 0.32 mg/kg diazepam on visual reaction
time, a small but consistent increase in reaction time, with no
apparent changes in visual thresholds. Tolerance to the drug's
effects on reaction times developed gradually, and by Day 6
reaction times were back to normal values. Starting at Day 15 an
anomalous decrease in visual reaction times occurred, possibly
related to the appetite-inducing properties of the drug (we have
previously shown that large changes in deprivation can shift
baseline reaction times). Diazepam was withheld from the animal
starting on Day 22, and reaction times then approximated normal
values, although the within-session variability increased
considerably during the withdrawal period. Visual thresholds
continued to show little change.
FIGURE 2. Changes in visual thresholds (top graph) and
visual reaction times (bottom graph) over 21 consecutive
days of daily i.m. administration of 0.32 mg/kg diazepam,
and for subsequent days of saline administration.
Threshold and reaction time changes from baseline are
plotted for each successive block of trials within each
session, and within-session points are connected by solid
lines on drug days, and by dashed lines on saline days.
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This general picture of reaction time effects, the development of
tolerance to these effects, and highly variable changes in reaction
times during withdrawal, became magnified at the daily dose of 1.0
mg/kg diazepam shown in Figure 3. Again, visual thresholds showed
little or no change during either drug administration or withdrawal
periods, while the initial effect of this dose of diazepam on
reaction time was slightly greater, with tolerance to this
reaction-time-increasing effect developing over 10 days as compared
to 6 days for the 0.32 mg/kg dose. When the drug was stopped,
reaction times showed a progressive and dramatic increase that
peaked at Day 10 following cessation of the drug, with a gradual
recovery following. Again, during this withdrawal period the
variability of within-session estimates of reaction times was
FIGURE 3. Changes in visual thresholds (top graph) and
visual reaction times (bottom graph) over 21 consecutive
days of daily i.m. administration of 1.0 mg/kg diazepam,
and for subsequent days of saline administration.
Further description as in Figure 2.
Increasing the dose again to 3.2 mg/kg diazepam produced even more
dramatic effects on visual reaction times. The cumulative effects
of the drug on reaction time peaked at Day 2, while the first clear
effects on visual thresholds occurred on Days 4 and 5. Initial
recovery from the reaction time effects was evident by Day 6, but
not completed until Day 21. Stopping drug administration again
produced an immediate effect upon reaction time, with complete
recovery from this effect not occurring for the 19 days shown after
drug administration was stopped.
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D. Relationship between Reinforcing Properties and Sensory/Motor
Toxicity of CNS Stimulants and Depressants
In a previous report (Brady et al. 1983), comparisons between the
relative potency of a drug as a reinforcer maintaining self-
administration, on the one hand, and its relative potency as
regards disruptive effects upon sensory and motor functions, on the
other, were described in terms of a "reinforcement/toxicity ratio."
The reinforcing properties of three barbiturates (amobarbital,
pentobarbital, secobarbital) and two dissociative anesthetics
(ketamine and PCP), were determined using the procedure described
in section B above. The same drugs were also evaluated to
determine the criterion dose which produced a 50% change in
auditory and/or visual thresholds, and/or a 10% change in motor
reaction time using the procedures detailed in section C above.
Over the past year, additional reinforcement/toxicity ratios have
been determined for a short- (triazolam) and a long- (diazepam)
acting benzodiazepine and for the stimulant d-methylamphetamine.
Figure 4 summarizes in graphic form the relationship between the
criterion sensory and motor change doses and the criterion self-
FIGURE 4. Relationship between criterion sensory and
motor toxicity doses and criterion self-administration
doses for three barbiturates, two benzodiazepines,
two dissociative anesthetics, and a stimulant. The
broken diagonal line represents equality between the
reinforcing and toxic doses.
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administration dose for the five previously reported compounds and
the three drugs added over the past year. With the broken diagonal
line representing equality between the reinforcement and toxic
doses, all three barbiturates, the short-acting benzodiazepine
triazolam, and d-methylamphetamine are characterized by ratio
values which fall above the diagonal, indicating that the doses
which produce disruptive sensory/motor changes are generally higher
than the doses required to maintain self-administration of these
compounds. There is also a consistent relationship between the
sensory and motor effects of these compounds which is also shared
by the long-acting diazepam in that the motor effects appear at
lower doses than the sensory effects. In' the case of diazepam,
however, the disruptive motor effects (i.e., slowed reaction times)
appear at doses below those required to maintain self-
administration as indicated by the reaction time value falling well
below the diagonal line. In the case of both dissociative
anesthetics, ketamine and PCP are readily differentiated by the
consistent appearance of sensory changes at doses below those which
produce motor effects, while PCP appears unique among the compounds
thus far studied in that both the sensory and motor change values
fall below the diagonal, indicating that the doses required to
maintain self-administration are generally higher than the doses
which produce significant behavioral toxicity.
E. Comparison of Benzodiazepine Behavioral and Subjective Effects
in Humans
A study with 14 outpatient volunteers with histories of
recreational benzodiazepine use compared the effects of diazepam
(0, 10, 30, and 40 mg) and lorazepam (0, 1.5, 3, and 6 mg) on a
series of performance (digit symbol substitution, saccadic
fixation) and subjective self-report (drug liking scale) tasks.
Drugs were administered double blind over 4 test days (one each for
the above indicated 4 doses) with experimental sessions for both
drug groups (i.e., diazepam and lorazepam) separated by at least
one week.
The dose-related changes in performance and subjective self- report
of drug liking were generally similar for the two drugs. The
higher doses of both diazepam and lorazepam were associated with
higher drug liking scores and with larger decrements on psychomotor
performance and digit symbol substitution tasks. Lorazepam proved
to be significantly more potent than diazepam, however, with 6 mg of
lorazepam having consistently more marked effects than 40 mg of
diazepam. Lorazepam also tended to produce effects of longer
duration than diazepam. Figure 5 presents illustrative results on
a psychomotor performance task. These results demonstrate that the
magnitude and duration of benzodiazepine effects can be
differentiated by such performance and subjective self-report
measures, and that the direction and extent of these changes are
not predicted by the fact that lorazepam is more rapidly eliminated
than diazepam.
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CIRCULAR LIGHTS
MINUTES POST-INGESTION
FIGURE 5. Effects of oral doses of lorazepam
and diazepam on a circular lights psychomotor
performance task.
A second study completed over the past year with an additional
twelve human volunteers with histories of sedative drug abuse
compared the effects of diazepam and oxazepam on psychomotor
performance and subjective self-report measures. Drugs were
administered orally every third day under double-blind conditions
with the order of the drugs counterbalanced over the dose range for
10-160 mg for diazepam (i.e., 0, 10, 20, 40, 80 and 160 mg), and
30-480 mg for oxazepam (i.e., 0, 30, 60, 120, 240, 360 and 480 mg).
Area under the curve (AUC) analysis showed diazepam was 2.6 to 5.7
times more potent than oxazepam on a variety of psychomotor,
behavioral, and subjective self-report measures. Comparison of
relative potencies across measures showed diazepam to be relatively
more potent in producing liking than in producing psychomotor and
behavioral effects. Diazepam produced greater peak effects than
oxazepam on a number of staff- and subject-rated measures,
including liking. Analysis of time course showed that onset of
effect was more rapid and time to maximal effect was shorter (1-2
hr vs. 4-12 hr) with diazepam than oxazepam, while time to offset
of effect was similar for the two drugs. Diazepam was categorized
as producing barbiturate-like subjective effects (38.3%) more
frequently than was oxazepam (13.8%), while oxazepam was identified
as placebo more often than diazepam. Repeated administration of
160 my of diazepam and 480 mg oxazepam showed that AUC liking was
greater for diazepam than oxazepam, and that tolerance to
psychomotor and behavioral effects occurred with oxazepam but not
diazepam. This study suggests that diazepam may have a higher
abuse liability than oxazepam.
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F. Human Residential Programmed Environment Studies of Caffeine,
Nicotine, and Marijuana Use
These studies are being conducted in a self-contained human
programmed laboratory environment which has been previously
described in detail (Brady et al. 1975), and which provides
accommodations for small groups of three or more human volunteer
research participants during periods of continuous residence from
several days to several weeks. The overall floor plan of the
laboratory and its arrangement within the external building shell
are illustrated in Figure 6. The three identical private
FIGURE 6. Diagrammatic representation of the overall
floor plan of the laboratory and its arrangements
within the external building shell.
rooms (P - each 2.6 x 3.4 x 2.4 m) are similar to small efficiency
apartments containing kitchen and, bathroom facilities, bed, desk,
chair, rug, and other furnishings. The social living area (SL - 4.3
x 6.7 x 2.7 m) is equipped with tables; chairs, sofa beds, storage
cabinets, and a complete kitchen facility. The workshop (WS - 2.6
x 4.1 x 2.7 m) contains benches, stools, storage cabinets, tools,
and a washer-dryer combination. A common bath (B, Figure 6) serves
the social living area and the workshop. Access to the exterior
walls of the laboratory is provided by a four- to six-foot corridor
between the residential chambers and the external building shell
that permits transfer of supplies and materials through two-way
storage facilities accessible from both sides. Remotely controlled
solenoid locks on doors and cabinets throughout the environment
provide for experimental programming of access to various
facilities and resources, though at least one unlocked door in each
compartment permits departure from the laboratory at any time in
case of emergency and preserves the right of subjects to terminate
their participation in an experiment at any time. The electro-
mechanical control devices throughout the environment are
interfaced with a computer system located in an adjoining
laboratory support facility that provides for experimental
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monitoring, programming, recording, and data analysis. Each of the
private rooms of the residential laboratory is equipped with a
microcomputer which is also linked to the central computer system.
A communication panel in each individual chamber includes both a
cassette tape player and a telephone intercom for exchanges between
subjects within the environment. Audio and video equipment in each
of the residential chambers permits continuous monitoring during
conduct of an experiment.
 A series of three-person groups, both males and females, were
initially studied over periods of 7 to 12 days of continuous
residence in the programmed environment. During the experiments,
the participants engaged a behavioral program of contingently
scheduled activities which determined the sequence in which over
twenty activities were selected (Emurian et al. 1978; Emurian et
al. 1982). Throughout the experiments, cigarettes (each subject's
preferred brand) and coffee (instant Chase & Sanborn) were freely
available. Cigarette-smoking and coffee-drinking events were
defined by their onset, as indicated by (1) the operation of a
cigarette lighter or the first puff recorded by an automated
puff-detecting device, and (2) by the requisition of a cup of
coffee. An event time-series technique, the cross-interval
histogram (Sayers 1970), was used to reveal possible relationships
between the two series of events defined by cigarette smoking and
coffee drinking. For any given inter-cigarette interval in which
coffee drinking occurred, a coffee-drinking act was measured in
time from the immediately preceding cigarette ("backward waiting
time") and from the immediately succeeding cigarette ("forward
waiting time"). From many such observations, frequency
distributions of backward waiting times and forward waiting times
were constructed. This event time-series analysis based upon
instances in time of each substance's use revealed a relationship
between cigarette smoking and coffee drinking: a coffee-drinking
event tended to occur late in the inter-cigarette interval, and a
cigarette-smoking event was most probable during the twenty minutes
immediately following a coffee-drinking event.
In a second series of studies, 3 female and 5 male participants
were exposed to a highly structured schedule in the programmed
environment which required activity changes every hour on the hour.
The program permitted selection in any sequence from a variety of
different recreational (e.g., reading, arts and crafts, etc.) and
work (e.g., computer tasks, manual labor, etc.) activities, thus
permitting examination of the frequency and distribution of
cigarette smoking, in particular, within equivalent 1-hr blocks of
time in which markedly different activities were engaged. The rate
and patterning of smoking were markedly different during activities
in which subjects were paid for their performance (work activities)
and during activities in which subjects engaged in recreational and
leisure pursuits (non-work activities). The majority of cigarettes
smoked during work occurred during the last 10 minutes of the hour;
during non-work activities, a larger number of cigarettes were
smoked and were more evenly distributed throughout the 1-hr period.
Seven of the eight subjects displayed this pattern, with slight
variations. The first cigarette was rarely ever smoked during the
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first 50 minutes of a work period, whereas during non-work
activities, the first cigarette tended to occur early in the 1 hr
period. An examination of the rate of smoking during 1 hr periods
preceding and following work periods revealed that the suppression
of smoking during work periods was not followed by a compensatory
increase in smoking rate during the succeeding activity.
A pilot study on smoked marijuana effects has recently been
conducted in the programmed human residential laboratory focusing
upon a number of continuous behavioral and physiological
parameters. Two NIDA-supplied standard experimental cigarettes
were self-administered on each of 4 consecutive days during 8-hr
continuous residences in the programmed environment by a volunteer
participant. In an ABBA design, the subject smoked a placebo
marijuana cigarette in the morning and afternoon of each "A" day
and an active mariiuana cigarette (approx. 8 mg delta-9-THC) in the
morning and afternoon of each "B" day. During -approximately 25% of
the time, the subject completed a performance battery and made
subjective mood ratings. During the remaining time, the subject
freely engaged in ordinary everyday activities (e.g., reading,
writing). Heart rate, general activity, and behavioral
performances were monitored continuously.
Figure 7 shows the cumulative number of activity transitions as a
function of day and time of day. The ordinate represents responses
FIGURE 7. Cumulative number of activity transitions
as a function of day and time of day. Arrows
indicate cigarette smoking onset.
(activity transitions) and the abscissa represents time (8 hr).
Each record covers a daily session, beginning at approximately
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10:30 a.m. and extending to 6:30 p.m. The subject's behavior was
continuously monitored via a television camera mounted in the
subject's private living chamber with his knowledge. A mutually
exclusive and exhaustive set of activity categories was defined
(e.g, computer games, reading, experimental tasks, general
maintenance etc.), and the time of onset and offset of each
activity was entered in an Apple II computer by trained observers.
The cumulative records shown in Figure 7 reflect a general
suppression of activity during the two drug sessions as compared to
the two placebo days. The total number of daily activity
transitions was consistently greater during the two placebo
conditions (M=119.5) than during the two drug conditions (M=77).
Figure 8 shows the heart rate and general activity level during
each daily session. Heart rate was continuously measured with a
FIGURE 8. Heart rate in beats per minute (bpm) and
general activity level in ultrasonic count frequencies
(ucf) presented as lo-minute averages over sessions.
Arrows indicate cigarette smoking onset. Brief
physical exercise periods are reflected in the
activity peak near the end of each daily session.
Lafayette heart rate monitor. The output of the monitor was
detected and counted by a SKED system and is presented in Figure 8
(upper section) as lo-minute averages. General activity was
measured with an ultrasonic motion detector which was sampled once
per second by the SKED system and is also presented in Figure 8
(lower section) as lo-minute averages. Persistent heart rate
accelerations were elicited by active marijuana cigarette smoking
(see arrows at Days 2 and 3), though no such heart rate
accelerations were observed following placebo cigarette smoking
(see arrows at Days 1 and 4). Figure 8 also shows that general
activity levels were higher and more variable during the two
placebo conditions than during the two drug conditions. This
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latter finding, together with the suppression of activity
transitions, suggests that marijuana smoking had a general effect
on the rate of behavior. Interestingly, cross-correlation analysis
between the heart rate and general activity series suggests that
the commonly observed relationship between activity and heart rate
was diminished in magnitude during marijuana smoking.
Figure 9 shows the within-session self-ratings on the subjective
"high" scale collected at hourly intervals. Clear drug effects
obtained immediately following active marijuana smoking were also
seen in the subject's ratings on the ARCI marijuana short form
(MAR-15-2). Immediately prior to smoking active marijuana, the
subject's average MAR score was 3.0 compared to an average score of
8.75 following active marijuana smoking. The average score
preceding placebo marijuana smoking was 1.0 and the average score
following placebo marijuana smoking was 1.75. These self-report
findings are consistent with the results obtained in a companion
study at the Addiction Research Center in which smoking this 8 mg
marijuana cigarette produced subjective "liking" scores comparable
to a 20 mg oral dose of delta-9-THC or a 15 mg subcutaneous dose of
morphine.
FIGURE 9. Subjective rating of "high" as measures
on a 1OOmm visual line analog scale. A score of
0 indicates "not at all high" and a score of 100
indicates "very high." Arrows indicate
cigarette smoking onset.
In the present pilot programmed environment study, each cigarette
was smoked through an automatic puff-detecting device consisting of
a cigarette holder connected to a pressure transducer. The output
of the puff detector was hard wired to a PDP-8 computer where the
onset and offset of each puff was timed and stored. A preliminary
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analysis of the data suggests that patterns of puffing differ for
self-administered active marijuana compared to placebo marijuana.
Figure 10, for example, shows the puffing pattern from an active
marijuana cigarette (upper record) compared to the puffing pattern
from a placebo marijuana cigarette (bottom record), both smoked as
the first cigarette of the day. Although the number of discrete
puffs did not differ markedly, there was a clear difference between
the two cigarettes in the patterning of puffs and in the total
duration of smoking time.
FIGURE 10. Cumulative number of puffs as a function
of time from smoking onset for a single marijuana
cigarette and a single placebo marijuana cigarette.
A battery of performance tasks was administered after each
cigarette in both conditions. While performance on a computerized
multiple task battery (e.g., pattern identification, probability
monitoring, mathematical calculations, etc.) was not systematically
affected -by marijuana smoking, a time estimation task did show
differential drug effects. Intervals of 3, 5, and 10 seconds were
consistently underestimated following active marijuana smoking
(mean error = -.43, standard error = .10) while the same intervals
of 3, 5, and 10 seconds were overestimated following placebo
marijuana smoking (mean error = .15, standard error = .10).
The concurrent and continuous recording of general activity level,
behavioral performance transitions, and autonomic function, as well
as discrete measures of smoking topography, provide for a unique
analysis of the interacting processes which characterize the abuse
potential of this widely used substance.
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Probes for Narcotic Receptor
Mediated Phenomena 3. Oxide
Bridged 5-Phenylmorphans
Terrence R. Burke, Jr., Arthur E. Jacobson,
Kenner C. Rice, Ben Avi Weissman, and
James V. Silverton
In one phase of our program to characterize the opiate receptor
subpopulations on a molecular basis and obtain insight into the elusive
question of the physiological role of these subpopulations in the overall
modulation of the CNS (Rice et al. 1983, Klee et al. 1983), we are preparing
a series of conformationally restricted 5-(m-hydroxyphenyl)morphans to
map topological requirements for in vitro binding to receptor subpopulations
and for in vivo activity. Racemic 5-(m-hydroxyphenyl)morphan (1), first
synthesized by May (May and Murphy 1954) shows morphine-like in vivo
activity (May and Murphy 1955) and is resolvable into enantiomers which
exhibit different degrees of physical dependence capacity (May and Takeda
1970). Examination of 1 shows it to contain a piperidine ring with a freely
rotating m-hydroxyphenyl substituent in the “4” position of the piperidine
ring. (This is the 5 position of the 2-azabicyclo [3.3.1] nonane ring system.)
The equatorial orientation of the phenyl ring relative to the piperidine ring
is in contrast to the axial phenyl orientation of most rigid opiates.
Since the phenyl ring of 1 is freely rotating, any angle relative to the
piperidine ring can be adapted when binding to the receptor matrix. The
importance of the phenyl ring torsion angle has previously been cited as one
factor affecting the enantiomeric difference in potency between prodine
isomers (Larson and Portoghese 1973). We are utilizing an oxide bridge to
restrict the phenyl ring to a known conformation relative to the piperidine
ring. An oxide bridge between the phenyl ring and atoms 4, 6 or 9 of 1
allows a possibility of six isomeric oxide bridged phenylmorphans since each
site of attachment offers an alpha or beta orientation. Such a series of
compounds retains the basic 5-(m -hydroxyphenyl)morphan skeleton while
successfully changing the angle of the phenyl ring in 60° increments relative
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to the previous member of the series. This paper describes the general
synthesis, preliminary biological evaluation and receptor binding of the first
two isomers of the series, 2 and 3. The detailed chemical synthesis of 2 is
presented elsewhere (Burke et al.).
SYNTHESIS
Construction of both the methanobenzofuro[3, 2-d]azocine skeleton of 2
and the propanobenzofuro [ 2, 3-c] pyridine skeleton of 3 made use of the
heteroatom directed photoarylation developed by Schultz and Fu (1976) and
subsequently used in the synthesis of lycoramine (Schultz et al. 1977). Both
2 and 3 were prepared from 6, which in turn was obtained in six steps from
starting amine 4 via aryloxyenone 5. The synthesis of 2 required formation
of a carbon-nitrogen bond at the position ß to the carbonyl function in 6.
This ring closure was achieved by first introducing the double bond present
in 7 (four steps from 6 by the method of Weller and Rapoport, 1976) then
allowing acid catalyzed 1, 4 Michael-type addition of the nitrogen to give 8.
Treatment of 8 with LiAlH4 reduced the ketone to an epimeric mixture of
alpha, beta alcohols with accompanying partial hydrogenolysis of the
aromatic chlorine in addition to reduction of the N-formyl function to
N-methyl. Dechlorination was completed by subjecting the crude product to
hydrogenation over 10% Pd/C. The resulting mixture of epimeric alcohols
was deoxygenated by conversion to the corresponding mesylate esters
followed by hydride displacement of the methanesulfonate groups with
LiEt3BH to yield methyl ether 9. O-Demethylation with BBr3 under
conditions similar to those employed for the high yield conversion of codeine
to morphine (Rice 1977) gave an excellent yield of the phenolic product 2.
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For the synthesis of 3, reduction of 6 with NaBH4 gave alcohol 10 which was
converted to the methanesulfonate ester 11. Reduction of the N-CHO
function with diborane yielded the corresponding N-CH compound which
underwent intramolecular displacement of the methanesulfonate group.
Hydrogenolysis of the chlorine atom gave methyl ether 12 which was O-
demethylated with BBr3 as in the case of 9 to provide the desired phenolic
derivative 3. Single crystal X-ray analysis confirmed the structures of 2 and
3 and showed that the phenyl ring was held at angles of 86° and 8°
respectively relative to least squares planes through atoms 1, 3, 4 and 9 of 1.
Results of biological evaluation are shown below.
PHARMACOLOGICAL AND BIOCHEMICAL PROPERTIES OF 5-(m-HYDROXYPHENYL-MORPHANS
AND OXIDE BRIDGED 5-(M-HYDROXYPHENYL)MORPHANS
aAtwell and Jacobson, 1978. bAceto et al. 1983. CMethod: according to
Itzhak et al. 1981. Only 10% of. mice were affected at 50 mg/kg. eOnly
20% of mice were affected at 50 mg/kg. f53% of mice were affected at 30
mg/kg and 62% were affected at 60mg/kg at which doses convulsions were
observed.
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CONCLUSION
While both 2 and 3 are inactive in the hot plate assay for
antinociceptive activity, 3 does exhibit appreciable binding to opiate
receptor preparations from whole rat brain homogenate (IC50 = 96 nM for 3
may indicae that the 8° phenyl torsion angle of 3 is approaching that
as compared to IC50 = 5.2 nM for (+)-1 and IC50 = 1,766 nM for 2.) This
required for optimal binding. Work is in progress on the synthesis of the
remaining four isomers in the series. It seems likely that completion of the
series will provide valuable insight concerning the requirements of the
phenyl torsion angle for binding to opiate receptors.
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An In Vivo Pharmacological
Analysis of Benzomorphan
Binding Sites in Rats
Alan Cowan and Debra E. Gmerek
INTRODUCTION
Bombesin, a tetradecapeptide which was originally isolated from
frog skin, causes excessive scratching when given i.c.v. to rats.
Within 1 min of injection, low doses of the peptide (A = 0.013
µg, i.c.v.) elicit vigorous scratching (of mainly the ace, head
and neck) which continues, almost constantly, for at least 45 min
(Gmerek and Cowan, 1983a). Scratching is not a behavior that has
commonly been monitored in preclinical opiate research. This
situation may change, since pruritus is often an annoying side
effect of epidural or intrathecal analgesia in humans. It is
known that several opioids and opioid peptides antagonize the
reciprocal hindlimb scratching response associated with intra-
cerebral or intrathecal substance P in mice (Share and Rackham,
1981; Hylden and Wilcox, 1983). Also, when monkeys that have
received cyclazocine, nalorphine or certain oripavines chronically
are challenged with naloxone, or are abruptly withdrawn from these
agents, scratching is very prominent (Cowan, 1973).
We report here that scratching caused by bombesin in rats is
attenuated in a stereospecific and dose-related manner by several
important benzomorphan analgesics but is essentially unaffected by
a wide range of opioids. Our pharmacological analysis of this
antagonism has provided in vivo evidence for benzomorphan-selective
binding sites in rats. Such sites have previously been postulated
fran binding studies with, for example, rat brain membranes (Chang
et al. 1981) and homogenates of rat lumbo-sacral spinal cord
(Gouarderes et al. 1982).
MATERIALS AND METHODS
Animals and Surgery
Male Sprague Dawley albino rats (Zivic-Miller, 180-200 g) were
each implanted stereotaxically with a stainless steel cannula into
the right lateral cerebral ventricle. They were then housed
individually and allowed 4-7 days for recovery prior to testing.
Each rat was used on only one occasion.
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Compounds and Injections
The following agents were dissolved in saline: azidomorphine
bitartrate. (Dr. J. Knoll, Semmelweis University of Medicine,
Budapest), buprenorphine HCl (NIDA), codeine phosphate (MS & D),
dextrorphan (NIDA), ethylketocyclazocine (EK) methanesulfonate
(Sterling-Winthrop), heroin HCl (NIDA), ketocyclazocine methane-
sulfonate (Sterling-Winthrop), levorphanol tartrate (Roche),
meperidine HCl (Sterling-Winthrop), methadone HCl (NIDA), morphine
sulfate (Mallinckrodt), nalbuphine HCl (Endo), nalorphine HCl
(MS & D), -naloxone HCl and -naloxone (Dr. A.E. Jacobson, NIH),
naloxone HCl (Endo) and thebaine (NIDA).
Bremazocine (Dr. D. Romer, Sandoz, Basel), cyclazocine, and
EK, -pentazocine (all Sterling-Winthrop), phenazocine HBr, and
-SKF 10,047 (N-allylnormetazocine HCl) (all SK & F) and Win
44,441-3 (2 6 llS*)- -l-cyclopentyl-5-(1,2,3,4,5,6-hexahydro-
8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-ll-yl)-3-
pentanone methanesulfonate (Sterling-Winthrop) were dissolved in
a minimal volume of glacial acetic acid, the pH adjusted to 5 with
sodium bicarbonate and made up to volume with saline.
Aliquots of the following peptides were each dissolved in saline
daily as needed: ß-endorphin (Dr. A.A. Manian, NIMH), synthetic
bombesin (Sigma and Boehringer Mannheim), DADLE (D-Ala2, D-Leu5-
enkephalin) (Sigma), dynorphin (1-13) (U.S. Biochemical), ICI
154,129 (N,N-bisallyl-Tyr-Gly-Gly (CH2S)-Phe-Leu-OH) (DR. M.J.
Turnbull, ICI, England) and metkephamid (Dr. R.C.A. Frederickson,
Eli Lilly).
ICI 154,129, metkephamid and the alkaloid opioids were injected
S.C. in a volume of 1 ml/kg 15 min before a standard submaximal
scratch-inducing dose of bombesin (0.10 µg, i.c.v.; Gmerek and
Cowan, 1983a). ß-Endorphin and dynorphin (1-13) were given i.c.v.
15 min before bombesin; DADLE, was administered i.c.v. immediately
before the bombesin. I.c.v. injections to hand-held, conscious
rats were in volumes of 3-4 µl (over 20 sec) followed by 0.5-1 µl
saline washes.
Doses of the enantiomers of naloxone were calculated in terms of
the freebase. Doses of other agents refer to the particular salt.
Dosing schedules that involved injecting rats with EK, morphine,
phenazocine or saline twice daily (at 8 a.m. and 5 p.m.) for 4
consecutive days are shown in table 1. Challenge with bombesin
took place 19-20 hr after the last of the multiple injections.
TABLE 1 Dosing schedules for test compounds
Compound Day 1 Day  2 Day 3 Day 4
Ethylketocyclazocine 5a 10 20 20
morphine 10 30 100 100
Phenazocine 1 3 10 10
a(mg/kg, s.c.)
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Quantitation of Behavior
The rats were placed singly in Plexiglas observation boxes (22 an
long; 18 cm wide; 25 an high) at least 15 min before testing.
Monitoring sessions began immediately after the last bombesin
injection. Four rats were observed at a time with the help of a
microcomputer, as described previously (Murray et al. 1981). Each
rat was monitored for 5 sec out of every 20 sec for 30 min.
Positive scores were given for the demonstration of grooming
behavior during any 5 sec observation period. There was conse-
quently a maximum of 90 positive grooming scores per rat in each
30 min session. The percent of the maximum number of grooming
episodes (%MGE) was calculated for each rat. Groups containing a
minimum of 5 rats were used for each data point. Absolute groan-
ing scores were examined statistically by analysis of variance
followed by Dunnett's test or the Mann-Whitney U test, as approp-
riate. A values were determined by linear regression analysis
of absolute data from which saline control values had been sub-
tracted. Confidence limits (95%) of A50 values are shown within
parentheses.
RESULTS
Classification of Opioids
Behaviorally nondepressant doses of 6 benzomorphan analgesics
significantly attenuated the excessive scratching elicited in rats
by a standard dose of bombesin (0.10 µg, i.c.v.). The benzo-
morphans (and highest nondepressant doses) were bremazocine (10
mg/kg), cyclazocine (5 mg/kg), EK (0.75 q/kg), ketocyclazocine
(1 mg/kg), -pentazocine (20 mg/kg) and phenazocine (1 mg/kg).
The A50 values for EK and phenazocine were 0.36 (0.33-0.40) mg/kg
and 0.29 (0.19-O.43) mg/kg, respectively.
Even at a dose as high as 10 mg/kg, and -enantiomers of the
benzomorphan SKF 10,047 (the prototype agonist at sigma opiate
receptors; Martin et al. 1976) did not markedly affect bombesin-
induced scratching. The rats were behaviorally excited by the
drug combinations used in this experiment. A high dose of Win
44,441-3 (20 mg/kg), a benzomorphan that is a pure opioid antag-
onist (Ward et al. 1983), had no great influence on the scratching.
The opioids and opioid peptides listed below were tested against
bombesin at their highest behaviorally nondepressant dose. None
are benzomorphans. None had a statistically significant atten-
uating effect on the scratching. The inactive agents were as
follows: azidomorphine (0.05 mg/kg), buprenorphine (0.50),
codeine (40), dextrorphan (30), heroin (0.50), levorphanol (1),
meperidine (25), methadone (1), morphine (10), nalbuphine (10),
nalorphine (50), naloxone (10), thebaine (25), ICI 154,129 (30),
metkephamid (30) and ß-endorphin (10 µg). Classification of
dynorphin (1-13) and DADLE could not be accomplished because
these peptides caused excessive grooming by themselves.
Further Studies with EK and Phenazocine
The antagonism of bombesin-induced scratching in rats by EK was
stereospecific, with -EK (0.50 mg/kg; %MGE = 14±4, P<0.001), but
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not -EK (0.50 mg/kg; %MGE = 71±6, P>0.05), being active.
-Naloxone (50-100 µg/kg) prevented the antagonizing effect of EK
(0.50 mg/kg) in a dose-related manner. The A50 value for
naloxone was only 76 (68-86) µg/kg; -naloxone was essentially
inactive.
EK (10 µg) and phenazocine (10 µg) lost their ability to attenuate
the scratching if they were given i.c.v.
Pretreatment with Buprenorphine
Buprenorphine (0.50 mg/kg), given 0.5 hr before EK and phenazocine
(both at 0.50 mg/kg), or 24 hr before EK, did not counter the
ability of the benzomorphans to antagonize the scratching.
Tolerance and Cross-Tolerance Studies
Four twice-daily injections of EK (5-20 mq/kg) caused tolerance to
the anti-bombesin action of EK. Similarly, twice-daily injections
of phenazocine (1-10 mg/kg) for 4 days caused tolerance to the
anti-bombesin action of phenazocine (figure 1). When rats were
given 8 injections of morphine (10-100 mg/kg) across 4 days,
bombesin still elicited excessive scratching. The same dosing
schedule with morphine did not affect the ability of either EK or
phenazocine to attenuate the scratching (figure 1).
DISCUSSION
In this study, we found that bombesin-induced scratching in rats
is attenuated in a stereospecific and (dose-related manner by
benzomorphan analgesics. Other commonly used opioids and opioid
peptides were ineffective against bombesin when tested at behav-
iorally nondepressant doses.
We used EK and phenazocine as prototype benzomorphans for further
study of the inhibitory opiate link modulating bombesin-induced
scratching. The S.C. A50 value for EK (0.36 mg/kg) against
scratching is comparable to the corresponding antinociceptive A50
value (0.40 mg/kg) in the tail compression test with OUT strain
of rat. The activity of EK resides largely in the levo enantiomer
in both procedures. The ability of EK to attenuate scratching was
prevented by naloxone in a potent and stereospecific manner.
These results, together with our demonstration of tolerance
development to the inhibitory action of EK (and phenazocine),
suggest that stereospecific opiate receptors are involved.
Recall, however, that opioids other than benzomorphans are not
active in this model. Mu opiate receptors (Martin et al. 1976)
can probably be excluded from consideration. Thus, an eight-
injection dosing schedule of morphine that, in our hands, causes
tolerance to even the gastrointestinal slowing effect of morphine,
had no marked influence on the ability of either EK or phenazocine
to antagonize scratching. Furthermore, when mu receptors were
occluded by buprenorphine, a partial agonist that dissociates very
slowly from mu receptors, EK and phenazocine could still antag-
onize bombesin-induced scratching.
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FIGURE 1 Effect of 4 twice-daily injections of saline (S),
ethylketocyclazocine (EK), phenazocine (P) or morphine (M)
on the ability of EK (0.50 mg/kg, s.c.) and P (0.50 mg/kg) to
attenuate grooming induced by bombesin (0.10 µg, i.c.v.) in
rats. %MGE is the percent of the maximum possible number of
grooming episodes in 30 min.
aP<0.001 compared to (8xS) + EK controls.
b
P<0.001 compared to (8xS) + P controls (ANOVA and Mann-Whitney
U test).
EK and phenazocine show site specificity in their ability to
antagonize scratching elicited by bombesin. When given i.c.v.,
neither benzomorphan influenced scratching. It therefore appears
that, despite bombesin being given into the lateral cerebral
ventricle, the sites mediating anti-bombesin effects are not
readily accessible to EK or phenazocine after i.c.v. injection.
Five of the six benzomorphans found to be active in our study
(bremazocine, cyclazocine, EK, ketocyclazocine and pentazocine)
are conventionally regarded as kappa agonists, that is, they are
ligands for the kappa subtype of opiate receptor (Martin et al.
1976). Recent findings from in vitro ligand competition studies
support the existence of distinct binding sites for kappa agonists
in the brains of several species (see Gmerek and Cowan, 1983b
for references). Binding sites showing selectivity for benzo-
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morphans (both kappa and sigma agonists) have been identified in
the brains of rats, toads and humans (see Gmerek and Cowan, 1983b
for references). Interestingly, Gouarderes et al. (1982) claim
that benzomorphan and kappa sites in rat lumbo-sacral spinal cord
are distinct, with the former resembling benzomorphan sites of rat
brain.
The parallel activities of EK and phenazocine in our study suggest
that (a) phenazocine interacts with kappa binding sites to
influence rat behavior, and/or (b) the sites mediating inhibition
of bombesin-induced scratching are selective for benzomorphan-
derived agonists (Win 44,441-3, a benzomorphan that is a pure
opioid antagonist, is not active). The latter view may be the
more valid since nalorphine and nalbuphine are both inactive in
the test yet possess kappa-like features. Further experiments
with non-benzomorphan kappa agonists may help to clarify this
issue. Also, cross-tolerance studies between phenazocine and EK
will provide useful information on the mode of action of these
agents in our test.
In summary, we have used classic pharmacological approaches for
inferring opiate receptor mediation in vivo. Since bombesin-
induced scratching in rats is antagonized by benzomorphan analges-
ics, but not by other standard opioids, our results provide in
vivo evidence for the existence of previously postulated benzo-
morphan selective binding sites. The model affords a simple, yet
novel, behavioral endpoint that can be used when defining the
pharmacological profile of new benzomorphans and their antagonists.
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Differential Tolerance and Cross-
Tolerance to Chronic Treatment
with Mu and Kappa Opioid
Agonists in the Rat
Gerald A. Young and Naim Khazan
INTRODUCTION
We recently assessed the acute effects of mu, kappa and sigma ooioid
agonists on cortical EEG and EEG power spectra in the rat and re-
ported on differential dose-related effects of morphine, ketocycla-
zocine and SKF-10,047 (N-allyl-normetazocine) on these parameters
(Young et al. 1981; Young and Khazan 1983). Intravenously admini-
stered morphine produced high-voltage cortical EEG bursts associ-
ated with increases in EEG spectral power in the zero to 10 Hz
range. Ketocyclazocine produced high-voltage EEG bursts associated
with a predominant spectral peak in the 5-8 Hz band, SKF-10,047
produced desynchronized cortical EEG along with frequent theta wave
activity whose EEG power spectra peaked at about 7.5 Hz and had the
least power. Furthermore, the (-) enantiomers of methadone (mu
agonist) and ketocyclazocine were active, producing EEG and EEG
power spectral effects qualitatively similar to those produced by
the respective racemic mixtures. The (+) enantiomers were found to
be inactive. The (+) enantiomer of SKF-10,047, however, produced
behavioral changes that were, in part, similar to those produced by
the psychotomimetic agent dimethyltryptamine (Kovacic and Domino
1976).
Another characteristic of the opioid agonists is their ability to
produce tolerance with variable degrees of cross-tolerance. In
this regard, it has been reported that chronic administration of
morphine, ketocyclazocine and SKF-10,047 to the chronic spinal dog
produced tolerance to their agonistic effects (Martin et al. 1976).
Using the same preparation, tolerance development to the agonistic
effects of cyclazocine, an opioid with purported kappa and sigma
agonistic and mu antagonistic oroperties, was also demonstrated.
However, morphine-dependent dogs demonstrated no cross-tolerance to
the agonistic effects of cyclazocine (Gilbert and Martin 1976). On
the other hand, ketocyclazocine-dependent dogs seemed to have de-
veloped cross-tolerance to morphine. Furthermore, in an in vivo
preparation utilizing tissue from guinea pig ileum, while toler-
ance to the effects of mu and kappa opioid agonists was produced,
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cross-tolerance was not demonstrated (Schulz et al. 1981).
The objective of the present study was to further assess the develop-
ment of tolerance and cross-tolerance to chronic administration of mu
and kappa opioid agonists (morphine and ethylketocyclazocine, re-
spectively) by studying their effects on EEG power spectra and be-
havior in the rat.
METHODS
Sixteen female Sprague-Dawley rats (250 - 300 g) were implanted with
bipolar epidural frontoparietal EEG and temporalis EMG electrodes
and with chronic indwelling jugular cannulae. Surgical procedures.
have been previously described (Khazan 1975). The i.v. cannulae
were prepared and implanted according to the method of Weeks (1962,
1972). During the experiments, rats were housed in individual cages
(12" x 12" x 24"). To permit free movement of the rat, each cage
was equipped with a swivel connector having concentric mercury pools
which served as noise-free sliding contacts (Khazan et al. 1967).
These freely-moving rats were allowed to acclimatize to the experi-
mental cages for two to three days before experimentation. Lighting
conditions consisted of a timer-regulated lights-off period from
10 pm to 6 am.
For each rat, direct EEG activity was filtered to pass frequencies
between 1 and 35 Hz. The EEG and integrated EMG activities were con-
tinuously recorded on a Grass polygraph. The EEG was simultaneously
recorded on FM magnetic tape using a Hewlett-Packard. Model-3940-A
recorder. Power spectral analysis was performed offline using a
Nicolet MED-80 minicomputer system; EEG power spectra were derived
from 10-sec samples of EEG that were digitized at a sampling rate of
lOO/sec, and power spectral densities were estimated at 0.05 in-
tervals from zero to 50 Hz (Young et al. 1978; Khazan and Young
1980). Average power spectra were obtained by averaging spectra de-
rived from six 10-sec epochs; weighted geometric smoothing over three
neighboring frequencies was used.
Behavioral states of sleep, REM sleep and wakefulness were identified
by corresponding changes in EEG and EMG recordings (Khazan et al.
1967; Khazan 1975). Occurrences of opioid-induced high-voltage EEG
bursts and of hyperarousal were also identified from EEG and EMG re-
cordings.
One day prior to the initiation of chronic morphine treatment, each
of eight rats was given an i.v. dose of morphine (10 mg/kg), and the
effects of the injection on EEG, EEG power spectra and behavior were
studied. These eight rats were then chronically treated with mor-
phine by a series of automatic i.v. injections. Morphine sulphate
was dissolved in isotonic saline at a concentration of 10 mg/ml.
On the first day, rats received hourly injections of 1.25 mg/kg of
morphine. The dose was then increased to 2.5, 5.0 and 10.0 mg/kg/hr
on successive days. On the fifth day, the rats received 10.0 mg/kg
of morphine every three hours and were subsequently maintained on
this injection schedule. Effects of 10 mg/kg doses of morphine on
122
EEG, EEG power spectra and behavior during the seventh day were com-
pared with those before initiation of chronic morphine treatment.
Challenge doses of ethylketocyclazocine (EKC, 10 mg/kg) were sub-
stituted for morphine on the eighth 1 day. Effects of EKC on EEG, EEG
power spectra and behavior in rats chronically treated with morphine
were compared to the effects of EKC in non-tolerant rats and in EKC-
tolerant rats.
In a second group of eight rats, one day prior to the initiation of
chronic EKC treatment, each rat was given an i.v. dose of EKC (10
mg/kg). The same experimental parameters were assessed in these rats
and in the same way as those in the first group, These eight rats
were then chronically treated with EKC by a series of automatic i.v.
injections. EKC methanesulfonate was dissolved in a small amount of
0.5 N NaOH and brought up to a concentration of 2.5 mg/ml with iso-
tonic saline. On the first day, rats received a dose of 2.5 mg/kg/
2 hrs. The dose was then increased to 5.0 and 10.0 mg/kg/2 hrs every
other day. On the eighth day, challenge doses of morphine (10 mg/kg)
were given in the place of regularly scheduled automatic EKC in-
jections.
RESULTS
Representative effects of morphine administration (10 mg/kg) on EEG
and behavior before and after chronic treatment are depicted in
Figure 1 for an individual rat, In the non-tolerant state, morphine
induced a predominance of behavioral stupor that was associated with
high-voltage EEG bursts for 90 min, followed by a predominance of be-
havioral arousal associated with low-voltage desynchronized EEG for
another 90 min. The first occurrence of slow-wave sleep emerged
three hrs after morphine administration. In the morphine-tolerant
state, however, morphine produced behavioral stupor for only ten min
followed by an arousal state for 80 min. In this case, the first
occurrence of slow-wave sleep after morphine injection emerged after
90 min. All eight rats demonstrated similar degrees of tolerance to
the EEG and behavioral effects of morphine challenge. Mean latency
for the eight rats to the occurrence of the first REM sleep episode
after morphine administration was found to be 246 ± 5 (mean ± s.e.m.)
min in the non-tolerant state and 90 ± 4 min in the tolerant state.
Representative examples of EEG and derived EEG power spectra during
the morphine-induced stuporous state are shown in the too of Figure
2 during non-tolerant and tolerant states. Five minutes after mor-
phine injection in the non-tolerant state, the EEG consisted of al-
most continuous high-voltage bursting, the spectral power of which
predominated over the zero to 10 Hz range. Five minutes after mor-
phine injection to the morphine-tolerant rat, however, the amount of
EEG bursting and the peak-to-peak amplitude of individual bursts
were substantially less than that which occurred in the non-tolerant
rat. This is reflected by a difference in the magnitude of the re-
spective power spectra; the power spectra associated with high-
voltage EEG bursts in the tolerant state consist of only about 25%
of total density area compared to that associated with the non-
tolerant state.
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FIGURE 1
EEG and behavioral responses of an individual rat to a
10 mg/kg dose of morphine during the non-tolerant and
tolerant states.
In the case of EKC in the non-tolerant state, an injection of EKC
(10 mg/kg) typically produced a predominance of behavioral stupor
and associated high-voltage EEG bursts for 70 min followed by a pre-
dominance of behavioral arousal and associated low-voltage desyn-
chronized EEG for 50 min. The first occurrence of slow-wave sleep
emerged 2 hrs after the EKC injection. In the tolerant state, EKC
typically induced oscillations between behavioral stupor and wakeful-
ness for 25 min, and the first occurrences of slow-wave sleep emerged
in about 30 min. All eight rats demonstrated similar degrees of
tolerance to EEG and behavioral effects of EKC. Mean latency to the
first REM sleep occurrence after EKC administration was 220 ± 9 min
in the non-tolerant state and 68 ± 3 min in the MC-tolerant state.
Representative examples of EEG and derived EEG power spectra during
the EKC-induced stuporous state are shown in the bottom of Figure 2
in both the non-tolerant and tolerant states. During the first five
min after EKC injection in the non-tolerant state, the EEG consisted
of closely spaced high-voltage EEG bursts. The correlated EEG power
spectra had a predominant peak in the 5-8 Hz band. During the first
five min after EKC injection in the tolerant state, the amount of
EEG bursting and the peak-to-peak amplitude of individual bursts
were substantially less than that which occurred in the non-tolerant
state. This is reflected by a difference in the size of the re-
spective power spectra; the power spectra associated with high-
voltage EEG bursts in the tolerant state decreased to about one-
third of the total power density area compared to that associated
with the non-tolerant state.
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MORPHINE (10 MG/KG)
NON-TOLERANT TOLERANT
ETHYLKETOCYCLAZOCINE (10 MG/KG)
NON-TOLERANT TOLERANT
FIGURE 2
Cortical EEG samples and associated EEG power spectra
are shown for individual rats during opioid-induced
behavioral stupor. Effects of morphine are shown in
the top of the figure during the non-tolerant and
tolerant states. Similar data are shown after MC
administration in the bottom of the figure.
During cross-tolerance assessment, EKC administration (10 mg/kg) to
the morphine-tolerant rats induced a predominance of behavioral
stupor and associated high-voltage cortical EEG bursts for about 70
min, followed by a oredominance of behavioral arousal and associated
low-voltage desynchronized EEG for about 50 min. This overall effect
of EKC administration in the morphine-tolerant rats was analogous to
that seen when EKC was given to the non-tolerant rats; thus, no
cross-tolerance to EKC was seen in the morohine-tolerant rats. Fur-
thermore, mean latency to the first REM sleep occurrence after EKC
was 220 ± 10 min in the morphine-tolerant rats, In the EKC-tolerant
rats, on the other hand, morphine administration (10 mg/kg) produced
behavioral stupor and associated high-voltage EEG bursts for about 10
min, followed by a predominance of behavioral arousal and low-voltage
desynchronized EEG for about 75 min. This overall effect of morphine
in the EKC-tolerant rats was similar to that seen when morphine was
administered to the morphine-tolerant rats; thus, cross-tolerance
was demonstrated. Mean latency to the first occurrence of REM sleep
after morphine administration was 98 ± 5 min in the EKC-tolerant rats
compared to 90 ± 4 min in the morphine-tolerant rats.
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DISCUSSION
Studies dealing with opioid-receotor interactions have demonstrated
that in the rat morphine does not readily displace radiolabeled EKC,
but that both ketocyclazocine and EKC displace radiolabeled dihydro-
morphine (mu agonist) and EKC equally well (Wood et al. 1981; Wood
1982). However, the nature of the interaction of EKC with mu re-
ceptors is not clear at present. Based upon these in- vitro data,
one might predict that chronic morphine treatment would have an
effect on the pharmacodynamics of kappa receptors, and that, there-
fore, no cross-tolerance to EKC in morphine-tolerant rats should
develop. On the other hand, one might predict that chronic EKC
treatment would alter characteristics of mu receptors, and, there-
fore, cross-tolerance to morphine in EKC-tolerant rats might de-
velop if EKC has mu receptor agonistic activity. Our EEG and EEG
power spectral data support these predictions, While EKC-tolerant
rats demonstrated full cross-tolerance to the effects of morphine
on EEG and EEG power spectra, no cross-tolerance to effects of EKC
was observed in morphine-tolerant rats. Lack of reciprocal cross-
tolerance between different opioids has been previously noticed in
other in vivo experiments (Martin et al. 1976; Gilbert and Martin
1976). These authors noted that morphine-tolerant dogs demonstrated
no cross-tolerance to the agonistic effects of cyclazocine, while
ketocyclatocine-dependent dogs may have developed cross-tolerance to
the effects of morphine.
Although it is generally accepted that EKC demonstrates a significant
property to bind to mu receptors, the nature of the biological re-
sponse resulting from such binding needs further evaluation. Thus, 
further studies will be necessary to more fully understand inter-
actions between mu and kappa opioid agonists at both the behavioral
and molecular levels.
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Relationship of Plasma Level and
Pharmacological Activity of
Methadone
Shean-Jang Liu and Richard I. H. Wang
INTRODUCTION
The metabolism and disposition of methadone in experimental animals
(Pohland et al. 1971; Misra et al. 1973; Ling et al. 1981) and man
(Inturrisi and Verebely 1972; Anggard et al. 1975; Verebely et al.
1975) have been reported. However, no report has appeared on the
quantitative relationship between the levels of methadone in brain
and plasma and the analgesic activity of methadone. Based on sev-
eral drug interaction studies in rats, we have shown that brain
concentration of methadone may be directly related to the analgesic
effect of methadone (Liu and Wang 1975; Liu et al. 1975; 1978).
In addition to being used as a potent analgesic, methadone is used
for treatment of opiate dependence. It has been suggested that
methadone maintenance patients with steady-state plasma concentra-
tions of methadone above 200 ng/ml have a better record of rehabil-
itation (Holmstrand et al. 1978). However, there are conflicting
reports regarding the relationship between the concentrations of
methadone in the plasma and several pharmacological effects of
methadone (Inturrisi and Verebely 1972; Blake et al. 1973; Horns
et al. 1975; Holmstrand et al. 1978). Whether monitoring of blood
methadone levels is helpful in adjusting the dosage of methadone
in patients maintained on methadone has not been established.
The present study was designed to investigate the quantitative
relationship between the levels of methadone in the brain and plasma
of rats and to provide insight into the possible utilization of mon-
itoring methadone levels in the plasma as an index of the pharmaco-
logical effect of methadone. Analgesia was chosen as the pharmaco-
logical effect of methadone evaluated for this study. The results
demonstrate that a good correlation exists between the analgesic
activity of methadone and the levels of methadone in brain and
plasma. This paper also gives evidence that decreased blood level
of methadone in methadone maintenance patients, as a result of
phenobarbital-induced acceleration of methadone biotransformation,
precipitates opiate withdrawal symptoms.
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METHODS
Analgesic studies. Male Sprague-Dawley rats (King Animal Labs,
Oregon, WI) weighing 120-160 g were used. The rats were fasted
overnight with free access to water before being used for experi-
ments. Analgesia was measured by a modified hot-plate method of
Eddy and Leimback (1953) as described previously (Liu and Wang
1975). The percentage of maximal possible effect (%MPE) of anal-
gesia was calculated by the method described by Dewey and Harris
(1971).
Analysis of methadone in brain and plasma. For tissue distribu-
tion study of methadone in rats, rats were given 14C-dl-methadone
hydrochloride (1.5-5.0 mg/kg, 15 µCi/kg) and killed by decapitation
at different times. Concentrations of total 14C in brain and
plasma were determined by directly counting 0.5 ml of 20% (w/v)
brain homogenate in distilled water or 0.3 ml of plasma in 15 ml
of Aquasol scintillation solution (New England Nuclear Corporation,
Boston, MA). The concentrations of 14C-methadone and its major
metabolites in brain and plasma were determined by high-performance
liquid chromatography (HPLC) as described by Roerig et al. (1982).
Samples of brain homogenate and plasma were lyophilized and extrac-
ted three times with methanol. The combined extracts were evapor-
ated to dryness under a stream of nitrogen and the residue was
redissolved in methanol. Portion of the methanol was injected into
the HPLC system.
Methadone in the plasma of human subjects was extracted by n-butyl
chloride as described by Inturrisi and Verebely (1972), except that
methadol was used as an internal standard. The concentration of
methadone was determined by gas-liquid chromatography (GLC). The
GLC analysis was performed on a Hewlett Packard gas chromatograph
model 5711A equipped with a hydrogen flame ionization detector and
electronic integrator. The column is 1 m x 4 mm ID glass, packed
with 3% OV-17 on 80-100 mesh chromsorb W. Temperature for the
injector, detector and column oven were 250°, 300° and 220°,
respectively. The carrier gas was nitrogen at a flow rate of
60 ml/min. Hydrogen and air flow rates were 60 and 240 ml/min,
respectively.
Analysis of the regression line and calculation of ED50 and LD50
values were made according to the computer programs of Tallarida
and Murray (1981) using an Apple II Computer. Significance was
attributed at p <0.05 using Student's t test.
RESULTS
Concentrations of methadone in the brain and plasma and the anal-
gesic effect of methadone in rats. Figure 1 indicates that more
than 90% of the 14C in the brain was unchanged methadone while
only about 7% of the 14C was 2-ethyl-5-methyl-3,3-diphenylpyrroline
(EMDP). The pyrrolidine metabolite, 2-ethyllidine-1,5-dimethyl-3,
3-diphenylpyrrolidine (EDDP) was not detectable in the brain. The
percentage of l4C in the brain as unchanged methadone was constant
during a 3-hr period after administration, of l4C-methadone. There-
fore, the 14C in the brain was considered to be unchanged methadone
for practical purposes.
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FIGURE 1. High-performance liquid chromatogram of rat brain
extract after administration of 14C-methadone. The abscissa
shows the retention time of the sample.
FIGURE 2. Time-response curves of analgesia and concentrations
of methadone in brain and plasma. One group of 8 rats were given
methadone (5 mg/kg, SC) for measurement of analgesia. Another
four groups of 6 rats each were given 14C-methadone (5 mg/kg,
15 µCi/kg, SC) and killed by decapitation 30, 60, 90 or 120 min
after injection. Each point and vertical bar represents a mean
± SE for 6-8 rats.
Figure 2 illustrates the time-response curves of methadone over
a 3-hr period after administration of methadone. It can be seen
that both the analgesic reaction time and brain concentration of
methadone fell sharply after reaching the peak time of 30 min.
There were significant differences between the brain concentrations
of methadone at 30-min vs 60-min and 60-min vs 90-min intervals.
There were also significant differences between the analgesic
reaction times at the same two time intervals.
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The concentration of methadone in the plasma was much lower than
that in the brain at all the corresponding times after administra-
tion of methadone as shown in figure 2. The percentages of 14C
in the plasma of rat as unchanged methadone were 78, 68, SO and
53% at 30, 60, 90 and 120 min, respectively, after administration
of 14C-methadone.
In order to test whether there are dose-response relationships
between the dose of methadone and the concentrations of methadone
in the brain and plasma, groups of rats were tested for analgesia
30 min after administration of several different doses of metha-
done and killed immediately after analgesia was measured. As
illustrated in figure 3, the relationship between the observed
DOSE OF METHADONE (mg/kg. S.C.)
FIGURE 3. Dose-response effects of methadone for brain and plasma
methadone concentrations and analgesic activity of methadone.
Groups of 5 rats each were injected with a dose of 14C-methadone
(1.5-3.0 mg/kg, 15 µCi/kg, SC) and analgesia was measured 30 min
after injection. Immediately after the analgesic reaction time
was taken the rats were killed by decapitation for &termination
of brain and plasma methadone concentrations. Each point and
vertical bar represents the mean ± SE for 5 rats.
brain methadone concentration, plasma methadone
concentration, %MPE).
analgesic response (expressed as %MPE) and the dose of methadone
administered was linear. The analgesic ED50 was estimated to be
2.04 mg/kg (1.58-2.63, 95% confidence limit). Figure 3 also indi-
cates that a linear relationship existed between the dose of metha-
done administered and the brain concentration of methadone.
Regression analysis of these data indicates a highly significant
correlation between the dose of methadone and the brain concentra-
tion of methadone (correlation coefficient r = 0.973, p <0.001).
A linear relationship also existed between the dose and plasma
concentration of methadone. Regression analysis of the data shows
a significant regression (p <0.001) with a correlation coefficient
0f 0.748.
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FIGURE 4. Relationships between the analgesia and the concentra-
tions of methadone in brain and plasma. Treatment of rats is as
described in figure 3. Values are means ± SE for 5 rats.
A highly significant correlation (r = 0.861, p <0.001) between the
brain concentration of methadone and the analgesic %MPE was found
as shown in figure 4. A 50% MPE methadone analgesia corresponded
to a brain concentration of 1.44 nmole/g. Figure 4 also indicates
a significant correlation between the plasma concentration of
methadone and the analgesic %MPE (r = 0.718, p <0.001. A plasma
concentration of 0.52 nmole/ml corresponded to SO% of the analgesic
MPE.
Plasma concentrations of methadone in methadone maintenance patients.
Blood samples of a few selected patient volunteers from our metha-
done maintenance program were analyzed to determine methadone plasma
concentrations as a function of methadone dose. As shown in table 1
there are large individual differences in the plasma concentrations
of methadone. However, the time course of methadone in the plasma
was similar for each subject with peak methadone plasma concentra-
tions occurring at about two hours. The concentration of methadone
in the plasma of each subject at each time interval and the area
under the plasma methadone concentration-time curve were all
increased with increased doses of methadone.
Phenobarbital-induced decrease in methadone plasma levels and
withdrawal syndrome in a methadone maintenance patient. While we
were determining the plasma levels of methadone in patients main-
tained on different doses of methadone, we observed a case which
provided evidence of metabolic drug interaction between, pheno-
barbital and methadone. A 28-year-old former heroin addict was
maintained and stabilized on 95 mg methadone per day. Two months
after the patient had been maintained on this dose of methadone his
mean zero time plasma concentration was 283 ng/ml and the mean peak
plasma methadone concentration was 591 ng/ml which occurred 2 hours
after methadone administration as shown in figure 5. While the
patient was being maintained on this stabilized dose he was com-
fortable and without any complaint of withdrawal symptoms. Three
months after the blood methadone levels were monitored, the patient
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TABLE 1
Plasma Concentrations of Methadone and Area Under
the Plasma Methadone Concentration-time Curve (AUC)
in Methadone Maintenance Subjectsa
METHADONE CONCENTRATION
Hours After Methadone
AUC
Dose
Subject (mg) Ob 1 2 4 8 O-8
T.L. 55 135 150 198 175 175 1375
80 170 255 380 250 305 2083
T.W. 80 78 125 177 113 105 956
100 75 345 356 306 220 2277
D.N. 45 26 145 135 87 75 775
60 16 117 97 114 56 809
A.C. 50 90 195 260 218 147 1552
70 115 188 318 275 205 1914
a Plasma concentrations of methadone are expressed as nano-
grams per milliliter. AUC is expressed as nanograms per
milliliter x hour. Each figure is the mean obtained from
3 consecutive days.
b The zero time samples were taken 24 hours after the pre-
vious dose and just prior to the administration of next
dose of methadone.
FIGURE 5. Comparison of plasma levels of methadone in a 28-year-
old patient before, during and after he abused barbiturates while
maintained on methadone. Methadone was quantitated by gas-liquid
chromatography method. Each point is the mean of 3 samples col-
lected from 3 consecutive days.
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complained that his methadone dose was not holding him and with-
drawal symptoms were appearing several hours before his next daily
methadone dose. The withdrawal symptoms included abdominal cramps,
nausea, sweating, restlessness, bone and muscle pain, anxiety and
tremor. Both the mean zero-time and mean peak methadone plasma con-
centrations at this time were found to be lower than those observed
three months previously as shown in figure 5. The area under the
plasma methadone concentration-time curve at this time was 3.03
nmole/ml·hr as compared to 3.84 nmole/ml·hr three months ago, indi-
cating the patient's plasma methadone level had declined. Routine
bi-weekly urine monitoring revealed the patient had abused barbit-
urates constantly for the previous month and when confronted, the
patient admitted constant use of phenobarbital for the previous
month.
After counseling by his physician and social worker, the patient
agreed to discontinue barbiturate abuse and this was confirmed by
routine urine monitoring during the next six weeks. At this time
the methadone plasma concentration at each time interval increased
to the original level (figure 5) and the area under the plasma
methadone concentration-time curve increased from 3.03 to 3.92
nmole/ml•hr. The patient reported feeling good with no more with-
drawal symptoms before his next methadone dose.
DISCUSSION
The present study demonstrates that there is a good correlation
between the brain concentrations of methadone and the subcutaneous
administration of different doses of methadone in rats. In addi-
tion, our data demonstrate that there is a quantitative relation-
ship between the concentration of methadone in the brain and its
analgesic effect on the hot-plate test. This finding provides a
basis for understanding changes in this relationship which may
occur after administration of other drugs and after chronic admin-
istration of methadone. Both these conditions may change the brain
concentration of methadone and result in a change of the analgesic
effect of methadone. In this regard, we have previously reported
that increased methadone-induced analgesia by desipramine or diaze-
pam was associated with an increase in brain concentrations of
methadone (Liu and Wang 1975; Liu et al. 1978). On the other hand,
we showed that decreased methadone-induced analgesia after chronic
pretreatment with phenobarbital or methadone was associated partly
with a decrease in brain concentrations of methadone (Liu et al.
1978; 1979).
In our previous studies, we reported that measurements of changes
in the concentration of total 14C in plasma by TLC after adminis-
tration of 14C-methadone provided no practical information in deter-
mining changes in the pharmacokinetics of methadone induced by other
drugs (Liu et al. 1978; Roerig et al. 1975). In the present study
we separated and analyzed the plasma concentration of unchanged
methadone by HPLC and showed that there is a good correlation be-
tween the plasma concentration of methadone and the different doses
of methadone administered in rats. Similarly, the plasma levels
of methadone in methadone maintenance patients, expressed as areas
under the plasma concentration-time curves, were increased with
increased doses of methadone, In addition, our data demonstrate
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that levels of methadone in plasma correlated well with the anal-
gesic activity of methadone in rats. The peak analgesia corresponded
with the occurrence of peak levels of methadone in plasma and in
the brain in our study. Therefore, measurements of changes in
plasma methadone levels may reflect changes in methadone disposi-
tion and in pharmacological activity. The findings of the case in
the methadone maintenance patient support this suggestion. Our
findings clearly demonstrate that chronic phenobarbital intake
results in an increase in methadone metabolism which was reflected
in the decrease in plasma concentrations of methadone. As the
level of methadone decreased, the duration of pharmacological
action of methadone was shortened, resulting in a withdrawal syn-
drome. Our findings in this case thus confirmed our previous
reports in rats that phenobarbital induction of methadone metabo-
lism in man is possible, resulting in a decrease in the duration
of methadone (Liu et al. 1978; 1979). Our findings are consistent
with the reports of others that significant metabolic drug inter-
actions with methadone occurred in methadone maintenance patients
simultaneously receiving rifampin (Kreek et al. 1979) and phenytoin
(Finelli 1976; Tong et al. 1981). Both rifampin and phenytoin have
been shown to increase methadone biotransformation and cause nar-
cotic withdrawal symptoms in patients previously well-maintained
on the same dose of methadone (Kreek et al. 1979; Tong et al. 1981).
These and our present findings thus provide some direct evidence
that metabolic drug interactions with methadone which are sufficient
to alter pharmacological action can be detected from changes in
methadone plasma level, particularly from changes in the area under
the plasma methadone concentration-time curve.
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Irreversible and Reversible
Narcotic Agonists: Discriminative
and Analgesic Effects of
Buprenorphine, Oxymorphazone,
and Morphine
Charles P. France, Arthur E. Jacobson, and
James H. Woods
Buprenorphine is a highly lipophilic thebaine derivative with a
rapid onset and long duration of action. Classified as a partial
agonist of the morphine type (Martin et al., 1976), buprenorphine
has clearly been shown to have both agonist and antagonist be-
havioral actions--ranging from morphine-like analgesia in man
(Houde, 1979; Jasinski et al., 1978) and animals (Bryant et al.,
1983; Dum & Herz, 1981), to naloxone-like precipitation of with-
drawal in opiate-dependent animals (Cowan et al., 1977b; Dum &
Herr, 1981; Swain & Seevers, 1975). Some actions of buprenorphine
appear to be irreversible in that they can be prevented but not
reversed by opiate antagonists. While some dose-effect relations
with buprenorphine are monophasic, in many cases, dose-effect
curves are bi-phasic, e.g., rat tail flick (Cowan & Watson, 1980;
Cowan et al., 1977b; Dum & Herz, 1981). In these latter cases,
supramaximal doses of buprenorphine result in a partially or
completely diminished behavioral response.
Drug discrimination procedures have been used extensively to
investigate the stimulus properties of opiates (e.g., Colpaert,
1978), yet very little is known about the discriminative effects
of long-acting agents; to date, the reversibility and long-term
effects, as both an agonist and antagonist, have yet to be charac-
terize-d for buprenorphine.
The purpose of these experiments was to compare buprenorphine,
oxymorphazone, and the prototypic opioid agonist morphine, in the
mouse hot plate analgesic assay and in pigeons trained to discrim-
inate morphine from saline. Oxymorphazone was selected for
comparison because unlike the mixed agonist-antagonist actions of
buprenorphine, oxymorphazone is thought to be a pure, irreversible
morphine-like agonist (Galetta et al., 1982; Hahn et al., 1982;
Pasternak & Hahn, 1980).
METHODS
Potency (ED50) and time course data in mice were derived by
procedures that have been described elsewhere (Atwell & Jacobson,
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1978). Drugs were administered subcutaneously, and 8 mice were
tested at each of five dose levels.
Five pigeons were trained to discriminate intramuscular injections
of morphine from equal volume injections of saline for food
reinforcement. A multiple-trial training procedure was used, and
daily training sessions consisted of between 2 and 6 trials. Each
trial was preceded by an injection (saline or morphine). After a
10-minute pretreatment period, two response keys were illuminated
red and up to 10 reinforcements could be earned in 5 minutes, on a
fixed-ratio 20 schedule of food presentation. For non-drug
training trials, 20 consecutive responses on the right (saline-
appropriate) key resulted in food delivery. On drug training
days, a single injection of morphine (5.6 mg/kg) was administered
randomly before one of the 2-6 trials, and only 20 consecutive
responses on the left key resulted in food delivery. Incorrect
responses reset the fixed-ratio requirement on the correct key.
Testing was conducted essentially the same as training, except
that 20 consecutive responses on either key resulted in food
delivery. A cumulative dosing procedure was used, and all drugs
were tested up to doses that markedly suppressed responding.
Dose-effect curves were determined for morphine, oxymorphazone,
and buprenorphine, each when administered alone, and following
pretreatments with various doses of naltrexone.
To test the reversibility of the acute effects of morphine,
oxymorphazone, and buprenorphine, the smallest dose of each that
reliably produced morphine-approrpriate responding within the 10-
minute pretreatment period, was administered on the first trial,
followed by increasing doses of naltrenone.
The duration of action for each drug was determined during two
saline injection test trials (i.e., 20 responses on either key
were reinforced) on days following a cumulative suppressing dose
of each.
Finally, buprenorphine was evaluated for its ability to antagonize
morphine. Buprenorphine was administered either 24 hours or 10
minutes before a cumulative dose-effect curve for morphine. Small
(subthreshold) doses of buprenorphine were administered 10 minutes
prior to morphine to test whether buprenorphine antagonized the
discriminative or rate effects of morphine. However, because
large doses (greater than 0.1 mg/kg) of buprenorphine occasion
morphine-appropriate responding when given alone, and did so under
these conditions, those doses could be evaluated only for their
ability to antagonize the rate-suppressing effects of morphine.
RESULTS
Results of the hot plate test are given in Table 1. The ED50 for
morphine and oxymorphazone did not differ significantly. Bupren-
orphine was approximately 30 times more potent than morphine in
producing analgesia in mice. The mean onset for analgesia was
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rapid for all three drugs. However, the time until peak analgesic
effect was longer for buprenorphine than for morphine or
oxymorphazone. Conversely, oxymorphazone had a longer duration of
action than either morphine or buprenorphine.
TABLE 1
Mouse Hot Plate
ED50 Time Course
mg/kg umol/kg (minutes)
(95% C.I.) (95% C.I.) Onset Peak Duration
Morphine sulfate 1.05 3.16 3.6 31.5 154
(0.8-1.4) (2.40-4.18)
Oxymorphazone 0.76 (1.7-3.5) 3.8 34.4 273
(0.54-1.1)
Buprenorphine HCl 0.035 0.09 3.5 42.7 191
(0.028-0.045) (0.07-0.12)
Figure 1 shows representative cumulative dose-effect curves for
morphine, oxymorphazone, and buprenorphine from a single subject.
All three drugs occasioned drug-appropriate responding in a dose-
related manner, and at large doses suppressed food-reinforced
responding completely. Greater than 90 percent of the trial res-
ponses were made
on the drug-
appropriate key
at a cumulative
dose of 0.32
mg/kg bupren-
orphine, 10.0
mg/kg morphine,
or 1.0 mg/kg
oxymorphazone.
With increasing
doses, subjects
continued to
respond on the
morphine-approp-
riate key up to
a suppressing
dose of 32.0
mg/kg oxymorph-
azone. 56.0
bupren-
orphine, or
100.0 mg/kg
morphine. Thus,
oxymorphazone
was 10 times,
Figure 1. Dose-effect curves for cumulative and buprenor-
doses of morphine oxymorphazone phine 30 times,
and bupernorphine in a pigeon trained to more potent than
discriminate 5.6 mg/kg morphine from saline.
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morphine as discriminative stimuli; in suppressing food-reinforced
responding oxymorphazone and buprenorphine were approximately 2-3
times more potent than morphine. A much wider range of doses
occasioned drug-appropriate responding without completely suppres-
sing behavior for buprenorphine (0.32-32.0 mg/kg) than was the
case for morphine (10.0-32.0 mg/kg) or oxymorphazone (1.0-10.0
mg/kg).
Naltrexone, administered 10 minutes prior to a test, antagonized
the discriminative effects of morphine, oxymorphazone and bupren-
orphine. Small doses of naltrexone (0.01 and 0.1 mg/kg) shifted
the morphine dose-effect curve approximately l/2 log unit to the
right. The oxymorphazone and buprenorphine dose-effect curves
were shifted slightly to the right following 0.01 mg/kg nal-
trexone; however the dose necessary to occasion complete (greater
than 90%) drug-appropriate responding was unchanged. Following a
pretreatment injection of 0.1 mg/kg naltrexone, the oxymorphazone
and buprenorphine curves were shifted in parallel to the right 1
full log unit. The largest dose of naltrexone (1.0 mg/kg) com-
pletely antagonized the discriminative effects of both morphine
and oxymorphazone, in that subjects continued to 'respond on the
saline-appropriate key up to a suppressing dose. In contrast to
this apparent insurmountable antagonism, 1.0 mg/kg naltrexone
caused a 100-fold shift to the right in the buprenorphine dose-
effect curve, with all subjects responding on the morphine-
appropriate key at a cumulative dose of 32.0 mg/kg buprenorphine.
The surmountability of the antagonism with buprenorphine, but not
with morphine or oxymorphazone, may be due to the wider range of
doses for buprenorphine that occasion responding on the drug key
without suppressing rates. The rate-decreasing effects of all
three test drugs were not significantly altered by naltrexone
pretreatments.
The smallest acute dose of each drug that occasioned responding on
the drug key following a 10-minute preteatment period, and con-
tinued to produce drug-appropriate responding for the duration of
the experimental session (1.5-2 hours), was 5.6 mg/kg morphine,
1.0 mg/kg oxymorphazone or 0.32 mg/kg buprenorphine. When nal-
trexone was administered on subsequent trials, it dose-dependently
antagonized the discriminative effects of morphine and oxymorpha-
zone. In the presence of 5.6 mg/kg morphine or 1.0 mg/kg oxy-
morphazone, a cumulative dose of 0.32 mg/kg naltrexone completely
antagonized the drug cue in all subjects. The discriminative
effects of buprenorphine however were not completely reversed by a
dose of naltrexone 30 times greater than the effective dose in
reversing morphine or oxymorphazone. Despite a cumulative dose of
10.0 mg/kg naltrexone , all but 1 of the subjects made greater than
90 percent of the trial reponses on the morphine-appropriate key.
Figure 2 presents the data from a single subject showing nal-
trexone reversibility of an acute injection of morphine, oxy-
morphazone and buprenorphine.
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Oxymorphazone displayed a slightly longer duration of action than
morphine, as determined by drug-appropriate responding and rate
suppression on days following a cumulative suppressing dose.
While no discriminative or rate effects of morphine were evident
24 hours after a suppressing dose of 100.0 mg/kg, the day after
32.0 mg/kg oxymorphazone approximately 70 percent of the responses
were on the morphine-appropriate key. By 48 hours, however, the
discriminative effects of oxymorphazone were no longer present and
subjects once again responded on the saline key. Buprenorphine
had a duration of action that was significantly longer than either
morphine or oxymorphazone. Following a cumulative suppressing
dose of buprenorphine, subjects continued to respond on the
morphine-appropriate key for up to 5 days (mean=2.6 days).
Figure 2. Dose-effect
curves showing the
reversibility of an
acute injection of
morphine, oxymorph-
azone or bupren-
orphine in a pigeon
trained to discrim-
inate 5.6 mg/kg
morphine from saline.
A single injection of
5.6 mg/kg morphine
1.0 mg/kg oxy-
morphazone or
0.32 mg/kg bupren-
orphine w a s
administered prior to
the first trial (X),
followed by increas-
ing doses of nal-
trexone on subsequent
trials.
Buprenorphine failed to antagonize either the discriminative or
rate effects of morphine. A wide range of doses (0.01-10.0 mg/kg)
of buprenorphine were administered either 10 minutes or 24 hours
before morphine, and in no case did the morphine dose-effect curve
differ significantly from control determinations.
DISCUSSION
Duration of action in the mouse hot plate test was longest for
oxymorphazone, shortest for morphine, and intermediate for bupren-
orphine. The duration of analgesia for oxymorphazone was 273
minutes, which is far less than the 24-48 hour duration of action
reported by others (Galetta et al., 1982; Pasternak & Hahn, 1980).
These investigators, however, used doses 130-260 times greater
than the ED50 for oxymorphazone as determined in the present
experiment. Thus, when equipotent doses were compared, the
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duration of action for oxymorphazone was slightly less than twice
that of morphine.
Oxymorphazone and buprenorphine displayed morphine-like actions in
pigeons trained to discriminate morphine from saline. While there
was no evidence of oxymorphazone acting as an irreversible agon-
ist, the results with buprenorphine satisfy one criterion for
irreversible agonists: the acute effects were prevented but not
reversed by naltrexone.
The behavioral profile of oxymorphazone in this experiment does
not establish it as a unique pharmacological agent. In comparison
to morphine, oxymorphazone had a longer duration of action in the
mouse and the pigeon, and was approximately 10 times more potent
as a discriminative stimulus. The acute actions of oxymorphazone
as a discriminative stimulus were both prevented and reversed by
naltrexone, clearly demonstrating that it does not act irre-
versibly in the pigeon.
Once a discriminative effect was established with buprenorphine,
it was not completely reversed by very large doses of naltrexone.
Others (Cowan & Watson, 1980; Cowan et al., 1977a) have reported
difficulty in reversing the acute effects of buprenorphine, and in
subjects treated chronically with buprenorphine, opiate antagon-
ists fail to precipitate withdrawal (Cowan et al., 1977b; Jasinski
et al., 1978). Thus, while buprenorphine clearly acts via an
opiate mechanism, as evidenced by parallel shifts in discrim-
inative dose-effect curve after naltrexone pretreatments, it does
so irreversibly.
Duration of action of the magnitude demonstrated for buprenorphine
in the present experiment is a novel finding in behavioral
pharmacology. After a cumulative suppressing dose of bupren-
orphine, pigeons continued to respond on the morphine-appropriate
key for 24-120 hours; whereas, following suppressing doses of
morphine or oxymorphazone, subjects were responding on the saline
key within 48 hours, A long duration of action has been reported
for buprenorphine in the rat, monkey, and man (Cowan et al.,
1977b; Jasinski et al., 1978). Leander (1983) has reported that
in pigeons trained to discriminate fentanyl from vehicle, 10.0
mg/kg buprenorphine results in 75% of subjects selecting the
fentanyl-appropriate key 48 hours later. In opiate receptor
binding (Hambrook & Rance, 1976; Rance & Dickens, 1978), and in
isolated smooth muscle preparations (Kosterlitz et al., 1975),
buprenorphine has been shown to have a much slower dissociation
constant than morphine. The extremely slow pharmacokinetics of
buprenorphine are thought to be responsible for the long delay, or
even absence, or withdrawal signs upon termination of chronic
treatment with buprenorphine (Cowan et al., 1977b; Jasinski et
al., 1978).
No ceiling effect or bi-phasic dose-effect curve, suggestive of a
partial agonist, was obtained with buprenorphine in these experi-
ments. Buprenorphine also failed to antagonize either the
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discriminative or rate-suppressing effects of morphine. While
some investigators have shown buprenorphine to antagonize the
effects. of morphine on schedule-controlled behavior (Leander,
1983), others have reported no antagonism (Dykstra, in press). In
this experiment, both naltrexone and buprenorphine failed to
antagonize the rate-suppressing effects of morphine. This nega-
tive result suggests that these animals are tolerant to the
rate-decreasing effects of morphine, and thus under these con-
ditions, morphine may suppress responding by a non-opiate mechan-
ism. Narcotic-naive pigeons, responding on a schedule of food
reinforcement similar to that used in the present experiment, are
usually suppressed by 10.0 mg/kg morphine; pretreatment with 1.0
mg/kg naltrexone shifts the response rate dose-effect curve 1
full log unit to the right (unpublished observation). In these
same animals, a wide range of doses of buprenorphine (0.1-10.0
mg/kg) antagonize the rate-suppressing effects of morphine.
However, in both cases the shift to the right is no further than
the control curves determined in the present study, Thus,
tolerance to the rate-decreasing effects of morphine, in pigeons
receiving a training drug on a regular basis, may account for the
lack of antagonism by naltrexone and buprenorphine of this effect.
This comparison between morphine, oxymorphazone, and buprenorphine
clearly shows that in the pigeon, buprenorphine has irreversible
agonist actions; oxymorphazone, on the other hand, did not differ
significantly in its profile of action from morphine, and there-
fore cannot be considered a prototypic irreversible agonist in the
pigeon. The evidence in support of oxymorphazone acting as an
irreversible agonist, has in large part, come from in vitro
experiments. Thus, these data exemplify the problems involved in
attempting to predict a behavioral response in vivo from in vitro
data. Finally, these experiments demonstrate the application of
drug discrimination procedures to the study of irreversible
pharmacological agents, in such a way that the reversibility of a
drug can be evaluated within a single experimental session.
ACKNOWLEDGEMENT
Research supported by USPHS Grant DA 00154, from the National In-
stitute on Drug Abuse.
REFERENCES AND ADDITIONAL DATA
A full set of references is available from the first author. In
addition, a complete description of the observations referred to
above is available from the first author.
AUTHORS
Charles P. France and James H. Woods, University of Michigan,
Departments of Psychology and Pharmacology, Ann Arbor, MI 48109
Arthur E. Jacobson, Medicinal Chemistry Section, Laboratory of
Chemistry, National Institute of Arthritis, Diabetes and Digestive
and Kidney Diseases, National Institutes of Health, Bethesda, MD
20205
142
Morphine Abstinence Syndrome:
Cholinergic Mechanisms in the
Ventral Periaqueductal Gray of
the Dog
Lawrence G. Sharpe and Wallace B. Pickworth
Central cholinergic systems appear to be involved in the opiate
abstinence syndrome. Morphine decreases, whereas naloxone
increases, acetylcholine (ACn) release in peripheral and central
tissues (Domino and Wilson 1973; Jhamandas et al. 1971; Paton
1957; Waterfield and Kosterlitz 1975; Yaksh and Yamamura 1977).
The cholinomimetic, physostigmine, potentiates abstinence signs
in the morphine-dependent rat (Jhamandas et al. 1973) and mimics
the morphine abstinence syndrome in the nondependent chronic
spinal dog (Martin and Eades 1967; Wikler and Frank 1948).
Atropine suppresses some manifestations of the morphine absti-
nence syndrome in the rat (Collier et al. 1972; Jhamandas et al.
1973; PinSky et al. 1973) and dog (Martin and Eades 1967). But
results concerning the effectiveness of atropine to diminish
opiate withdrawal signs are conflicting (Karczmar 1976; Way and
Bhargava 1976). One problem is that atropine alone, through its
peripheral action, produces some manifestations of the morphine
abstinence syndrome, such as mydriasis, tachypnea and tachy-
cardia. To evaluate central cnolinergic processes in the opiate
abstinence syndrome we microinjected either carbachol, morphine,
methylatropine or naloxane into the periaqueductal gray (PAG)
and adjacent regions of 6 nondependent and 1 morphine-dependent
dogs. Our purpose was to compare Carbachol-elicited responses
with those elicited by morphine withdrawal and naloxone in the
morphine-dependent dog, to map the distribution of carbachol-
elicited responses in the PAG region and to test whether
atropine could reduce any of the withdrawal-like signs through
its action in the PAG and surrounding sites.
METHODS
Six beagle dogs (9-13 kg) were selected for their ability to
adapt to a sling restraint. All procedures for surgery, micro-
injections, response measurements, data analysis and histology
are described in detail elsewhere (Sharpe and Pickwort:. 1981).
The data far pupillary diameter, respiratory rate, pulse rate
and temperature were analyzed by paired t tests in which the
areas under the time-action curve (1 hr) for the different drug
and control conditions were compared. All Other responses
(shiver, activity, lick, whine, rhinorrhea, salivate, yawn and
pant) were combined as one score for each animal by adding the
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number of 15-min periods in which the response occurred. A
score was assigned if the response was different from baseline
and occurred in at least half of the 15-min time period. For
example, salivation was given a maximum score of 4 if it was
absent during baseline but was present during 50% or more of the
time in the four 15-min time periods (1 hr). A maximum score of
12 could be assigned to shiver and activity because of the rated
intensities from 0 to 3.
One animal (site 12, Fig. 1) was made dependent on 7 mg/kg/day
morphine for 175 days. Except on test days, this animal re-
ceived two subcutaneous injections of morphine every day; one at
0800 hr (2.3 mg/kg) and one at 1600 hr (4.7 mg/kg). The micro-
injection procedure (Sharpe and Pickworth 1981) was used as
preliminary experiments to test whether methylatropine (1-3.µg)
could antagonize any withdrawal signs precipitated by naloxone
injected either intravenously or into site 12 (Fig. 1).
RESULTS
Fig. 1 snows that microinjections of carbacnol evoked several
responses, the most susceptible being shiver or tremor, followed
in order by mydriasis, tachypnea, tachycardia, licking, saliva-
tion, EEG signs of arousal, behavioral activation and temper-
ature. Response susceptibility to carbachol was determined by
ranking responses based on frequency, magnitude and. duration
following the 3 doses of carbachol (0.05, 0.1 and 0.25 µg). The
active carbachol sites were clustered primarily in the
ventral PAG (sites 4, 5, 8, 9, 10, 11, 12). Inactive Carbachol
sites (0) included tne third ventricle (site l), dorsomedial PAG
(site 2), dorsolateral PAG (sites 3, 7) and the ventral teg-
mental area (site 13). Microinjections of methylatropine (1 µg)
significantly antagonized the responses evoked by 0.1 µg
carbachol (Table 1). Microinjections of morpnine (5 µg) into
the 4 ventral PAG sites (sites 4, 8, 9, 11, Fig. 1) produced a
general depression in behavior, which, except for licking,
appeared opposite in direction of that stimulated by carbachol.
In preliminary experiments on the morphine-dependent dog, we
precipitated abstinence with several doses of either intravenous
or microinjected naloxone at different times after the last
morphine dose. At 19 to 21 hr after the last morphine dose,
naloxone produced equivalent amounts of mydriasis when injected
intravenously (33 µg/kg) and into site 12 (5 µg; Fig. 2). The 5
µg naloxone dose elicited no Other sign of witndrawal, whereas
intravenous naloxone (33 µg/kg) elicited several typical absti-
nence signs that were equivalent to those caused by carbachol
microinjections. Microinjections of metnylatropine (1 µg in 1
µl) antagonized the mydriasis precipitated by naloxone given by
both routes of administration (Fig. 2). However, other absti-
nence signs produced by intravenous naloxone (33 µg/kg) were not
antagonized by metnylatropine microinjections.
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Fig. 1. Results from 6 dogs receiving a total of 31 micro-
injections of carbachol (0.05, 0.1 and 0.25 µg) into 13 sites
at 2 levels of the rostra1 midbrain (R 14 and R 15, Lim et al.
1960). Responses are ordered from the most (shiver) to the
least (temperature) sensitive in being stimulated, by carbachol
(indicated by +). Except for lick, morphine (5 µg, in
parentheses.) depressed (-) most of the responses that
carbachol stimulated. Abbreviations: EW--Edinger-Westphal
nucleus; PAG--periaqueductal gray; PC--posterior commissure;
R--red nucleus; SN--substantia nigra; III--oculomotor nerve;
8--carbachol sensitive site; O--carbachol insensitive sites;
RESP.--respiratory rate; SALIV.--salivation; EEG--+ denotes
EEG signs of arousal and (-) denotes EEG signs of sedation;
ACTIV.--Behavioral activation; TEMP.--colonic temperature.
Table 1. Responses produced by carbachol (0.1 µg in 0.5 µl)
microinjected into the ventral PAG region of 4 dogs (sites 8,
9, 11, 12; Fig. 1) were antagonized by methylatropine (1 µg/µl
in 1.0 µ1) microinjected 30 min before carbachol.
RESPONSE
METHYLATROPINE
SALINE CARBACHOL CARBACHOL
PUPILLARY DIAMETER (mm-min)1
RESPIRATORY RATE (breaths-min)1
PULSE RATE (beats-min)1
OTHER RESPONSES ( x score )2
2 129* 7 * *
3 7 2580* 173**
61 8 4 9 * 127**
3 14* 6
* *
lAreas under the time-action curve for 1 hr.
2Other responses (shiver, salivate, yawn, rhinorrhea, lick,
pant, whine and activity) represent number of 15-min periods
in which responses occurred. *P < 0.05 compared with saline.
**P < 0.05 compared with carbachol.
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Fig. 2. Methylatropine (1 and
3 µg microinjected into site
12, Fig. 1, 30 min before
haloxone) antagonized the
mydriasis produced by naloxone
either microinjected (MICRO-
INJECT) into site 12, or
injected intravenously in the
morphine-dependent dog (N = 1).
DISCUSSION
Several years ago Paton (1969) and Crossland (1972) proposed
that the morphine abstinence syndrome was caused in part by a
sudden increase in the release of ACh. In this study, the
striking parallelism between signs observed during microinjec-
tions of carbachol and those observed during morphine abstinence
in the dog (Martin et al. 1974) promotes the proposal that
increased ACh output in the PAG region may lead to a major
portion of the morphine withdrawal syndrome. That microinjec-
tions of morphine produced opposite reactions supports this
proposal because morphine has been shown to inhibit ACh release
(Jhamandas et al. 1973; Paton 1957). The effects of 5 µg
morphine microinjected in the ventral PAG resemble the effects
produced by an i.v. dose of 1 mg/kg morphine--an amount 2,000
times the microinjection dose (Pickworth and Sharpe 1979).
In the morphine-dependent dog, naloxone, injected either intra-
venously or into site 12 (Fig. l), produced mydriasis--one of the
principal withdrawal signs in the dog (Martin et al. 1974).
Since pretreatments with microinjections of methylatropine
antagonized both instances of naloxone-precipitated mydriasis,
it is reasonable to argue that mydriasis during withdrawal
resulted from an increased release of ACh in this region. Given
systemically, atropine would potentiate this mydriasis. The
reason that changes in pupillary diameter were easily affected
by microinjections in the ventral PAG is most likely because the
Edinger-Westphal nucleus (EW) is located 0 to 2 mm from the
sites yielding changes in pupillary diameter after carbachol and
morphine (Fig. 1). A simple and testable neuronal model to
explain morphine miosis and carbachol- or withdrawal-induced
mydriasis is schematized in Fig. 3.
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Fig. 3. Edinger-Westphal nucleus (EW) neuronal model. An
increase in the muscarinic inhibitory tone to the EW
(mydriasis) is caused by either carbachol microinjections
or morphine abstinence (increased ACh release), perhaps
through a mechanism of postsynaptic hyperpolarizing in-
hibition. A decrease in inhibitory tone (miosis due to
increased activation of the excitatory pupillary light
reflex path) is produced by morphine, perhaps through a
mechanism of inhibiting presynaptically ACh release.
We found that, like morphine, clonidine (5 µg) produced miosis
when microinjected in the ventral PAG of the dog (unpublished
observations). The presynaptic action of morphine and clonidine
to inhibit neurotransmitter release in multiple neuronal systems
(see Vizi 1979) may partially explain the similar pharmacologic
profiles of these two drugs in the dog (Pickworth and Sharpe
1979) and why clonidine suppresses opiate withdrawal in humans
(Gold et al. 1978). We can argue that different but function-
ally redundant receptors exist at presynaptic sites if opioid
and nonopioid drugs inhibit neurotransmitter release as a major
function in their mechanism of action. Such redundant receptors
would include the µ receptors (morphine), the 2-adrenoceptors
(clonidine) and more recently, the adenosine receptors (see
Tucker this volume). Thus nonopioid drugs acting presynaptic-
ally as morphine does would be expected to be effective in the
clinical management of opiate detoxification. Conversely,
selective antagonists (i.e., atropine) that act postsynaptically
on single neurotransmitter systems would be less effective in
suppressing morphine withdrawal signs, especially if they produce
mixed or opposite effects depending on their site of action in
the central and peripheral nervous system. The preliminary
evidence on atropine in this report lends support to this view.
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When microinjected in the PAG of the morphine-dependent dog,
naloxone failed to elicit withdrawal signs except for mydriasis
and methylatropine failed to antagonize naloxone (i.v.) pre-
cipitated withdrawal signs except for mydriasis. However inter-
esting and puzzling these results may be, reasonable explana-
tions without further experimentation on more dogs would be
highly speculative and premature. A "multipartite" basis for
morphine dependence has been proposed (Collier et al; 1972) in
which several neurochemical systems participate. The method of
microinjecting opiates and transmitter agonists/antagonists into
discrete brain regions is an attempt to understand these dif-
ferent "parts" of morphine dependence by elucidating how specific
neurotransmitters in a given brain locus control one or more
withdrawal signs.
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The Discriminative Stimulus
Properties of Cocaine and
d-Amphetamine: A Comparison of
Three Routes of Administration
Rene de la Garza, C. E. Johanson, and C. R. Schuster
The placement of new drugs into pharmacological classes is based on a
comparison of the spectrum of action of a test drug with prototypic
standards. One method designed to classify psychoactive drugs measures
their  subjective effects in humans. For instance, studies have
demonstrated that morphine and related compounds produce a unique
spectrum of subjective effects that can be reliably discriminated from
subjective effects produced by other classes of psychoactive drugs
(Goldberg et al., 1982). Other studies have shown that the methods for
measuring the subjective effects of drugs are also useful for the
classification of other abused substances (e.g., psychomotor stimulants,
sedative-hypnotics). In recent years, drug discrimination procedures in
animals have been used as an alternative method to compare the spectrum
of action of drugs. A striking concordance has been found between
drug classes obtained on the basis of similarities in subjective effects
and those obtained on the basis of similarities as discriminative stimuli.
These findings have led to the suggestion that the components of drug
action responsible for discrimination among classes by animals are the
same as those responsible for the subjective effects reported by humans
(Schuster et al., 1981).
In drug discrimination procedures, reinforcement is made contingent upon
the presence of a drug or its vehicle so that differential responding is
maintained under stimulus control. When doses lower than the training
dose are administered under test conditions, they produce a lower
proportion of drug-appropriate responding, i.e., a generalization gradient
is obtained. Furthermore, when drugs other than the training drug are
substituted, they produce drug-appropriate responding to the extent that
they resemble the training drug, i.e., there is drug class specificity.
Drug discrimination studies can as well be used to compare the spectrum
of action of the same drug or related drugs administered by different
routes. Such comparisons may be especially useful for evaluating a drug
such as cocaine which presumably has relatively little effect when given
orally, or amphetamine which is used therapeutically by the oral route
but often abused parenterally.
The purpose of the present experiment was to compare the discriminative
stimulus properties of cocaine and amphetamine given orally and
parenterally in rhesus monkeys using an avoidance/escape procedure
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(Schaefer and Holtzman, 1977; Shannon and Holtzman, 1976, 1977).
Rhesus monkeys were first trained to discriminate intramuscular cocaine
from saline, and generalization gradients for cocaine administered by
different routes ( intramuscular,  intravenous,  intragastric)  were
determined during test sessions. In addition generalization gradients for
c&amphetamine delivered intramuscularly or intragastrically were also
determined.
METHODS
Subjects. Five rhesus monkeys were used in this study. The subjects
were between 8 and 10 kg and were housed in stainless steel cages.
They were given ad lib water and were fed approximately 180 g
immediately after each experimental session. All subjects had previous
experimental histories in self-administration and schedule-controlled
studies with a variety of psychoactive drugs.
Apparatus. During experimental sessions, the subjects were seated in
Plas-Lab primate restraining chairs and placed in a cubicle containing
two response levers and stimulus lights. In order to decrease the
likelihood of responding on both levers simultaneously, a Plexiglas plate
was attached to the chair perpendicular to the body of the animal. The
monkey’s feet were placed into shoes fitted with brass plates that
allowed electric shocks to be delivered to the feet.
Avoidance/escape training phase. The monkeys were initially trained to
avoid/escape the delivery of electric shocks in a trial procedure with
only the right lever present. Trials were initiated with the illumination
of a houselight and the lights above the lever. Five seconds after the
initiation of the trial, a shock period began. During this period shocks
were delivered every 2 sec (250 msec in duration, 10 mA in intensity)
until a response occurred (escape). Immediately after a response
occurred, the houselight, lever lights and shock deliveries were
terminated. If a response occurred before the 5-sec period had elapsed,
the houselights and lever lights were terminated and no shocks were
delivered (avoidance). In both cases, a 55-sec inter-trial interval (ITI)
followed before a new trial was initiated. During the ITI the cubicle
remained dark. The session lasted until 30 trials were completed or
until 40 min had elapsed, whichever came first. When the avoidance
response occurred on more than 90% of the trials for 3 consecutive
days, the left lever was made operational and the right lever was
covered. The same contingencies remained in effect until 90% of the
trials were. avoidance trials for 3 consecutive days. Thereafter, the
operational lever was changed daily. Concurrently, appropriate drug
injections were administered 10 min prior to the session. The right
lever was operative after the administration of 0.25 mg/kg cocaine (i.m.)
for two of the monkeys and the left lever for the other three. The
alternative lever was operative after saline. These conditions remained
in effect until 5 consecutive days with more than 90% avoidance trials
were obtained. Initially, the front of the chair was placed flush with
the lever boxes. However, in order to decrease the probability of
responding on both levers simultaneously, the distance between the chair
and the lever boxes was increased so that the monkey had to extend
its arm to depress the lever.
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Drug discrimination phase. During this phase the subjects were presented
with both levers simultaneously for the first time. The lever that
terminated the trial was made conditional upon cocaine or saline
administration. All other conditions were the same as previously
described. If a correct response occurred, i.e., a response on the lever
associated with the drug condition, the trial was terminated. If the
monkey responded on the incorrect lever, a change-over delay (COD)
period was started. During this period, responding on the correct lever
did not terminate the trial until 2 seconds had elapsed since the last
incorrect response (COD 2 sec). Further incorrect responses reset the
COD timer. Correct responses during the COD period were signalled by
a brief flicker of the houselight and lever lights. A trial was counted
as correct when no incorrect responses were emitted.
An additional procedure was introduced during this phase to facilitate
discrimination training. The intertrial interval was reduced to a few
milliseconds at the start of the training session but all other contingencies
remained the same. After several responses on the correct lever without
incorrect responses, the intertrial was increased during the session in
small steps (approximately 5 to 10 sec at a time) provided the subjects
continued responding on the correct lever. This procedure was continued
until the subject’s performance remained above 90% over several sessions
with the’ interval reaching 55 sec for at least a portion of the session.
Subsequently, the monkeys were reintroduced to the initial condition in
which the intertrial interval was 55 sec throughout the entire session.
Initially, cocaine and saline injections alternated on a daily basis. When
five consecutive sessions under the terminal contingencies occurred with
more than 90% correct, the drug conditions were presented in a
semirandom sequence. All other conditions remained the same.
Testing. When six consecutive sessions of more than 90% correct trials
were obtained, the ability of other doses of cocaine administered by
the intramuscular, intravenous or intragastric route to control cocaine-
appropriate responding was determined during test sessions. Similar
determinations were done with intramuscular and intragastric d-
amphetamine. When these drugs were tested intragastrically, the solution
was generally given 60 min prior to the session. For the other routes,
drugs were administered 10 min pre-session. During testing conditions,
responding on either lever terminated the trial. All other conditions
remained the same. Each dose of a drug was given twice by each
route. All doses of a compound were tested before a new route or
drug was tested. Test sessions occurred no more frequently than twice
a week and at least 2 training sessions (i.e., only one lever operative)
intervened.
Data Analysis. The percentage of cocaine lever trials was used as a
measure of drug substitution. The cumulative latency to the termination
of the trial was used as measure of non-specific effects.
RESULTS
Figure 1 shows that cocaine administered intramuscularly to five monkeys
(0.01 - 0.5 mg/kg) or intravenously to four monkeys (0.03 - 0.125 mg/kg)
produced cocaine-appropriate responding in a dose-dependent manner.
Regardless of route, the drug did not significantly increase the latency
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to the first response compared to saline. Likewise, intragastric cocaine
(1.0 - 16.0 mg/kg) produced cocaine-appropriate responding when
administered 60 min pre-session. In one monkey tested with intragastric
cocaine with a 10 min pretreatment (not shown), the same dose range
led to saline-appropriate responding while the latency to the first-
response remained unaffected.
d-Amphetamine delivered intramuscularly to three monkeys (0.03 - 0.25
mg/kg) or intragastrically to four monkeys (0.03 - 0.5 mg/kg) produced
cocaine-appropriate responding in a dose dependent manner at doses that
did not increase the latency to the first response.
DOSE (MG/KG)
FIGURE 1. The percent of drug lever trials during test sessions with
cocaine (top panel) and d-amphetamine (lower panel) averaged across all
monkeys tested. Symbols indicate the route of administration:
i.m.; i.g.; and i.v. All i.m. and i.v. administrations were given
10 min pre-session and the i.g. administrations were given 60 min pre-
session.
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Responding following both i.g. cocaine and d-amphetamine was more
variable both within and across monkeys than when the other routes
were tested. One monkey given 16 mg/kg of i.g. cocaine responded
only 30% on the cocaine-appropriate lever but died unexpectedly of
convulsions at least 8 hrs after the administration. A second monkey
tested with 8 mg/kg cocaine responded only 47% on the cocaine-
appropriate lever, but died 2 days later of kidney and liver complications.
Table 1 shows the ED50’s of all the dose-response functions and the
ratio of each over the ED50 of i. m. cocaine. Intravenous cocaine and
both intramuscular and intragastric &amphetamine were not significantly
different from i.m. cocaine in potency. In contrast, intragastric cocaine
was approximately 40 times less potent than i.m. cocaine. Significantly,
i.m. d-amphetamine was not different from i.m. cocaine whereas i.g.
cocaine dramatically differed from i.g. &amphetamine.
TABLE 1: RELATIVE POTENCIES
DRUG
D-AMPHETAMINE
D-AMPHETAMINE
COCAINE
COCAINE
COCAINE
DISCUSSION
With cocaine there is a clear separation in potency between the
intragastric route as compared to the i.m. and i.v. route of administration
in the ability to produce drug-appropriate responding. Intragastric
cocaine is at least 40 times less potent than i.m. cocaine. In addition,
the data from one monkey suggest that intragastric cocaine is ineffective
when given 10 min prior to a 30-min session. In rhesus monkeys, similar
effects of cocaine have been reported in studies that compared the
effects of different routes of administration on behavior maintained
under a variable-interval schedule. Downs et a1.(1980) showed that oral
cocaine was 16 times less potent than i.m. and i.v. cocaine.
ROUTE ED 50 (C.L.) IN MG/KG
I.M. 0.09 (0.07-0.11)
I.G. 0.12 (0.02-4.9)
I.M. 0.10 (0.06-0.14)
I.V. 0.10 (0.08-0.13)
I.G. 4.37 (2.1-14.8)
RATIO
0.9
1.2
1.0
1.0
43.7*
In humans, van Dyke et al. (1978) showed that orally administered
cocaine produced high cocaine plasma levels and subjective effects only
30 minutes after its delivery. These authors suggested that the early
belief that cocaine was ineffective through the oral route (Ritchie and
Cohen, 1975) may have been surmised from experiments that did not
allow enough time for cocaine to pass from the highly acidic stomach
to the small intestine where absorption of bases is more rapid. Similarly,
the results in the present experiment can be explained by the low
absorption rate of cocaine in the stomach, since approximately 1 hour
had to pass before the discriminative stimulus effects were detectable.
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d-Amphetamine was also tested by Downs et al. (1980) using different
routes of administration and it was found that both i.m. and oral d-
amphetamine produced similar dose-dependent changes. Likewise, in
the present experiment i.m. and i.g. d-amphetamine were equipotent
even though by the i.m. route drug was administered 10 min before the
session and by the i.g. route, 60 min before the session.
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Alcohol Self-Administration by
Female Primates: Effects on
Reproductive Function
N. K. Mello, M. P. Bree, J. H. Mendelson, and
J. E. Ellingboe
Alcoholism in women is often associated with derangements of re-
productive function. Amenorrhea, infertility (anovulatory cycles
and short luteal phases) as well as spontaneous abortions are re-
ported in the clinical literature (Harlap and Shiono, 1980;
Hugues et al, 1980; Moskovic, 197.5; Ryback, 1977). The mechanism
of amenorrhea in alcoholic women is unknown, and it is not clear
if the toxic effects of alcohol occur primarily at the hypotha-
lamic-pituitary level (Hugues et al, 1980); at the ovary
(Valimaki and Ylikahri, 1981; Moskovic, 1975) or both in combina-
tion. Since alcoholic women are often malnourished and also have
liver disease, it has been difficult to determine the relative
contribution of alcoholism and these related disorders to the de-
rangements of reproductive function observed clinically. Either
malnutrition associated with profound weight loss (Frisch and
MacArthur, 1974) or hepatic dysfunction can disrupt menstrual
cycle regularity (Hugues et al, 1980). These clinical findings
indicated that systematic evaluation of alcohol effects on female
reproductive function under controlled conditions would require
a model of alcoholism.
Since the reproductive physiology of female rhesus monkeys is
most similar to human women, and the neuroendocrine regulation of
primate reproductive function has been studied extensively (Knobil,
1974, 1980, 1981; Pohl and Knobil, 1982), we chose this species
to develop a female model of alcoholism. The feasibility of using
rhesus monkeys for alcohol self-administration studies (Woods et
al, 1971; Winger and Woods, 1973; Woods and Winger, 1974; Karoly
et al, 1978), as well as self-administration of other drugs (cf.
Griffiths et al, 1980; Johanson and Schuster, 1981), has been
well established.
This report describes the effects of chronic alcohol self-adminis-
tration on reproductive fiction in female Macaque monkeys. We
have previously shown that acute administration of alcohol (1.5,
2.5, 3.5 g/kg) that produced blood alcohol levels averaging
136, 260 and 344 mg/dl did not suppress 17-ß estradiol or lutein-
156
izing hormone (LH) levels at the premenstruum, menstruation,
the periovulatory period or the mid-luteal phase (Mello et al,
1983a and b).
METHODS
Sexually mature female Macaque monkeys (4.6 to 7.5 kg) were housed
individually in a cage room with adult males. A 12-hour light-
dark cycle (7 a.m. to 7 p.m.) was in effect. Monkeys were main-
tained on ad lib food and water with daily supplements of fresh
fruit, vegetables and multiple vitamins. Vaginal swabs were done
daily to determine the onset and duration of menstrual bleeding.
Blood samples were collected two or three times each week for
radioimmunoassay of pituitary and gonadal hormones and to deter-
mine levels of alcohol in blood. Details of radioimmunoassay and
blood alcohol analysis methods have been published (Mello et al,
1983a and b). Monkeys were periodically evaluated with laboratory
tests to monitor the status of liver function, lipid and carbohy-
drate metabolism, electrolyte homeostasis and hematologic function.
Data are reported for five females, each of whom had occasionally
received single doses of alcohol via nasogastric intubation to
evaluate the acute effects of alcohol on pituitary and gonadal
hormones (Mello et al, 1983a and b). All monkeys appeared to have
normal ovulatory menstrual cycles as indicated by the mid cycle
luteinizing hormone (LH) surge. Menstrual cycles were stable for
at least 10 months before the initiation of the behavioral studies.
Animal maintenance and research was conducted in accordance with
the guidelines provided by the Committee on Laboratory Animals
Facility and Care, the National Research Council Institute of
laboratory Animals Resources. The facility is licensed by the
U. S. Department of Agriculture. The health of the monkeys was
periodically monitored by a consultant veterinarian from the New
England Regional Primate Center.
Monkeys were trained to work for food in an operant paradigm on
gradually increasing response requirements on a variable ratio
(VR) schedule in which the number of responses required for each
reinforcement varied irregularly. An average of 16 responses
(VR 16) produced a brief stimulus light (S+) and a 1 gram banana
pellet. When response behavior was stable, a second order sched-
ule was used where only a brief stimulus light (S+) was delivered
after completion of each VI 16 response requirement. After four
consecutive VR 16 components were completed, both the brief stim-
ulus light and a food pellet were delivered. This is a second
order fixed ratio (FR) of 4 schedule with VR 16 components
(FR 4 [VR 16:S]).
Once food-maintained responding was stable, each monkey was sur-
gically implanted with an intravenous catheter under ketamine
anesthesia (25 mg/kg/i.m.) using aseptic procedures. Eight to 10
days after surgery, monkeys were given access to alcohol during
menstruation or the late luteal phase of the menstrual cycle.
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Monkeys learned to self-administer alcohol intravenously on the
same operant schedule of reinforcement used for food acquisition.
An average of 64 responses was required for each food pellet or
alcohol injection (0.12 g/kg/inj) under a second order schedule
of reinforcement (FR 4 [VR 16:S]).
Food and alcohol each were available during four l-hour sessions
each day. Food sessions began at 11 a.m., 3 p.m., 7 p.m. and
11 p.m.; alcohol sessions at 12 noon, 4 p.m., 8 p.m. and 12 mid-
night. The conditions of food and alcohol availability and time
out (when responses had no programmed consequence) each were as-
sociated with a colored stimulus light (S+) projected on a trans-
lucent Plexiglas response key. Complete details of the apparatus
and basic operant paradigm used in our previous studies of drug
self-administration have been published (Mello and Mendelson,
1978).
RESULTS AND DISCUSSION
Alcohol produced an immediate and sustained disruption of men-
strual cycle regularity in three monkeys. Each monkey began to
self-administer high doses of alcohol as soon as it was available.
During the first 30 days of alcohol access, these monkeys self-
administered an average of 2.29 (± 0.26), 3.15 (± 0.27) and 3.24
(± 0.38) g/kg of alcohol per day. After the menstruation coinci-
dent with or within 10 days after initial access to alcohol,
menstruation did not recur for 84 to over 180 days.
Each monkey that developed amenorrhea showed signs of physical
dependence on alcohol. After the 11-hour interval between the
midnight and noon alcohol session, these monkeys had gross tremor
of the extremities and nystagmus which diminished appreciably af-
ter alcohol self-administration. Monkeys appeared intoxicated
after alcohol sessions and blood alcohol levels measured imme-
diately after a session ranged between 266 and 438 mg/dl.
Alcohol and food self-administration over successive 10-day inter-
vals by the amenorrheic monkeys for 84, 93 and 160 consecutive days
are shown in Figure 1. Despite daily alcohol intoxication, two
monkeys showed no change in operant food self-administration from
pre-alcohol baseline levels during the first 50 to 60 days of al-
cohol exposure. Monkey 10-80 worked for significantly more food
than baseline (p < .01-.001) after 70 days of alcohol self-adminis-
trat ion. After 80 consecutive days of alcohol self-administration,
Monkey T681 showed a significant decrease in food intake for 20
days (p < .02-.001). However, after 100 days of alcohol intoxica-
tion, food intake returned to levels that were not significantly
different from baseline and then significantly exceeded baseline
after 140 and 150 days of alcohol intoxication (p < .02-.001).
Only Monkey B428 reduced operant food intake significantly (p <
.05-.001) after the first 10 days of alcohol self-administration.
After 60 days of alcohol self-administration, banana pellet intake
returned to levels not significantly different from baseline.
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FIGURE 1. Reprinted with permission, from Mello et al., Science
221:677-679, 1983. Copyright 1983 by the AAAS.
Two of the three amenorrheic monkeys died after 84 and 93 consecu-
tive days of alcohol self-administration. One monkey (10-80) ap-
parently died of an overdose of alcohol; the postmortem blood alco-
hol sample was 502 mg/dl. A second monkey (B428) died of alcohol-
related pulmonary disease. Necropsy revealed pathological changes
in the reproductive system of both monkeys. The uterus was marked-
ly atrophied and ovarian mass significantly reduced. Decreased
ovarian mass appeared to reflect an absence of corpus lutea, which
suggested that ovulation had not occurred (Mello et al, 1983c).
Comparable pathology of the reproductive system has been reported
in alcoholic women at autopsy (Jung and Russfield, 1972) and in
rodents after chronic alcohol feeding (Van Thiel, Gavaler and
Lester, 1978; Gavaler et al, 1980).
Luteinizing hormone (LH) levels were significantly depressed below
pre-alcohol LH levels measured at menstruation (p < .02-.001) in
each monkey that developed amenorrhea during chronic alcohol self-
administration. Before the introduction of alcohol, LH values
during menstruation ranged between 27 (± 1.06) and 36 (± 1.36)
ng/ml. During chronic alcohol self-administration, LH values
ranged between 18 (± 1.36) and 24 (± 1.41) ng/ml.
One amenorrheic monkey also had an unusual lesion of the adeno-
hypophysis characterized by many small cells with hyperchromatic
nuclei scattered among the the larger, polyhedral parenchymal cells.
The origin of the cells in the pituitary lesion was undetermined.
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Details of these pathological changes in brain, uterus and ovaries
are described elsewhere (Mello et al, 1983c; Mendelson et al, 1983).
It is possible that this unusual degenerative pituitary lesion
occurred as a direct consequence of prolonged high dose intra-
venous alcohol self-administration. It is also possible that a
derangement in pituitary gonadotropin secretory function induced
the pathological changes observed in the ovaries and in the uterus.
Amenorrhea and the reproductive system pathology observed appear
to be due to chronic alcohol intoxication and not to malnutrition
or liver disease. Food self-administration remained relatively
stable during alcohol self-administration (cf. Figure 1) and each
monkey consistently ate daily supplements of fresh fruit, vegetables
and biscuits. Laboratory tests were within normal range. After
98 days of alcohol self-administration, onemonkey had a slight
elevation of alkaline phosphatase suggestive of mild hepatic im-
pairment, but SGOT and SGPT levels were normal. No monkey had
evidence of liver disease, i.e., hepatitis or cirrhosis.
The effects of alcohol on reproductive function were dose-related.
Two monkeys self-administered relatively low doses of alcohol
averaging 1.35 (± 0.26) and 1.66 (±0.38)g/kg/day for 119 and 173
days respectively. These monkeys continued to have stable men-
strual cycles (28 days [± 0.89] and 31 days [± 1.35]) which were
almost identical to the 10 menstrual cycles that preceded the al-
cohol self-administration studies (27 days [± 1.41] and 31 days
[± 1.14]). LH levels did not differ significantly from pre-alcohol
control levels.
This is the first report of alcohol-induced disruption of repro-
ductive function in a female Macaque monkey model. Monkeys con-
trolled their daily dose of alcohol in an operant paradigm so re-
sults cannot be attributed to non-physiological alcohol doses im-
posed by the investigators. The critical determining variable was
the average dose of alcohol self-administered. High alcohol doses
(2.95 - 4.41 g/kg/day) resulted in amenorrhea and pathological
changes in the uterus and ovaries (Mello et al, 1983c) whereas
lower alcohol doses (1.35 - 1.66 g/kg/day) were compatible with
normal menstrual cycle function. This behavioral model of alcohol-
ism in female monkeys provides an opportunity to systematically
assess the critical alcohol dose and duration of exposure necessary
to disrupt menstrual cycle regularity; to examine the neuroendo-
crine mechanisms underlying menstrual cycle disruption; and to
evaluate the capacity for recovery of function following a period
of chronic alcoholism.
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Benzodiazepines: Drug
Discrimination and Physiological
Dependence
Roland R. Griffiths, Nancy A. Ator, Scott E. Lukas,
R. J. Lamb, and Joseph V. Brady
The benzodiazepines are among the most widely used of all
prescribed drugs. Concern about abuse of these drugs has
prompted the development of preclinical methods for assessing
various pharmacological effects of diazepam-like drugs which are
relevant to their abuse and dependence liability. This abstract
describes results from a series of ongoing experiments to assess
discriminative stimulus effects and physiological dependence-
producing properties of benzodiazepines.
Drug discrimination: In drug discrimination procedures,
animals are trained to respond differentially depending on the
nature of drug pretreatment. The procedure can provide infor-
mation analogous to a human testing situation in which subjects
catagorize drugs with respect to their subjective effects.
In ongoing drug discrimination experiments, four baboons
were trained to discriminate lorazepam (1.0 mg/kg) and two
baboons were trained to discriminate pentobarbital (5.6 mg/kg)
in a two-lever drug versus no-drug discrimination procedure.
Food delivery depended on 20 consecutive responses on one lever
in sessions preceded by an intramuscular injection of the
training drug (60-min pretreatment time), and on 20 consecutive
responses on the other lever following no drug. All baboons
completed 100% of the response runs on the appropriate level in
training sessions. Test sessions were conducted in which a drug
dose different from the training dose was administered (either
orally or intramuscularly), and 20 consecutive responses on
either lever produced food. Pentobarbital-trained baboons con-
sistently generalized to lorazepam, diazepam, alprazolam, and
pentobarbital. Although lorazepam-trained animals consistently
generalized to lorazepam, diazepam, alprazolam, bromazepam, and
triazolam, only one of four baboons generalized to pentobarbital
(tested through a wide range of doses, and at 30- and 60-min
pretreatment intervals). These results demonstrate an inter-
esting asymmetry in cross- generalization with benzodiazepines
and barbiturates. In related experiments, oral doses of Ro 15-
1788 (a benzodiazepine antagonist), naltrexone (an opioid
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antagonist), and caffeine were administered alone or immediately
before an injection of lorarepam or pentobarbital. Ro 15-1788
(0.1-1.0 mg/kg) had no effect on the pentobarbital stimulus and
produced a surmountable antagonism of the lorazepam stimulus.
Naltrexone (1.0-10.0 mg/kg) had no effect on the pentobarbital
or lorazepam stimulus. Caffeine (0.1-10.0 mg/kg) produced
variable effects within and across animals. When administered
alone, neither Ro 15-1788, naltrexone, nor caffeine generalized
to the pentobarbital or lorazepam stimulus. The differential
effects of Ro 15-1788 on the stimulus effects of lorazepam and
pentobarbital along with the asymmetry in cross-drug generali-
zation between lorazepam- and pentobarbital-trained baboons
suggest that the stimulus effects of these two compounds depend
upon different mechanisms of action.
Physiological dependence: Physiological dependence is an
important aspect of the behavioral toxicity of benzodiazepines
and may be related to the abuse liability of these drugs. In
ongoing experiments to explore the development of physiological
dependence on benzodiazepines in baboons, reliable observational
procedures were developed for assessing benzodiazepine with-
drawal by scoring a series of 15 withdrawal signs and body
postures. In one study baboons implanted with intragastric
catheters were given diazepam (20 mg/kg/day) continuously for 45
days. Termination of diazepam administration (spontaneous
withdrawal) resulted in a mild to intermediate withdrawal
syndrome over the next 15 days characterized by suppressed food
intake, tremor and abnormal body posturing. Parametric studies
have been undertaken to characterize precipitated withdrawal by
administering intramuscular injections of the benzodiazepine
antagonist, Ro 15-1788, 5.0 mg/kg, after periods of chronic
benzodiazepine administration. Intensity and consistency of
withdrawal signs are an increasing function of diazepam dose
(0.125-20.0 mg/kg/day) and duration of diazepam administration
(1 hr, 1, 3, 7, 35 days). Results to date indicate that
reliabie precipitated withdrawal occurs with diazepam doses as
low as 0.25 mg/kg/day administered for 7 days. Precipitated
witndrawal after higher diazepam doses administered for longer
durations is characterized by emesis, retching, tremor, and
convulsion. Compared to spontaneous withdrawal, precipitated
withdrawal is more intense, has a more rapid onset, and is of
briefer duration.
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An Investigation of Brain
Reinforcement Systems Involved in
the Concurrent Self-Administration
of Food, Water, and Morphine
Steven I. Dworkin, John D. Lane, and James E. Smith
Since the demonstration in 1954 by Olds and Milner that animals
will self-administer minute electric currents into various brain
regions, the existence of central reinforcement pathways has
been under vigorous investigation. Studies of the
neurobiological substrates of reinforcement have used two
general approaches. The first procedure has investigated
responding maintained by central pathways involved in the
presentation of an intracranial electrical stimulus
(intracranial self-stimulation).The second general procedure
is drug self-administration where responding is maintained by
the presentation of intravenous or intracranial drug infusions.
Variations of these procedures have been used to investigate the
neurochemical, neuroanatomical, and neurophysiological mechanisms
of reinforcement. Results from these studies have implicated
both dopamine-or norepinephrine-releasing neurons, although some
controversy has existed as to which catecholamine is "most"
important in central reinforcement mechanisms.
Generalization from studies of these two behavioral procedures
to a theory of the neurobiological mechanisms of reinforcement
is risky, especially considering the complexity of reinforcement
demonstrated at the behavioral level. The behavioral effects of
many stimuli, including intracranial electrical stimulation and
drug presentations, have been shown to be influenced by several
variables. These factors include the schedule of event
presentation, the rate of ongoing behavior, and the behavioral
and drug history of the organism.
Consequential events cannot be considered to have invariant
properties. For example, experiments with squirrel monkeys have
shown that responding can be maintained by a fixed-interval
schedule of electric-shock presentation in one component of a
multiple schedule and punished by the same intensity shock in a
second component (Barrett and Glowa, 1977). Using the same
species, cocaine has been shown to be both a negative and a
positive reinforcer at the same time (Spealman, 1979).
Furthermore, responding by rats can be maintained by the
termination of self-produced rates of brain stimulation (ICSS)
(Steiner et al., 1969). The behavioral effects of several
variables. including psychoactive drugs have also been shown to
depend on the event and/or schedule used to maintain its
presentation (for review, see Barrett and Katz, 1981). To avoid
165
these problems in investigations of the neurobiological
substrates of reinforcement, it is necessary to monitor more
than one behavior.
The present study was designed to investigate the behavioral and
neurobiological effects of neurotoxin lesions on responding
concurrently maintained by food, water, and morphine
reinforcement. Such procedures allow for assessment of the
specific involvement of small populations of neurons in
reinforcement processes associated with different reinforcers.
The results from this study indicate that kainic acid lesions of
the nucleus accumbens may selectively attenuate the reinforcing
efficacy of morphine.
METHOD
Subjects
Seven adult male Fisher-344 rats between 90-150 days old at the
beginning of the experiment were studied in an
operant-conditioning chamber with three reinforcers.
Food and Water
The rats were initially trained to lever press on two separate
retractable levers under a concurrent schedule of food and water
presentations. After stable responding was observed, the
schedule was then changed to a concurrent chained (conc chain)
schedule (Autor, 1969). Under this schedule requirement, the
first response on the food or water lever resulted in the
retraction of the other lever (FR1 initial link). A fixed
number of responses, that was gradually increased from 1 to 9,
was then required on the extended lever (terminal link). Food
presentations consisted of the delivery of one 45 mg pellet, and
water reinforcers were 20 sec access to a 0.1 ml dipper of tap
water containing tetracycline. Following completion of the
schedule requirement, both levers retracted for 30 sec (time out
or TO). A limited hold 100 sec contingency (from the first
response) was also used. Elapse of the limited hold without
completion of the terminal ratio resulted in the scheduling of a
TO without reinforcer presentation. Following the TO, the
levers were extended and the schedule contingencies were reset.
The stimulus lights above each lever were only illuminated
during lever extension. After stable performance was observed
under the conc chain FR1 FR9 schedule, the animals were
surgically prepared as described below.
Surgical Procedure
Each rat was implanted with a chronic jugular catheter using
previously described methods (Weeks, 1962, 1972). Intracranial
injection cannulae were also implanted into the nucleus
accumbens using a previously described procedure (Myers, 1966).
Guide cannulae (26 gauge stainless steel tubing) were implanted
stereotaxically using the appropriate coordinates for the
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nucleus accumbens (Konig and Klippel, 1963; 9.5 mm A to lambda,
1.2 mm L, 5.1 mmV). The guide cannulae were permanently cemented
to the skull with dental cement and a stainless steel 32 gauge
stylet inserted.
Morphine
The rats were placed in one-lever operant conditioning chambers
and made physically dependent on morphine over a 12-day period by
delivering hourly infusions of morphine. The dose ranged from
1.25 - 10 mg/kg/infusion and was increased every third day. A
lever was then introduced and the rats were trained to respond
under an FR10 schedule. Subjects were then placed back into the
original conditioning chamber and a morphine reinforcer option
added to the initial food and water schedule. Subsequent re-
sponding was maintained under a conc chain FR 1 FR9 schedule
of food, water and morphine presentation.
Morphine Dose-Effect Study
Five subjects were used for the dose-effect determinations.
Morphine sulfate was dissolved in a bacteriostatic 0.9% sodium
chloride solution containing 0.83 USP units/ml of sodium heparin.
Dosages were determined as the salt and were calculated using the
average weight of 0.333 Kg. A range of doses from 2.5-40
mg/kg/infusion or dosages of O/83-13.33 mg/infusions was inves-
tigated. Morphine presentations consisted of a 0.2 ml infusion
delivered over a 5.5 sec period and were followed by a 30 sec
tone presentation. Dose-effect curve determinations were made
by replacing the daily morphine dose (10 mg/kg/infusion) with
another dose of morphine or saline for 24 hours. Drug substi-
tutions were always made at the start of the dark cycle (5 a.m.).
At least two determinations of each dose or vehicle were made.
Kainic Acid Lesion
Chemical lesions were produced by the microinjection of kainic
acid through the implanted cannulae using a previously described
procedure (Myers, 1966) (see Surgical Procedures above). On the
day of microinjection, the animal was anesthetized with Valium,
the stylet removed and an injection cannula (32 gauge stainless
steel tubing that extends 0.5 mm beyond the end of the guide
cannula when inserted ) that is attached to a 1 µl microsyringe
by PE tubing, was inserted into the guide cannula and secured. A
0.2 µl injection of 2 µg kainic acid in artificial CSF was then
made using a precision microinfusion pump that delivers 0.033 µl
of solution per minute. The injection cannula was removed after
10 minutes and the stylet replaced. Artificial CSF alone was
microinjected into control animals.
Histological Procedures
The histological method used to verify cannulae placement has
been previously reported (Pisa et al. 1980). The rats were
sacrificed by decapitation and 16 or 32 micron frozen sections
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cut and stained with the Kluver and Barrera (1953) method for
identification of both cell bodies and myelinated fiber
bundles. Location and extent of lesions were assessed by light
microscopy.
RESULTS
Control Performance
Characteristic rates and temporal patterns of responding were
maintained by the conc chain FR1 FR9 schedule of food and water
presentation. Responding consisted of a short pause after the
TO followed by a high rate of responding. Similar local rates
of responding were maintained by the two reinforcers. A large
number of consecutively completed ratios (runs) on the food
lever were followed by runs on the water lever. These runs on
the food lever were longer than the runs on the water lever,
resulting in twice the mean number of food presentations for the
six rats per day (285 ± 39) (values are mean ± S.D.) compared to
the mean number of water'presentations, 143 ± 57 per day. Over
90% of the responding occurred during the animals' dark cycle
(5:00 a.m. to 5:00 p.m). The addition of the third reinforcer,
morphine, to the schedule did not alter the local rate or
temporal response patterns. The three reinforcers maintained
characteristic fixed-ratio patterns of responding. Responding
maintained by morphine presentations was evenly distributed
over both light and dark cycles and the mean number of morphine
presentations was 14 ± 3 per day for the six subjects. The
addition of morphine to the food and water schedule produced a
small increase in the number of food presentations (333 ± 68)
and a decrease in the number of water presentations (115 ± 23)
delivered per day.
Morphine dose-effect curve
The effects of substituting several doses of morphine (2.5-40
mg/kg/infusion) or saline for the fixed daily dose of morphine
on the number of ratios completed on the three levers are shown
in Figure 1A. Only the lowest dose produced a slight decrease in
the number of ratios completed on the food and water levers.
Higher doses did not affect responding on either the food or
water lever.
Increasing the doses of morphine above the fixed daily dose of
10.0 mg/kg/infusion resulted in dose-related decreases in the
number of morphine infusions delivered. Decreasing the dose
below the daily dose increased the number of ratios completed on
the morphine lever. The most prominent effect of saline
substitution was the large increase in the number of ratios
completed on the morphine lever and the almost complete
elimination of responding maintained by water presentation (see
Figure 1A).
Effects of lesions
The effects of the kainic acid lesion of the nucleus accumbens
on the number of ratios completed (percent of control) on each
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of the three levers are presented in Figure 1B. The lesion
resulted in a small increase in responding on the water lever
and no change in responding on the food lever. However,
responding on the morphine lever was significantly decreased
(see points above 10.0 mg/kg/inj). Furthermore, in contrast to
the effects observed before the lesion, morphine dose (2.5 - 40
mg/kg/inj) after the lesion did not significantly alter
responding on any lever. The lowest dose of morphine
investigated resulted in occasionally increased responding on
the morphine lever after the lesion. Moreover, the behavioral
effects of saline substitution after the lesion were very
different from the effects observed before the lesion. Saline
substitution did not alter responding on either the food, water
or morphine manipulanda.
Figure 1. Morphine dose-effect curves for concurrent responding
maintained by food, water and intravenous morphine before (A)
and after (B) the kainic acid lesion. Data are expressed as
percent of control or baseline intake determined by exposure to
10 mg/kg per infusion of morphine. "S" represents exposure to
saline. Points are means for double determinations of 24-hours
exposure to each dose (except 10.0 mg/kg - mean of 10
determinations) and the error values ± standard deviations for
N=5 animals. Significant differences determined by Student's
t-tests comparing each point with the baseline condition were:
+=p<0.01, =p<0.001.
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DISCUSSION
Investigations of the neurobiological substrates of
reinforcement should include procedures for studying behavior
maintained by several different consequent events. Studies in
which responding is reinforced using a variety of different
events (e.g., food, water, and drug presentation) permit the
determination of specific neuronal mechanisms of reinforcement.
For example, two recent studies have demonstrated the
independence of neuronal systems mediating the reinforcement of
opiates and stimulants (Ettenberg et al, 1982; Petit et al,
1982). Demonstration of the reinforcer-specific effects of
neurobiological manipulations on behavior maintained by
different consequent events questions the involvement of only a
single neurotransmitter system in brain reinforcement
processes. In the present study, responding was concurrently
maintained by response-dependent food, water, and morphine
presentation. Changing the morphine dose was shown to alter
morphine responding, but had little or no effect on responding
maintained by food or water. Furthermore, kainic acid lesions
of the nucleus accumbens were shown to selectively reduce the
reinforcing efficacy of morphine.
A second advantage of the procedure used in the present study
was that non-selective effects due to motor impairment could be
independently evaluated. The fact that the neurotoxin lesions
only changed responding on the morphine lever indicated that the
lesion did not produce a non-specific motor deficit. Several
previous reports that suggest the involvement of dopamine
reinforcement systems in mediating food reinforcement have not
controlled for non-specific motor effects (Wise, 1980).
The dose-effect curves demonstrated that effects of morphine
observed were not the result of a shift in the dose-effect
curve. Behavior after the lesion was not sensitive to different
doses of morphine. Kainic acid lesions destroy interneurons and
outputs from the injected region. These data suggest that these
interneurons and output from the nucleus accumbens are
excitatory to opiate processes, but not necessary for food and
water reinforcement.
Several recent studies have demonstrated the complexity of
neurobiological substrates of reinforcement and have implicated
the involvement of several different neurotransmitter systems in
these processes. Furthermore, both common as well as
independent neurotransmitter systems appear to be involved in
the ability of different consequent events to maintain
behavior. Studies that attempt to determine both the general
and specific neuronal systems involved in responding maintained
by different reinforcing events provide a more complete
assessment of neurobiological substrates of reinforcement.
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Buprenorphine, Heroin, and
Methadone: Comparison of
Relative’ Reinforcing Properties
N. K. Mello, M. P. Bree, and J. H. Mendelson
Buprenorphine is a partial agonist of the morphine type. It is
both a long-acting opiate antagonist, like naltrexone, and a potent
opiate agonist with respect to analgesia, physiological and sub-
jective reactions in man (Houde, 1979; Jasinski et al, 1978; Lewis
et al, 1983) . However, buprenorphine does not induce physical de-
pendence in several species and appears to produce only minimal
physical dependence in man (Jasinski et al, 1978; Mello et al, 1982;
Rance, 1979).
Buprenorphine’s positive morphine-like agonist effects combined
with its antagonist potency, low toxicity, and minimal capacity for
producing physical dependence, suggested that it should be valuable
for the treatment of opiate addiction (Jasinski et al, 1978).
Clinical studies have shown that buprenorphine maintenance (8 mg/
day s.c.) significantly suppressed self-administration of heroin
(21 to 40.5 mg/day) by male heroin addicts over 10 days of heroin
availability in comparison to buprenorphine placebo (Mello and
Mendelson, 1980; Mello et al, 1982). Buprenorphine (0.282 to 0.789
mg/kg/day i.v.) also significantly suppressed opiate self-administra-
tion in the rhesus monkey drug self-administration model (Mello et
al, 1983). Recent clinical studies have shown that sublingual ad-
ministration of buprenorphine (l-2 mg) should be suitable for daily
maintenance for the treatment of narcotic addiction (Jasinski et
al, 1983).
The opiate agonist effects of buprenorphine resemble those of meth-
adone and morphine in terms of reported subjective responses
(Jasinski et al, 1978). The degree of euphoria and other positive
subjective effects of 8 mg/day of buprenorphine were equivalent to
those produced by 120 mg/day of morphine (30 mg q.i.d.) or 40 to 60
mg of methadone (Jasinski et al, 1978). There is usually a high
concordance between subjective reports of opiate effects and animal
drug self-administration data (Griffiths and Balster, 1979), and
buprenorphine has also been shown to be a positive reinforcer in
rhesus monkeys (Woods, 1977; Mello et al, 1981; Yanagita et al,
1982 and baboon (Lukas et al, 1983).
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The abuse potential of buprenorphine relative to the abuse potential
of the opiate agonist methadone is unknown, and the relative efficacy
of buprenorphine and methadone in attenuating opiate self-administra-
tion has not been compared in inpatient or outpatient clinical stud-
ies . The accumulated clinical experience with methadone abuse
(Kreek, 1978) argues for the importance of systematic evaluation of
the potential abuse liability of new pharmacotherapies. One approach
to evaluating relative reinforcing efficacy of various drugs, and
inferring potential abuse liability, is the progressive ratio pro-
cedure. This procedure provides a quantitative index of the number
of responses that a monkey will emit for a single drug injection, a
measure sometimes described as “response cost.” Different doses of
a single drug or different drugs can be ranked according to the
maximum number of responses emitted to acquire a single drug in-
jection (Yanagita, 1976; Yanagita et al, 1965). This report de-
scribes preliminary data obtained on the relative reinforcing pro-
perties of buprenorphine, methadone, and heroin using progressive
ratio procedures.
METHODS
Six male Macaque monkeys (1 Macaca mulatta and 5 Macaca nemestrina)
weighing 6.0 to 8.4 kg were studied. Five monkeys had a history of
opiate agonist and mixed agonist-antagonist self-administration and
one monkey was drug-naive at the beginning of these studies. Mon-
keys were surgically implanted with chronic indwelling catheters to
permit intravenous drug self-administration. All surgical proce-
dures were performed under aseptic conditions. Monkeys were
anesthetized with either pentobarbital (30 mg/kg/i.v.) or ketamine
(25 mg/kg/i.m.) and a double lumen silicon rubber catheter (I.D.
0.028”; O.D. 0.088”) was placed in a vein. Following surgery,
animals were given 1 ml of combiotic every other day for a total of
five injections.
Animal maintenance and research was conducted in accordance with
the guidelines provided by the Committee on laboratory Animals
Facility and Care, the National Research Council Institute of lab-
oratory Animals Resources.
Department of Agriculture.
The facility is licensed by the U.S.
The health of the monkeys was periodi-
cally monitored by a consultant veterinarian from the New England
Regional Primate Center.
Monkeys worked at an operant task for food (1 gm banana pellet) and
for buprenorphine (.01, .03, .05, .10 mg/kg/inj), heroin (.01, .05,
.10 mg/kg/inj), methadone (.03, .10, .25 mg/kg/inj) and saline.
Food and baseline drug self-administration were maintained under a
second-order schedule of reinforcement [FR 4 (VR 16:S)]. An average
of 16 responses on a variable ratio schedule (VR 16) produced a
brief colored stimulus light (S+). However, a drug injection or a
food pellet was delivered only after a fixed ratio of 4 (FR 4) of
the VR 16 response requirements had been completed; i.e., each food
pellet or drug injection required an average of 64 responses. De-
tails of the apparatus have been published (Mello and Mendelson,
1978). Monkeys were maintained at ad lib weight and given multiple
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vitamins, fresh fruit and vegetables daily to supplement a banana
pellet diet.
Food sessions began at 11 a.m., 3 p.m., 7 p.m. and 11 p.m. each
day, and drug sessions began one hour later at 12 noon, 4 p.m.,
8 p.m. and midnight. Each food or drug session lasted either one
hour or until 20 drug injections or 65 food pellets were delivered.
The chamber was dark between 1 a.m. and 9 a.m.
Each dose of buprenorphine, heroin, and methadone was available for
a minimum of 40 sessions over 10 days or until baseline drug self-
administration was stable. Subsequently, the second order schedule
response requirement was systematically increased by increasing
the number of responses required in the Fixed Ratio (FR) component
of the second order schedule in increments of two. The resulting
progressive ratio response requirements per drug injection are
summarized below.
Average Response
Schedule Requirement Per Number of
Requirement Drug Injection Sessions
FR 4  (VR 16:S)
64 8
96 8
FR 8 (VR 16:S) 128 8
FR 10 (VR 16:S) 160 8
FR 12 (VR 16:S) 192 8
FR.. . N (VR 16:S) . ..N 8
Each increase in the FR schedule component was run for eight
sessions over two days. Progressive increases in the response
requirement were continued until drug self-administration de-
creased significantly below baseline levels. The usual ‘break-
point” criterion is two consecutive days of no drug self-adminis-
tration, The in-mediately preceding response requirement for a
single drug injection indicates the maximum number of responses
that the monkey will emit for that dose of the drug.
Once the “breakpoint” at a single drug dose was reached, the monkey
was returned to the baseline schedule requirement (FR 4 VR 16:S)
at the same drug dose until drug self-administration resumed.
This procedure was useful to reduce the extinction-like effects of
the progressive increases in response requirements for drug. Monkeys
were then given access to the next dose of drug and run at the
basic second order schedule response requirement until drug self-
administration was stable over 40 consecutive sessions or 10 days.
Response requirements were then increased progressively as before
and continued until the monkey reached the “breakpoint” at that
dose. All monkeys were not run at every dose of each drug.
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RESULTS
These studies are still in progress and all 10 drug doses and sa-
line have not yet been evaluated in all monkeys. The group aver-
age breakpoints for buprenorphine (.01-.10 mg/kg/inj), heroin
(.01-.10 mg/kg/inj) and methadone (.03-.25 mg/kg/inj) are shown in
Figure 1.
The reinforcing efficacy of buprenorphine appears to be greatest
at low doses. Buprenorphine at doses of .01 and .03 mg/kg/inj
maintained responding on progressively increasing values of second
order schedules for longer than higher doses of buprenorphine
(.05 and .10 mg/kg/inj) . Yanagita and co-workers (1982) also re-
ported that rhesus monkeys worked longer for a low (.015 mg/kg/inj)
than for a high (.06 mg/kg/inj) dose of buprenorphine on a pro-
gressive ratio schedule. This pattern is consistent with the no-
tion that the antagonist component of this mixed agonist-antagonist
drug attenuates its agonist effect at higher doses. Several agonist
effects of buprenorphine such as euphoria (Jasinski et al, 1978),
“stupor” (Kareti et al, 1980), antinociception and respiratory de-
pression in rats (Cowan et al, 1977a and b) each are maximal at
relatively low doses and are significantly reduced or fail to in-
crease at higher doses.
These data are also concordant with observations in baboons that
self-administered buprenorphine on an FR 160 schedule (Lukas et al,
1983). Buprenorphine self-administration tended to plateau over a
dose range of 0.1 to 1.0 mg/kg/inj (Lukas et al, 1983). Changes in
buprenorphine injections per day as a function of dose were less
consistent in rhesus monkey when responding was maintained on a
second order FR 3 (VR 16) schedule. Only 2 of the 5 monkeys showed
a consistent decline in buprenorphine injections as the dose per
injection was increased over a range of .005 to .10 mg/kg/inj
(Mello et al, 1981).
Monkeys consistently emitted more responses for heroin than for bu-
prenorphine across the range of doses studied. These data suggest
that the abuse potential of buprenorphine relative to heroin is
low. Moreover, in contrast to buprenorphine, the progressive ratio
breakpoint for heroin increased as a function of increased heroin
dose. These data are consistent with previous progressive ratio
studies of heroin (.001 to 0.5 mg/kg/inj) and codeine (.01 to 16
mg/kg/inj) self-administration in rhesus monkey (Hoffmeister, 1979),
but a number of procedural differences limit further comparisons
between these studies.
The lowest dose of methadone (.03 mg/kg/inj) maintained less re-
sponding in a progressive ratio paradigm than either buprenorphine
or heroin. At an intermediate methadone dose (.10 mg/kg/inj) pro-
gressive ratio breakpoints were almost twice as high as those for
buprenorphine. However, the abuse potential of methadone relative
to heroin and buprenorphine cannot be estimated with confidence
until additional progressive ratio data for methadone self-administra-
tion are available.
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Figure 1: Group average maximum number of responses per injection
emitted for ascending doses of buprenorphine (.01-.10 mg/kg/inj),
heroin (.01-.10 mg/kg/inj) and methadone (.03-.25 mg/kg/inj) on a
progressive ratio schedule.
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Behavioral Interactions of Opioid
Agonists and Antagonists With
Serotonergic Systems
Richard H. Rech, David J. Mokler,
Randall L. Commissaris, and Judith W. Henck
Morphine interacts with brain serotonergic (5-HT) systems; these systems
have been implicated in morphine analgesia and dependence see Cervo et
al., 1981). The 5-HT agonist quipazine induces analgesia in rats that is
attenuated by naloxone and 5-HT antagonists (Minnema et al., 1980;
Samanin et al., 1976). Behavioral disruption by the hallucinogens LSD,
DMT and mescaline, mediated primarily through brain 5-HT effects (Rech
and Commissaris, 1982), is potentiated by naloxone and naltrexone (Com-
missaris et al., 1980; Ruffing and Domino, 1981) and is variably antago-
nized or potentiated by morphine and methadone (Ruffing and Domino,
1981). Cyclazocine causes a disruption of operant behavior similar to that
of the hallucinogens which is reversed in part by naloxone and the 5-HT
antagonist metergoline, and to a greater extent by the combination of
naloxone and metergoline (Henck et al., 1983). These studies indicate
that indole and phenethylamine hallucinogens interact to some extent
with brain opioid mechanisms as well as brain 5-HT components, whereas
opioid drugs influence behavior in part by actions on 5-HT systems.
We have extended these drug studies in an attempt to characterize
interactions with 5-HT mechanisms and to identify the various types of
opioid receptors involved.
METHODS
Male Sprague-Dawley rats were food deprived to 75-80% of free-feeding
weights and trained to a fixed ratio-40 (FR-40) schedule of food rein-
forcement. The number of reinforcers (Bioserve 45 mg food pellets) and
“pause intervals” (a 10 sec period without a response, Commissaris et al.,
1980; Rech and Commissaris, 1982) were recorded for daily 40-min
sessions. Changes in the patterns of responding were determined after
combinations of lysergic acid diethylamide (LSD) or 2,5-dimethoxy-4-
methylamphetamine (DOM) with naloxone (NAL), cyclazocine (CYCL)
with quipazine (QUIP) or metergoline (MTG), ethylketocyclazocine (EKC)
with NAL or MTG, and N-allyl-normetazocine (SKF 10,047; SKF) with
NAL or MTG. Dose-response curves were analyzed by a one-way ANOVA
using the least significant differences (lsd) test for comparing individual
doses to baseline; multiple dose-response curves were compared by a two-
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way ANOVA using the lsd test for individual comparisons. The signifi-
cance level was set at p< 0.05.
RESULTS
LSD (12.5-100 µg/kg) or DOM (0.125-1.0 mg/kg) caused a dose-related
increase in pause intervals (Fig. 1) that was reciprocally related to a
decrease in reinforcers delivered. Pretreatment with 4 mg/kg NAL
potentiated the disruptive effects of LSD and DOM, but neither dose-
response curve was shifted in a parallel fashion.
CYCL disrupted FR-40 responding as shown in Fig. 2. Like the hallucino
gens, CYCL caused a dose-related decrease in reinforcers that was
reciprocally related to increases in pausing. This disruption was attenu-
ated over the entire dose range, at least for pauses, by pretreating with a
low dose of QUIP (0.5 mg/kg). Additional pretreatment with MTG (1.0
mg/kg) nullified the QUIP antagonism only at the highest dose of CYCL
tested. A previous report indicated that the CYCL effects were
antagonized over the middle-dose range by both NAL (4 mg/kg) and MTG
(1 mg/kg) pretreatment, and combination of these pretreatments showed
additive protection (Henck et al., 1983).
FR-40 disruption was also observed with QUIP (Fig. 3) and a dose-related
reciprocal increase in pausing was again associated with the decrease in
reinforcers. Therefore, the hallucinogens, certain opioids, and 5-HT
agonists appear to affect FR-40 responding in this manner. Pretreatment
with NAL (4 mg/kg) slightly potentiated the disruptive effects of low
doses of QUIP but had no significant effect at higher doses. Likewise,
pretreatment with a small dose of CYCL (0.5 mg/kg) slightly potentiated
low dose QUIP without influencing the effect of higher doses. However,
when the NAL and CYCL pretreatments were combined, the marked
disruption observed after 2.0 mg/kg QUIP. alone was greatly attenuated.
Thus, the disruptive effects of QUIP may involve both 5-HT and opioid
mechanisms.
The prototype kappa agonist EKC (Fig. 4) decreased reinforcers in a dose-
related manner with a reciprocal increase in pauses, but, unlike the
hallucinogens, exhibited a steep dose-response curve. Pretreatment with
NAL slightly potentiated the disruptive effects of low doses of EKC but
prominently antagonized the effects of higher doses. Pretreatment with
MTG also enhanced the effects of low doses of EKC and antagonized EKC
disruption only at the 1.0 mg/kg dose. A low dose (0.5 mg/kg) of CYCL
was also administered as a pretreatment (not illustrated) and interacted
with EKC in a pattern very similar to that noted with MTG pretreatment.
Since SKF has hallucinogenic properties and may be a selective agonist at
sigma receptors, its effects on the FR-40 operant pattern were examined
(Fig. 5). Once more the hallucinogenic profile of decreased reinforcers
with a reciprocal increase in pause intervals was obtained. In this case
pretreatment with 4 mg/kg NAL did not significantly influence the
disruptive pattern of the drug. Pretreatment with MTG slightly antago
nized the effects of SKF at several intermediate doses. Therefore, SKF
does not appear to exert these disruptive effects via NAL-sensitive opioid
receptors, but may act to some extent through 5-HT mechanisms.
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with 4 mg/kg naloxone (NAL) (closed circles) on FR-40 behavioral
response pattern.
Fig. 1. Dose-response of LSD or DOM alone (open circles) or combined
Fig.  2 .  Dose-response of
cyclazocine (CYCL) alone,
Fig. 3. Dose-response of quipazine
combined with 0.5 mg/kg
(QUIP) alone, combined with 4 mg/kg
quipazine (QUIP), or com-
naloxone (NAL), with 0.5 mg/kg cycla-
bined with 0.5 mg/kg QUIF’
zocine (CYCL), or with both NAL and
CYCL.
and 1.0 mg/kg metergoline
(MTG ) .
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Pretreating with a low dose (0.5 mg/kg) of CYCL (results not illustrated)
slightly attenuated the increase in pausing at the highest dose (16 mg/kg)
of SKF, but otherwise had no appreciable effect.
Fig. 4. Dose-response of
ethylketocyclazocine (EKC)
alone, combined with 4
mg/kg naloxone (NAL), or
combined with 1 mg/kg me-
tergoline (MTG).
DISCUSSION
Fig. 5. Dose-response of
SKF 10,047 (SKF) alone, combined
with 4 mg/kg naloxone (NAL), or
combined with 1 mg/kg meter-
goline (MTG).
The shifts of the dose-response curves of LSD, DOM (Fig. 1 and
mescaline (Commissaris et al., 1980) to the left by pretreatment with 4
mg/kg NAL were not parallel, suggesting that the opioid interaction is
modulatory and not exerted at the same receptors as those affected by
the hallucinogens. Similar results were found for LSD and DMT by
Ruffing and Domino (1981). Additionally, they observed antagonism of
the operant behavioral disruption of hallucinogens by pretreating with low
doses of morphine or methadone. The dose of NAL required to produce
these interactions (2-8 mg/kg) is in the range optimal for kappa receptor
antagonism rather than that which is optimal for mu antagonism (0.2-1.0
mg/kg).
Disruption of the FR-40 operant pattern by these hallucinogenic drugs is
characterized by dose-related decreases in responses (reinforcers earned)
correlated with increases in pause intervals (10-sec intervals without a
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response) over the entire dose-response curve (Rech and Commissaris,
1982). This pattern of impairment is not observed with many other
psychoactive drugs (chlorpromazine, d-amphetamine, pentobarbital), but
is seen with other 5-HT agonists, such-as QUIP and lisuride. The operant
behavioral effects of hallucinogens and non-hallucinogenic 5-HT agonists
are attenuated by pretreating with MTG and other 5-HT antagonists, but
the rate-decreasing effect of the other classes of psychoactive agents is
not affected by these pretreatments. However, the opioid mixed agonist-
antagonist CYCL was found to disrupt the FR-40 operant pattern in the
same way as the hallucinogens did, i.e., a decrease in reinforcers
correlated with a reciprocal increase in pause intervals (Henck et al.,
1983). Furthermore, this impairment was partly antagonized by pretreat-
ing with NAL, MTG, or a combination of the two.
The behavioral effects of CYCL were attenuated by a low dose of QUIP
(Fig. 2). This antagonism may relate in part to the opioid-like effects of
QUIP (Minnema et al., 1980; Samanin et al., 1976). However, 5-HT
influences may also pertain, since combined pretreatment with QUIP and
MTG reversed the protection by QUIP at the higher doses of CYCL. QUIP
itself, at higher dose levels, caused a decrement in FR-40 responding (Fig.
3), which was little affected by pretreatment with NAL or a low dose of
CYCL. Nevertheless, the combined pretreatment with NAL and CYCL
reversed both the decrease in reinforcers and the increase in pausing
caused by the 2 mg/kg dose of QUIP. It seems likely that both opioid and
5-HT mechanisms are involved in this complex interaction.
If the CYCL effects on FR-40 behavior act in part through kappa opioid
receptors, the more selective kappa agonist EKC might show similar
effects. However, interactions of EKC with NAL or MTG were quite
complex (Fig. 4). The slight potentiation of lower doses of EKC by NAL
may relate to subtle opioid influences at other than kappa receptors. The
prominent protection by NAL against higher doses of EKC probably does
involve kappa receptors. The fact that MTG pretreatment enhanced the
disruptive effects of low doses of EKC but attenuated those from a higher
dose suggests that EKC interacts in a complex manner with 5-HT
mechanisms that influence this behavior.
Lastly, the actions of SKF (Fig. 5) must be mediated via mechanisms
different from those involved in the effects of indole and phenethylamine
hallucinogens and QUIP and CYCL. NAL had no effect on the SKF dose-
response pattern in keeping with a mechanism involving sigma receptors,
which are considered NAL-insensitive (Simon and Hiller, 19781 MTG
pretreatment exerted only a slight protection against the behavioral
decrement caused by SKF, indicating that the latter drug does not act
primarily via 5-HT receptors.
The results of this study show that the opioids CYCL and EKC produce
their disruption of operant behavior by interacting, at least in part, with
5-HT and NAL-sensitive opioid systems. Thus, they appear to exert their
effects in a manner related to the actions of indole and phenethylamine
hallucinogens. On the contrary, the effects of SKF appear to be mediated
mainly through mechanisms different from those of the indole and
phenethylamine hallucinogens.
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Bioassay of Subjective Effects
Associated With Benzodiazepine
Withdrawal in Animals: A Novel
Direction in Dependence
Research
Michael W. Emmett-Oglesby, David G. Spencer, Jr.,
Marilyn W. Lewis, and Harbans Lal
In humans, the earliest arising and most readily detectable symptom
of withdrawal from drugs of dependence are subjective in nature.
For example, cessation of high-dose use of a number of drugs,
including benzodiazepine anxiolytics, initially produces complaints
of anxiety or a general sense of uneasiness. For most substances
with dependence liability, as withdrawal progresses, subjective
symptoms are superseded by more vivid physical manifestations of
abstinence, and it is only these latter phenomena that have been
well characterized in the drug-dependence literature. Signif-
icantly, however, continuation of the self-administration cycle in
man is not contingent on the emergence of overt behavioral signs of
withdrawal; therefore, subjective events occurring early during drug
withdrawal may be an important factor in continued drug dependence.
By definition, subjective events are not directly verifiable by
experimenter observation, and becauseo f the dangers of anthro-
pomorphism, animal investigations of subjective events are
particularly difficult. On the other hand, subjective events can be
tested experimentally if behavioral responses can be made
specifically contingent upon detection of the subjective occurrence
by the test subject. For example, subjects can be trained to use
the interoceptive discriminative stimuli (IDS) arising from drug
injection as the basis for choosing which of several potential
responses is correct. When only two responses are available, the
response emitted, be it human-verbal or animal-choice behavior,
resolves to "yes, the stimulus is present," or "no, it is not." The
qualitative nature of such a binary decision can then be quantified
through the method of population analysis; that is, the percent of
subjects reporting the presence of the subjective event is a
function of the stimulus intensity. In the past decade, many
investigations have shown that drug effects thus measured are
classified in parallel (e.g. LSD-like, narcotic-like) by humans
(Altman et al. 1977) and animals (Glennon and Rosecrans 1981).
This paper illustrates application of drug discrimination technology
to quantify in animals a subjective factor that frequently occurs in
man during withdrawal from drugs of dependence. The rationale was to
train animals to discriminate a drug possessing IDS properties that
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can be related to a subjective symptom often noted in man during
withdrawal: anxiety. Pentylenetetrazol (PTZ) administered in
sub-convulsant doses was chosen as the training drug because the IDS
produced by PTZ are correlated with the reported anxiogenic effect
of this compound in man (Rodin and Calhoun 1970), and discrimination
of these IDS has been proposed as an animal model of anxiety (Lal
and Shearman 1980) because 1) clinically efficacious anxiolytics
block PTZ IDS, 2) drugs known to be anxiogenic in man generalize to
PTZ IDS, and 3) although PTZ is a convulsant, non-anxiolytic
anti-convulsants do not block PTZ IDS (Lal and Emmett-Oglesby 1983).
In this paper we summarize results from pilot experiments designed
to detect PTZ-like stimuli occurring following termination of
short-term administration of diazepam and pentobarbital. The
results show that PTZ-like stimuli are produced by diazepam
withdrawal, whether precipitated by a benzodiazepine antagonist or
produced by termination of diazepam administration, and that these
stimuli are alleviated by diazepam and pentobarbital. Short-term
administration of pentobarbital failed to produce similar signs.
METHODS
Male Long-Evans hooded rats were trained and tested in conventional
behavioral chambers (Coulbourn Instruments) as described by Lal and
Emmett-Oglesby (1983). Scheduling of reinforcement contingencies
and-recording of data was done through TRS-80 microcanputers and
printers (Radio Shack) connected to the chambers through LVB
interfaces (Med Associates, Inc. using a program described by
Emmett-Oglesby et al. (1982). Briefly, subjects were trained to
press one of two levers to obtain a food reward. During training,
the correct lever to press was determined by injection conditions:
following administration of PTZ, 20 q/kg, only responses on one of
theleverswererewarded; following non-PTZ treatments, only
responses on the other lever were rewarded. In either case, 10
responses had to be emitted on the correct lever in order to obtain
reinforcement. Once subjects had learned the PTZ-saline
discrimination to the criterion of selecting the correct lever on
ten consecutive training days, experimental testing was begun. On
test sessions, independent of the injection condition, the lever
upon which ten responses were first emitted was considered selected
and was reinforced.
Following training, subjects were tested for the ability of various
treatments to generalize to or block PTZ IDS. Subsequently,
training and testing were stopped, and diazepam, 20 q/kg, was
injected every 8 hours. After 5 days of this regimen, the ability
of Ro 15-1788 to elicit PTZ-IDS was tested. Fifteen minutes
following diazepam administration, Ro 15-1788 was administered, and
rats were tested for lever selection 15 minutes later. Following
these tests, chronic diazepam administration was continued, and on
days 7-10, the ability of various treatments to generalize to or
block PTZ IDS was tested at 8 hours after a preceding diazepam
injection. After 11 days of diazepam administration, chronic
injections were terminated, and lever selection was tested at
various times over the next days. In a second experiment,
pentobarbital was injected in doses of 160 mg/kg/day for 7 days
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followed by 240 mg/kg/day for an additional 7 days. Subsequently,
chronic injections were terminated, and generalization to the PTZ
stimulus was tested at various times over the next 36 hours.
RESULTS
The PTZ discrimination was well established after training (Table
1). Prior to diazepam dependence, all rats selected the PTZ-correct
lever following PTZ injection and the saline-correct lever following
saline injection (Table 1). In addition, on acute administration,
neither diazepam, clonidine (Table 1) nor Ro 15-1788 (Figure 1)
generalized to the PTZ stimulus. Diazepam did, however, antagonize
the PTZ cue (Table 1).
TABLE 1. Generalization of various treatments to the pentylene-
tetrazol stimulus prior to chronic diazepam.
------------------------------------------------------
Dose Number of % Selecting
Test Drug (mg/kg) Rats Tested PTZ Lever(1)
------------- --------- ------------- ------------
Saline -- 26 0
Pentylehetetrazol 20.0 26 100
Diazepam 10.0 10 0
Clonidine 0.04 5 0
0.16 4 0
Pentylehetetrazol 20.0
+ Diazepam 5.0 9 ll
Pentylenetetrazol 20.0
+ Clonidine 0.04 5 100
Pentylenetetrazol 20.0
+ Clonidine 0.16 5 100
--------------------------------------------------------------
(1) % subjects emitting the first 10 responses on the PTZ-
correct lever.
PTZ-like IDS occurred in diazepam-treated subjects after both
precipitated and spontaneous withdrawal. In contrast to the failure
of Ro 15-1788 to generalize to PTZ prior to dependence, in rats
treated with diazepam for 5 days, Ro 15-1788 produced dose-dependent
selection of the FTZ lever with an ED50 of 7.1 mg/kg (Fig. 1).
Termination of two weeks of chronic pentobarbital administration did
not produce significant generalization to PTZ IDS (Table 2).
However, spontaneous withdrawal from 11 days of 60 mg/kg/day of
diazepam did produce generalization to the PTZ stimulus (Table 2).
This generalization was greatest at 8 hours (chi square = 12.5,
p<.OO1) of withdrawal (earliest time tested), and was still
detectable 16 days after termination of chronic diazepam. At the
8-hour spontaneous withdrawal point, pentobarbital blocked the
appearance of PTZ-like IDS, whereas clonidine did not (Table 3).
When these subjects were moved from the chamber, injected with Ro
15-1788 and returned to the chambers, pentobarbital still blocked
PTZ-lever selection, but clonidine did not (Table 3).
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Figure 1. Dose-dependent generalization of Ro 15-1788 to the
pentylenetetrazol stimulus. Abscissa: dose of Ro 15-1788.
Ordinate: percentage of rats canpleting the first ten responses on
the PTZ lever. 0 = non-diazepam dependent . X = diazepam
dependent.
TABLE 2. Generalization to the pentylenetetrazol stimulus following
termination of chronic pentobarbital(1) or diazepam(2).
Pentobarbital Diazepam
Hours After % selecting Days After % Selecting
Last Dose PTZ Lever(3) Last Dose PTZ Lever
2 22 0.33 60
6 11 1 55
12 33 2 35
24 0 3 40
36 11 8 30
33
16 25
(1) Pentobarbital was given i. p., 40 mg/kg/injection, 4 times per
day for one week follwed by 6 times per day during the second week.
(2) Diazepam was given i. p., 20 mg/kg/injection, 3 times per day
for eleven days.
(3) See Table 1 for testing criterion. Spontanous occurrence of
PTZ-like stimuli during withdrawal was tested by determining lever
selection following saline injection.
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TABLE 3. Generalization of various treatments to the pentylene-
tetrazol stimulus after 8-hour withdrawal fran chronic diazepam.(l)
Number of % Selecting
Treatment(2) Dose Subjects PTZ Lever(3)
Saline 16 56
Pentobarbital 10 6 0
Clonidine 0.04 7 43
Pentobarbital 10
+ RO 15-1788 10 6 0
Clonidine 0.04
+ Ro 15-1788 10 9 54
(1) Tests were conducted on days 7 through 10 of chronic
diazepam administration, 20 q/kg, every 8 hours.
(2) Treatments occurred 8 hours post diazepam.
(3) See Table 2.
DISCUSSION
Physical dependence on diazepam has been reported in man (Marks
1978) and laboratory animals (Martin et al. 1982). What is novel in
the present results is that a subjective aspect of withdrawal can be
detected and quantified in laboratory animals. The discrimination
of non-convulsant doses of pentylenetetrazol, an animal assay for
drug effects related to anxiety in man (Lal and Emmett-Oglesby
1983), detects withdrawal from diazepam, whether precipitated or
spontaneous. Previous studies using overt physical signs of
withdrawal typically have found that benzodiazepine dependence in
rats can only be obtained after high-dose and/or prolonged
administration (Boisse et al. 1982; Martin et al. 1982). The
relatively short period taken in this study to demonstrate
withdrawal suggests that subjective aspects of withdrawal can be
detected and quantified after far less dependence than is required
to produce overt signs of abstinence.
Physical dependence on pentcbarbital has also been reported in
laboratory animals Martin et al. 1982), although demonstration of
physical manifestations of withdrawal requires prolonged and
high-dose administration. Thus, the failure to detect pentobarbital
withdrawal in the present experiment may be a reflection of
inadequate dose or duration of pentobarbital treatment. These
results can be contrasted with those for diazepam, suggesting that,
benzodiazepines may have a greater propensity for producing
subjective signs of withdrawal, even after relatively brief periods
of administration.
Acute administration of Ro 15-1788, a benzodiazepine receptor
antagonist (Mohler et al. 1981), generalized to PTZ only during
chronic diazepam administration. When combined with the results
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from spontaneous withdrawal, these data suggest that Ro 15-1788
precipitated diazepam withdrawal. This conclusion is supported by
previous studies showing that Ro 15-1788 precipitates physical signs
of withdrawal in animals exposed to prolonged high-dose
benzcdiazepine treatment (Boisse et al. 1982).
Spontaneous withdrawal signs, as wellas those precipitated by Ro
15-1788, were blocked by pentobarbital, but not by clonidine.
Pentobarbital is a non-benzodiazepine drug with anxiolytic
properties, and there is substantial evidence that its effects are
not mediated by benzodiazepine receptors (Davis and Ticku 1981).
The present findings support the hypothesis that a non-
benzodiazepine receptor mechanism is responsible for the
pentobarbital alleviation of benzodiazepine withdrawal. Clonidine
is effective in relieving signs of opiate abstinence in man (Gold et
al. 1978) and animals (Fielding et al. 1978), but the ability of
clonidine to allieviate benzodiazepine withdrawal signs is unknown.
The present data suggest that clonidine would not be expected to
relieve anxiety symptoms produced by benzodiazepine withdrawal.
Thedetection of PTZ IDS has been proposed as an animal modelof
anxiety, and the appearance of PTZ-like IDS during withdrawal from
diazepam is in agreement with reports in man that anxiety is a
protracted and frequently seen symptom of benzodiazepine withdrawal
(Marks 1978). The present results may thus aid in resolving a
controversy surrounding the role of drug dependence in the
appearance of subjective complaints when a drug is terminated.
Clinically, there is debate as to whether such anxiety is a
manifestation of drug withdrawal or is only a return of the
patient's preexisting condition. Petursson and Lader (1981) have
argued that anxiety often goes unrecognized as a true withdrawal
sign because anxiety was usually the condition for which the
benzodiazepine was initially prescribed. The present data support
their conclusion that subjects do indeed experience witbdrawal-
induced anxiety.
In summary, our data suggest that a subjective manifestation of drug
withdrawal, related toanxiety in man, can be assayed in animals.
This sign can be detected and quantified at levels of dependence
much less than those necessary to produce more overt signs (e.g.,
convulsions) of withdrawal. Thus, the pentylenetetrazol
disc rimination paradigm can be used to test subjective signs of drug
withdrawal, and it can be employed to investigate neurochemical and
behavioral factors mediating these signs.
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Self-Administration of Clonidine
and Oxazepam by Methadone
Detoxification Patients
Kenzie L. Preston, George E. Bigelow, and Ira A. Liebson
The benzodiazepines and clonidine have frequently been used to
alleviate withdrawal symptoms during methadone detoxification.
Clonidine has been shown to be effective in decreasing the symp-
toms of abrupt withdrawal from chronic methadone (Washton and
Resnick 1981; Charney et al. 1981); however, its usefulness in
gradual methadone detoxification, a procedure more commonly used
in outpatient methadone clinics, has yet to be demonstrated.
Because of the apparent efficacy of clonidine as a treatment
agent in opioid withdrawal, it has been suggested that clonidine
may possess some potential abuse liability -- either because of
its opioid-substitution properties or because of other sedative
or euphorigenic properties which it might have. Clonidine has
been shown to support intravenous self-administration in both the
rat (Davis and Smith 1977; Shearman et al. 1977) and the rhesus
monkey (Woolverton et al. 1982) . The availability of clonidine
in the illicit street market and the existence of some degree of
drug abuse has been reported (Gold et al. 1980).
The use of benzodiazepines and related compounds as adjuncts in
the treatment of the opioid withdrawal syndrome has been commonly
recommended (Goldstein 1972; Kleber and Gold 1978) and is commonly
practiced. Although insomnia, anxiety, and muscle cramps associ-
ated with methadone detoxification would appear to indicate the
use of these drugs, their efficacy as adjuvants in methadone de-
toxification has not been demonstrated in controlled studies.
It is well established that the benzodiazepines possess some de-
gree of abuse potential and will be self-administered by opioid
addicts (Woody et al. 1975; Stitzer et al. 1981). The reinforcing
properties of these agents may account for their popularity in the
treatment of methadone withdrawal symptoms.
The purpose of the present study was to examine the extent and
pattern of self-administration of clonidine and oxazepam during
methadone detoxification and to examine the extent to which these
drugs alleviate the symptoms of opioid withdrawal. Two groups of
methadone detoxification patients were used. In one group we com-
pared clonidine and placebo, and in the second group we compared
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oxazepam and placebo. The procedures used were the same for both
groups and consisted of two components: (1) to assess efficacy,
patients were given exposure to active drug and placebo, and the
acute effects of the two agents and their effects on withdrawal
symptoms were monitored; and (2) to assess drug preference, follow-
ing the forced exposure, subjects were given the opportunity to
self-administer the drug of their choice and to choose the dose
of that drug. These preference data gave an indication of patient
acceptability of the drug and possibly some measure of abuse li-
ability. The two components were repeated six times over the
course of the detoxification to assess the relationship between
drug efficacy and preference and withdrawal symptomatology.
METHODS
Subjects and general procedures: The participants were 12 male
methadone maintenance patients who requested inpatient detoxifi-
cation from methadone, and who gave their informed consent to
participate in this six-week research protocol. The average age
of the subjects was 32 years (range 23 - 41 years). The subjects
reported an average of 13 years (range 3 - 25 years) prior nar-
cotic addiction. The average daily methadone maintenance dose was
39.6 mg (range 30 - 50 mg).
Subjects participated while residing on an 8-bed behavioral
pharmacology research ward. On the basis of admission data sub-
jects were assigned to either the clonidine (N=6) or oxazepam
(N=6) group. The study was run in double-blind fashion; neither
the subjects nor the staff were informed of the methadone detoxi-
fication schedule or group assignment.
Methadone detoxification schedule: Methadone was administered in
a constant volume (60 ml) of cherry syrup solution once daily at
6:00 p.m. Subjects were maintained on their maintenance doses
for the first 5 to 6 days that the protocol was in effect,
followed by five days at one-half of the maintenance dose. The
methadone dose was then decreased to zero over the next 10 days.
The subjects continued to receive a constant volume of methadone
placebo (cherry syrup) throughout the rest of the study (15 days).
Adjunct medications: Placebo (lactose) and commercially available
preparations of oxazepam and clonidine hydrochloride were admin-
istered in colored opaque capsules and given an arbitrary letter
code (e.g., A and B). Codes and colors varied between subjects
but were held constant over each subject’s protocol.
The adjunct medication schedule began on the first day of metha-
done dose reduction (50% maintenance dose) and was arranged into
six blocks of five days. Due to occasional early subject dropout,
some subjects completed fewer than six blocks. On day 1 of each
block (baseline) no adjunct medications were given. On days 2 and
3 of each block (no-choice trials), the subjects were administered
three capsules of placebo or drug (oxazepam 10 mg/capsule or
clonidine 0.1 mg/capsule) two times daily at 9:00 a.m. and 3:00 p.m.
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The order of the administration of placebo or drug was counter-
balanced over the six blocks and across subjects.
On days 4 and 5 of each block (choice trials), subjects were given
the opportunity at each of the scheduled dosings (9:00 a.m. and
3:00 p.m.) to choose which of the two drugs they would receive
and the number of capsules (1, 2, or 3 capsules) they would re-
ceive. Subjects were required to take at least one capsule of
their choice at each drug administration. The opportunity to
choose the number of capsules to take allowed subjects to titrate
the drug effect.
Subjective and performance measures: Multiple subjective effect
measures were recorded throughout the day. A physical symptoms
questionnaire, developed in this laboratory to measure opioid
withdrawal symptoms experienced over the previous 24 hours, was
filled out by the subjects daily at 8:30 a.m. The questionnaire
consisted of 60 items which the subjects rated on a 4-point scale
from not at all (0) to severe (3). At 11:30 a.m. and 5:30 p.m.,
2.5 hours after each adjunct medication administration, subjects
filled out a visual-analog questionnaire which contained scales
for strength of drug effects, drug liking, and “good” and “bad”
drug effects. Also at 5:50 p.m. subjects performed two psycho-
motor performance tasks -- a computerized Digit Symbol Substitu-
tion Test (McLeod et al. 1982) and a test of hand-eye coordination
(Saccadic Fixator and Sequence Rotator, Wayne Engineering).
Data were analyzed to assess: (1) comparative effects of active
drug versus placebo on symptomatology, other subjective measures,
drug preference and self-administration behavior, and psychomotor/
cognitive performance; and (2) changes in these effects over the
course of the methadone detoxification (i.e., over successive test
blocks).
RESULTS AND DISCUSSION
Overall results have shown, at the doses tested, that: (1) neither
drug showed significantly greater efficacy than placebo in re-
lieving the discomfort associated with this gradual methadone
detoxification; (2) both drugs showed considerable between-subject
variability in free-choice self-administration, with some subjects
consistently choosing each of the active drugs in preference to
placebo; and (3) clonidine, to a greater extent than oxazepam,
produced a significant disruption in psychomotor/cognitive per-
formance.
Table 1 shows for successive test blocks (indicated by Roman
numerals) the mean methadone doses dispensed, mean physical
symptom scores for no-choice trials, and mean percent of choice
trials in which active drug was chosen (parenthetical numbers are
standard errors of the mean). For all subjects as a whole, symp-
tom scores tended to increase as methadone dose decreased, peaked
as the methadone dose reached zero (Block IV), and then declined.
However, for neither oxazepam nor clonidine was there a signifi-
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cant reduction in symptomatology relative to their respective
placebo control conditions -- either for specific test blocks or
for the detoxification as a whole. Mean preference for active
drug over successive test blocks was fairly stable for the oxaze-
pam subjects, but more variable for the clonidine subjects; in
neither case was there a marked preference for the active drug
and in neither case did preference appear to be related to
position in the methadone dose reduction schedule or to reported
withdrawal symptomatology
TABLE 1: Symptom scores and drug preference during methadone
detoxification.
Values shown are means; standard errors are in parentheses.
Examination of the choice-trial data for individual subjects re-
vealed considerable between-subject variability in drug versus
placebo preferences, both among oxazepam and among clonidine sub-
jects. These data are shown in Table 2. While the group average
data show no significant overall preferences, several individual
subjects in each group did show consistent preferences. Three out
of six subjects consistently chose oxazepam over placebe; one
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subject appears to have avoided oxazepam, and two subjects showed
no preference. Oxazepam was chosen in a mean of 65.9% (SE 13.4)
of all choice trials, not significantly more than placebo. On
trials in which oxazepam was chosen, subjects took an. average of
26.5 mg (or about 2½ capsules). Clonidine was chosen consistently
by four of six subjects; the remaining two subjects appeared to
avoid clonidine. Clonidine was chosen in a mean of 61.3%. (SE 15.3)
of all choice opportunities, not significantly different from
placebo. The average dose of clonidine was 0.24 mg (or about
2½ capsules).
TABLE 2: % Active drug choices for individual subjects
Oxazepam Clonidine
(N=6) (N=6)
100 100
100 92
87 81
58 75
38 20
12.5 0
X % Choices 65.9 61.3
S.E. 13.4 15.3
Both oxazepam and clonidine produced deficits in psychomotor per-
formance at the doses tested (Table 3). Both drugs significantly
decreased performance on the hand-eye coordination task; between-
drug comparison showed that the performance deficit produced, by
clonidine was significantly greater than that produced by oxazepam
(p<0.05; two tailed t-test). Only clonidine significantly de-
creased performance on the Digit Symbol Substitution Test.
TABLE 3: Psychomotor performance decrements: Mean differences
from placebo
Oxazepam Clonidine
Digit Symbol -0.76 -5.35"
Substitution Test (0.90) (1.12)
Hand- Eye -3.41* -15.29”
Coordination Test (1.00) (2.01)
Standard errors are shown in parentheses.
* p<0.05, two tailed t-test.
In addition to producing significant deficits in psychomotor per-
formance, both drugs were reported on the visual analog scales to
be significantly different from placebo for strength of drug ef-
fects and for good drug effects. Thus, the doses of clonidine
and oxazepam were high enough to produce appreciable objective
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effects and to be discriminated from placebo.
In summary, the results from clonidine, a proposed specific with-
drawal treatment, and oxazepam, a more symptomatic treatment, were
similar. Neither drug alleviated withdrawal symptoms as measured,
nor were the patterns of self-administration of the agents related
in any apparent way to the schedule of detoxification or pattern
of withdrawal symptoms. Although some individual subjects con-
sistently preferred each of the active drugs over placebo, the
preferences between placebo and the active drugs in the overall
group data were not significant. Two points, however, are note-
worthy: (1) at least half of the subjects in each group consis-
tently chose active drug over placebo in spite of the fact that
these drugs did not appear to be better than placebo in allevi-
ating withdrawal symptoms; and (2) clonidine produced substantial
impairments in psychomotor performance, indicating a risk of be-
havioral toxicity associated with its use as a detoxification
adjunct.
REFERENCES
Chamey, D.S., Steinberg, D.E., Kleber, H.D., Heninger, G.R., and
Redmond, E. The clinical use of clonidine in abrupt withdrawal
from methadone. Arch Gen Psychiatry, 38:1273-1277, 1981
Davis, W.M., and Smith, S.G. Catecholaminergic mechanisms of
reinforcement: Direct assessment by drug self-administration. .
Life Sci, 20:483-492, 1977.
Gold, M.S., Pottash, A.C., Sweeney, D.R., and Kleber, H.D. Opiate
withdrawal using clonidine. JAMA,  243:343-346, 1980.
Goldstein, A. Heroin addiction and the role of methadone in its
treatment. Arch Gen Psychiatry, 25:291-297, 1972.
Kleber, H.D., and Gold, M.S. Use of psychotropic drugs in treat-
ment of methadone maintained narcotic addicts. Ann NY Acad Sci,
311:81-98, 1978.
McLeod, D.R., Griffiths, R.R., Bigelow, G.E., and Yingling, J.
An automated version of the digit symbol substitution test (DSST).
Behav Res Methods Instrum, 14:463-466, 1982.
Shear-man, G., Hynes, M., Fielding, S., and Lal, H. Clonidine
self-administration in the rat: A comparison with fentanyl self-
administration. Pharmacologist, 19:171, 1977.
Stitzer, M.L., Griffiths, R.R., McLellan, A.T., Grabowski, J.,
and Hawthorne, J.W. Diazepam use among methadone maintenance
patients: Patterns and dosages. Drug Alc Depend, 8:189-199, 1981.
Washton, A.M., and Resnick, R.B. Clonidine in opiate withdrawal:
Review and appraisal of clinical findings. Pharmacother, 1:
140-146, 1981.
197
Woody, G.E., O'Brien, C.P., and Greenstein, R. Misuse and abuse
of diazepam: An increasingly common medical problem. Int J
Addict, 10:843-848, 1975.
Woolverton, W.L., Wessinger, W.D., and Balster, R.L. Reinforcing
properties of clonidine in rhesus monkeys. Psychopharmacology,
77:17-23, 1982.
ACKNOWLEDGMENTS
Supported by USPHS Research Grant DA-01943, Research Training
Grant DA-07209, and Research Scientist Development Award DA-00050,
from the National Institute on Drug Abuse.
AUTHORS
Kenzie Preston, Ph.D.
George Bigelow, Ph.D.
Ira Liebson, M.D.
The Johns Hopkins University School of Medicine
and
Behavioral Pharmacology Research Unit
D-S-West, Psychiatry Department
Baltimore City Hospitals
Baltimore, Maryland 21224
198
Marijuana, Affect and Tolerance:
A Study of Subchronic Self-
Administration in Women
Thomas F. Babor, Barbara W. Lex, Jack H. Mendelson,
and Nancy K. Mello
The study of differential tolerance development has important
implications for evaluation of the abuse potential of a
particular drug. Tolerance to the disruptive behavioral and
physiological effects of marijuana could make it possible for
experienced users to function at their "normal" level of
efficiency, even after heavy, daily consumption. On the other
hand, tolerance to the positive psychological effects that users
variously describe as euphoric, pleasurable and consciousness-
expanding, would diminish the reinforcing value of the drug at a
given dose, and thereby increase the necessity of more intense
or more frequent consumption to achieve previous levels of
intoxication. In the light of evidence that chronic marijuana
consumption may be related to impaired respiratory function and
other health consequences, tolerance to these effects might
prove detrimental to the user (Institute of Medicine, 1982).
To demonstrate that tolerance to THC leads to increased
consumption, it would be necessary to establish that:
1) reliable changes are produced by acute doses of marijuana to
psychological states, behavioral performance, or physiological
function; 2) these effects diminish over a period of time when
marijuana iS administered repeatedly; 3) marijuana self-
administration increases progressively in those individuals who
have developed tolerance. To date, several studies of
subchronic self-administration conducted in controlled settings
provide some evidence of the inadequacy of this tolerance model
to fully explain the often noted tendency for regular users of
marijuana to increase consumption over time (Mendelson, Meyer
and Rossi 1976; Babor et al. 1975).
One limitation of these studies is that they have been conducted
exclusively on male research subjects. In view of the growing
concern over adverse effects of marijuana on female hormonal
function (Institute of Medicine, 1982), it would seem important
to investigate the determinants of marijuana consumption in women
as well as men. Another limitation is that they have been re-
stricted to only a few of the potentially relevant variables,
specifically. pulse rate and subjective feelings of intoxica-
tion. Since affective states have often been implicated as pos-
sible reinforcers for marijuana consumption, it would also seem
important to study tolerance development to these variables as
well.
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The present study was therefore designed to replicate previous
research on tolerance development (Babor et al. 1975), using
females with a previous history of either moderate or heavy mari-
juana consumption. Expanding the assessments employed in the
previous investigation of males, this study included systematic
measures of affective states. The relationship between
tolerance development and marijuana consumption was evaluated by
analysis of how the acute effects of marijuana on pulse rate,
affective states, and subjective intoxication change during a
21-day period of free-choice marijuana self-administration.
METHODS
Subjects. Twenty-one adult female volunteers between the ages
of 21 and 36 years were recruited through advertisements placed
in local newspapers, On the basis of interviews and question-
naire data, subjects Were classified as either "moderate" or
"heavy" users of marijuana. Moderate users were persons who
smoked marijuana more than five times per month but less than
daily during the previous year. Heavy users were persons who
smoked marijuana between five and seven times per week during
the previous year. All subjects had a history of at least two
years marijuana use prior to admission to the study. The two
groups did not differ significantly on any variable except prior
marijuana consumption. Subjects tended to be lower middle or
middle class single females in their late 20s with some college
education. Experience with drugs other than marijuana and
alcohol was infrequent, although all subjects indicated polydrug
use patterns to some degree.
Experimental Design and Setting. The research was conducted
within the context of an extensive multidisciplinary investi-
gation of behavioral and biological concomitants of-free-choice
marijuana smoking in women. Six identical studies were con-
ducted, three of four-person groups and three of three-person
groups. Each study lasted 35 days and consisted of three
phases: a pre-drug baseline period lasting seven days; a 21-day
drug acquisition period during which marijuana cigarettes could
be purchased and smoked on a free-choice basis; and a seven-day
post-drug period. During all three phases of the study, sub-
jects had an opportunity to work at a simple operant task to
earn points which were exchangeable for money. Money earned
could be used to buy marijuana or could be retained by the
subject at the Conclusion of the study. A full battery of
assessments was performed daily to evaluate biochemical,
physiological, and behavioral concomitants of subchronic
marijuana smoking. The investigation took place on a closed
research unit at McLean Hospital, Belmont, Massachusetts.
Although 21 subjects eventually completed the research, only 18
were included in the present analyses for reasons described
below.
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Marijuana Dosage. Marijuana cigarettes were obtained from the
National Institute on Drug Abuse in a lot standard dosage form.
Each cigarette contained approximately one gram of marijuana
with a THC content of 1.8 percent. During the 21-day drug
acquisition period, subjects were free to determine frequency,
amount, and duration of marijuana consumption. No attempt was
made to standardize the ingestion procedure since the associated
inconvenience might have inhibited free-Choice smoking
behavior. However, a record was kept of the amount of unsmoked
marijuana returned by each subject and this provided a basis for
estimating amount consumed (and presumably, absorbed). Since it
was important to control for cumulative and acute dosage in
evaluating affective changes and the development of tolerance,
only those subjects who self-administered marijuana on a regular
schedule were included in the analysis. Using these criteria it
was determined that nine "moderate" users and nine "heavy" users
had administered relatively constant doses throughout the
smoking period. On the average, the moderate smokers consumed
more than 70 percent of each marijuana cigarette, while the
heavy smokers consumed more than 84 percent. The differences in
average dosage were statistically significant (t=2.59, p
.05). The three subjects omitted from this analysis consumed an
average of only 50 percent of each marijuana cigarette.
Procedure. The major dependent variables selected for analysis
were ratings of subjective intoxication level, readings of
standing pulse rate, and ratings of an adjective checklist
measuring eight dimensions of mood. Each assessment was
conducted immediately before, immediately after, and 25 minutes
after the first marijuana cigarette consumed each day. Ratings
of subjective intoxication level were obtained by means of an
11-point scale based on the following question: "In comparison
to the highest you've ever been on marijuana, rate below how
high you feel now." The response categories ranged from (o) "No
effect, not high at all" through (10) "Highest ever."
Standardized mood reports were obtained by means of a 72-item
version of the Profile of Mood States (POMS). Used widely as a
measure of mood changes in drug evaluation research McNair,
Lorr and Droppleman 1971). this simple adjective checklist
provides interval measures of the following mood dimensions:
tension, anger, depression, fatigue, confusion, elation,
friendliness, and vigor.
To determine whether any of these assessments was sensitive to
the acute effects of marijuana, comparisons were first made
between ratings obtained before and after the first cigarette of
the day. The first, cigarette of the day was used in these
analyses in order to obtain response measures that were
relatively independent of the previous acute dose, but
nevertheless sensitive to the possible effects of cumulative
doses on tolerance development. Those measures proving
sensitive to the acute effect of marijuana were subjected to a
correlational analysis, designed to measure the extent to which
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the acute effect diminished with continued consumption. In this
analysis, within-subjects correlation coefficients were first
computed between the dependent measure obtained after each daily
acute dose and the cumulative amount of marijuana consumed to
that point. Cumulative dose was calculated by summing the
amounts consumed over all previous doses, beginning on the first
day of availability. To control for possible variations in
self-determined dosage as well as in baseline levels of the
dependent measure, these variables were partialled out of the
resulting coefficient. Each subject's partial correlation
coefficient was then transformed using Fisher's "z"
transformation, and the transformed coefficients were averaged
across subjects. To determine if the mean correlation was
significantly different from zero, t values were computed by
dividing the group mean by the standard error of the mean. To
summarize the magnitude of the relationship, the average
Fisher's z transformation was reconverted into a correlation
coefficient, herein referred to as the average Pearson r.
RESULTS
The data were first analyzed to determine the extent to which
acute effects of marijuana were manifested on the various
dependent measures. Acute effects were evaluated immediately
after and 25 minutes after marijuana smoking. In the first set
of t-test comparisons, pulse rate, intoxication level and POMS
scores recorded before the first marijuana cigarette smoked on
the first day of availability are compared to corresponding
values immediately after and 25 minutes after smoking. These
comparisons, referred to as initial reactions, reflect the acute
effects of marijuana after a period of at least seven days of
total abstinence. The second set of comparisons was based on
individual means of pulse rate, intoxication level, and POMS
scores, averaged across all days that subjects self-administered
marijuana. These comparisons reflect the consistency of the
acute effect over the 21-day Self-administration period.
On average, moderate users chose to smoke marijuana on 18 of the
21 days of availability, while heavy users smoked on an average
of 20 days. moderate users indicated initial reactions by
significant increases in intoxication level, pulse rate, and in
feelings of confusion and vigor after the first marijuana
cigarette smoked. Intoxication level, pulse rate, vigor and
confusion remained consistently elevated above pre-drug levels,
as indicated in comparisons based on average values across all
smoking days. In addition, increases in elation and friendli-
ness were also manifested consistently during the entire smoking
period.
On the first day of availability, heavy users showed a signif-
icant increase in pulse readings, intoxication level, and in
feelings of elation and friendliness. Pulse, intoxication, and
elation continued to be elevated over all subsequent trials as
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well. In addition, heavy users showed a significant reduction
in tension over all trials, and a significant increase in vigor.
Partial Correlation coefficients were next computed to determine
the extent to which the acute effects of marijuana decline in
relation to the cumulative amount smoked over the entire self-
administration period. Moderate users showed a significant
decline in level of intoxication, as well as significant reduc-
tions in feelings Of depression, fatigue, confusion, friendli-
ness, and vigor. Heavy users indicated a progressive decline in
intoxication level, tension, elation, and friendliness.
In summary, moderate users show evidence of tolerance to
intoxication level, negative feeling states (depression,
confusion), and several positive feeling states (vigor,
friendliness): However, they do not indicate tolerance to
elation. Heavy users whose acute effects were primarily in the
areas of increased intoxication, tension reduction, elation,
friendliness, and vigor, give evidence of tolerance to all of
these effects except vigor: Neither group demonstrated
tolerance to the pulse rate effect.
The final question addressed in this study pertains to the
predicted association between tolerance development and
increased marijuana consumption. To evaluate this hypothesis,
the amount of change indicated on each variable after the first
cigarette of the day was correlated with the amount of marijuana
consumed in the subsequent 24-hour period. If tolerance
development leads to increased marijuana consumption, then
consumption should increase in direct relation to the decrease
in acute effects over time. The results showed that on days
when moderate smokers were feeling less elated, they tended to
smoke more marijuana. These subjects also smoked more marijuana
on days when, after the first cigarette smoked, they reported
themselves more angry, depressed, and fatigued. Heavy users, on
the other hand, showed no significant correlations between
declining acute effects and Subsequent consumption.
DISCUSSION
The results of this study are consistent with several
investigations on tolerance to marijuana in males (Babor et al.
1975; Mendelson, Meyer,and Rossi 1974). The findings suggest
that tolerance develops differentially to a variety of acute
effects in women, depending on previous drug history and
cumulative dosage ingested over time. Further, the data suggest
that the tendency to increase consumption over time may not be
associated with tolerance to the acute effects of marijuana in
women.
Acute effects after the first cigarette of the day were
generally rated as pleasurable and stimulatory, although the
less experienced moderate users also reported cognitive
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confusion initially. Positive effects persisted over a three-
week period of daily self-administration. Many of the
subjective effects showed- a subtle but statistically significant
decay over time, particularly the global rating of subjective
intoxication.
Even though moderate users gave evidence of tolerance, there was
no tendency for consumption to increase over the course Of the
study. Although heavy users did increase consumption over time,
further examination of the data provided no evidence to support
the tolerance-consumption hypothesis. Nevertheless, the findings
did show that moderate users tended to smoke more on days when
anger or depression increased after the first dose of the day.
In conclusion, the results suggest that while tolerance develop-
ment may be a necessary condition for increased marijuana use,
it is by no means a powerful explanatory variable in accounting
for individual differences in consumption, and for the tendency
for consumption to increase over time. In the absence of a
strong relation between tolerance development and consumption,
it appears that a broader conceptualization of acquisition and
dependence is necessary to account for chronic marijuana use as
it occurs in the natural environment.
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Oral Fenoprofen Compared to
Intramuscular Morphine and Oral
Aspirin in Cancer Patients With
Postoperative Pain
Robert F. Kaiko, Stanley L. Wallenstein, Jeanne Lapin,
and Raymond W. Houde
The search for more effective non-narcotic analgesics has prompted
the evaluation of selected nonsteroidal anti-inflammatory agents.
Fenoprofen is one of several such drugs being evaluated for its
analgesic effectiveness relative to narcotic analgesics in a variety
of pathological pain models. These studies, however, have not been
designed to provide estimates of relative analgesic potency compared
to a "strong" narcotic analgesic such as intramuscular morphine.
The primary objective of this study is to determine the potency of
oral fenoprofen relative to intramuscular morphine. Secondary ob-
jectives are to determine: the effectiveness of fenoprofen relative
to aspirin, 650 mg; the relative occurrence and spectrum of side
effects; whether there is a relationship between age and relative
analgesic potency; and the relationship between analgesia and mood
for fenoprofen as compared to morphine.
METHODS
The assay consists of three equi-log-spaced doses of oral fenopro-
fen (50, 100 and 206 mg) and intramuscular morphine (4, 8 and 16 mg).
Each patient receives two study medications on separate days: a
lower dose of one drug and an upper dose of the other, or the middle
doses of each drug on a double-blind, randomized basis, and balanced
for order. Aspirin (656 mg) is substituted for half of the 8 mg
morphine doses to provide for a second standard of comparison. The
design incorporates a series of blocks of six patients each. Pa-
tients are assigned to a particular series of blocks according to
three age groups: 18-35, 36-64 and 65 years and older.
The methodology adheres to the principles of clinical design and
study previously employed and reported (Houde et al. 1960; Wallen-
stein and Houde 1975). Adult cancer patients with moderate to se-
vere postoperative pain are seen hourly by an analgesic nurse ob-
server who obtains the patient's subjective reports of pain intensi-
ty, pain relief and mood, employing both categorical and visual ana-
log scales. Volunteered and observed side effects are also record-
ed. Observations are continued for either six hours or until pain
returns to the premedication level, at which time the patient's
routine analgesic is administered.
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RESULTS
This assay remains in progress and, to date, 50 patients have re-
ceived fenoprofen and morphine within balanced blocks, and 10 pa-
tients have received both fenoprofen and aspirin. There is, how-
ever, considerable data from yet uncompleted blocks and, also, from
patients who had not completed the crossover.
Relative Potency
Estimates of relative potency were calculated using both the data
from the twin-crossover comparisons within balanced blocks and the
data from all first doses. Table 1 details the results.
TABLE 1. Relative analgesic potency of oral fenoprofen and intra-
muscular morphine in cancer patients with moderate to severe post-
operative pain.
1Sum of hourly visual analog scale scores (total) or peak score.
2Ratio of morphine to fenoprofen doses consistent with equi-anal-
gesic effect.
3The 95% confidence interval for the estimate of relative potency.
4An estimate of assay precision, the common standard error divided
by the common slope; inversely related to precision.
To date, there is generally good agreement between the relative po-
tency estimates using crossover and first dose data. Oral fenoprofen
is about one-tenth as potent as intramuscular morphine in terms of
analgesia. Comparisons of peak, total and duration estimates indi-
cate little differences. While slopes do not significantly deviate
from parallelism, dose-response curves for fenoprofen are consistent-
ly more shallow than those-for morphine, especially between- upper
doses. While most potency estimates for mood are not yet signifi-
cant, they are lower than those for analgesia.
Side Effects
Side effect data is based on all patients who had received a study
medication, irrespective of whether or not they had completed the
crossover, or whether or not they are within balanced blocks.
Since analgesia following all doses of fenoprofen combined was com-
parable to that following all doses of morphine combined, we can be
confident that we are comparing side effect data at equianalgesic
doses, overall. The analgesic effect of aspirin, however, was
significantly less.
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TABLE 2. Occurrence of side effects (SE) following intramuscular
morphine, oral fenoprophen and aspirin in cancer patients (Pts) with
postoperative pain.
Table 2 details the occurrence of side effects following each of the
study treatments. The overall occurrence of side effects following
morphine was about 50% greater than that following fenoprofen at
combined doses providing equianalgesic effects. While the occur-
rence of side effects was considerably less following aspirin, as
noted above, aspirin provided considerably less pain relief.
Table 3 details side effect data in terms of the particular side
effects and their distribution among treatments. Each side effect
is following by a number indicating its occurrence.
TAELE 3. Side effect spectrum of intramuscular morphine (M), oral
fenoprofen (F) and aspirin (ASA) in postoperative cancer patients.
Most side effects were common to fenoprofen and morphine, the most
common being "sleepiness." The next most. common for morphine was
"dry mouth" and for fenoprofen, "sweating." These, however, had a
considerably lower occurrence relative to "sleepiness." If
"sweating", "hot" and "flushed" can be considered symptoms of a
common drug effect, then this effect tends to be greater with feno-
profen than with morphine.
Age: Relative Effectiveness and Potency
Table 4 shows the results of the regression of total pain relief
(visual analog scale) on patient's ages. Significant positive
linear regression correlation coefficients were obtained only for
morphine doses. To date there have been too few patients entered
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into the study who are at the extremes of adult age in order to
provide for valid relative potency estimates in these stratified
patient groups. Nevertheless, preliminary calculations demonstrate
a trend toward age-related differences in relative analgesic poten-
cy. For example, in terms of duration of analgesia, fenoprofen
appears to be approximately one-third as potent as morphine in the
youngest group (18-35 yr), one-tenth as potent in the middle-aged
group (36-64 yr) and one-thirtieth as potent in the oldest group
(65 yr and older). The regression analyses (Table 4) indicate that
these apparent differences in relative analgesic potency are due to
an age-related increase in the effectiveness of morphine, rather
than to any age-related change in the effectiveness of fenoprofen.
TABLE 4 Regression analyses of total pain relief1 on age
Analgesia and Mood
While estimates of relative analgesic Potency were approximately
one-tenth, estimates of relative potency in terms of mood improve-
ment were approximately one-twentieth (Table 1). Regression analy-
ses were carried out in order to determine whether there were dif-
ferences between fenoprofen and morphine in terns of the degree of
of Mood improvement provided at comparable degrees of analgesia
(Table 5).
Table 5. Regression of total mood improvement on total pain
decrease for morphine and fenoprophen in cancer patients with
postoperative pain.1
1
Sum of hourly visual analog scale scores for IECKI improvement
and pain intensity decrease.
A significant positive linear correlation coefficient was obtained
with the morphine data, but not with the fenoprofen data: while
increasing analgesia is accompanied by significant mood improvement
following morphine, mood improvement and analgesia do not go hand-
in-hand following fenoprofen administration.
DISCUSSION
This assay is continuing. The data presented here represents just
more than half that which we expect to obtain at the completion
of the assay.
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Analgesic Effectiveness and Relative Potency
Preliminary data indicate that oral fenoprofen, 50 to 200 mg, is
as effective as intramuscular morphine, 4 to 16 mg, in the dose
range commonly employed in postoperative patients with moderate to
severe pain. While definitive estimates of relative analgesic po-
tency remain to be obtained, preliminary data indicate that oral
fenoprofen is approximately one-tenth as potent as intramuscular
morphine. While there is a consistent trend toward shallower dose-
response slopes for fenoprofen relative to morphine, these do not
significantly deviate from parallelism in our analyses. It is
likely, however, that these slopes do, in fact, differ, as has been
previously reported in terms of a shallower dose-response slope for
fenoprofen at higher doses, an indication of a "ceiling" for feno-
profen analgesia (Sunshine et al. 1978).
Side Effects
Side effect evaluation is difficult in our patients population,
primarily due to the many effects unrelated to study drug that may
be observed or reported. Nevertheless, the difference in the oc-
currence of side effects is substantial, 50% greater following
morphine than following fenoprofen.
Age: Relative Effectiveness and Potency
It has been reported that the disposition of oral fenoprofen in the
plasma of geriatric patients differs from that in the plasma of
young normal volunteers only in terms of a slightly slower rate of
absorption, with no differences in the area under the plasma con-
centration - time curves (Kamal and Koch 1981). In contrast, it
has been reported that the elimination half-life of morphine in-
creases (Kaiko et al. 1978) and the total body clearance decreases
(Kaiko et al. 1982) in relation to the age of the subject. There
is also ample evidence that aging is accompanied by an increased
analgesic response to intramuscularly administered morphine (Bell-
ville et al. 1971; Kaiko 1980; Kaiko et al. 1983).
While our preliminary data shows a trend toward progressively lower
relative analgesic potency values for fenoprofen compared to mor-
phine with patient groups of increasing age, it is likely that this
results primarily from a greater effectiveness of morphine with in-
creasing age, as indicated by the results of the regression analy-
ses . In the clinical setting, the use of an overall estimate of
relative analgesic potency of one-tenth in the substitution of in-
tramuscular morphine for oral fenoprofen in an elderly patient
would likely result in a greater than predicted analgesic effect.
Estimates of relative analgesic potency have traditionally been
established without regard for differences that might exist as a
function of differences in patient's age. The results of this and
other of our current studies in which we are examining the data for
such differences suggest that age-related differences in relative
analgesic potency can be quite significant, especially if the two
analgesics differ in terms of their pharmacological class, or me-
chanism of action, or in terms of whether or not biotransformation
processes produce active or inactive metabolites.
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Analgesia and Mood
While narcotic analgesic drugs exert their analgesic effect via in-
teraction with receptors within the central nervous system, non-
steroidal anti-inflammatory agents are primarily acting on the per-
ipheral nervous system. Consonant with these differences is the
concept that narcotic analgesics alter not only the sensation of
pain, but one's reaction to pain. Narcotic-induced analgesia has
both a sensory and an affective component. Furthermore, the effects
of centrally acting narcotic analgesics on mood are thought to be
reinforcing factors, and involved in these drugs' high abuse lia-
bility.
Our preliminary data indicates that mood improvement is less after
fenoprofen than after morphine administration at doses which pro-
vide comparable analgesia. Fenoprofen is approximately one-tenth
as potent as morphine in terns of analgesia, but only in the range
of one-twentieth as potent as morphine in terms of mood improvement.
While morphine-induced mood improvement parallels pain decrease,
no such relationship is apparent as yet for fenoprofen-induced
mood improvement and pain decrease. The present study does not
directly address the issues of whether or not the mood improvement
observed with morphine is either clinically significant or desira-
ble.
CONCLUSIONS
On the basis of the preliminary data presented here we may tenta-
tively provide the following conclusions.
Oral fenoprofen, in the dose range employed, is approximately one-
tenth as potent as intramuscular morphine in terms of analgesia in
cancer patients with moderate to severe postoperative pain.
Fenoprofen is as effective as commonly used doses of morphine.
The higher doses of fenoprofen appear to be more effective than
aspirin, 650 mg.
Side effect occurrence is less following fenoprofen than following
morphine at doses providing comparable analgesia.
The potency of morphine relative to fenoprofen increases with in-
creasing patient age.
Increasing analgesia following fenoprofen is not accompanied by in-
creasing mood improvement as observed with morphine.
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Measurement and Extinction of
Conditioned Withdrawal-Like
Responses in Opiate-Dependent
Patients
Anna Rose Childress, A. Thomas McLellan, and
Charles P. O’Brien
INTRODUCTION
As O'Brien has reviewed elsewhere in this volume (O'Brien et al.
1983), there has been much experimental work on opiates and
Pavlovian conditioning processes since Wikler's original observa-
tions of withdrawal-like responses in drug-free patients (Wikler
1948). Several studies have found evidence of conditioned with-
drawal-like and opiate-like responses in rats, monkeys, and humans
(Eikelboom and Stewart 1979; Grabowski and O'Brien 1980). Addict
patients viewing slides or videotapes of drug-related stimuli
(Teasdale 1973; Sideroff and Jarvik 1980) or handling drug objects
in a preparation ritual (Ternes et al. 1979) experience subjective
craving and withdrawal-like changes in physiological measures of
skin temperature, heart rate, pupillary dilation, etc. Research
from our own laboratory has demonstrated that opiate withdrawal-
like responses in humans can be conditioned to an arbitrary con-
ditioned stimulus (O'Brien et al. 1977).
These studies leave little doubt that conditioned withdrawal-like
phenomena exist and can be both reliably elicited and measured.
They do not, however, address the clinical significance of these
responses. Though Wikler (1948) proposed conditioned withdrawal
as the primary cause of relapse in drug-free patients, this link
has not been clinically tested and is still controversial. Based
on interviews with Baltimore street addicts, McAuliffe (1982) had
recently suggested that conditioned withdrawal-like phenomena are
relatively infrequent and rarely trigger opiate use.
RATIONALE
Though interesting, the McAuliffe interview data cannot substitute
for research to empirically determine 1) the actual incidence of
conditioned withdrawal-like phenomena, and 2) their role in clin-
ical outcome, including relapse. We are currently conducting a
large-scale treatment-outcome study which directly addresses both
these issues. In this study, each patient's conditioned with-
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drawal-like responses are first measured in the laboratory, Fol-
lowing measurement, one group of patients is given repeated, non-
reinforced exposure to drug-related stimuli in an attempt to
extinguish the conditioned withdrawal-like responses. If condi-
tioned withdrawal-like responses trigger drug use/relapse, then
reducing or removing these responses through extinction should
have a beneficial effect on clinical outcome.
The present paper will present the methodology and early results
of our attempts to measure and to extinguish conditioned with-
drawal-like responses in opiate-dependent patients. Clinical
outcome data concerning the possible benefits of extinction are
currently being collected and will be presented in future papers.
METHODOLOGY
Subjects - The subjects for this ongoing study are male veteran
methadone patients from the Drug Dependence Treatment Unit of the
Philadelphia VA Medical Center. Patient volunteers are recruited
through direct contact or referral from their drug counselor. All
patients are clinically screened to rule out diagnoses of major
thought disorders (schizophrenia) or organic brain syndrome.
Design Considerations - In an earlier protocol (O'Brien et al.
1979) we attempted extinction of conditioned withdrawal-like
responses by asking patients maintained on an opiate antagonist
(naltrexone) to undergo double-blind cook-up and unreinforced
self-injection rituals. In this procedure, opiate administration
was either omitted (saline trials) or pharmacologically blocked
due to the antagonist treatment. After a few initial trials, most
patients experienced such strong dysphoria, withdrawal and craving
that they refused to participate in further extinction sessions.
Though no subject completed extinction, there was some suggestion
that patients who completed more trials had somewhat better out-
comes at six-month follow-up than other non-extinction naltrexone
patients (O'Brien et al. 1979).
In the current study, the extinction procedure was modified in two
ways designed to increase patient comfort and compliance: 1) pa-
tients were given early trials with a graded hierarchy or drug-
related stimuli as a prelude to the highly-evocative cook- up/
self-injection ritual; 2) each extinction trial was followed by
15-20 minutes of deep relaxation training to allow the patient to
"wind down" from any discomfort or craving stirred by exposure to
the drug-related stimuli.
As a final consideration, we recognized that an extinction proce-
dure--even if well-tolerated by patients--would address only the
conditioned factors of their disorder. If the significant psy-
chological, social and vocational components of the addiction were
left untreated, the possible clinical benefits of the extinction
could be overshadowed and perhaps not even measurable. With this
in mind, we decided to integrate our laboratory-derived extinction
procedure with professional psychotherapy, a clinical treatment
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which had previously produced pervasive therapeutic benefits for
our clinical population (Woody et al. 1981).
Procedure - Patients eligible for the study are randomly assigned
to one of three treatment groups. The clinical outcome of patients
receiving cognitive-behavioral (CB) psychotherapy, extinction, and
relaxation will be compared against two control groups: one group
receiving CB therapy and relaxation (but no extinction) and a stan-
dard treatment control group which receives extra drug counseling
and educational/control materials. Professional attention, session
length, and small payments contingent upon session attendance are
equivalent for all treatment groups.
Measurement of Conditioned Withdrawal-Like Responses - Prior to
treatment, and at the end of treatment, and at 1 and 6 month follow-
up points; each patient's conditioned withdrawal-like responses
are assessed in laboratory measurement sessions. All laboratory
sessions are conducted in an environmentally controlled, electri-
cally shielded recording chamber. Physiological measures include
skin temperature, galvanic skin resistance (GSR. a qeneral arousal
index), heart rate; respiration and blood pressure. These physio-
logical measures (except blood pressure) are continuously recorded
on a polygraph and then converted to computer storage for later
analysis.
In addition to the physiological measures, patients are asked to
rate the degree of subjective high, carving or withdrawal they
experience in response to test stimuli.
Both physiological and subjective responses are measured under two
types of stimulus conditions: Neutral and Drug-Related. Each pa-
tient experiences both conditions, acting as his own control. For
either stimulus condition, the following sequence obtains, lasting
approximately one hour: 1) Resting Baseline; 2) Videotape (Neu-
tral or Drug-Related); 3) Baseline; 4) Activity (Neutral or Drug-
Related); and 5) Baseline.
The neutral videotape features a travelogue; the neutral (non-drug-
related) activity allows patients to play a computerized "pong"
game. The drug-related videotape features a cook-up-shoot-up rit-
ual; the drug-related activity requires patients to go through a
mock cook-up and tie-off, with optional self-injection of saline.
Previous research in our center has shown pre-injection (drug pre-
paration and cook-up) stimuli to be powerful elicitors of condi-
tioned withdrawal-like responses (Ternes et al. 1979).
Extinction - Each hour-long treatment session for patients in the
extinction group begins with 30 minutes of psychotherapy. followed
by approximately 10 minutes of exposure to extinction stimuli.
Each session ends with 15-20 minutes of relaxation, guided by audio
cassette. Extinction stimuli include self- produced verbal imagery
("drug stories"), audiotapes of drug talk, color slides of cook-up-
shoot-up rituals, videotape of drug purchase, cook-up and injec-
tion, and finally, handling of drug objects in a mock cook-up/tie-
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off procedure. Saline self-injection, the final member of the
extinction series, is encouraged but optional. For each patient;
the ordering of extinction stimuli across sessions is the same,
and we now employ a fixed trials procedure which determines the
number of exposures to each stimulus category.
Data for the extinction trials is currently based on the Within-
Session Rating Scale (1982), a quantified subjective report list-
ing 24 withdrawal-like and 24 high-like symptoms. The WSRS is
administered before and immediately after exposure to the extinc-
tion stimuli. We have also recently begun to record GSR and skin
temperature during treatment sessions, allowing us to track the
course of the extinction across sessions and to compare subjective
with physiological responses.
Extinction sessions for outpatient subjects are conducted three
times weekly, with 35 sessions comprising a complete course of
treatment. We have recently initiated the same study with in-
patients undergoing gradual methadone detoxification over a four-
week period. For these inpatients, extinction trials are con-
ducted five times weekly, for a total of 22 treatment sessions.
Daily methadone is administered immediately after measurement or
extinction sessions so that its onset effects not interfere
with physiological or subjective measures.
RESULTS
Pretreatment Measurement of Conditioned Withdrawal - We have now
obtained laboratory measurement of responses to drug-related stim-
uli for more than 35 patients. In the measurement sessions, pa-
tients respond to drug-related stimuli with a variety of physio-
logical responses, including an increase in arousal (a decrease in
GSR) and transient charges in heart rate and respiratory patterns.
Of all the physiological measures recorded, a time-linked decrease
in skin temperature has usually provided the most reliable and
specific index of a conditioned withdrawal-like response.
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Figure 1. Skin temperature change as a function of exposure
to neutral or drug-related stimuli.
Thus far, 35 to 40% of the patients tested exhibit a withdrawal-
like decrease in skin temperature which is specific to drug-related
stimuli. Temperature change data from a representative 'responder'
is presented in Figure 1. In this figure, the vertical bars repre-
sent temperature difference scores obtained by subtracting the mean
skin temperature (°F) for a 4-minute baseline period (immediately
preceding the neutral or drug-related video) from the mean skin
temperature for an equivalent stimulus period (video, activity,
post-activity). As shown in the right half of the graph, a de-
crease in skin temperature begins to develop during the drug video
presentation and becomes quite pronounced during the cook-up rit-
ual, persisting into the post-cook-up interval. Temperature re-
sponse to the neutral stimuli (left half of Figure 1) is negligi-
ble or shows no consistent pattern.
The average decrease in skin temperature to drug-related stimuli
for clear-cut 'responders' is nearly 7°F. Some responders have
experienced drops in skin temperature exceeding 12°F in a 15-20
minute period. Recovery time of skin temperature back to baseline
level is usually roughly proportionate to the degree of temperature
decrease, and usually occurs within 10 to 15 minutes of its nadir.
As many as one-third of the patients tested can be characterized as
non-responders - they show no withdrawal-like temperature response
to the drug-related stimuli. The remaining patients are more dif-
ficult to characterize, but several fall into the category of 'non-
specific arousers', showing mild arousal patterns to both neutral
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and drug-related activities, but no differential response in skin
temperature or the other physiological measures.
More than a third of the patients report increases in subjective
craving and withdrawal following exposure to the drug-related test
stimuli. Interestingly, though subjective intensity of craving/
withdrawal is roughly correlated with the degree of physiological
response, patients sometimes show a withdrawal-like decrease in
skin temperature without reporting an increase in subjective with-
drawal or craving. The reverse situation, in which a patient re-
ports increased subjective craving but exhibits no profound change
in physiological response also occurs, but is less common.
Extinction - Within extinction sessions, from one-half to two-
thirds of the patients report increases in subjective craving and/
or withdrawal following exposure to the drug-related stimuli: In
the early extinction trials, a few patients have also reported an
increase in high-like symptoms, but these responses usually fade
quickly and are replaced by relatively persistent withdrawal-like
symptoms. Withdrawal symptoms elicited by the drug-related stimuli
usually subside by the end of the 15-minute relaxation period.
Of patients who reliably respond to extinction stimuli with an in-
crease in withdrawal-like symptoms, over half show a reduction in
subjective response across the 35 sessions, suggestive of extinc-
tion. For at least two pilot patients the withdrawal-like re-
sponses persisted beyond 50 extinction trials.
Post-Treatment Measurement of Conditioned Withdrawal - Though the
number of 'responder' patients who have completed this measurement
phase is still relatively small, we do have early encouragement
that extinction trials may reduce conditioned withdrawal-like re-
sponses. In general physiological 'responders' who undergo ex-
tinction tend to show a diminution of the temperature response to
drug-related stimuli in post-treatment testing. 'Responder' pa-
tients in the non-extinction groups (therapy or extra counseling)
do not exhibit this trend; and the temperature response is often
similar to that at the outset of treatment.
SUMMARY
Data from laboratory measurement sessions indicate that a substan-
tial proportion--at least 40%--of opiate-dependent patients show
physiological evidence of conditioned withdrawal in response to
drug-related stimuli. The index response, a time-linked decrease
in skin temperature, is often accompanied by increases in
subjective craving and withdrawal. In extinction sessions, up to
two-thirds of the patients tested respond with an increase in sub-
jective craving and/or withdrawal to drug-related stimuli. Pre-
liminary extinction data suggest that conditioned withdrawal-like
responses, though relatively persistent, may be reduced with suf-
ficient trials. Post-treatment laboratory measurements indicate
that the extinction procedure may attenuate the withdrawal-like
reduction in skin temperature.
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Up to one-third of our patient population can be characterized as
'non-responders '--they fail to show physiological and/or subjective
withdrawal-like responses to the drug-related stimuli used in our
procedure. This lack of response is particularly intriguing since
many of these 'non-responders' have had extensive drug use histo-
ries which should have allowed ample opportunity for conditioning
to occur. We are currently exploring the possibility that certain
emotional states (anxiety, etc.) may have become an integral part
of the conditioned stimulus complex which elicits craving/with-
drawal (Poulos et al. 1981), such that drug-related stimuli alone-
unaccompanied by the mood state--are insufficient to elicit the
conditioned response.
Although the clinical impact of our integrated treatment package
awaits determination from outcome data, the presence of conditioned
withdrawal-like responses in a significant proportion of our pa-
tient population suggests its possible benefit. The modified ex-
tinction procedures have been successfully integrated with psycho-
therapeutic techniques to produce a treatment with retention rates
approaching 70%. We are optimistic that this combined methodology
will finally allow evaluation of the role of conditioned factors
in opiate use and relapse.
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Perinatal Addiction: The Effects
of Maternal Narcotic and
Nonnarcotic Substance Abuse on
the Fetus and Neonate
Ira J. Chasnoff, William J. Burns, and Sidney H. Schnoll
Although a great deal of research has been devoted to the
evaluation of the effects of intrauterine exposure to heroin and
methadone on the fetus and neonate, information regarding the
outcome of nonnarcotic-exposed neonates is sparse and consists
primarily of case reports (Rementeria and Bhatt 1977; Mazzi 1977,
Hill et al. 1977, Mangurten and Benwara 1980, Golden et al. 1980).
At the Perinatal Addiction Project of Northwestern Memorial
Hospital’s Institute of Psychiatry and Prentice Women’s Hospital
and Maternity Center, the number of pregnant women using and
abusing nonnarcotic substances has increased dramatically in the
last few years. This paper is a review of all infants delivered to
women enrolled in our program since 1976 and will review and
compare the intrauterine growth and neonatal neurobehavior of
these infants.
SUBJECTS AND METHODS
From April 1976 to December 1982, 95 infants were born to
mothers enrolled in the Perinatal Addiction Project. All of the
women were enrolled in the first or early second trimester of
pregnancy and completed a course of intensive prenatal care.
Maternal urine samples were obtained regularly in order to screen
for illicit drug use. The 95 infants were divided according to the
type of primary maternal addiction: heroin/methadone (N=51),
mixed sedative/stimulant (N=22), pentazocine/tripelennamine (N=13)
and phencyclidine (N=9). Women with a history of heavy alcohol
use were enrolled in a different section of the program and thus
were not included in this study.
Mothers in Group I conceived while on heroin.. Forty-seven of
these women were abusing heroin alone while the remaining four
women abused either one or two nonnarcotic drugs in addition.
Upon admission to the program, each woman was placed on a
variable initial daily dose of methadone. This dosage was steadily
decreased to the lowest level which would prevent craving or
withdrawal in the mother. By the beginning of the third trimester,
each woman was on a maintenance dose of methadone which ranged
from 5 to 40 mg daily (mean=15.9, S.D.=10.4). This dose was
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held at the same level for the rest of the pregnancy, and no
woman was completely withdrawn during pregnancy. On daily
urine screens the women, with three exceptions, remained clean
of narcotic and nonnarcotic drugs other than the prescribed
methadone.
Mothers in Group II were addicted to multiple licit or illicit non-
narcotic drugs. Each woman used two to five of the following drugs
in various combinations before and during pregnancy: phenobarbital,
diazepam, marijuana, codeine and cocaine. These women received
the same regimen of prenatal care as Group I except that they did
not receive methadone. Although abstinence was the objective for
this group, only five of the women remained clean of drug use
throughout the third trimester of pregnancy.
Thirteen infants were delivered to women who abused a combination
of pentazocine and tripelennamine (T’s and blues) during pregnancy
(Group III). All of the women in this group sporadically used
other, nonnarcotic drugs, but T’s and blues were the only drugs
consistently used throughout pregnancy. Although abstinence was
the objective of the program, none remained clean of T’s and blues
during the third trimester of‘ pregnancy.
Group IV infants were delivered to nine women whose primary drug
of abuse throughout pregnancy was phencyclidine hydrochloride
(PCP). All of the women had positive urine screens which demon-
strated sporadic use of other nonnarcotic drugs in addition to the
PCP, but PCP was the only substance used heavily throughout the
third trimester.
Three of the Group II women sporadically used T’s and blues or
PCP during pregnancy, but this use was very limited and did not
occur in the third trimester; hence these three women were included
in Group II based on their primary abuse of various sedative and
stimulant substances throughout pregnancy.
A group of drug-free mothers was selected in the order they
presented for prenatal care to the clinic of Prentice Women’s
Hospital and Maternity Center (Group V, N=27). These women had
no history or evidence of drug or alcohol abuse, and management
of prenatal care and nutrition was similar to the four drug-abusing
groups of women.
All groups were evaluated for maternal factors which might affect
neonatal outcome: race, maternal age, education, gravidity, pre-
natal care, nutrition, cigarette smoking, alcohol ingestion, and drug
use. Analysis of variance and Chi square analysis were utilized
for statistical analysis of these parameters. All neonates were
examined at birth when weight, crown-to-heel length and fronto-
occipital head circumference were recorded. The Brazelton Neonatal
Behavioral Assessment Scale (Brazelton 1968) (BNBAS) was
administered at two days of age by trained examiners who were
blinded to the infants’ prenatal history. Results were analyzed
utilizing analysis of variance. For those items which reached
statistical significance (< .05), ‘the Fischer’s LSD was utilized to
identify homogenous subsets.
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RESULTS
Demographic data for the five groups of women was similar as was
the frequency of cigarette smoking in each of the groups (Table I).
TABLE I. Maternal demographic data
I II III IV V
Methadone Sedative/ T & B PCP Drug-free
N 51
Stimulant
22 13 9 27
Age (mean) 23.0 22.4 23.0 22.0 22.2
Education (mean ) 10.7 11.5 11.4 11.1 10.7
Gravidity 2.8 2.5 3.3 2.0 2.2
Cigarettes
(% users) 60 69 62 57 59
Weight gain
in pregnancy (kg) 10.5 10.2 9.8 10.6 11.1
Mean weight gain during pregnancy for all five groups of women
was similar. However, racial distribution varied between the groups
(Table II). Thus, for analysis of data, race was controlled through
covariate analysis when each drug-using group was compared to the
Group V (drug-free) mothers and infants.
TABLE II. Racial distribution
I II III IV V
N % N % N % N % N %
White 33 65 10 45 1 8 8 89 7 26
Black 16 32 11 50 12 92 1 11 12 44
Hispanic 2 3 1 5 0 - 0 - 7 26
Oriental 0 - 0 - 0 - 0 - 1 4
All infants were delivered at term gestation as determined by the
criteria of Ballard et al. (1977). There was an even distribution
of infants by sex in each group. Apgar scores in the five
groups were similar, and no significant perinatal complications
occurred in any group. Two infants delivered to mothers on
methadone maintenance (Group I) had meconium aspiration
syndrome and one had seizures on the second day of life controlled
with phenobarbital. Twelve infants in Group I required therapy
for significant withdrawal based on clinical criteria of marked
irritability, poor feeding and/or excessive weight loss. No infant
in the other drug groups required therapy for withdrawal.
Somatic measures. Infants delivered to mothers in Group I and
in Group III had a significantly lower weight and length than
control (Group V) infants (Table III). These Group I and Group
III infants in addition had a significantly smaller head circumference
than both the control infants and those in Groups II and IV.
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TABLE III. Somatic growth parameters
I II III
Methadone Sedative/ T & B
Stimulant
IV V
PCP Drug-free
X S.D. X S.D. X S.D. X S.D. X S.D.
Weight (gm) 2840* 600 3165 560 2799* 430 3201 440 3479 623
Length (cm) 48.2* 3.5 50.0 3.1 48.1* 1.8 49.3 2.6 51.1 2.8
Head
circumference (cm) 32.2* 2.4 33.9 1.5 32.9* 1.2 33.7 2.0 34.7 1.7
*ANOVA (Specific Drug Group x Group V), p< .01
†Significant difference from Groups II and IV (Multiple Range Test)
These differences remained when race was statistically controlled.
The birth weights, lengths and head circumferences of the
sedative/stimulant and PCP-exposed infants were not significantly
different from those of the control infants.
Neonatal behavior. Means and standard deviations for those
BNBAS items for which statistically significant differences were
obtained are listed in Table IV. Significant differences were
obtained in items related to interactive ability, motor. maturity and
state control. Items related to visual and auditory orientation and
motor maturity differentiated the methadone-dependent group from
both the control and all other drug groups (Fischer’s LSD). All
four groups of drug-exposed neonates showed deficits in state
control with an abnormal predominant state, an increased lability
of state and poor consolability. In addition, PCP-exposed infants
(Group IV) showed significantly increased lability of states and
poorer consolability when compared to all other drug groups
(Fischer’s LSD).
DISCUSSION
With the increasing frequency of nonnarcotic substance use and
abuse by pregnant women, it is incumbent upon physicians to be
able to recognize and evaluate the neonate passively exposed to
these substances. In the present study, newborns delivered to
women addicted to sedative/stimulants or PCP were found to
demonstrate marked deficits in neonatal behavior. These two
groups of infants showed significantly poorer state organization
and consolability than the drug-free controls. However, they did
not manifest significant differences from normals in somatic growth
measures, orientation or motor maturity responses. Deficits in
intrauterine growth appeared to affect mainly narcotic-exposed
infants, especially in relation to poor head growth. T’s and
blues-exposed infants showed significantly lower somatic growth
rates and poorer state control than the drug-free controls,
similar to methadone-exposed neonates. In addition, the methadone-
addicted infants could be further differentiated by poorer visual
and auditory orientation responses and poor motor control.
From the data presented, it is evident that the neurobehavioral
risks of perinatal addiction extend to nonnarcotic- as well as
narcotic-addicted infants. These behavioral risks identified at
birth with the Brazelton scale will have repercussions for later
development, since infants who have deficits in their ability to
maintain alertness and to interact do not respond appropriately
to caretaker attempts at comforting and nurturing. Consequently,
the withdrawing, irritable infant enters into a pattern of behavior
which increases maternal frustration and anxiety. resulting in a
greater likelihood of maternal rejection. Professional intervention
at this point is necessary if this cycle of infant passivity and
maternal rejection is to be interrupted.
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TABLE IV. BNBAS items which discriminated between the groups*
I
Methadone
II
Sedative/
Stimulant
III
T & B
IV
PCP
-
X S.D. X S.D. X S.D. X S.D. X S.D.
V
Drug-free
Interactive
Inanimate Visual
Orientation
Inanimate Auditory
Orientation
Animate Visual
Orientation
Animate Auditory
Orientation
Consolability
Motoric
Motor Maturity
Organization, State
Predominant State
Lability of State
3.3*
3.4*
3.9*
3.9*
4.4*
3.3* 1.4 4.5 1.4 4.7 2.4 5.0 2.2 4.8 1.6
4.1* 1.4 4.8* .4 4 . 5 *  1 . 9 4.8* .5 3.9 1.0
3.2* 1.6 3.7* 1.9 3 . 3 *  1 . 5 5.0* 1.9 1.6 1.1
2.2 5.7 2.1
1.2 5.6 1.4
1.7 4.9 2.1
1.6 5.2 1.6
2.4 3.7* 2.2
5.2 2.7 6.0 2.0
5.4 1.7 4.3 2.0
4.5 1.9 4.5 1.3
4.3 .5 4.5 1.0
4.2* 2.2 2.5* 1.0
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Drug Preference in Humans:
Lorazepam
Harriet de Wit, C. E. Johanson, and E. H. Uhlenhuth
A drug's capacity to reinforce behavior in a laboratory setting usually
correlates with its dependence potential in the general population. In
laboratory tests, diazepam is not an effective positive reinforcer, either
in laboratory animals using drug self-administration tests (Griffiths and
Ator, 1980) or in normal human volunteer subjects using a choice test
(Johanson and Uhlenhuth, 1980; de Wit et al., 1983). The failure to
find evidence for a positive reinforcing effect of diazepam in these
experimental tests is inconsistent with clinical reports that diazepam is
used excessively by some people.
The failure to demonstrate the positive reinforcing efficacy of diazepam
in an experimental situation may be due in part to the drug's long
duration of action (half-life = 24 - 48 hours; Hillestad, 1974). In animal
self-administration studies that test the reinforcing efficacy of drugs,
it has been found that benzodiazepines that have shorter durations of
action are also more effective reinforcers (Griffiths et al., 1981). In
the present study, human subjects were tested for preference for
lorazepam, a benzodiazepine with effects similar to diazepam but with
a shorter half-life than diazepam (half-life = 12-15 hours; Greenblatt
et. al., 1979; Ameer and Greenblatt, 1981).
METHOD
Subjects. Twelve normal healthy volunteers, aged 21 to 27 (4 males, 8
females) participated in this study. They were recruited using
advertisements in the local student newspaper, notices posted on the
University campus, and word-of-mouth referrals. Prior to acceptance,
subjects were interviewed to explain the nature of the study and to
ascertain their medical, psychiatric and drug use histories. Subjects
were accepted if they were considered normal and healthy on the basis
of this interview and a subsequent EKG. Most subjects had some
experience with psychotropic drugs but none had a history of any type
of drug abuse.
Subjects signed a consent form prior to participation which outlined the
study in detail and indicated all possible side effects of any drug they
might be given. They were informed that they would not be told what
drug they ingested at the time, except that it would either be a
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psychomotor stimulant, minor tranquilizer, or a placebo, and that the
dose would be within the daily therapeutic range. Bach subject also
agreed not to take other drugs, except their normal amounts of coffee
and cigarettes, 12 hours before and 6 hours after taking a capsule.
Except for the actual drug ingested, subjects were completely informed
of all other procedural details as outlined below.
Procedure: All subjects participated in each of four experiments,
presented in counterbalanced order. The procedure for each experiment
was identical except for the drugs available, which were as follows:
Experiment 1: lorazepam, 0.5 mg versus placebo
Experiment 2: lorazepam, 1.0 mg versus placebo
Experiment 3: lorazepam, 2.0 mg versus placebo
Experiment 4: lorazepam, 1.0 mg. versus diazepam, 5 mg
The doses of lorazepam are within the therapeutic range for the drug’s
anxiolytic effect, and the doses of lorazepam and diazepam tested in
Expt. 4 are considered therapeutically equipotent (e.g., Yalarino and
Perez-Lopez, 1976).
Every experiment consisted of three sessions per week over a 3-week
period, resulting in a total of nine sessions. During the first four
sessions, the subject reported to the experimental room between 9 and
10 a.m. At that time, he/she filled out mood forms (see below) and
received a colored capsule for immediate ingestion. Approximately half
of the subjects received drug during sessions 1 and 3 and placebo (or
diazepam in Expt. 4) during sessions 2 and 4. The order was reversed
for the other half. For each subject, each drug was dispensed in a
capsule of a consistent and distinctive color in order to facilitate
identification. Capsule colors were assigned randomly across subjects
to avoid the influence of color preference. Each subject was instructed
during the initial four sessions to note the capsule. colors, and to try
to associate each of the two colors with the effects of the substances
contained in them. After ingesting the capsule, subjects were free to
leave. They took three additional mood forms with them, which they
were to fill out 1, 3, and 6 hr later. In addition, subjects filled out a
questionnaire at hour 6, indicating whether they liked the drug (from
“disliked a lot” to "liked a lot”), what they thought it was (stimulant,
tranquilizer and placebo), and whether they had experienced any unusual
reactions. During the last five sessions, the procedure was identical in
every respect except that the subjects were given a choice of the two
colored capsules to ingest.
Subjective Effects. The scales used to assess mood were an experimental
version of the Profile of Mood States (POMS) and a shortened version
of the Addiction Research Center Inventory (ARCI). Both have been
shown to be sensitive to the effects of psychotropic drugs (Johanson
and Uhlenhuth 1960; Haertzen, 1966). The POMS consists of 72 adjectives
commonly used to describe momentary mood states. Subjects indicate
how they feel at the moment in relation to each of the 72 adjectives on
a 5-point scale ranging from “not at all” (0) to “extremely” (4). There
are eight clusters of items (subscales) which have been separated
empirically using factor analysis (Anxiety, Depression, Anger, Vigor,
Fatigue, Confusion, Friendliness, and Elation). The value of each subscale
is determined by adding the numbers checked for each adjective in the
cluster and dividing the total by the number of adjectives. Two additional
subscales, Arousal and Positive Mood, were derived from the other
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subscales as follows: Arousal = (Anxiety + Vigor) - (Fatigue + Confusion),
Positive Mood = Elation - Depression. The ARCI consists of 49 true/false
items which have been separated into 5 clusters described as measuring
typical drug effects such as stimulant-like (A and BG), euphoric (MBG),
sedative (PCAG) and dysphoric (LSD).
For each experiment the ten POMS scores were averaged across sessions
for each subject separately for drug and placebo at each of the four
time periods. A two-way analysis of variance (drug x hour) was performed
separately for each factor. If a significant (P < 0.05) drug x hour
interaction was found, further statistical tests were conducted to
determine at which hours the scores for the two drugs were significantly
different.
Drug Preparation. Drug tablets (Ativan, Wyeth Laboratories; Valium,
Hoffman-LaRoche) of the required dose were placed in opaque gelatin
capsules (size 00) which then were filled with dextrose powder. Placebo
capsules were identical in size and contained dextrose powder alone.
Results. The number of drug choices in each of the four experiments
is illustrated in Figure 1. The mean number of lorazepam choices out of
5 were as follows: 0.5 mg dose: 2.5 (49%); 1.0 mg: 1.6 (32%); and 2.0
mg 0.6 (16%). Only the- proportion of choices for 2.0 mg lorazepam
over placebo differed significantly from chance (one-sample t-test, t =
4.2, df = 11, p < .01) but a trend of decreased preference related to dose
is apparent. Subjects showed no preference for either drug in the
comparison between lorazepam and diazepam (46% lorazepam choice).
The POMS and ARCI scores reflected lorazepam's known anxiolytic and
sedative effects. At the 0.5 mg dose only Anxiety scores (POMS) were
decreased at hour 6. At 1.0 mg the drug decreased Arousal and increased
Fatigue and Confusion on the POMS. At 2.0 mg, Anxiety, Vigor and
LORAZEPAM DOSE (MG)
Figure 1. Mean (and S.E.M.) number of lorazepam choices (out of 5)
in comparisons between lorazepam (0.5, 1.0 or 2.0 mg) and placebo, and
lorazepam (1.0 mg) and diazepam (5.0 mg). Dashed line indicates level
of choice that would be expected by chance; asterisk indicates significant
differences from chance.
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Figure 2: Examples of POMS (Arousal) and ARCI (Sedation) subscales
showing subjective effects of lorazepam (solid lines) versus placebo
(broken lines) or diazepam (dashed line, last panel) over a 6-hour period.
Asterisks indicate significant (p < .05) differences between drug and
placebo (Fisher’s LSD post hoc test).
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Arousal were decreased, and Confusion increased. On the ARCI, PCAG
scores (sedative effects) were increased and BG (stimulant effects) scores
were decreased at 1.0 mg and 2.0 mg. LSD scores were elevated at
the 2.0 mg dose. There were no significant differences in the comparison
between lorazepam and diazepam. For purposes of illustration, the
drug’s effects on one POMS (Arousal) and one ARCI (PCAG) subscale
are presented in Fig. 2 (a and b).
Although the data are not shown here, the results from the post-session
questionnaires on liking and drug identification were consistent with the
choice and subjective effects results already described. Accuracy in
labelling lorazepam as a tranquilizer increased as the dose increased,
and mean ratings of drug liking were in agreement with mean drug
choices for the three doses, that is, both measures decreased with
increasing doses. The degree of concordance between the liking rating
on Sessions 1 - 4 and the number of times the drug was subsequently
selected was determined by calculating Pearson’s r between these two
measures for each of the 3 experiments. Only in the 2.0 mg comparison
did this correlation reach significance (r = 0.798, df = 10, p < .01).
Discussion
These experiments showed that normal volunteer subjects did not prefer
lorazepam over placebo in a laboratory test of choice. At the lowest
dose tested (0.5 mg), subjects appeared to be indifferent to the drug
whereas at the highest dose (2.0 mg) there was a clear preference for
the placebo. When therapeutically equipotent doses of lorazepam and
diazepam were compared, subjects showed no preference for either drug.
The subjective effects of lorazepam were in general consistent with the
drug’s known sedative properties, and, with some exceptions (see below),
the same as the effects of diazepam. The most notable and surprising
finding from the point of view of the purpose of this study was the
relatively long duration of effect of this drug. On each of the subscales
where there was a significant drug x hour interaction, the difference
between drug and placebo was present 6 hours after drug ingestion (as
measured by Fisher’s LSD post-hoc tests). In some cases the drug’s
effect was also evident at hours 1 and 3, but in no case did the effects
peak before hour 3 or disappear by hour 6. These results are in marked
contrast to previous findings with 5 and 10 mg diazepam (Johanson and
Uhlenhuth, 1980; de Wit et al., 1983), when the drug effects peaked at
hour 1 and had largely dissipated by the 6th hour.
While it seems paradoxical that a drug (lorazepam) whose half-life is
shorter than another (diazepam) should have a longer duration of effects,
closer examination of the pharmacokinetic properties of these two drugs
provides an explanation. After oral administration, peak plasma
concentrations of lorazepam are reached at about 2 hours (Greenblatt
et al., 1976) whereas for diazepam peak levels are reached 30 minutes
after administration (Hillestad et al., 1974). In both cases, the peak
clinical effects of the drugs correspond to the peak plasma levels. In
addition, lorazepam crosses the blood-brain barrier less readily because
of its lower lipophilicity. The drugs also differ in the extent to which
they are distributed to tissue. Diazepam is more readily absorbed by
peripheral tissue, decreasing plasma levels somewhat but delaying total
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elimination time. Thus, plasma levels of lorazepam remain higher after
peak levels are reached, but are then also more rapidly eliminated.
Lorazepam’s effects on mood are very similar to the effects of diazepam.
In the experiment comparing equipotent doses of the two drugs (1 mg
lorazepam versus 5 mg diazepam), there were no differences on the
POMS or ARCI subscales. Furthermore, the results of the three dose
comparisons with placebo can be compared to previous findings with
diazepam versus placebo. Both drugs produced dose-dependent increases
in Fatigue and Confusion, and decreases in Vigor and Arousal (Johanson
and Uhlenhuth, 1980; de Wit et al., 1983). While direct comparisons
cannot be made across experiments, casual inspection of the data indicate
that the direction and magnitude of the effects of the two drugs are
similar, although the time course of effects is notably different, as
described above. Anxiety scores on the POMS were decreased after
lorazepam, an effect reported with diazepam in one study (de Wit et
al., 1983) but not in another (Johanson and Uhlenhuth, 1980). The drugs
appear to have similar effects on the PCAG and BG subscales of. the
ARCI, but the increased LSD scores observed after the highest dose of
lorazepam have never been reported with diazepam.
It is notable that decreased Anxiety was the only measurable mood
effect after 0.5 mg lorazepam, and that it occurred in the absence of
any measurable sedative-like effects. This dissociation of effects has
implications both for the drug’s usefulness in treatment, and for our
understanding of the mechanisms of action of anxiolytic drugs.
In conclusion, these experiments provide data on the reinforcing property
of another benzodiazepine, lorazepam, in normal volunteer subjects. The
results with lorazepam are in agreement with previous findings using
diazepam, both in the drug’s sedative-like effects on mood, and the
notable absence of a preference for the drug over placebo. The absence
of preference for these drugs suggests that in this subject population
their dependence potential is low. The hypothesis that a shorter-acting
benzodiazepine is more reinforcing could not be tested, due to the
unexpectedly long duration of lorazepam’s effects.
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Ultradian Consummatory Cycles
and Smoking
Judith Green and Walter N. Tapp
INTRODUCTION
Smoking is a major preventable cause of life-threatening disease.
However, we succeed poorly in preventing disease due to smoking
because most intervention efforts exe relatively ineffective and
are marked by high rates of recidivism (Jaffe 1980; Russell and
Feyerabend 1978). One major obstacle to the effective treatment
of smoking is the failure to unravel the complex tangle of physio-
logical, pharmacological, psychological and social factors that
seem to play a role in initiating and sustaining compulsive smoking
behavior. In this study we examined cyclic consummatory behavior,
a manifestation of a physiological process that may either pre-
dispose people to become habitual smokers or may later maintain
their smoking behavior. Cyclic consummatory behavior encompasses
not only conventional meal patterns, but shorter cyclic patterns
of ingestion known as ultradian consummatory rhythms. These rhythms
occur in people and nonhuman primates with periods that typically
range from 60-150 minutes, involving eating and drinking (Natelson
and Bonbright 1978; Bowden et al. 1978) and such nonnutritive oral
activities as smoking (Friedman and Fisher 1967; Friedman 1972;
Oswald et al. 1970). While ultradian cyclicity is but one of a
host of biological rhythms that modulate physiological and behav-
ioral fluctuations, the ultradian consummatory rhythm seems to re-
flect an underlying rhythm of oral drive (Friedman and Fisher 1967;
Friedman 1972; Oswald et al. 1970). In this study, smokers and
exsmokers exhibited significantly shorter cycles of ingestive
activity (eating and drinking) than nonsmokers, suggesting that
shorter physiological cycles, I.e., more frequent peaks of oral
drive contribute to the impulse to smoke.
METHODS
Three groups of subjects between the ages of 18 and 39 participated
in the study. Subject groups were equivalent in age, sex, and
height-weight index (ratio of observed pounds of body weight per
inch of height to ideal pounds per inch; ideal weights from Fishbein
1970). There were 11 nonsmokers, 11 smokers, and eight exsmokers.
The smokers' mean current cigarette use was 18.0 + 5.5 SEM (range
= 3 to 70) cigarettes per day, with an average of 7.2 ± 1.7 SEM
years as a smoker. Exsmokers' prior mean cigarette use was
17.9 ± 4.3 SEM (range = 3 to 42) cigarettes per day for an average
of 8.1 ± 2.1 SEM years followed by an average of 3.8 + 1.9 SEM years
of abstinence from tobacco. Nonsmokers reported never having used
tobacco.
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Each subject was observed individually through one-way glass for a
period of six or seven hours beginning at 9 A.M. The subject's
room was ccmfortably furnished and had a refrigerator stocked with
beverages, cheeses, and fruit. Snacks and hot drinks were located
on a table. Subjects were told that they were participating in a
study concerned with the ways in which people structure time in an
environment without time cues. Subjects brought work, leisure
reading, and hobby materials and were instructed to follow their
inclinations as though spending a quiet day at home.
Consummatory activities were recorded as they occurred in each five-
minute interval of the observation period. Number of sips, bites,
and puffs, as well as total amounts of items consumed, were noted.
Patterns of sips + bites were treated as the dependent variable
in the time series analysis of the data and in the computation of
consummatory episodes. Puff patterns were not included in the
present analysis because there was no comparable measure across
all three groups.
A time series technique, spectrum analysis, was used to identify
and evaluate ultradian rhythms in consummatory data. Spectrum
analysis decomposes a waveform into its component sine and cosine
waves, providing information on the relative contributions of a
spectrum of underlying frequencies to the total variance of the
series. Each frequency component of a time series is associated
with a value that represents the percentage of the total power of
the spectrum contributed by that frequency. A scheme that was
developed by Tapp et al. (1981) to evaluate short time series
similar to those of the present study was used to compute each
subject's individual spectrum.
RESULTS
The time series analysis revealed that ultradian rhythms in eating
and drinking occurred in all groups of subjects (table 1). More-
over, smokers and exsmokers had similar cycles which in both cases
were significantly shorter (that is, of higher peak frequencies)
than those of nonsmokers. The spectrum values in table 1 were
derived by computing a mean within each group from the peak f're-
quency in each subject's spectrum. The peak spectrum frequency is
the frequency with the greatest power; i.e, the one that most con-
tributed to the variance of the subject's time-related pattern of
data. Spectrum frequencies are expressed in radians; for conve-
nience, the corresponding period lengths (minutes) have been listed.
It is important to note that smokers and exsmokers did not eat or
drink more on the whole than nonsmokers, either in terms of sips +
bites, or in terms of estimated calories. Rather, it was differ-
ences in the distribution of intake that produced higher frequency
consummatory patterns in those with histories of smoking. There
were no significant differences between the mean frequencies of
smokers and exsmokers.
Examination of the mean power distributions of the spectra of the
three groups of subjects for sip + bite patterns clearly reveals
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TABLE 1. Comparison of peek spectrum values of consummatory (sip +
bite) activity, frequency of consummatory episodes (CE), number of
sips + bites (S+B) and caloric intake in nonsmokers (Nsmok),
smokers (Smok) and exsmokers (Xsmok). Values are the mean ± the
standard error of the mean of each variable.
Spectrum Power Peaks
Cycle Cycle No.
length frequency No. CE No. S+B calories
(min.) (radians) per hr. per hr. per hr.
Nsmok 95.45 0.3681 0.588 24.6 172
± 9.91 ±0.0411 ±0.043 ±3.5 ± 27
Smok 72.20 0.4633* 0.785+ 21.6 153
± 5.91 ±0.0356 ± 22±0.050 ±2.7
Xsmok 63.02 0.5323** 0.730** 19.5 108
±5.87 ± 0 . 0 5 4 3  ± 0 . 0 5 3  ± 2 . 9 ± 15
*Significantly greater then nonsmokers, p< 0.05 by Student's t-
test for unpaired values; **p< 0.025; +p< 0.005.
the higher frequencies observed in smokers and exsmokers (figure 1).
Compared with nonsmokers, the mean spectrum power peaks of smokers
and exsmokers are shifted to the right (to higher frequencies).
Smokers and exsmokers had average cycle lengths 20 to 30 minutes
shorter than nonsmokers.
Corroborating the spectrum analysis findings, smokers and exsmokers
also engaged in significantly more frequent consummatory episodes
(table 1). A measure of ingestive tendency, consummatory episodes
were defined as eating, drinking or same combination of these,
exceeding a total of three bites or sips, which began 15 or more
minutes after a prior episode and which ended at least 15 minutes
before the onset of a subsequent episode. On an hourly basis
nonsmokers engaged in 0.59 ± 0.04 SEM consummatory episodes, while
smokers engaged in 0.78 ± 0.05 episodes (p< 0.005) and exsmokers
engaged in 0.73 ± 0.05 (p<0.025).
DISCUSSION
'The present findings suggest that shorter ultradian consummatory
periods contribute to the impulse to smoke. Both smokers and
exsmokers showed significantly shorter consummatory periods than
nonsmokers, resulting in more frequent peaks of oral activity
(eating and drinking). Clearly these rhythms of consummatory
activity are independent of smoking, since nonsmokers, exsmokers
and smokers all manifested rhythms in the ultradian frequency
range. Previous studies have focused only on smokers (Friedman
and Fisher 1967; Friedman 1972; Oswald et al. 1970). This finding
supports prior evidence that ultradian consummatory cycles represent
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FIGURE 1 Mean percent spectral power in 23 spectral frequencies for sip.
+ bite patterns of smokers, exsmokers, and nonsmokers. The X-axis shows
frequency (in radians); every other frequency has been labeled with its
corresponding period, or cycle length (in minutes) to aid interpretation.
endogenous physiological rhythms (Natelson and Bonbright 1978;
Bowden et al. 1978; Emde et al. 1975; Kleitman 1969). The similar
length of consummatory periods of smokers and exsmokers indicate
that the more frequent oral impulses are not a pharmacological
effect of nicotine or a result of other aspects of tobacco use.
Instead, short consummatory cycles seem to be characteristic of
people who have histories of smoking and are apparent even after
individuals cease to smoke.
At present we cannot determine whether the short ultradian periods
precede the smoking habit or whether habitual smoking shortens the
period of the ultradian rhythm. If the period is fixed before a
person begins smoking, then it would appear that short cycles of
oral activity predispose toward cigarette use. Alternatively,
if smoking shortens the ultradian period, then an important con-
sequence of the smoking habit would be a relatively permanent in-
crease in the frequency of oral activity, since short cycles were
observed in exsmokers after several years of abstinence. In either
event, the relationship between between smoking behavior and the
length of the ultradian consummatory period appears to be important
in understanding the nature of compulsive smoking. However it is
established, the shorter period of a smoker's ultradian rhythm
may contribute greatly to the persistence of the smoking habit or
to the degree of difficulty in quitting or remaining abstinent.
In the future it may be possible to develop empirically based
intervention strategies that target the short consummatory cycles
of smokers and thus alleviate or permit better management of the
heightened oral drive.
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Clinical Evaluation of
Mecamylamine for Withdrawal
From Nicotine Dependence
Forest S. Tennant, Jr., Anita L. Tarver, and
Richard A. Rawson
ABSTRACT
Mecamylamine (MCL) has been shown to extinguish nicotine depend-
ence in rats and monkeys. MCL was administered to fourteen
nicotine-dependent persons to determine if it may be effective in
withdrawing nicotine-dependent humans at doses which have accept-
able toxicity. Subjects smoked 20 to 60 cigarettes per day for a
mean of 2.4 years, and none had been nicotine abstinent for as
much as one day for at least one year. MCL was started in a dose
of 5 to 10 mg per day and progressively raised until the subject
experienced nicotine blockage and/or toxic effects. During MCL
administration, 7 of 14 (50%) totally ceased smoking within the
first 11 days'of treatment, and an additional 4 (28.6%) subjects
reduced cigarette consumption to less than five per day by the
end of three weeks. Thirteen of 14 (92.9%) subjects stated that
MCL blocks nicotine, reduces nicotine craving, and "works." At
least some minor side-effects of MCL were observed in every sub-
ject. The most intolerable side-effects were constipation,
urinary retention, abdominal cramps, and weakness, and these were
responsible for drop-out of 5 (35.7%) subjects. Although there
is a high prevalence of side-effects, MCL is probably a viable
withdrawal treatment for some cases of recalcitrant nicotine
dependence.
INTRODUCTION
Nicotine dependence is widely recognized as a problem which needs
specific pharmacologic treatment.1,2 Recent studies in rats and
monkeys revealed that it is possible to extinquish nicotine
dependence with the ganglionic blocker, mecamylamine (MCL).3,4
When given to humans MCL will block the acute physiologic effects
of nicotine. This study was undertaken to determine if MCL may
be effective in the clinical withdrawal of nicotine-dependent
humans at doses which have acceptable toxicity.
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METHODS
Fourteen nicotine-dependent volunteers were selected for study.
Criteria for selection were as follows: smoked at least 20 (one
pack) cigarettes per day; had not been nicotine abstinent for
more than one day for at least one year; no history of hyperten-
sion, pregnancy, cardiovascular disease, prostate enlargement,
glaucoma, or dependence upon alcohol or other drugs. Subjects
also had to have the perception that they were "addicted" to
nicotine (Table One). Following informed consent, subjects
underwent physical examination, blood pressure recording, pulmon-
ary function testing, 6and urine analysis for the qualitative
presence of nicotine.
Subjects were instructed to attend the clinic daily for five con-
secutive days, and every other day for two more weeks to make a
maximum study period of 21 days. The first day's dose of MCL was
2.5 mg given two or three times for a 24-hour total of 5 to 7.5
mg. Beginning on day two, doses of MCL were raised by 2.5 to 5
mg per day until the subject perceived nicotine blockade and/or
experienced significant side-effects. When significant side-
effects occurred, the dosage of MCL was either reduced or held
constant. If a subject stopped smoking cigarettes, he or she was
allowed to continue MCL up to a maximum of 21 days.
During each clinic visit, the subject's blood pressure was re-
corded in the sitting and standing positions, and physical
assessment was done for sedation, tremor, and motor impairment.
A nicotine withdrawal score was determined on each day of atten-
dance by assigning a numerical score of 0 for absent; +1 for
mild; +2 for moderate; and +3 for severe to each of the following
eight symptoms: agitation; depression; energy; myalgia/arthral-
gia; chills; nausea-vomiting; insomnia and anorexia. The maximum
daily withdrawal score was 24. A daily check list of 24 side
effects was assessed, and the list included abdominal cramps,
blurred vision, constipation, dizziness, drowsiness, dry mouth,
dysphoria, headache, irritable, lethargy, palpitation, photo-
phobia, tremor, urinary hesitancy, urinary retention, and weak-
ness. Subjects were specifically asked on each day of attendance
if MCL blocked the effects of nicotine, if it "works," helps
reduce nicotine craving, and if they wanted to continue MCL.
RESULTS
Subjects were a very experienced and dependent group of nicotine
smokers (Table One). They had smoked a mean of 24.4 years and
had not been nicotine-abstinent for even one day for periods
ranging from one to 36 years (mean of 10.2 years). Half (7 of
14: 50%) reported they had to awaken at night to smoke.
Thirteen of 14 (92.9%) subjects reported that MCL at least part-
ially blocked the effects of nicotine, reduced nicotine craving,
and that MCL "works " Seven (50%) subjects completely stopped.
smoking between the fourth and eleventh day of the study after
progressively reducing, on a daily basis, their cigarette intake
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(Table Two). The mean 24-hour dose of MCL on the day that each
stopped smoking was 26.7 mg. Four additional subjects progres-
sively reduced their cigarette intake to less than five per day,
but never totally stopped. Ten of 14 (71.4%) converted their
urine from nicotine positive to nicotine negative during the
study (Table Three).
Very little nicotine withdrawal was observed in or reported by
these subjects. The highest withdrawal score for any subject was
5 out of a maximum possible score of 24. Subjects appeared to
definitely perceive MCL's ability to block nicotine's effects.
This perception was described as cigarettes tasting bad, "wasting
time," loss of craving, or smoking a low-nicotine cigarette.
Statements relayed to us were quite descriptive, and some actual
quotes are given here (Table Four). Side-effects were very
common and severe enough to cause drop-outs in five (35.7%) sub-
jects (Table Five). Urinary retention occurred in two subjects.
One of these was a 25-year-old female who weighed 55.9 kg and who
received 12.5 mg of MCL on the second day of the study, which
produced the urinary retention. The other subject in whom this
occurred was a 56-year-old male who received 40 mg of MCL on the
day of urinary retention. The other side-effects which were most
intolerable to subjects and caused study drop-outs were consti-
pation, abdominal cramps, and weakness. Blood pressure dropped
slightly in only one subject (110/80 mm Hg to 100/60 mm Hg).
After cessation of cigarettes by the seven successful subjects,
each challenged MCL by smoking at least one cigarette on two
different days (Table Five). Each expressed the view that they
were "wasting time" and had no further challenges during the
three week trial.
DISCUSSION
A number of pharmacologic treatments have been unsuccessfully
attempted for nicotine dependence.4,6-10 Schuster and co-
workers were unable to alter smoking behavior in normal human
subjects with d-amphetamine, meprobamate, and lobeline and Hanson
and co-workers were unable to extinguish nicotine dependence in
rats with pentolinium, amphetamine sulfate, caffeine, ethanol,
chlordiazepoxide, phenobarbital, diphenylhydantoin, and chlorpro-
mazine. Rosecrans has extensively studied rats who were trained
to discriminate between nicotine and saline and found that
arecoline, hexamethonium, atropine, dibenamine, and propanolol
would not antagonize nicotine. Nicotine gum may assist smoking
cessation by preventing abstinence symptoms, but its clinical
usefulness is still uncertain.2,8,9 MCL was first observed by
Stone et al. in 1958 to antagonize nicotine-induced convul-
sions. Dominio, in 1967, showed that nicotine's arousal
effects could be antagonized by MCL.12 Rosecrans confirmed these
observations. Henningfeld and co-workers demonstrated that MCL
will selectively block at least some of nicotine's acute
behavorial effects in humans.5
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The dose of MCL used to extinguish nicotine self-administration
in rats and monkeys was 1 to 4 mg/kg.3,4 This dose is consider-
ably higher than the daily dose of MCL normally used for treat-
ment of hypertension, so a first consideration in testing MCL was
to determine if toxicity may be too great to use in clinical
treatment. Although side-effects were severe enough to cause 5
of 14 (35%) to drop out of treatment, the majority tolerated MCL
well despite our attempt to progressively and rapidly increase
the daily dose to reach blockade or toxic effect. Side-effects
could possibly be lessened by slower induction of MCL, and it
could also be taken over a longer period than 21 days. An
initial first-day dose of 10 mg appeared to be tolerated well by
all subjects. Hypotension was not a limiting factor in these
subjects, and urinary retention was the most serious side-effect.
Even though the majority of subjects tolerated MCL, the high
prevalence of toxic side-effects observed with a nicotine block-
ing dose is such that MCL should probably not be used for nico-
tine dependence treatment unless all other methods have failed.
MCL's nicotine blocking effects were impressive as indicated by
subjects' quotes and perceptions. Thirteen of 14 (92.9%) sub-
jects, including subjects who dropped out, perceived that MCL
blocked the effects of nicotine. The seven subjects who totally
stopped smoking in the three-week study period progressively re-
duced cigarette intake each day until all smoking stopped. They
also challenged MCL by smoking one or more cigarettes after they
had gone a full 24 hours without smoking. Challenge during an-
tagonist treatment is apparently to be expected, since it commonly
occurs during naltrexone treatment for opioid addiction.13 Sub-
jects surprisingly reported that MCL reduced nicotine craving.
Little nicotine withdrawal was documented by the method used
here, but it was difficult to separate side-effects from nicotine
withdrawal symptoms.
Subjects in this pilot study were very experienced smokers who
smoked a mean of 24.4 years and who had not been nicotine
abstinent for as much as a day in over a year. Seven of the 14
ceased nicotine during the 21-day study period and five of these
relapsed within 30 days after stopping MCL. Therapeutic outcome
may have been better if a less dependent group of subjects had
been selected. Whether these persons ceased or reduced nicotine
consumption due to MCL or placebo effect is unknown, since
placebo and psychologic treatments may be effective in treating
many nicotine-dependent persons.9,14 Further clinical trials and
double-blind, placebo-controlled studies will be needed to
determine this. Regardless, preliminary observations of subjects
studied here indicate that the clinical efficacy and safety of
MCL should be studied more extensively, since MCL may be useful
treatment in recalcitrant nicotine dependence.
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TABLE ONE
CHARACTERISTICS OF SUBJECTS
N=14
Males
Females
Age Range (Yrs.)
Mean Age (Yrs.)
Weight Range (kg) Females
Mean Weight (kg) Females
Weight Range (kg) Males
Mean Weight (kg) Males
Range Nicotine Use (Yrs.)
Mean Nicotine Use (Yrs.)
Range Cigarettes Per Day
Mean Cigarettes Per Day
Mean Time Between Cigarettesin Daytime (Mins.)
Number Who Perceived "Addicted"
Awake at Night to Smoke
Failed Previous Attempts to Stop
TABLE TWO
RESULTS AND OUTCOME
Range Days MCL Administration
Mean Days MCL Administration
No. Ceased Smoking
No. Decreased Cigarettes to Less Than 5 Per Day
Highest Withdrawal Score Observed
No. Who Converted Urine to Nicotine Negative
No. Dropped Out Due to Side-Effects
No. Dropped Out Due to Non-Effectiveness
6 (42.9%)
8 (57.1%)
24-61
39.7
51.8-85.9
62.1
66.3-103.6
90.4
10-44
24.4
20-60
43.9
18
14 (100.0%)
7 (50.0%)
14 (100.0%)
2-21
13.5
7 (50.0%)
4 (28.6%)
5
10
5 (35.7%)
2 (14.3%)
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TABLE THREE
DATA ON SUCCESSFUL SUBJECTS
N=7
Stopped on Which Days of Study 4-11
Range Dose of MCL Which Produced Cessation (mg) 7.5-50
Mean Dose of MCL Which Produced Cessation (mg) 26.7
Relapsed Within 30 days 5 (71.4%)
Females 4 (57.1%)
Males 3 (42.9%)
No. Who Smoked at Night 4 (57.1%)
TABLE FOUR
SOME ACTUAL QUOTES OF SUBJECTS CONCERNING
MECAMYLAMINE'S EFFECTS ON SMOKING
I FOUND OUT I'M WASTING TIME SMOKING
HARDLY THINK ABOUT IT
AFRAID TO NOT TAKE MEDICINE
DIDN'T DESIRE TO SMOKE WHEN I GOT UP
THEY TASTE TERRIBLE
LOTS OF ENERGY
JUST DON'T WANT THEM
DON'T SMOKE WHOLE CIGARETTE
TASTE LINGERS IN MY MOUTH
MOST OF TIME HALF THE CIGARETTE IS SMOKED
HORRIBLE TASTE
HAVE A RANK TASTE
LIKE SMOKING A LOW TAR CIGARETTE - LOTS OF AIR
NAUSEA WHEN I SMOKE
ONLY TWO PUFFS OF CIGARETTES AND PUT REST OUT
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TABLE FIVE
SIDE-EFFECTS OBSERVED IN SUBJECTED
N=14
SIDE EFFECT
ABDOMINAL CRAMPS
BLURRED VISION
CONSTIPATION
DIZZINESS
DROWSINESS
DRY MOUTH
DYSPHORIA
HEADACHE
IRRITABLE
LETHARGY
PALPITATION
PHOTOPHOBIA
NUMBER
8 (57.1%)
3 (21.4%)
12 (85.7%)
6 (42.9%)
8 (57.1%)
11 (78.6%)
2 (14.3%)
1 (7.1%)
5 (35.7%)
2 (14.3%)
1 (7.1%)
1 (7.1%)
TREMOR 1 (7.1%)
URINARY HESITANCY 2 (14.3%)
URINARY RETENTION 2 (14.3%)
WEAKNESS 3 (21.4%)
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Adverse Effects of Cocaine Abuse
Arnold M. Washton and Andrew Tatarsky
ABSTRACT
Specific, consequences of cocaine abuse on health and psycho-
social functioning were assessed in 55 cocaine-abusing subjects
who called a telephone "helpline." Results showed a high in-
cidence and wide range of adverse consequences including: (a)
impairment of job functioning, interpersonal relationships, and
financial status; (b) disturbances of mood and cognitive func-
tioning; (c) psychiatric symptoms of depression, paranoia, and
increased suicidal/violent tendencies; and (d) physical symp-
toms of exhaustion, weight loss, sleep problems, and seizures.
Cocaine-related automobile accidents, suicide attempts, and
violent acts, including a cocaine-related homicide, were also
reported. Intranasal users reported no fewer and no less severe
adverse consequences than free-base smokers or intravenous
users. Our findings challenge popular notions that cocaine is a
benign "recreational" drug and that the intranasal route of
administration guarantees protection against addictive patterns
of use and adverse effects.
INTRODUCTION
Cocaine use has escalated to epidemic proportions in the U.S. in
recent years. Nationwide surveys estimate that over 22 million
American have used cocaine and the numbers continue to soar at
an alarming rate. Moreover, cocaine use has spread considerably
into the middle-class and working-class segments of American
society. It is no longer a drug used only by the wealthy or
elite.
Health consequences of escalating cocaine use are reflected in
figures showing more than a 200% increase in cocaine-related
deaths and emergency room visits and more than a 500% increase
in cocaine-related admissions to federally funded treatment pro-
grams between 1976 and 1981. Despite these alarming trends, the
247
popular belief that cocaine is a benign "recreational" drug con-
tinues to be perpetuated. Recent studies of cocaine use have
focused primarily on "social-recreational" users (Seigel, 1977)
or on individual case reports of dysfunctional use (Wesson and
Smith, 1977). Such reports tend to underestimate the prevalence
of dysfunctional cocaine use and resulting adverse consequences.
This is especially true for intranasal use which is commonly
regarded as much safer than free-base smoking or intravenous
use.
We now report data on specific adverse effects of cocaine use on
health and psychosocial functioning in a sample of intranasal,
free-base, and intravenous users.
SUBJECTS AND METHODS
A telephone "helpline" for cocaine abusers was established at
out facility in February 1983. Local television and radio
stations publicized the helpline by informing cocaine users that
they would call anonymously for information, advice or referral
to treatment. We conducted a 20-30 minute telephone interview
and administered an extensive questionnaire to the callers to
obtain data on demographic variables, drug use, psychiatric
history, and particularly on consequences of cocaine use within
specific areas of physical health and psychosocial functioning.
Consequences were grouped into several categories each contain-
ing a checklist of specific items, as follows: (1) Physical
Consequences - nausea/vomiting, sweating, nasal sores/bleeding,
headaches, persistent cough/sore throat, feel run down and Weak,
sleep problems, chills, hands tremble, double vision,
seizures/loss of consciousness; (2) “Major” Psychological or
Behavioral Consequences - paranoid ideation, physically injured
someone, hallucinations; (3) "Minor" Psychological or Behavioral
Consequences - irritable, short-tempered, depressed, anxious,
lazy, low on energy, difficulty concentrating, confused
thoughts, memory problems, loss of sex drive; (4) Vocational
Consequences - lateness, absence, reduced productivity at Work;
(5) Interpersonal Consequences - increased discord with spouse/
mate, spouse leaves or threatens to leave, impairment of social
life and friendships, impaired sexual relationship; (6) Legal,
Consequences - arrests for possesion or sale of cocaine or
related crimes; (7) Financial Consequences - depleted bank
acounts, unable to keep up with bills, no extra money, accumu-
lated debts; (8) Automobile Accidents - any cocaine-related auto
accident involving damage to property and/or persons.
RESULTS
Over 2,000 calls Were received on the helpline during its first
eight weeks of operation and calls continue to be received at a
rate of 25-100 per day. Approximately 70% of the calls are from
cocaine abusers themselves and the remainder from concerned
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family members, friends, or professionals. Data presented here
are fran the first 55 cocaine abusers who were interviewed on
the helpline.
Our sample was: 78% male, 22% female, ages 22-59 years (X=33
yrs); 56% were white, 35% black, 9% Hispanic. Mean level of
education was 14.1 years, range 9-18 years. Forty-nine percent
had annual incomes over $25,000; 53% had occupations in the
categories of white collar, professional, or self-employed
business owner. Preferred route of cocaine administration was:
intranasal (IN) 51%; free-base smoking (FB) 22%; and intravenous
(IV) 27%. Estimates of weekly cocaine use ranged from 1-32
gram/week with a mean of 8.2 grams. Forty-eight Percent used 6
grams or more per week. Frequency of cocaine use averaged 5.7
days/week; 56% used at least 5 days/week. At prices of
$lOO-$125 per gram, the average amount of money spent per week
on cocaine was over $800 and ranged fran $109 to $3,150. No
differences were found between the IN, FB, and IV groups with
regard to weekly dose estimates or frequency of cocaine use.
Percentages who responded "yes" to each of the following state-
ments about their cocaine use were: (a) psychologically
addicted to cocaine - 92%; (b) have lost control over cocaine
use - 91%; (c) crave cocaine and feel a compulsion to use it -
81%; (d) want to stop using cocaine - 80%; and (e) feel unable
to stop using cocaine without help - 75%. Sixty-four percent
reported no concurrent regular use of drugs other than cocaine;
the remaining 36% reported using tranquilizers, marijuana,
alcohol, or heroin to reduce the stimulant effects of cocaine or
to relieve the dysphoric "crash" when cocaine effects wore off.
A high incidence and wide range of adverse consequences of
cocaine use were reported. The percentage of subjects reporting
at least one, but usually several consequences within each cate-
gory were as follows: (a) Physical Health - 98%; (b) Inter-
personal - 93%; (c) "Minor" Psychological - 93%; (d) "Major"
Psychological - 56%; (e) Vocational - 64%; (f) Financial - 84%;
(g) Legal - 13%; and, (h) Auto Accident - 6%. A characteristic
pattern of disruptive functioning was reported by most subjects,
consisting of: (a) absenteeisn and reduced effectiveness at
work; (b) increased discord with spouse/mate leading to actual
separation or threat to separate; (c) diminished or exhausted
financial resources and accumulation of debts; and, (d) feeling
depressed, anxious, irritable, and overwhelmed with problems.
The incidence of specific consequences within areas of physical
health and psychological functioning is shown in Table 1.
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TABLE1
INCIDENCE OF REPORTED CONSEQUENCES OF COCAINE USE
(N=55)
# S’s
PHYSICAL HEALTH
Exhausted and weak 33
Sleep difficulties 32
Nasal sores/bleeding 18
Hands tremble 18
Significant weight loss 18
Headaches 16
Nausea/vomiting 14
Cough/sore throat 12
Double vision 8
Seizure and loss of consciousness 6
"MAJOR" PSYCHOLOGICAL/BEHAVIORAL
Paranoid ideation
Panic attacks
Feel violent
Hallucinations
Physically injured someone
Suicidal ideation
Attempted suicide
26 47%
11 20%
10 18%
9 16%
6 11%
4 7%
4 7%
"MINOR" PSYCHOLOGICAL/BEHAVIOR
Irritable, short-tempered
Depressed, bad mood
Nervous, anxious
Lazy, unmotivated
Loss of sex drive
Difficulty concentrating
Confused thoughts
Memory problems
37 67%
36 65%
35 64%
30 55%
24 44%
20 36%
19 35%
18 33%
% S’s
60%
58%
33%
33%
33%
29%
25%
22%
15%
11%
The most common physical complaints were exhaustion and exces-
sive sleeping following a binge of cocaine use. Nasal problems
and headaches were characteristic of IN users with one reporting
a perforated nasal septum. Persistent cough and sore throat was
characteristic of FB smokers. The most disturbing physical con-
sequence was seizure with loss of consciousness which reportedly
occurred on at least several occasions of high-dose cocaine use
in some of our subjects. Reported "minor" psychological con-
sequences included mood disturbances, loss of sex drive, and
impaired cognitive functioning. Among "major" psychological
consequences, the most commonly reported was paranoid ideation
consisting of exaggerated concerns about intruders as well as
extreme mistrust of family members, friends, and neighbors. Two
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subjects reported symptoms of cocaine-induced psychosis charac-
terized by eleaborate paranoid delusions with ideas of reference
and persecution, as well as auditory and visual hallucinations.
Increased violent and suicidal feelings or behaviors were re-
ported in some cases. One subject reported committing a murder
while high on cocaine. No consistent relationship was found be-
tween the incidence of reported consequences and either dose or
frequency of cocaine use. A substantial number of consequences
were consistently reported across a Wide range of doses and
frequencies of cocaine use. Also, the IN, FB, and IV groups did
not differ with regard to the incidence or type of reported
consequences. Contrary to expectation, IN users reported no
fewer and no less severe consequences than FB or IV users. The
psychoactive, mood-altering effects of cocaine considered most
desirable by our subjects included: feelings of elation,
mastery, confidence, self-control, and sexual arousal; increased
talkativeness, physical energy, and contentment; and, elimina-
tion of boredom, fatigue, and stress. However, almost without
exception these desirable effects diminished or disappeared en-
tirely With continued, chronic use and were eventually replaced
by an increasing number of adverse effects such as depression,
irritability, loss of sex drive, and intense guilt. In a futile
attempt to recapture the desirable effects and to Ward off the
unpleasant "crash," behavior Was driven toward continued and
intensified patterns of cocaine use. Our subjects found them-
selves progressively drawn into a powerful, vicious cycle of
obtaining, using, and recuperating from cocaine. The accumu-
lated adverse consequences of cocaine use and resulting psycho-
logical distress are what ultimately led them to call our
helpline for assistance.
DISCUSSION
The large volume of calls to our helpline appear to reflect the
increasing prevalence of cocaine dependence in the U.S., espe-
cially among White, middle-class males who are otherwise not
heavily involved in drugs. Not only are more people using
cocaine, but increasing numbers are developing addictive
patterns of use and suffering serious disruption to their func-
tioning. The popular belief that cocaine is a non-addictive,
social drug, With low abuse potential, especially if used by the
intranasal route, is challenged by our findings that all three
routes of administration (snorting, smoking, injecting) were
associated With compulsive use patterns characterized by loss of
control over use, persistent craving and compulsion to use
cocaine, and continued use despite serious adverse consequences.
Although addictive patterns might develop more rapidly with
free-base smoking or intravenous use, our findings and others
(Helfrich et al. 1983) demonstrate that intranasal users are not
exempt from uncontrollable use or from adverse consequences.
Recent reports of death from intranasal use (Wetli and Wright,
1979) underscore the fact that toxic blood levels of cocaine can
be achieved by this route. Individuals With epilepsy, hyper-
tension, or cardiovascular disease might be especially prone to
fatal reactions.
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Admittedly, our sample was biased since all subjects were
problematic users as self-defined by their calling the helpline.
Moderate users, by definition, tend not to suffer medical or
psychological consequences. Nonetheless, it cannot be concluded
that even moderate levels of intranasal use guarantee protection
against eventual dependence and other adverse effects. Most of
our subjects began with occasional use and were rather surprised
at how quickly and intensely their use escalated to compulsive
patterns especially because they had thought cocaine was non-
addictive. The question of why some users escalate to addictive
patterns is of substantial clinical importance, but remains
largely unanswered at present. Comparison of social-
recreational users with compulsive users might elucidate some
important individual differences.
Although psychological dependence on cocaine does occur, whether
cocaine produces true physical dependence remains a question.
After cessation of chronic cocaine use, the user usually does
not experience a clearly definable withdrawal syndrome as with
heroin or barbiturates. However, the generalized dysphoria and
feelings of malaise following cocaine use may be viewed as a
withdrawal state especially since they are associated with drug
craving and drug-seeking behavior and are relieved by resumption
of cocaine use. Furthermore, our findings suggest that with
chronic use of cocaine tolerance develops to many of its
effects.
The large volume of anonymous calls to our helpline suggests
that a substantial portion of cocaine abuse is otherwise hidden
from scientific or public analysis. Estimates of the prevalence
and consequences of cocaine abuse based on death rates,
emergency-room visits, and treatment admissions may grossly
underestimate the current extent of the problem. Nearly all our
subjects had no history of treatment for any aspect of drug
abuse, especially the more middle-class abusers who had dis-
missed the idea of seeking help in the usual type of drug abuse
clinic that is known to treat mainly heroin addicts. There is
currently no specific treatment for cocaine abuse with demon-
strated efficacy. A number of pharmacologic agents (e.g.,
desipramine, methylphenidate, lithium carbonate) are being
evaluated in the treatment of cocaine abusers at our outpatient
facility and elsewhere (Rawson et al. 1983; Khantzian, 1983).
Preliminary findings suggest the potential usefulness of these
medications in selected patients when combined with frequent
contact and supportive counseling or psychotherapy. Some
cocaine abusers require hospitalization because of psychosis,
acting-out behavior, or inability to refrain from cocaine use.
It is likely that adverse consequences of cocaine use will
become increasingly prevalent and visible during the next few
years. Cocaine's reputation as a relatively safe recreational
drug has already contributed to more widespread abuse. If
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cocaine were more readily available and at a substantially lower
cost, or if social sanctions and scientific information failed
to caution against intensified use, even larger numbers Would
suffer serious consequences from this very seductive drug. It
is imperative, therefore, that accurate information be gathered
and disseminated about specific consequences of cocaine abuse.
There is a pressing need for expanded research and treatment
efforts to combat the current epidemic of cocaine abuse in the
U.S. and prevent it from escalating further.
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Comparison of a Behavioral and a
Pharmacological Treatment for
Reduction of Illicit Opiate Use
Maxine L. Stitzer, Mary E. McCaul, George E. Bigelow,
and Ira A. Liebson
Although many methadone maintenance patients eliminate their use
of illicit opiate drugs after enrolling in treatment, continuing
use of heroin or other opiates is commonly observed in methadone
maintenance clinics. Typically, 20 - 40 percent of methadone
maintenance patients show at least an occasional opiate-positive
urine test over a period of several months of urinalysis screen-
ing (Bigelow et al. 1980; Ling et al. 1978; Newman and Whitehill
1979; Stitzer et al. 1980), while a smaller subset of these
patients show persistent illicit opiate use during methadone
maintenance treatment. Recent studies have suggested that
patients maintained on higher methadone doses show lower rates of
illicit drug use than patients maintained on relatively lower
methadone doses (Ling et al. 1978; McGlothlin and Anglin 1981).
This observation suggests that raising the methadone dose for
individual drug-abusing patients may decrease supplementation
with illicit opiate drugs, and in fact raising the dose is a
common strategy employed by drug abuse clinics for patients who
engage in persistent opiate supplementation. However, the effects
of methadone dose increases on rates of illicit drug supplementa-
tion have not been systematically evaluated. The present study
will provide such an evaluation.
Another line of research has suggested that contingency management
procedures can effectively reduce illicit drug supplementation
among methadone maintenance patients. In previous studies, money
and take-home privileges have been offered to chronic opiate
supplementers for providing opiate-free urine samples (Hall et al.
1979; McCaul et al. 1983; Stitzer et al. 1980). A methadone dose
increase might also serve as a reinforcer for maintenance patients
since these patients claim that dose increases are desirable
(Stitzer and Bigelow 1978) and reliably self-administer such in-
creases when given the opportunity (Stitzer et al. 1983). In the
present study, dose increases were offered contingent upon pro-
vision of opiate-free urine samples. If dose increases serve as
reinforcers, this contingent arrangement should increase the
number of drug-free urines delivered. The study hypothesis is
that a contingent methadone dose increase may be more effective
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than a noncontingent increase for influencing supplemental opiate
drug use since the contingent procedure should specifically moti-
vate behavior change in addition to providing a beneficial pharma-
cological intervention.
The present study, then, is a comparison between two procedures,
both of which were expected to have a beneficial impact on chronic
opiate supplementation. One procedure was purely pharmacological,
consisting of a blind methadone dose increase. The second pro-
cedure was a behavioral intervention which involved patient-con-
trolled dose increases available contingent upon opiate-free
urinalysis test results.
METHODS
Participants were seven male methadone maintenance patients, se-
lected because of persistent opiate-positive urine test results
during routine clinic urinalysis screening. Five subjects were
black and two were white. Average age was 33.4 years (range
29 - 40 years). Subjects reported an average of 11.4 years of
continuous opiate use and had been enrolled in this clinic for
an average of 4.3 months prior to study participation (range
2 - 7 months).
All subjects received their regular 50 mg/day methadone dose
throughout this study and provided urine samples routinely. Urine
samples were tested for presence of opiates using an on-site EMIT
system (Syva Corp.). Urines were also tested for a variety of
additional drugs of abuse (including opioids, benzodiazepines,
sedatives, and stimulants) by an outside urinalysis laboratory
employing thin layer chromatography. Urine samples were collected
twice weekly (Mon and Fri) during the 6 - 8 week baseline evalua-
tion period which preceded each intervention and during the
pharmacological intervention; urines were collected three times
weekly during the behavioral intervention.
The pharmacological intervention consisted of an abrupt blind
methadone dose increase from 50 mg to 75 mg/day. The dose was
held at this level for six weeks then gradually decreased back to
its original stable level over a 2 - 3 week period. Neither sub-
jects nor counseling staff were aware of the dose alterations.
During the behavioral intervention, dose alteration opportunities
were based on urinalysis test results. If a given urine sample
was opiate-positive, no dose change was allowed. If the sample
was opiate-free, the subject could increase his stable dose by a
maximum of 25 mg per day. The dose could be increased each day,
with the size of the increase selected daily until the next
urinalysis test day. At this point, the procedure in effect was
again determined by the urinalysis test result. That is, if the
urine was opiate-positive, no dose increase was allowed; while
if the urine was opiate-free, the patient could continue to re-
quest dose increases. The contingent dose increase procedure WAS
described to subjects 3 - 4 days prior to their first dose in-
256
crease opportunity and was in effect for six weeks. At the end
of this time, the opportunity to increase dose was no longer
available, resulting in an abrupt withdrawal of extra methadone
and a return of dose to the original maintenance level.
Three subjects have been exposed to both treatment conditions in
a cross-over design while four subjects have been exposed to only
one study intervention. Cross-overs have not been possible to
run with all subjects either because the subject left the clinic
or because illicit drug use did not return following exposure to
the first treatment intervention.
Subjects completed a 60-item symptomatology report form twice
weekly on Monday and Friday on which they rated the extent of
each symptom on a scale of 0 (not present) to 3 (severe). Symp-
toms included those typical of opiate withdrawal and opiate in-
toxication as well as a variety of miscellaneous complaints.
Changes in symptomatology related to the implementation and with-
drawal of study procedures were assessed by subtracting each
subject’s average baseline symptom score from the average score
obtained during and after each intervention; average scores were
generally based on data collected during 6-week blocks of time.
RESULTS
Figure 1 summarizes urinalysis results as percent of opiate-free
urine samples collected for successive two-week time periods be-
fore (open bars) and during (closed bars) the two study inter-
ventions. During pre-intervention baseline periods, only about
20 percent of urine samples were opiate-free for the group and no
subject delivered more than 50 percent opiate-free urines during
any given two-week time period.
Overall, the behavioral intervention produced a greater and more
immediate increase in opiate-free urines than the blind dose in-
crease procedure. Following the blind dose increase, 48 percent
of urines were opiate-free, a nonsignificant increase from base-
line. Two of the four subjects studied showed marked increases
in opiate-free urines following the blind dose increase. However,
increases in drug-free urines generally were not apparent until
the third week after initiation of the blind dose change.
In contrast, 74 percent of urines were opiate free during the
contingent dose increase procedure. This is a significant in-
crease from baseline levels in a test of differences between pro-
portions (p < 0.01). Four of six subjects showed marked in-
creases in opiate-free urines during the behavioral procedure.
Furthermore, the effect of the behavioral procedure was generally
immediate.
Six patients exposed to the contingent methadone dose increase
procedure amassed a total of 211 opportunities to raise their
methadone dose. The dose increase opportunity was never refused,
but neither did patients invariably choose the maximum allowable
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FIGURE 1. Percent opiate-free urine specimens are shown during
successive two-week blocks of baseline evaluation (open bars) and
study intervention (filled bars). Shown in the upper panel are
data from an intervention in which methadone dose increases were
available contingent upon opiate-free urine specimens (N=6).
Shown in the lower panel are data from an intervention in which
blind methadone dose increases were given independent of urine
test results (N=4).
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increase. The maximum allowable dose increase was selected on
65.4 percent of opportunities, while the remaining choices were
about equally distributed between doses of 10, 15, and 20 mg.
Symptom reports were examined for evidence of withdrawal com-
plaints or opiate intoxication during and after each of the study
procedures. No consistent changes in symptom scores were observed
during either the behavioral or the pharmacological intervention.
Nor, surprisingly, did symptom complaints increase following with-
drawal of the blind 25 mg methadone dose increase. The one con-
sistent effect noted in the four subjects who responded to the
behavioral procedure and received dose increases was an elevation
of symptom scores following termination of the contingent dose
increase procedure.
Examination of full urine screens revealed that these subjects
were primarily heroin abusers. Only three of the subjects ever
showed drug positives other than morphine, and the use of other
drugs was not consistently related to study conditions.
DISCUSSION
This preliminary study conducted with a small number of subjects
has shown that a blind methadone dose increase can reduce opiate
drug supplementation in some methadone maintenance patients.
Improvement was noted in 2 of the 4 patients assigned to this
procedure; onset of improvement was delayed by about two weeks
after the dose increase was initiated. On the other hand, a
behavioral procedure which involved the opportunity for subjects
to raise their own dose if they provided a drug-free urine speci-
men was effective more consistently across subjects, produced a
larger overall decrement in opiate drug supplementation, `and had
a more immediate impact on drug use than the blind increase pro-
cedure. Although these results must be considered tentative at
this point, they suggest that the effectiveness of methadone dose
increases for reducing illicit opiate drug supplementation can be
enhanced by scheduling dose increases contingent on urinalysis
test results.
It should be noted that patients were actually receiving more
total mg of methadone during the pharmacological than during the
behavioral dose increase procedure. This suggests that the mo-
tivational aspect of the contingent procedure, which targets a
specific behavior change in patients, is a more important element
of the intervention than the magnitude of the dosage increase
which patients receive.
The clinical utility of dose increase procedures rests on their
safety as well as their efficacy. It could be the case that
fluctuations in the methadone dose during the contingent procedure
or after dose alteration procedures were withdrawn, caused patient
discomfort which could potentially contribute to renewed drug use.
However, the dose increase procedures appeared to be safe as well
as effective. No increases in symptomatic complaints were noted
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while either intervention was in effect. Although there were in-
creased complaints observed after withdrawal of the behavioral
procedure, these appeared to be influenced by suggestibility
factors since subjects knew that extra methadone would no longer
be available and similar complaints did not occur following the
blind dosing procedure. Another indication of the safety of these
procedures is that no increase in the use of other drugs was
reliably observed during periods of time when illicit opiate drug
use was suppressed. This lack of "symptom substitution" is con-
sistent with results of previous studies which have used contin-
gent reinforcement procedures to reduce illicit drug use (Stitzer
et al. 1980, 1982).
The present study suggests that the way in which methadone dose
increases are scheduled may be important for determining the
efficacy of the procedure in suppressing illicit opiate use among
methadone maintenance patients. Specifically, the contingent dose
increase procedure described in the present study may be more ef-
fective than the noncontingent dose increase procedure which is
commonly employed. However, contingent procedures are suitable
for application only in clinics where on-site urinalysis testing
equipment is available. In other clinics, increasing the methadone
dose noncontingently is still a useful procedure for reducing sup-
plementation with illicit opiate drugs.
REFERENCES
Bigelow, G.E., Stitzer, M.L., Lawrence, C., Krasnegor, N.,
D'Lugoff, B., and Hawthorne, J. Narcotics addiction treatment:
Behavioral methods concurrent with methadone maintenance. Int J
Addict, 15:427-437, 1980.
Hall, S.M., Cooper, J.L., Burmaster, S., and Polk, A. Contingency
contracting as a therapeutic tool with methadone maintenance
clients: Six single subject studies. Behav Res Ther, 15:438-441,
1977.
Hall, S.M., Bass, A., Hargreaves, W.A., and Loeb, P. Contingency
management and information feedback in outpatient heroin detoxifi-
cation. Behav Ther, 10:443-451, 1979.
Ling, W., Klett, J., and Gillis, R.D. A cooperative clinical study
of methadyl acetate. Arch Gen Psychiatry, 35:345-353, 1978.
McCaul, M.E., Stitzer, M.L., Bigelow, G.E., and Liebson, I. Con-
tingency management interventions: Effects on treatment outcome
during methadone detoxification. J Appl Behav Anal, in press, 1983.
McGlothlin, W.H., and Anglin, M.D. Long-term follow-up of clients
of high- and low-dose methadone programs. Arch Gen Psychiatry,
38:1055-1063, 1981.
260
Newman, R.G., Whitehill, W.B. Double-blind comparison of
methadone and placebo maintenance treatments of narcotic addicts
in Hong Kong. Lancet, September 8, 1979, 485-488.
Stitzer, M., and Bigelow, G. Contingency management  in a  metha-
done maintenance program: Availability of reinforcers. Int J
Addict, 13:737-746, 1978.
Stitzer, M.L., Bigelow, G.E., and Liebson, I. Reducing drug use
among methadone maintenance clients: Contingent reinforcement
for morphine-free urines. Addict Behav, 5:333-340, 1980.
Stitzer, M.L., Bigelow, G.E., and Liebson, I. Contingent reinforce-
ment for benzodiazepine-free urines: Evaluation of a drug abuse
treatment intervention. J Appl Behav Anal, 15:493-503, 1982.
Stitzer, M.L., McCaul, M.E., Bigelow, G.E., and Liebson, I.A.
Human oral methadone self-administration: Effects of dose and
alternative reinforcers. Clin Pharmacol Ther, in press, 1983.
ACKNOWLEDGMENT
Research supported by National Institute on Drug Abuse grants
R01 DA-01472, K02 DA-00050, and T32 DA-07209.
AUTHORS
Maxine Stitzer, Ph.D.
Mary McCaul, Ph.D.
George Bigelow, Ph.D.
Ira Liebson, M.D.
Departments of Psychiatry
The Johns Hopkins University School of Medicine, and
Baltimore City Hospitals
Baltimore, Maryland 21224
261
Methadone Plasma Levels and
Persistent Drug Abuse in High
Dose Maintenance Patients
Forest S. Tennant, Jr., Richard A. Rawson, Allen Cohen,
Anita Tarver, and Diane Clabough
ABSTRACT
Methadone maintenance patients who maintained on a high daily
dose were divided into good performers and performers
based on whether they demonstrated persistent use of heroin,
non-prescription diazepam, and/or excessive alcohol consumption.
Mean methadone plasma levels 24 l-ours after an oral dose of 80
mg were found to be 410.4 ng/ml in good performers compared to
101.8 ng/ml in poor performers (P<.O5). Seven of nine (77.8%)
poor compared to two of 15 (13.3%) good performers had 24-hour
methadone plasma levels under 50 ng/ml (P<.01). High dose
methadone patients who show evidence of persistent drug or
alcohol abuse should have their 24-hour methadone plasma level
determined to help assess whether the patient should receive
more methadone or find an alternative treatment.
INTRODUCTION
Methadone maintenance (MM) has been the principal treatment for
recalcitrant heroin dependence for over a decade (4). A major
unresolved problem in MM treatment is the patient who persist-
ently abuses drugs and/or alcohol despite high daily doses of
methadone (4, 5, 16). This study was done to determine if some
persistent drug use may be related to methadone metabolism and
to develop a useful clinical technique to identify patients in
whom methadone will not provide maintenance for a full 24 hours.
METHODS
A 200-person MM program that allowed patients to maintain on a
maximum of 8O mg/day was surveyed. Out of this patient group,
24 (12.0%) persons who had been on MM for over three months
and who had voluntarily chosen to raise their MM dose to 80 mg/
day were selected for study. For one month, each subject was
tested weekly by urine analysis for morphine, amphetamines,
codeine, barbiturates, and diazepam (15). A physical
262
examination for fresh needle marks and a breath alcohol level
were also done each week (17). At the conclusion of the study
period, each subject was given a written questionnaire which
asked if the subject had used heroin or other non-prescribed
drugs, and if they drank more than two alcoholic drinks per day.
Also asked was whether they perceived themselves to be doing
"very well," "fair," or "not well" on the program, and if their
daily dose of methadone "holds" for 24 hours. Patients were
considered to be poor performers on MM if they demonstrated,
during the study month, abuse of alcohol or persistent use
of unprescribed diazepam or heroin. At some point in the study
period, a methadone plasma level was taken 24 hours after the
subject was observed to take an oral dose of 80 mg of methadone.
Analysis was done by use of gas liquid chromatography and each
plasma sample was analyzed twice (9). Alcohol abuse was docu-
mented by at least two separate, positive breath alcohol tests
during daytime clinic l-ours, plus admission on the questionnaire
that more than two alcoholic drinks were consumed each day.
Persistent use of non-prescription diazepam and heroin was
documented by at least two urine tests which showed the presence
of these drugs. Confirmation was obtained by the written
questionnaire or, for heroin, the presence of fresh needle marks.
The 24-hour methadone plasma levels were compared in the poor
and good performers.
RESULTS
Table One shows drug use and demographic characteristics of sub-
jects. There was no statistically significant difference in
mean weight, total years of heroin use, or length of time on
MM (Table One). Poor performers were older (t = 2.0; P<.O5).
Nine of 24 (37.5%) subjects were classified as poor performers.
Seven of the 9 (77.8%) regularly used heroin. Three of nine
(33.3%) also regularly used non-prescribed diazepam. No good
performer had a urine test that contained drugs other than
methadone; presence of fresh needle n-arks: or had a positive
breath alcohol test during the study period. The mean methadone
plasma level at the end of 24 hours was different in the poor
and good performing groups. (Poor: 101.8 ng/ml; Good: 410.4
ng/ml; P .05) (Table Two). Two patients in the poor group
and one in the good group had no detectible methadone levels,
and the highest level was 607 ng/ml in the poor group. Seven
of 9 (77.8%) poor compared to only 2 of 15 (13.3%) good per-
formers had blood levels under 50 ng/ml (P<.Ol). Three of 9
(33.3%) poor compared to 11 of 15 (66.7%) good performers
stated that their daily methadone dose of 80 mg "holds" for 24
hours (PNS). The two good performing patients who had blood
levels under 50 ng/ml stated that methadone did not "hold" for
24 hours.
COMMENT
Studies of small numbers of subjects have shown methadone plasma
levels obtained 24 hours after a high, oral dose of methadone to
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be very similar to those found in our good performing patients
(1,7,8,10,12,18). Twenty-four (24) hours after a 100 mg dose in
nine patients, Kreek found a mean plasma level of 480 ng/ml (12).
Verebey et al. found 420± 97 ng/ml after a dosage of 80 n-g in
six patients, and Inturrisi and Verebey found in five patients
a mean plasma level of 460 ng/ml following a 100 mg dose (10,18).
The mean plasma level 24 hours after an 80 mg dose in our good
performing patients was 410 ng/ml. In Sweden, Holmstrand et al.
attempted to determine if plasma levels showed correlation with
therapeutic outcome. Regardless ofwhether the patients received
a low (30 mg) or high (60 mg) daily methadone dose, a plasma
level of over 200 ng/ml was associated with fewer urines which
contained illicit drugs. Poor performing patients here had a
mean plasma level of only 101.8 ng/ml, and only 1 of 9 (11.1%)
had a plasma level of over 200 ng/ml.
Horns, Radol and Goldstein found that methadone plasma levels
and symptom complaints, including estimate of the degree of
"sickness" had no correlation (8). In general, patients at low
dosages had low mean plasma levels, and those at high dosage
had high mean plasma levels, although plasma levels varied over
a range of twofold to threefold. Blake and Distocio found that
high methadone plasma levels tended to correlate with reduced
anxiety levels, although plasma methadone levels varied as much
as tenfold with different oral doses (1). It is interesting to
note, however, that 5 of 15 (33.3%) good performers who had high
24-hour plasma levels subjectively felt their methadone was not
holding for 24 hours and 4 of 15 (26.7%) perceived they were not
doing "very well" on the program. It, therefore, appears that
subjective symptoms and perception have little correlation with
plasma levels, although ancillary drug and alcohol use appear
to be associated with low plasma methadone levels (6,7).
There have been conflicting reports as to whether the levels of
daily methadone dosage influence goals and outcomes of treat-
ment (2,3,6,7,13,14). All reports beginning with Jaffe et al.
in 1970 (11), with the exception of Goldstein et al. in 1971 (6),
indicate that programs which are flexible and allow daily metha-
done doses up to 80 mg per day retain patients longer, and that
high dosage patients have less drug use, higher employment rates,
and less criminal behavior (2,3,13,14). The peculiar tendency
of some programs to restrict daily methadone dosages to under 50
mg doesn't appear rational in view of these reports. Data pre-
sented here provides a logical explanation as to why some
patients must have a high daily methadone dose to adequately
maintain a satisfactory blood level for 24 hours. This study
does not, however, provide an explanation for the low plasma
levels observed, and it may be due to absorption, degradation,
or disposition of methadone. Patients who showed low plasma
levels were older (38.5 years versus 32.9 years; P<.05), so it
is possible that age may affect methadone metabolism.
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The majority of MM patients on a high dose of 80 mg/day who per-
sistently used non-prescription diazepam, heroin, and/or excess-
ively consumed alcohol had low 24-hour methadone plasma levels
compared to patients on the same dose who showed no drug or
alcohol abuse. The abuse of opioids, diazepam, and alcohol have
emerged, as major problems in MM patients (4,5,16), and these
were the three problems identified most praninently in patients
who had 24-hour plasma levels below 50 ng/ml. At present, it
is not definitely known whether methadone dosages higher than
80 mg/day can correct the problem of inadequate methadone plasma
levels over a 24-hour period, but several studies now show that
MM programs that allow high doses have superior treatment out-
comes (2,3,13,14). If a higher daily methadone dose is not
utilized in patients with a plasm level below 50 ng/ml, it
appears particularly appropriate to switch to a longer-acting
opioid, such as levo-alpha-acetylmethadol (LAAM) (11). Since
MM patients attend a clinic almost daily, it is feasible and
practical to collect a methadone plasma specimen 24 hours after
the last oral dose. This procedure should particularly be
utilized in MM patients who demonstrate persistent use of
diazepam, heroin, or excessive alcohol consumption.
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TABLE I
Demographic And Drug Use Characteristics
of Good and Poor Performers*
Males
Mean Age (yrs.)
Weight (Kgs.)
Number Years Used
Heroin
Length Time on
Methadone
Good Poor Statistical
N=15 N=9 Significance
12(80.0%) 8 (88.9%) PNS
32.8 38.8 (t=2.10;P<.05)
70.2 73.6 PNS
13.8 15.8 PNS
15.8 22.0 PNS
*Poor performers demonstrated persistent use of non-prescription
diazepam, heroin, and/or excessive alcohol consumption at the
time this study was conducted.
TABLE II
Methadone Blood Levels After 24 Hours
Patients Perception In Good And poor Performers*
Good
N=15
Mean Methadone Blood Level 410.4
(ng/ml)
Poor Statistical
N=9 Significance
101.8 (t=1.99;p<.05)
Range Methadone Blood
Levels 0-1300 ng/ml 0-607 ng/ml
Blood Levels Below 50 ng/ml 2 (13.3%) 7 (77.8%) (x2=9.98;P<.01)
Blood Levels Above 200 ng/ml 8 (53.3%) 1 (11.1%) (x2=4.62;P<.05)
Doing "Very Well" in Program 11 (73.3%) 3(33.3%) PNS
Methadone "Holds" 24 Hours 10 (66.7%) 4 (44.4%) PNS
*Poor performers demonstrated persistent use of non-prescription
diazepam, heroin, and/or excessive alcohol consumption at the
time this study was conducted.
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Methadone Detoxification: Effects
of Methadone Dose Versus Time
in Treatment
Mary E. McCaul, Maxine L. Stitter, George E. Bigelow,
and Ira A. Liebson
Outpatient methadone detoxification is a frequently used treat-
ment modality for opiate dependence; unfortunately such detoxi-
fications are generally unsuccessful. Clients typically drop
out prior to treatment completion or relapse to illicit opiate
use while still receiving methadone at the clinic (Canada 1972;
Wilson et al. 1974). Treatment failures have generally been
attributed to the dosing regimen used for detoxification. However,
it is also possible that outcome measures deteriorate over time
because of the cyclic relapsing nature of drug abuse disorders.
The present study attempted to dissociate methadone dose and time
in treatment as contributing factors to detoxification treatment
outcome. Three groups of subjects received different dose re-
duction protocols during a 6-week period in the detox. One group
received a rapid dose reduction to 10 mg at the beginning of the
6-week period and was then maintained at this low dose. A
second group was maintained-on a constant moderate 20 mg dose of
methadone throughout the 6-week period. In previous studies,
10 mg to 15 mg of methadone had been suggested as a critical dose
or a “breaking point” in the detox above which patients report
few withdrawal symptoms and generally do not supplement their
methadone dose with street drugs, but below which discomfort
appears and relapse to drug use increases. Thus, methadone dose
during the 6-week study period was stabilized above this theorized
critical dose for the 20 mg group and below the critical dose for
the 10 mg group. The third group in the present study received
a gradual dose reduction of 2 mg per week during the study weeks;
this group provided a comparison, employing the type of gradual
dose reduction schedule most commonly employed in clinic-controlled
detoxes. Illicit opiate and nonopiate drug use, clinic attendance
and withdrawal symptomatology were assessed throughout the 13-week
detoxification protocol.
METHODS
Subjects. Approximately 100 subjects dependent on illicit opiates
and not currently participating in treatment were enrolled in a
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90-day or 13-week detoxification. During the first three weeks
of the program, urine specimens were collected twice weekly on
Mondays and Fridays and analyzed on an EMIT system for the
presence of opiates. Clients were selected for the present study
if at least three of these six specimens were opiate free.
Sixty-four subjects met this criterion; 34 clients either dropped
out of treatment prior to study assignment or were excluded from
further participation in this study because of their high initial
levels of drug use. Illicit drug use was used as a selection
criterion in this study since the effects of the pharmacological ,
intervention would be obscured if subjects were frequently sup-
plementing their methadone dose with additional opiate drugs.
Subjects were eligible for detox on the basis of a self-reported
history of opiate use and urinalysis evidence of current opiate
use. Sixty percent of the subjects were black, 40 percent were
white . Subjects’ average age was 29 years and they reported an
average of 8 - 10 years of continuous opiate use prior to this
treatment enrollment.
Procedures. All doses of methadone were mixed with a cherry syrup
vehicle and administered under double-blind conditions by clinic
nursing staff. All clients were stabilized on 30 mg per day of
methadone during the first three weeks of the detox. In week 4,
the methadone dose was decreased abruptly to 20 mg per day for
all clients. From weeks 5 through 10, dosing regimens differed
for the three groups. For subjects in the 10 mg group, the
methadone dose decreased to 10 mg in week 5 and was then stabil-
ized at this level during weeks 6 through lb. For subjects in
the 20 mg group, the dose was held constant at 20 mg during
weeks 5 through 10. For subjects in the gradual dose reduction
group, methadone decreased 2 mg per week during weeks 5 through 9
and remained at 10 mg during week 10. All subjects received
10 mg/day methadone in week 11, 5 mg/day in week 12 and then
vehicle only in week 13. This protocol provided a 6-week period
during weeks 5 through 10 for assessing the impact of methadone
dose on a variety of outcome measures.
At the beginning of week 4, all subjects were enrolled in an
incentive procedure which was in effect for the rest of the detox.
Subjects could earn a take-home dose of methadone and $5.00 for
each opiate-free specimen provided on Monday, Wednesday and Fri-
day; they forfeited these incentives on days when the specimen
was opiate-positive. This incentive procedure was used in an
effort to maximize the impact of the pharmacological manipulation
by decreasing illicit opiate use and increasing length of enroll-
ment (McCaul et al. in press).
Dependent measures. The outcome variables examined in the present
Study included: treatment retention -- the number of days sub-
jects remained active in the clinic without missing three consecu-
tive days; clinic attendance -- the percentage of missed clinic
days out of the total number of opportunities to attend the
clinic; illicit opiate use -- the mean percentage of opiate-
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positive specimens out of the thrice weekly samples tested on
the EMIT system; and withdrawal symptomatology -- the change in
score on a 60-item self-report questionnaire in which symptoms
were rated on a 4-point scale of increasing severity.
RESULTS.
Treatment retention was similar in the three study groups; mean
number of days in treatment was 72.6 for the 10 mg group, 73.4
for the 20 mg group, and 74.7 for the gradual dose reduction
group. Five to seven subjects dropped out of each treatment group
for unidentified reasons prior to week 10 in the detox protocol.
These subjects had slightly poorer attendance and slightly more
illicit opiate use than those subjects who remained in treatment;
however, overall there were few differences between those who
remained in treatment and those who dropped out. Since the fre-
quency of dropout was similar across groups, dropouts were ex-
cluded from further analyses; the results for clinic attendance,
illicit opiate use and symptomatology include only those subjects
who completed the dose manipulation procedures and remained at
the clinic for at least ten weeks.
Clinic attendance was similar in the three study groups during
the stabilization and dose manipulation periods of the detox.
During weeks 2 and 3 of the stabilization period, subjects in
all three groups missed fewer than 5 percent of their clinic
doses. The percentage of missed clinic days then increased gradu-
ally throughout the detox. During week 10, at the end of the dose
manipulation period, all subjects were missing approximately
10 to 15 percent of daily clinic visits.
Figure 1 summarizes the mean percentage of opiate-positive speci-
mens for each treatment group throughout the detox. Less than
20 percent of specimens for all three groups were opiate positive
during weeks 2 and 3 of the stabilization period; this low level
of initial opiate use resulted in part from the subject selection
criteria used in this study. Urine-positive rates increased in
a similar fashion for the three study groups during weeks 6 to 10
such that approximately 40 percent of the specimens in the three
treatment groups were opiate positive by the end of the dose manip-
ulation period. Rates of urine-positive tests generally continued
to rise during the final three study weeks. During the last two
weeks in the detox, more than half of all specimens were opiate
positive in the 10 mg and 20 mg treatment groups, although no
further increase in urine-positive rates was seen in the gradual
detox group.
There were no between-group differences on symptom reports during
weeks 4 through 10 of the detox, while clients were exposed to
different dose reduction schedules. During the final two study
weeks, only the 20 mg group showed a gradual increase in symptom
scores. This might be expected, since this group was experiencing
a more precipitous dose reduction at this point than the other
two groups.
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FIGURE 1. The percentage of opiate-positive EMIT urine tests
for the gradual dose reduction 20 mg and 10 mg
groups throughout the detox. Data points represent the total
number of opiate-positive specimens provided during each two-
week period divided by the total number of specimens possible
during that period (3 specimens per week X 2 weeks X N). A missed
specimen was treated as an opiate-positive result. The broken
line following weeks 2 and 3 represents the introduction of the
dose manipulation procedure.
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DISCUSSION
The present study attempted to dissociate the effects of methadone
dose reduction schedule and time in treatment on outcome during
opiate detoxification. Treatment retention, clinic attendance,
illicit opiate use, and symptomatology were similar for subjects
assigned to three different dosing regimens in the present study.
These results suggest that treatment outcome is to some extent
independent of the particular dosing protocol used in detoxifi-
cation. If dose per se were critical, we would predict poorer
performance in the 10 mg group than in the other two groups -- this
clearly did not happen. Specifically, a rapid decrease in metha-
done dose from 30 mg to 10 mg did not increase the frequency of
opiate-positive specimens when it occurred early in the detox
and, therefore, was probably unexpected by the subjects. In
contrast, subjects in the 20 mg group provided twice as many
opiate-positive specimens in week 10 as in week 4, although their
methadone dose remained constant throughout this period. such
results suggest that the “threshold” or ‘breaking point” postu-
lated at 10 mg to 15 mg methadone may be more a function of time
in treatment rather than dose per se.
Self-reports of withdrawal symptomatology also demonstrate the
interaction of subjects' expectations and the methadone dose
regimen. There was little withdrawal discomfort reported by sub-
jects in the 10 mg group when their dose was decreased from 20 mg
to 10 mg in week 5 of the 13 week detox; however, when a comparable
dose reduction occurred in week 11 for subjects in the 20 mg group,
withdrawal symptom scores were elevated.
Finally, although there were few complaints of withdrawal
symptomatology in any of the treatment groups during weeks 4
through 10 of the detox, illicit opiate use increased steadily
throughout this period. This finding indicates that relapse to
illicit drugs is not necessarily precipitated by withdrawal
sickness and suggests that treatment interventions must specifi-
cally target decreased drug use as a therapeutic goal rather than
assuming that if withdrawal distress is minimized, relapse will be
avoided.
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Abstinence Treatments for Opiate
Addicts: Therapeutic Community
or Naltrexone?
lsabelle Arndt, A. Thomas McLellan, and
Charles P. O’Brien
INTRODUCTION
While naltrexone has been shown to be an effective narcotic
antagonist and has been in use for about ten years, the clinical
utility of naltrexone in the treatment of opiate-dependent
individuals is still under evaluation. The delay is probably
related to technical difficulties in studying this medication.
For example, in studies which use a double-blind, placebo-
controlled trial of naltrexone, the code can be broken by any
patient who uses opiates while on study medication. In
addition, most naltrexone studies are plagued by extremely high
drop-out rates. Therefore, more indirect methods of
investigation are necessary. In an effort to enhance the
understanding of the clinical utility of naltrexone, we felt it
would also be advantageous to compare naltrexone to another
abstinence-oriented treatment modality, the therapeutic
community. To this end, we evaluated "matched" groups of
patients at the point of starting either naltrexone, or TC
therapy and then six months later. We looked for changes with
treatment and differences in outcome between the two groups. We
would like to make the point at the onset that we do not feel
we are measuring "which therapy is better" but rather
investigating the outcomes of two groups of comparable patients,
treated in two different abstinence-oriented modalities.
METHODS
All subjects were male veterans admitted for drug dependence
treatment to either the inpatient, drug-free, therapeutic
community (TC) program at the Coatesville VA Medical Center, or
to the outpatient opiate antagonist (Naltrexone) program at the
Philadelphia VA Medical Center. All subjects had been
detoxified from opiates prior to their admission to these
rehabilitation programs and all subjects could have been
admittedtoeither program.
Subjects
Programs
Therapeutic Community - The TC is an intensive, 60-day,
30-bed program involving both personal and social treatment.
Individual and group (encounter) therapies in addition to the
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social structure of a self-governing community are the primary
therapeutic tools. Family therapy, as well as educational and
vocational counseling, is also offered. The program is directed
by a social worker and includes a staff of two psychologists,
two social workers, two nurses, and four rehabilitation
technicians. Limited use of psychotropic medications is
permitted when indicated by the attending physician.
b. Naltrexone - The naltrexone program is primarily an
outpatient treatment modality. The program is open to any male
veteran who abuses opiates in the absence of major medical
problems or organic brain syndrome. Naltrexone induction is
available in an inpatient or outpatient setting. The naltrexone
program requires weekly counseling sessions with a drug
rehabilitation technician and weekly visits with the nurse
practitioner for recording vital signs, filling out study
questionnaires, and promoting general health management.
Naltrexone is dispensed three times weekly by the pharmacist,
nurse practitioner, or physician. Psychotherapy is strongly
recommended and available but remains at the patient's
discretion.
Procedure
a. Subject Selection and Matching - All subjects were selected
retrospectively from the pool of patients in each program who
had been evaluated at admission to treatment and again at six
month follow-up during 1982 (see Data Collection, below).Since
it was not possible to randomly assign patients to the two
programs, we elected to equate the two groups by matching them
on a range of pretreatment characteristics that have
historically been important in determining treatment outcome.
In fact, since we had a much& smaller pool of naltrexone
subjects, we selected subjects from the TC program to match each
of the naltrexone patients. It is important to note that only
the pretreatment data from these patients was considered in the
matching procedure and no outcome information was used. A full
table of matching variables is available from the authors.
The groups did not differ significantly in terms of age, race,
years of education, years employed full time, or in the percent
with a skill or trade.
The groups were also similar with respect to years of alcohol
use, years of opiate use, years of depressant use, years of
stimulant abuse, prior drug abuse treatments and months of
longest abstinence (p> .10). However, the naltrexone sample did
have significantly more years of methadone use (3.5 vs. 1:
p<.05).
In legal status, the TC sample had a significantly greater
history of criminal charges (8 vs. 4; p< .05), but the groups did
not differ with respect to convictions, months incarcerated,
percent court stipulated, or the percent on probation or parole
(p> .10).
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In comparisons of the two groups on variables associated with
family relations, there were no significant differences in the
percent married or remarried, the percent divorced or separated,
and finally, the percent living alone (p> -10). Groups were
also matched in length of treatment.
In summary, the naltrexone group had a significantly (p< .05)
greater history of methadone use (3.5 vs. 1 year) than the TC
subjects, while the TC group had a significantly greater history
of criminal charges (8 vs. 4). However, the remaining 18
matching variables were not significantly different (p > -10)
between the two groups and we conclude that the 27 pairs of
matched subjects were at least roughly comparable in terms of
background and pre-treatment history at the start of treatment.
b. Data Collection - All data collected during the study were
obtained using the Addiction Severity Index (ASI) (McLellan et
al. 1980) at admission to treatment and again at follow-up, six
months later. The ASI is a structured, 30-40 minute, clinical
research interview designed to assess problem severity in areas
of life function commonly affected by addiction. Problem
severity in each area is assessed independently and six areas
are included: medical, legal, substance abuse, employment ,
family, and psychiatric problems. In each of the areas,
objective questions are asked measuring the number, extent, and
duration of problem symptoms in the patient's lifetime and in
the past 30 days. The patient also supplies a subjective report
of the recent (past 30 days) severity and importance of the
problem area.
All ASI follow-up interviews were done six months following
treatment admission by an independent research technician,
either in person or over the phone. No information from
secondary sources was used and all data were closely monitored
to preserve confidentiality. The validity of the follow-up data
was maintained through built-in consistency checks within the
ASI and through spot checks on subsamples of the population
assessing the ASI data against urinalysis, pharmacy, and
criminal justice system records.
C. Outcome Criteria - It was important for the aims of this
study to have general measures of treatment outcome, since
single item measures can be inherently unreliable (Nunnally,
1967). We therefore constructed criterion composites or factors
from sets of single items within each of the ASI problem areas.
Several items from each problem area were intercorrelated to
exclude those which were unrelated, and the remaining items were
standardized and tested for conjoint reliability using
Cronbach's formula (Cronbach & Furby 1970). Four to six items
from each ASI problem area were selected using this procedure
and each set of items showed a standardized reliability
coefficient of .73 or higher. Seven composites or factors
(medical problems, employment, drug use, alcohol use, legal
status, family problems, and psychiatric function) were
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constructed in this manner and scores on each were calculated
for all patients at admission and follow-up.
Higher scores on these composite measures indicate greater
severity, so improvement is shown through reduction in the
composite scores. While these composite scores do offer
reliable general estimates of patient status in each area they
have no literal meaning. For this reason we have included
additional items offering more concrete examples of patient
functioning during the 30 days prior to treatment admission and
30 days prior to six-month follow-up.
Analysis of Outcome
Paired t-test analyses were used to assess the nature and extent
of admission to six-month change in both groups. In addition we
examined differences between the two groups in the six-month
outcome status. For evaluation of out&me-we applied analysis
of covariance (ANCOVA) to the six-month outcome variables using
the admission values as covariates. This procedure adjusts the
outcome measures for differences between the groups in their
admission values (Cohen & Cohen 1975), permitting a fairer
comparison of outcome status.
RESULTS
The results are shown in Table I. Neither group changed
significantly in reported medical problems. In employment both
groups showed positive change, significantly so for the TC group
in the factor score and in days worked: and for the naltrexone
group in days worked and earned income (p<.05). However, there
was no significant difference between the treatment groups at
six-month follow-up on any of the employment measures (p> .10).
In the alcohol composite measure, the TC group improved
significantly (p< .05) while the naltrexone group stayed about
the same. However, the alcohol problems in the TC were more
severe at the outset of treatment. Consequently, results of the
ANCOVA on the alcohol composite measure indicated no significant
between-group differences, although the TC group improved more
than the naltrexone group in the number of days intoxicated
(p<.05).
In the comparison of drug use, again both groups improved
significantly (p< .01), particularly in the days of opiate use.
The naltrexone group also showed significant improvement in days
of depressant use (p< .O1).
Both groups improved in legal status, with significantly less
reported illegal income (p < .05). There were no significant
differences between groups (p > .10). Similarly, in the
psychiatric factor, both groups improved, but while the
naltrexone group improved significantly (p< .05) this was not
significantly more than the TC group (ANCOVA; p>.10).
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TABLE I
COMPARISON OF IMPROVEMENTS AND SIX-MONTH OUTCOMES
IN 27 PAIRS OF MATCHED MALE DRUG ABUSE PATIENTS
TREATED IN THERAPEUTIC COMMUNITY OR NALTREXONE
THERAPEUTIC COMMUNITY NALTREXONE
PRE POST Pre Post
POST
ANCOVA2
1 All criteria were measured during the 30 days prior to treatment start and prior to 6-mo.
follow-up. Larger factor scores equal worse status.
2 Covariate was the pre-treatment criterion score.
In short, both treatments seemed effective and improvement was
noted in several areas in most patients. However, neither
treatment group had a clear advantage over the other at
six-month follow-up.
DISCUSSION
Prior to discussion of the observed results it is important to
consider the limitations of the data. First, all the data were
self-reported and are therefore subject to potential
discrepancy. Two points are relevant here. First, we have
attended to the accuracy of these data through built-in
validation checks within the ASI and through spot checks of
patient reports against urinalysis, court records and employment
records. We and other workers using similar data (Sale et al.
1977) have been satisfied that systematic distortion is
minimal. Second, regardless of the degree to which these data
are subject to intentional or unintentional distortion, there is
no reason to believe that the subjects in the two groups
differed in their degree of distortion. Thus, the between
groups comparisons are appropriate.
A second potential problem with the presented data is that it
results from self-selected participation in treatment rather
than random assignment to the programs. It is possible that the
self-selection process by which patients applied for the
therapeutic community and the naltrexone programs produced
samples which were different on some unrecognized quality which
was important to their outcome. We attempted to reduce this
possibility through our matching procedure and while the Table I
data indicate considerable comparability between the samples,
the possibility of unrecognized but important differences
betweenthe samples must be recognized.
Again we would like to stress that we are not trying to assess
which therapy is better. We have selected a subsample of the TC
population which is comparable to our naltrexone population and
looked at how the two groups did following treatment.
It should be noted also that early dropouts are included in
the analysis of both the naltrexone and therapeutic Community
samples. Since the two samples were matched with regard to
treatment duration there were no differences between the two
groups in drop-out rates. Gains might be greater if drop-outs
were excluded, but including the drop-outs more accurately
reflects treatment effectiveness.
It could be argued that the longer history of methadone use in
the naltrexone group might indicate this would be a more
refractory group. However, several investigators have noted
that patients with longer histories of opiate use did better
with naltrexone and additional years of methadone use probably
means additional years of contact with therapy for drug abuse;
therefore the naltrexone group may have a slight advantage in
terms of outcome.
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With these limitations in mind, we will reconsider the results
of the present study. Within-group measures of change showed
that both groups improved in employment, drug use, and legal
status. In addition the naltrexone group improved in
psychiatric status. The TC group showed a change in alcohol use.
Between-groups comparisons showed the TC superior to naltrexone
in improving alcohol problems; however, the pretreatment alcohol
status was more severe in the TC group. Both groups actually
ended up at about the sane level of alcohol consumption.
Naltrexone seemed superior to the TC in reducing depressant use,
but it should be noted that this could be due to the frequent
use of ancillary medication (benzodiazepines), during
detoxification at the Philadelphia VA Medical Center. This
would cause an inflated self-report of sedative use during the
30 days prior to starting naltrexone. Thus, we are reluctant to
conclude that this is a meaningful difference between the groups.
In evaluating the respective “worth” of both treatments,
cost-effectiveness should be considered. The therapeutic
community is a relatively expensive form of treatment, requiring
a residential facility. The naltrexone program on the other
hand can be run on an outpatient basis and can be implemented by
a pre-existing clinic which serves drug-abusing clients. This
might suggest an economic advantage to naltrexone when the
choice of treatment is unclear.
In summary, then, subjects participating in the therapeutic
community who were matched to subjects participating in the
naltrexone program showed comparable improvement in a variety of
outcome variables. The between -groups comparison showed
significant differences in only 2 of 18 items. We do not feel
that these differences are clinically important and may, in
fact, be artifacts. In short, we see no clear advantage of one
treatment over the other. A prospective, randomized study would
be desirable to further assess relative program benefits.
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An Evaluation of Neonatal
Abstinence Treatment Modalities1
Loretta P. Finnegan, Herman Michael, Betty Leifer, and
Shobhana Desai
It has been well documented over the years that infants born to
heroin- or methadone-dependent mothers have a high incidence of
neonatal abstinence react ions. Recently, less potent opiates have
been identified as also precipitating the neonatal opiate absti-
nence syndrome. These include propoxyphene hydrochloride (Darvon)
(Tyson, 1974; Quillian and Dunn, 1976), codeine (Van Leeuwen et
al., 1965), and pentazocine (Talwin) (Goetz and Bain, 1974; Preis
et al., 1977). In addition, a number of non-opiate CNS depres-
sants have been implicated. These have been reviewed by Ostrea
et al. (1977) and include alcohol (Nichols, 1967), barbiturates
(Bleyer and Marshall, 1972; Blumenthal and Lindsay, 1977). bromide
(Rossiter and Rendel-Short, 1972). chlordiazepoxide (Athinarayanan
et al., 1976), diazepam (Rementeria and Bhatt, 1977). ethchlorvynol
(Rumack and Walravens, 1973), diphenhydramine (Parkin, 1974). and
imipramine (Webster, 1973).
Neonatal opiate or CNS depressant abstinence syndrome is described
as a generalized disorder characterized by signs and symptoms of
central nervous system hyperirritability, gastrointestinal dys-
function, respiratory distress, and vague autonomic symptoms,
which include yawning, sneezing, mottling, and fever. A high-
pitched cry, increased muscle tone, tremors, and irritability de-
velop. The infants tend to have increased deep tendon reflexes
and an exaggerated Moro reflex. The rooting reflex is increased,
and the infants are frequently seen sucking their fists or thumbs.
These infants’ respiratory systems are also affected during the
withdrawal stage, causing excessive nasal secretions, stuffy nose,
and rapid respirations, sometimes accompanied by chest retractions,
intermittent cyanosis, and apnea. Severe respiratory embarrassment
occurs most often when the infant regurgitates, aspirates, and
develops aspiration pneumonia. The high-pitched cry is similar to
that of infants with central nervous system hyperirritability.
Sucking reflexes are ineffectualand uncoordinated (Kron et al.,
1976), causing extreme difficulties in feeding behavior. Sleep
patterns are disturbed, and infants have excessive spontaneous
generalized sweating.
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The origin of the neonatal abstinence syndrome lies in the abnormal
intrauterine environment. The fetus undergoes a biochemical adapta-
tion to the presence of an abnormal agent in its tissues. Abrupt
removal of the drug at delivery precipitates the onset of symptoms.
Withdrawal symptoms are found secondary to abstinence from opiate
as well as nonopiate CNS depressants. Although infants born to
barbiturate addicts may manifest symptoms similar to those of in-
fants passively addicted to opiates, their symptoms tend to begin
at a later age, and undernutrition at birth has not been a usual
feature. Because the barbiturate withdrawal syndrome may not de-
velop until an infant has been discharged from the nursery, it
may not be treated unless suspicion has been aroused by the mother’s
symptoms or actions. Furthermore, there is a greater risk of
seizure activity in infants withdrawing from barbiturates than in
those withdrawing from opiates.
The time of onset of withdrawal signs ranges from shortly after
birth to two weeks of age, but for the majority, signs appear
within 72 hours. The type of drug used by the mother, her dosage,
the timing of the last dose before delivery, the character of the
labor, the type and amount of anesthesia and analgesia given during
labor, and the maturity, nutrition, and presence of intrinsic dis-
ease in the infant may all play a role in determining the time of
onset in the individual infant. Because of the variation in time
of onset and in severity, a range of clinical courses may be de-
lineated.
If mild symptoms appear, conservative measures such as swaddling,
infrequent handling and demand feeding should be instituted. If
the infants can no longer be managed by such conservative measures,
drug therapy must be instituted. The objectives of drug therapy
are to control symptomatology so that the infant sleeps or rests
between feedings, takes in calories sufficient for weight gain
and performs normally with regard to interaction with caretakers
(Finnegan, 1979).
Many pharmacological agents have been used in the treatment of
the neonatal abstinence syndrome and appear to be effective in
relieving symptoms. The agents most commonly employed have been
paregoric, phenobarbital and diazepam (Finnegan and MacNew, 1974).
Paregoric has been used for over 70 years with the rationale that
narcotic abstinence symptoms are most specifically relieved by
narcotic substitution. The major advantages of paregoric are its
ability to be orally administered, its apparent lack of adverse
effects, and its ability to provide a level of sedation that inhi-
bits bowel motility (Finnegan and MacNew, 1974). Sucking has been
found to be much closer to normal among paregoric-treated infants
than among those treated with phenobarbital or diazepam (Finnegan,
1979). Disadvantages associated with paregoric are that large
doses are often necessary to treat severe abstinence, and the
duration of therapy can be longer with paregoric than with some
other drugs.
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Phenobarbital has been used extensively for neonatal abstinence as
it supresses the major symptoms by a nonspecific central nervous
system depression (Finnegan, 1979). Phenobarbital is especially
effective in controlling irritability and insomnia. However, an
occasional infant paradoxically becomes more irritated after treat-
ment and although central nervous system symptoms are prevented
by barbiturates, they do not prevent loose stools (Finnegan and
MacNew, 1974). It has been shown that some infants are not fully
controlled even at doses that produce plasma levels considered to
be in the toxic range (Finnegan, 1979).
Diazepam therapy has also been advocated in the treatment of neo-
natal withdrawal. Nathenson and associates (1971) reported that
the use of diazepam appears safe and effective and that a short
course of diazepam therapy controls the symptomatology without
serious side effects or rebound symptoms when it is discontinued.
Kron et al. (1974) found that infants treated with diazepam be-
came severely obtunded and their sucking reflex markedly diminished
in comparison to infants treated with other drugs. In one study,
seizures were seen more often in a group of infants treated with
diazepam than in those treated with paregoric (Herzlinger et al.,
1977).
In our previous studies of the treatment of neonatal abstinence
(Finnegan et al., 1982), it was found that infants treated with
paregoric required a second drug infrequently in comparison to
those treated with phenobarbital or with diazepam. Of the in-
fants treated with paregoric, 22% required an additional drug
compared to 41% with phenobarbital loading, 42% with phenobarbital
titration and 65% with diazepam. The purpose of this study was to
further evaluate the efficacy of the three drugs for treatment of
specific abstinence syndromes.
MATERIALS AND METHODS
In the nurseries at Thomas Jefferson University, paregoric,
phenobarbital and diazepam were evaluated in the treatment of
abstinence. Infants (n=139) were assessed and managed using the
neonatal abstinence scoring system developed by Finnegan et al.
(1975). Procedure dictated that the infants receive varying dosages
of a specific drug dependent on abstinence severity. If the absti-
nence scores indicated a need for pharmacologic intervention, a
randomized schedule was used in selecting the pharmacologic regimen
unless clinically contraindicated.
The abstinence scores alsodictatedthe specific dose of the pharma-
cotherapeutic agents used to detoxify infants in two management
regimens. The two include the loading dose and the titration
regimens. With the score dose titration approach, the initial
dose and all subsequent doses are determined by and titrated against
the abstinence score. The infant is initially given a total dose
which is divided into 3-6 equal doses at 4-8 hour intervals. If
clinical observation and the results of the scoring system indi-
cate the abstinence syndrome is not controlled, the dosage is
increased.
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When using the phenobarbital loading dose approach, an initial
dose of 20 mg/kg is administered in an attempt to achieve an ex-
pected therapeutic serum level. If control is achieved, the ini-
tial dose is followed by daily maintenance doses of 5 mg/kg which
can be adjusted in order to maintain the desired steady state
phenobarbital level. If control is not achieved with the initial
dose, the phenobarbital level is increased by administering pheno-
barbital at 10 mg/kg every 12 hours. This increase in serum level
is continued every 12 hours until: 1) control is attained, 2) the
serum level reaches 70 mg/ml, or 3) the infant demonstrates signs
of phenobarbital toxicity.
For purposes of this study, the data obtained for the loading and
titration methods of phenobarbital therapy were combined for an
overall index of phenobarbital efficacy.
Abstinence, not controlled at the highest dosage of a specific
drug, requires a second agent. The effectiveness of the drug
therapies in this study was determined according to the necessity
for administering a second agent. A history of drugs to which
the infants were exposed in utero was obtained from medical re-
cords, social data forms, and routine urine toxicologies as re-
quired by law for methadone maintenance programs. Maternal drug
abuse was divided into 2 categories as follows: 1. Narcotic
use only which generally included methadone and/or heroin, and
2. Multi-drug abuse including a combination of narcotics and
other rugs such as diazepam, alcohol, barbiturates, or ampheta-
mines. Success or failure of the pharmacologic therapy was then
analyzed according to maternal drug categories.
RESULTS
As Table 1 shows, treatment for infants exposed only to narcotic
agents in utero was more often successful with paregoric than with
either phenobarbital or diazepam. Paregoric was able to control
withdrawal symptomatology in 93% of the infants while phenobarbi-
tal was only successful in 50% of the infants and diazepam was
not at all successful in the treatment of any infant whose prenatal
drug exposure was limited to narcotics (p<.001). When comparing
only the paregoric and the phenobarbital treatments, the results
remained significant (p < .01).
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TABLE 1
Treatment Results for Infants Exposed
Only to Narcotic Agents in Utero
Treatment Drug Paregoric Phenobarbital Diazepam Totals
Treatment Successes 13 13 -- 26
Treatment Failures 1 13 5 19
TOTALS 1 4 26 5 45
Treatment for infants exposed prenatally to multiple drugs was
more often successful with phenobarbital than with paregoric or
diazepam (See Table 2). Phenobarbital treatment was successful
in 89% of the infants while paregoric was successful in 61% and
valium in 40% (p<.001). Again, the paregoric/phenobarbital com-
parison was significant (p<.01).
TOTALS 18 6 1 1 5 94
Treatment Failures 7 7 9 23
TABLE 2
Treatment Results for Infants
Exposed to Multiple Drugs in Utero
Treatment Drug Paregoric Phenobarbital Diazepam Totals
Treatment Successes 11 5 4 6 71
In conclusion, these data suggest thatparegoric is the drug of
choice for the control of abstinence symptomatology due exclu-
sively to narcotic use and support the supposition that narcotic
abstinence symptoms are most specifically relieved by narcotic
substitution. Phenobarbital appears most efficacious when the
infant has been exposed prenatally to multiple drugs. Diazepam
appears the least efficacious of the three drugs. These results
have definite implications for the management and treatment of
specific neonatal abstinence syndromes.
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Five-Year Follow-up of Opiate
Addicts With Naltrexone and
Behavior Therapy
Richard A. Rawson and Forest S. Tennant, Jr.
ABSTRACT
A group of 58 heroin addicts were treated with naltrexone and be-
havior therapy and followed for 5 years. At one-year post-treat-
ment, almost half of the naltrexone-treated subjects were opiate
free. Follow-up results at 5 years post-treatment indicate that
over 90% of those patients treated with naltrexone became re-ad-
dicted for various periods of time. However, naltrexone-treated
subjects did feel their treatment with naltrexone had provided
them with the ability to remain opiate free for blocks of time.
The results suggest that naltrexone is not a "cure" for opiate
dependence, but is a medication which can be useful in protect-
ing patients from re-addiction and is a modality patients should
be encouraged to return to if they feel vulnerable to re-addiction.
INTRODUCTION
Narcotic antagonists are a class of drugs which received a great
deal of attention in the 1970's for the treatment of opiate addic-
tion.1,2 Naltrexone in particular was touted as having tremendous
potential for providing long-lasting, if not permanent, "cures" for
opiate dependence. The possibility of developing a treatment for
addiction which would allow addicts to develop drug-free lives
rather than settle for opioid substitution provided by such treat-
ments as methadone and LAAM was a tremendously appealing prospect.
Evaluations of naltrexone produced mixed conclusions. Naltrexone
has been administered to over 1000 addicts and has been found to be
well tolerated, physically, safe, and to produce a highly effective
blockade against opiates.1,2
There is general agreement of those evaluating the clinical effec-
tiveness of naltrexone that while an addict is receiving the anta-
gonist, he rarely, if ever, challenges the blockade with heroin.
Additional empirical support for the antagonist comes from subjec-
tive reports of addicts receiving naltrexone, which indicate that
the antagonist rapidly reduces cravings and urges for opiates.
289
Clinical reports indicated the naltrexone may only be utilized by
5-10% of opiate addicts due to difficulties in inducting patients
into treatment and problems involving a high rate of patient drop-
out during the early stages of treatment.1,2 However, for those
patients who entered treatment with naltrexone, use of illicit
opiates almost entirely stopped while on naltrexone, and one-year
follow-up results indicated that approximately one-half re-
mained opiate free.4
These results suggested that with some refinements of naltrexone
induction procedures and the development of ancillary treatment,
techniques, naltrexone could be conceptualized as a "cure" for
some addicts' addiction problems.
Before accepting the idea that the best way to view naltrexone
treatment is as a one-time intensive intervention resulting in a
permanent elimination of an opiate dependence problem, a more
longrange view is needed on the outcome of those patients who
had been successfully treated with naltrexone. The purpose of
this paper is to provide 5-year follow-up data on a group of
subjects treated with naltrexone from 1974-1977.
METHOD
Subjects And Setting
Subjects were 58 male opiate addicts who received treatment from
1974-1977 at the Heroin Antagonist and Learning Therapy Project in
Oxnard, California. Some demographic characteristics of the sub-
jects are presented in Table One.
TABLE ONE
SUBJECT CHARACTERISTICS
N = 58
Mean Age at Treatment Initiation 26 Yrs.
Mean Age at First Use of Opiates 18.0 Yrs.
Mean Years Addicted to Opiates 7.9 Yrs.
Mean Years of Education 10.8 Yrs.
Number of Subjects with Prior Treatment Experience 16
Number of Anglo, Subjects 34
Number of Chicano Subjects 19
Number of Black Subjects 5
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INTERVENTION PROCEDURES
Subjects were randomly assigned to one of three groups upon enter-
ing into treatment. The groups were:
1. Naltrexone Alone
Subjects in this group receiving blocking doses of naltrexone
on 3 clinic visits per week. For counseling or psychotherapy,
they were referred to a local mental health facility.
2. Behavior Therapy Alone
Subjects in this group received an intensive program combining
behavior therapy techniques, such as role playing, contingency
contracting, video feedback, relaxation training, systematic
desensitization, social skills training, and structured employ-
ment training.
3. Naltrexone Plus Behavior Therapy
Subjects in this group received both of the treatment programs
described above.
To summarize the study results, subjects on naltrexone stayed in
treatment approximately 6 months and stayed opiate free while on
naltrexone. Behavior therapy group subjects stayed in treatment.
Results of this study have been reported in a detailed report.4
FOLLOW-UP PROCEDURES
Last treatment contact for any subject was in August, 1977. Follow-
up interviews were conducted in November-December, 1982. Subjects
were contacted by telephone and in person and, asked to participate
in an interview about their current situation, and asked to give a
urine specimen to be screened for illicit drugs. Follow-up was
greatly enhanced by the fact that Oxnard is a geographically iso-
lated city with only one drug treatment program. Therefore, by
having access to the treatment records of the one treatment facil-
ity along with the prior background information, such as family
phone numbers collected during the patients' treatment, it was
possible to collect follow-up data on 52 of 58 subjects. In all
cases in which the subject was reported as being "opiate-free,"
this status was confirmed by a negative urinalysis. Subjects
categorized as "opiate-positive" provided urine samples which
assayed positive for opiates in all but six cases. In these six
cases, subjects reported having used opiates within the prior 48
hours, but did not wish to give a sample to document this fact for
fear of legal jeopardy.
RESULTS
This paper focuses on evaluating the long-term effect of treating
addicts with naltrexone. Little attention is given to the follow-
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p of the behavior therapy treatment since the conclusions reached
at the end of the study's completion in 1978 was that the treat-
ment had been almost totally ineffective. Therefore, the behavior
therapy alone group can be viewed as a control population to com-
pare the naltrexone-treated subjects against. Results from the
two naltrexone treatments were not significantly different.
Therefore, data from both naltrexone groups will be presented
together.
Table Two presents a breakdown of the number of subjects con-
tacted for follow-up.
TABLE TWO
NUMBER OF SUBJECTS CONTACTED FOR 5-YEAR FOLLOW-UP INTERVIEW
Number of Subjects Contacted
for Follow-Up
Number of Subjects Unable to
Locate
Number of Subjects Dead*
Behavior Combined
Therapy Naltrexone
Alone Group Group
N = 15 N = 43
12 (80%) 35 (81%)
1 (7%) 5 (12%)
2a'b(14%) 3c,d,e(7%)
*Causes of Death
a. Gunshot wound
b. Complication from hemophilia
c. Liverdisease
d. Stroke
e. Stomach cancer
One rather striking point illustrated by the data presented in
Table Two is that 9% of the total sample are known to be dead.
(This figure might be higher since two of the subjects we were
unable to locate are rumored to be dead, but this was not con-
firmed). This figure clearly emphasizes the high mortality rate
found in a group of addicts with a mean age of 32 years.
TABLE THREE
FOLLOW-UP STATUS AT 12-MONTH POST-TREATMENT INTERVIEW
Behavior Combined
Subject Status
Therapy Group Naltrexone Groups
N = 15 N = 43
Opiate-Free 4 (27%) 18 (42%)
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Opiate-Positive 4 (27%) 7 (16%)
Incarcerated 6 (40%) 10 (23%)
In Other Treatment 0 2 (5%)
Out of Contact 0 6 (14%)
Dead 1 (7%) 0
Total 15 43
Table Three presents data on the follow-up status of subjects, one
year post-treatment. These results were encouraging evidence
which suggested that one treatment episode with naltrexone pro-
duced a one-year elimination of the opiate use in 18 of 37 (49%)
subjects contacted for follow-up.
TABLE FOUR
FOLLOW-UP STATUS AT FIVE-YEAR POST-TREATMENT INTERVIEW
Behavior Combined
Therapy Naltrexone
Group Group
N = 15 N = 43
Opiate-Free 1 (7%) 7 (16%)
Opiate-Positive 4 (26%) 7 (16%)
Incarcerated 3 (20%) 8 (19%)
In Other Treatment 4 (26%) 13 (30%)
Out of Contact 1 (7%) 5 (12%)
Dead 2 (14%) 3 (7%)
Table Four presents a different picture on the five-year follow-up
status of these same subjects. At the time of the five-year inter-
views, 1 of 12 (8%) of the subjects contacted for follow-up in the
behavior therapy group were opiate free, while 7 of 35 (20%) of the
naltrexone-treated subjects were opiate free. Of the 7 subjects
opiate-free at 5 years, 4 reported having been re-addicted for
various periods of time during the 5-year post-treatment interval.
Therefore, only 3 of 35 subjects (9%) treated with naltrexone
achieved a 5-year continuous period of opiate abstinence. A sum-
mary of the follow-up data, therefore, could be interpreted to
indicate that about 50% of the patients treated with naltrexone
were opiate free for one year, but that by 5 years post-treatment,
fewer than 1 in 10 had sustained a treatment "cure."
293
This rather discouraging outcome does not accurately reflect the
subjects' perception of the value of their treatment experience.
Subjects in the behavior therapy group were fairly uniform in
their opinion that their behavior therapy treatment attempt had
been an interesting and novel experience. but had very little
effect upon their subsequent pattern of drug usage. Subjects
who had been in treatment with naltrexone reported, however, that
although the treatment with naltrexone had not permanently elimi-
nated their addiction problem, ait had provided them with a valu-
able experience. A majority of these subjects reported that the
naltrexone treatment experience had provided them with a learning
experience which indicated that it was possible to live for exten-
sive periods of time on the street without the use of illicit
opiates.
In order to illustrate this finding, subjects were asked to esti-
mate the longest period during the post-treatment period that they
had been opiate free while on the street. Table Five presents a
breakdown of these intervals.
TABLE FIVE
LONGEST OPIATE-FREE PERIOD DURING
5 YEARS POST-TREATMENT
Combined
Behavior Naltrexone
Therapy Group
Longest Period Opiate Free N = 15 N = 43
One week or less 8 (53%) 9 (21%)
One week - six months 0 9 (21%)
Six months - two years 3 (20%) 8 (19%)
Two years - five years 1 (7%) 6 (14%)
Continuously since
treatment termination 0 3 (7%)
Out of Contact 1 (7%) 5 (12%)
Dead 2 (14%) 3 (7%)
Of the 35 naltrexone-treated subjects contacted for 5-year follow-
up, 26 (74%) reported they had sustained opiate-free intervals of
more than one week. This is in comparison to only 4 of 12 (33%)
of the behavior therapy group subjects. This comparison was sta-
tistically significant (X2 = 6.3, P < .02). Even more impressive
is the fact that 49% of the naltrexone-treated subjects were able
to sustain opiate-free periods of 6 months or more during the post-
treatment period. Therefore, while the naltrexone treatment did
not produce a suppression of illicit opiate use for the entire
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follow-up period, the naltrexone experience does appear to have
produced a measureable effect. Naltrexone-treated subjects were
able to sustain longer periods opiate free during the 5-year
follow-up than behavior therapy controls.
DISCUSSION
The results of the study suggest that an extended treatment experi-
ence of naltrexone with or without ancillary therapy program is not
effective in eliminating re-addiction liability beyond the treat-
ment period. Naltrexone, in conjunction with the proper adjunct
therapy program, will not permanently protect former addicts from
re-addiction. However, a more realistic view of how naltrexone
fits into the addiction treatment arsenal can be developed from
the data collected.
Our 8-year experience with naltrexone suggests that naltrexone is
a useful treatment tool which, for some addicts, can provide pro-
tection from re-addicton liability. Naltrexone does not cure
opiate addiction, but gives addicts a mechanism for dealing with
urges and cravings which can lead to re-addiction. Patients
treated with naltrexone should not be given the hope that naltre-
xone will solve their opiate problem. Rather, they should be edu-
cated to the fact that naltrexone will eliminate their opiate pro-
blem for as long as they are in treatment. More importantly, they
should be educated that following their naltrexone treatment they
should return to treatment upon relapse, or if they feel vulner-
able to relapse.
REFERENCES
1. Julius, D.A., and Renault, P.F., eds. Narcotic Antagonists:
Naltrexone. National Institute on Drug Abuse Research Mono-
graph 9. DHEW Pub. No. (ADM)76-387. Washington, D.C.:
Superintendent of Documents, 1976.
2. Report of the National Research Council Committee on Clinical
Evaluation of Narcotic Antagonists. Clinical evaluation of
naltrexone in opiate dependent individuals. Archives of
General Psychiatry 1978; 35: 335-340.
3. Callahan, E., Rawson;R., Glazer, M., McCleave, B., and Arias,
B. Comparison of two naltrexone treatment programs; Naltrexone
alone versus naltrexone plus behavior therapy. In: Julius,
D.A., and Renault, P.F., eds. Narcotic Antagonists:
Naltrexone. National Institute on Drug Abuse Research Mnograph 9.
OHEW Pub. No. (ADM)76-387. Washington, O.C.: Superintendent
of Documents, U.S. Government Printing Office, 1976. pp. 150-
157.
4. Rawson, R.A., Glazer, M., Callahan, F., and Liberman, R.R.
Naltrexone and behavior therapy for heroin addiction. In
Krasnegor, N., ed. Behavioral Analysis and Treatment of Sub-
stance Abuse. National Institute on Drug Abuse Research Mono-
graph 25. DHEW Pub. No. (ADM)79-839. Washington, D.C.:
Supt. Docs., U.S. Govt. Print. Off., 1979. pp. 26-43.
295
Social Control as an Explanation
of Sex Differences in Substance
Use Among Adolescents
Margaret E. Ensminger, C. Hendricks Brown, and
Sheppard G. Kellam
A number of longitudinal studies of the use of alcohol, marijuana,
cigarettes, and other substances by teenagers have indicated that
males and females differ in their frequency of use of all substances
except cigarettes (Kandel 1980; Bachman et al. 1981; Ensminger
et al. 1982). Despite these sex differences, little attention has
been paid to explaining why males are more frequent users. A
major question is whether the processes that lead to substance use
by females are the same as the processes that lead to substance
use by males.
 The antecedents of substance use may be distinct for males and
females. First, the variables A, B, C, may lead to substance use
for males while variables X, Y, Z, may be those that are important
to female substance use. Second, the same variables may have dif-
ferent results for males and females--for example, school failure
may increase substance use by males but reduce substance use for
females. Third, the processes may operate similarly for males
and females, but one sex may be much more likely to encounter
certain risk factors than the other. For example, school failure
may be related to substance use for both sexes, but males may fail
more in school than females so that males' higher substance use
would be partially explained by this variable.
In this paper we focus on social control theory as a potentially
valuable explanatory framework for understanding substance use
and compare male and female teenagers to see if social control
processes relate to their substance use similarly. The research
model we will be examining includes substance use, gender, and
measures of social control.
Social Control
This theory as elaborated by Hirschi focuses attention on the
strength of the individual's bonds with conventional institutions,
norms, or persons (Hirschi 1969). The central thesis is that
individuals are more likely to conform to societal standards when
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their social bonds to conventional social order are strong.
Through social bonds, individuals internalize the society's values
and expectations regarding social behavior. The adolescent's tie
to the school and the family thus become crucial variables from
this perspective.
A potentially important aspect of social control theory is that it
may account for the considerable variation in drug use and other
kinds of antisocial behavior that occurs over the life course.
Young people have higher rates of such activity than adults
(Greenberg 1977). A social control perspective would suggest that
this is because young people do not yet participate as fully as
adults in important societal activities that strengthen social
bonds.
Compared to boys, girls are generally considered as having more
social bonds to teachers, parents, and conventional values (Jensen
and Eve 1976; Turk 1969). Such differences, according to control
theory, should relate to differences in the frequency of substance
use.
Research Questions
In this paper we examine whether (1) social bonds relate to sub-
stance use for males and females and (2) whether the social bonds
that relate to substance use operate in similar ways for males and
females. The social bonds to be examined include teenage reports
of bonds to home, school, and peers.
THE WOODLAWN STUDY
The data were gathered prospectively on a total population of
first-grade children in Woodlawn, a poor, black, Chicago community.
The children were assessed in first grade and were followed up
ten years later at age 16 or 17. Data were also gathered in first
grade and again at the time of the ten-year follow-up. These
community epidemiological data were gathered on a total population
of first-graders within a particular urban neighborhood.
In 1975-1976, we located and reinterviewed 939 (75%) of the
mothers or mother surrogates of the 1,242 fami-lies from the 1966-
1967 study. After the mother was interviewed and had given per-
mission, the teenager was approached for reassessment. Of the
939 teenaged children of the reinterviewed mothers, 75% (n=705)
participated in the reassessments, 14.5% refused to participate,
and 10.4% had moved out of Chicago or were unavailable because
they were in an institution or had unknown addresses. The study
population for this paper consists of the 705 teenagers whom we
reassessed.
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In order to assess possible bias resulting from sample attrition,
we compared the mothers and children whom we reinterviewed with
those we did not, using the extensive early information we had on
both. The mothers whom we could not reinterview were not distinc-
tive in their 1966-1967 psychological well-being, early family
income, welfare status, or the number or types of adults at home.
They were more likely to have started child rearing in adolescence,
had been more mobile before and during the child's first-grade
year, and their children were more likely to have been. in parochial
schools in first grade. We found little or no difference in the
social adaptational status or psychological well-being between
children reinterviewed and those not reinterviewed (Kellam et al.
1980).
METHODS AND MEASURES
Teenage Drug Use
The information on teenage drug use in this paper comes from
responses to items in the What's Happening?, an instrument
administered to the teenagers who participated in the follow-up
sessions. The questions concerned the lifetime frequency of use
of 12 categories of substances including alcohol and cigarettes.
We focus on four categories in this paper: (1) beer or wine, (2)
hard liquor, (3) cigarettes, and (4) marijuana or hashish.
The questionnaires were administered by two black college students
(one male and one female) to adolescents in groups of five to
eight. The college students emphasized confidentiality and trust
issues. The assessment questions were presented visually on
slides and orally on audiotape to control for reading ability dif-
ferences and to standardize the pace and the general administra-
tion of the questions (Petersen and Kellam 1977).
Measures of Social Bonds
Social bonds were assessed through measures of the teenager's
attachments and commitments to the important social fields of
adolescence--family, school, and peers. These measures were
obtained in the follow-up assessment. Cronbach alphas, a measure
of reliability, for these constructs ranged from 0.65 to 0.68.
The following items were used to measure bonds to these three
areas--family, school, and peers:
Family Bonds
I enjoy being with members of my family.
POW do your parents think you are doing at home?
HOW satisfied are you with your parents' opinion of how you’re doing?
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School Bonds
Doing well in school is important to me.
How far would you like to go in school if you had the chance?
How far do you think you will go in school?
How do your teachers think you are doing in school? 
How satisfied are you with your teachers' opinion of how you are
doing?
Peer Bonds
How many of your friends do you really feel close to?
How many close friends do you feel you can share secrets with
about private feelings and problems?
How many days during the week do you usually spend time with your
friends outside of school hours?
During the last month or so, about how many different friends did
you spend time with?
HOw "in" do you feel with your social group?
RESULTS
Overall, both males and females reported frequent substance use.
More than one-third of the males and about 16% of the females
reported using marijuana and beer or wine 20 times or more. Four-
teen percent of the males and five percent of the females used
hard liquor frequently. As a comparison, rates of use of illicit
drugs other than marijuana were low. Only one percent of these
16-17 year olds had tried heroin. About 8% reported using cocaine
at least one time, while 12% reported using unprescribed codeine
(Kellam et al. 1980).
Sex Differences in Substance Use
Males used significantly more beer or wine, hard liquor, and
marijuana than did females, as shown by Pearson chi-square tests.
There were no significant sex differences in the rates of cigarette
use. See Figure 1 for the graphic representation of male and
female use.
Teenage Social Bonds and Substance Use: Attachment to Family,
School, and Peers
Social bonds are strongly related to substance use for both males
and females. However, whether the social bonds are related simi-
larly for males and females depends on the substance.
Table 1 shows the odds ratios of heavy substance use'to less use.
The social bonds to family, school and peers are listed in rank
order of their importance for each sex. For alcohol use the
rank order of the odds ratio is reversed for females and males.
For both beer or wine and hard liquor, family bonds rank the
highest for females--family bonds are not related for males.
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FIGURE 1
Teenagers' Reports of Beer or Wine,
Hard Liquor, Marijuana and Cigaretes
(Percentages)
Beer or Wine
Males
Females
Hard Liquor
Males
Females
Marijuana
Males
Females
Cigarettes
Males
Females
Never Used
Key } 1-19 Times
20+ Times
Males N=345
Females N=360
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SOCIAL BONDS TO FAMILY, SCHOOL, AND PEERS
RELATIVE ODDS OF HEAVY SUBSTANCE USE TO NONHEAVY USE
TABLE 1
Rank Order of Odds Ratios
Females Males
Beer or Wine 1. Family 4.7 * 1. Peers 2.7 *
2. School 2.1 2. School 2.0 *
3. Peers 1.5 3. Family 1.9
Hard Liquor 1. Family 4.3 * 1. School 1.9 *
2. School 1.4 2. Peers 1.9 *
3. Peers 1.2 3. Family 1.3
Marijuana 1. School 4.0 * 1. School 3.9 *
2. Family 2.4 * 2. Family 1.7
3. Peers 1.2 3. Peers 1.6 *
Cigarettes 1. School 1.8 * 1. School 3.7 *
2. Peers 1.6 2. Peers 1.4 *
3. Family 1.1 3. Family 1.2
For family and school bonds the comparison is for low-bonded
vs. high-bonded teens; for peer bonds the comparison is for
high-bonded vs. low-bonded teens.
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For males, peer bonds and bonds to school are most important, and
neither are related to alcohol use for females. While social bonds
are important for alcohol use for both males and females, they
differ as to which social field influences their behavior.
We show here the ratio of the relative odds of heavy alcohol
use to use for low-bonded compared to high-bonded teens. An odds
ratio is a standard measure of association within four cells of a
contingency table (see Fleiss 1973; Bishop et al. 1975) and in
our case may be used to compare associations in tables for males
and females. An odds ratio of one indicates no difference in the
use of low-bonded compared to high-bonded teenagers. An odds
ratio larger than one indicates that for family bonds and school
bonds the low-bonded teenagers are higher alcohol users than are
high-bonded teenagers, while for the peers bonds it indicates
that high-bonded teenagers have higher alcohol use. The asterisk
indicates that the likelihood ratio chi-square test of associa-
tion was significant at the .05 level.
In contrast to the alcohol results, the rank order of social
bonds is similar for males and females for marijuana and cigarette
use. Attachment to school is ranked the highest in smoking
marijuana or cigarettes for both females and males.
SUMMARY
For females, stronger family bonds are associated with less use
for all substances except cigarettes. The odds of a female with
low family bonds using alcohol (beer, wine, or hard liquor) are
more than four times as large as the odds for a female with high
family bonds. By comparison, for males the family bonds have no
relation to substance use.
The strength of attachment to school is related to substance use
for both males and females. The odds of a teenager--male or
female--with weak bonds to school being a heavy marijuana user are
four times greater than the odds for one with strong bonds to
school. Similar results were found for males' cigarette use and
alcohol use. For both sexes, but especially for males, low school
bonds are thus associated with higher substance use.
Attachment to peers is very important for males' substance use
but not females'; males who report strong attachments to their
peers also report heavier use of all four substances. Although
the direction of the relationships between peer bonds and sub-
stance use are the same for females as they are for males, the
relationships for females are weaker; none are significant at the
.05 level.
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DISCUSSION
There are four important points worth considering:
First, certain subgroups differ in their likelihood of use of
drugs. Males and females are an example. The level of attach-
ment of individuals to institutions is another example. When
these two are put together, we get even more information about
the likelihood of using drugs, alcohol, and tobacco.
Second, when it comes to explaining why some people become heavy
users we need to explore issues of attachment and bonds. An
important question for future work concerns identifying the
origins of social bonds for males and females.
Third, social bonds are an important part of understanding sex
differences in substance use. For males, attachment to school
and peer bonds were primary. For females, family bonds and bonds
to school were important.
In regard to prevention efforts, the implications are that, at
least for the, population studied here, the school context is an
important arena for both males and females. The family is more
important in the substance use of females and less important for
the males. In systematic prevention research both sex differences
and the two social fields of school and home will need to be
part of the research design.
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Criminality During the Life Course
of Heroin Addiction
John C. Ball and David N. Nurco
STATEMENT OF THE RESEARCH PROBLEM
It has been established that opiate addiction in the contemporary
United States is associated with exceedingly high crime rates
(O'Donnell 1966; Chambers 1974; Ball et al. 1975; McGlothlin
et al. 1978; Inciardi 1979; Gandossy et al. 1980; Barton 1980a,
198Ob; Clayton and Voss 1981). Indeed, recent studies have
reported (Ball et al. 1982) that heroin addicts are frequently
involved in criminal behavior on a daily basis and that, con-
sequently, they comnithundreds and thousands of offenses per
individual during their addiction careers. Furthermore, it is
becoming apparent that the scope and magnitudeof the crime
problem associated with opiate addiction is not only due to the
frequency with which addicts commit "victimless" and
lesser offenses, but that many of their offenses are serious and
destructive (Chaiken and Chaiken 1982).
But further questions about the association of crime and addic-
tion remain to be answered. One of the most crucial of these
involves the continuity of crime among heroin addicts. What are
the long-term consequences of this crime-drug relationship? Do
active addicts become more, or less, enmeshed in criminal behavior
over their adult years? Do the types of crimes they commit
change? Or do they reach a high crime plateau which remains
stable? What is the effect of successive abstinence periods upon
criminality?
In order to investigate the life course of criminality among
heroin addicts, three questions were addressed: (1) What specific
types of offenses do addicts engage in over the years? (2) Do
the types and frequencies of their criminality increase or de-
crease over the years? (3) How does criminality during successive
periods of addiction compare with criminality during successive
non-addiction periods?
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SAMPLE AND RESEARCH PROCEDURE - Selection of the Baltimore Sample
In order to investigate the continuity of criminal behavior among
opiate addicts over the years of their addiction, a probability-
based sample of 354 male Baltimore addicts was selected for
study. The Baltimore sample was selected because it was repre-
sentative of the addict arrestee population of this city and,
furthernmre, because unusually ccmprehensive life history data
were available. With regard to representativeness, the 354 males
were a stratified random sample selected from a population of
6,149 knmn opiate users arrested (or identified) by the
Baltimore Police Department between 1952 and 1976. Of the 354
males, 159 were white and 195 were black.
Interview Procedure
Each of the 354 addicts was interviewed between July 1973 and
January 1978 by specially trained interviewers who were familiar
with the Baltimore addict subculture. Both the project staff's
knowledge of the local addict street culture (i.e., its history;
ecological, racial, and economic structure; major career pattems
of criminality; current relationship with police; and availability
of specific drugs) and the interviewers' interest in the daily
problems and aspirations of the subjects were important requisites
to obtaining comprehensive information in the interviews. The
interview lasted some three hours, and the questions were focused
upon six topics: drug use, criminal behavior, work, living
arrangements, drug selling, and sources of income.
The Crime-Day Measures Employed
In order to investigate the extent of criminal behavior by these
addicts accurately and comprehensively, an expanded set of
crime-day measures was derived. These measures were developed
from earlier research which employed a unidimensional crime-day
conceptualization. The new measures include five types of
crime-days:
Definition of terms:
Crime-Day Theft, (CD-1). A theft crime-day is defined as a
24-hour period during which a given individual engages in
stealing property one or more times.
Crime-Day Violence, (CD-2). A violence crime-day is defined
as a 24-hour period during which a given individual engages
in one or more violent offenses.
Crime-Day Dealing, (CD-3). A dealing crime-day is defined as
a 24-hour period during which a given individual engages in
one or more drug sale offenses. (In this study, drug use and
possession are not included as crimes.)
Crime-Day Con Games, (CD-4). A confidence crime-day is a
24-hour period during which a given individual engages in one
or more confidence game offenses or forgery of checks or pre-
scriptions.
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Crime-Day Other, (CD-5). A crime-day other (or miscellaneous)
is a 24-hour period during which an individual engages in one
or more offenses which are not included in CD-l, CD-2, CD-3 or
CD-4. These include illegal gambling, pimping, fencing and
other offenses.
RESEARCH FINDINGS
The prevalence of the five types of criminality among the 354
Baltimore addicts during their nine year risk period is depicted
in Table 1. The most frequent type of crime committed was theft
of property which accounted for 37.9 percent of the total crime-
days, or 293,308 of 774,777 crime-days. Next in frequency was
drug sales, which accounted for 26.5 percent of the crime-days
(or 205,692 crime-days). Third in frequency were other offenses,
which accounted for 25.6 percent of the total crime-days (or
198,579 crime-days). These three types of crime-days (CD-1,
CD-3 and CD-5) accounted for 90 percent of the overall crimes
committed by the male addicts.
The remaining two types of crime-days, con games and violent
offenses, accounted for, respectively, 7.9 percent and 2.1 per-
cent of the crimes committed. The total number of confidence
crime-days was 60,882, and the number of violence crime-days was
16,316.
The total number of crime-days committed by the 354 addicts
during the nine years that they were on the street after the
onset of their addiction was 774,777. This prevalence of crime
meant that the average addict committed over two thousand
offenses. The mean number of crime-days was 2,119.
TABLE 1. Total Crime-Days for Theft, Violence, Dealing,
Confidence and Other Offenses for 354 Male Addicts
Type of Number of
Crime-Days Crime-Days
1. Theft of
Property 293,308
2. Violent
Offenses 16,316
3. Drug Sales 205,692
4. Confidence,
Forg., etc. 60,882
5. other
Offenses 198,579
Mean
Crime-Days
Per Addict
Percent of
Crime-Days
of
Each Type
828.6 37.9%
46.1 2.1
581.1 26.5
172.0 7.9
561.0 25.6
TOTAL
CRIME-DAYS 774,777 2,188.6 100.0
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TABLE 2. Percent of Days in Each Addiction Period That Addicts
Engaged in Crime, By Each of Five Types of Crime
Addiction Mean Number of
Period Days Addicts
1. 815 354
2. 583 297
3. 470 226
4. 441 153
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
453 100
342 57
393 38
315 22
360 13
368 8
385 6
315 2
720 2
600 1
Percent of Each Period Engaged In:
CD-1 CD-2 CD-3 CD-4 CD-5
'heft Violence Dealing Con Games Other
34.2 2.3 23.1 7.4 27.6
29.7 4.2 25.0 8.8 19.0
35.1 0.4 29.8 8.5 21.6
30.9 0.8 28.7 7.1 23.2
49.9 0.3 17.7 7.4 14.4
46.4 0.7 22.7 5.5 18.2
63.2 0.2 32.9 2.4 15.9
45.5 3.7 7.8 12.8 8.2
48.8 3.8 7.1 3.7 34.5
90.5 5.1 5.1 11.5 10.2
37.9 5.2 7.8 67.5 42.9
28.6 -- 81.0 -- --
-- -- 27.1 11.6 --
-- -- 60.8 27.8 --
Percent of
Days in Crime *
69.8
66.9
70.9
70.5
70.5
69.7
92.2
64.7
69.8
100.0
88.3
86.3
27.1
77.7
*This is the percent of total days in period which were compsite crime-days. Thus, in the first period
of 815 days, 69.8 percent were days in which one or more types of crimes were committed; 30.2 percent
of the days were non-crime days.
TABLE 3. Percent of Days in Each Non-Addiction Period That Addicts
Engaged in Crime, By Each of Five Types of Crime
Off Mean Number of
Period Days Addicts
1. 887 319
2. 754 167
3. 625 78
4. 533 32
5. 639 14
6. 690 6
7. 750 2
8. 510 1
*Composite Crime-Days.
Percent of Each Pet-id Engaged In:
CD-1 CD-2 CD-3 CD-4 CD-5
Theft Violence Dealing Con Games Other
9.2 0.1 6.3 0.5 8.2
5.0 0.2 3.4 0.3 4.2
2.0 0.0 4.4 0.7 6.3
0.6 3.2 0.2
15.7 0.0 1.3
2.5
Percent of Days
In Crime"
22.4
12.4
11.9
3.7
15.8
2.5
0.0
0.0
Note: In the above table, a dash indicates no crime-days in the period for the type of crime;
0.0 indicates less than 0.05 percent of crime.
Continuity of Crime Rates During Successive Addiction Periods
The continuity of crime during successive addiction periods is
shown in Table 2. The percent of time in each of the five types
of crime-days is tabulated for all 14 periods. The last column
records the percent of days in each period that the addicts
were engaged in crime of any type: this is the percent of each
period that were composite crime-days (i.e., days during which
one or more of the five types of crime were committed).
A major finding about the continuity of criminality during the
addiction periods is that it is relatively stable in frequency.
This stability is evident in the lack of variation of the five
crime-day measures as well as in the composite crime-day findings.
Thus, with regard to each of the five crime-day measures, the
percent of time engaged in crime in successive periods usually
does not differ from that of the first period by as much as ten
percent. With regard to the overall amount of time in each
addiction period that the male addicts were involved in crime,
this too is quite stable. In only two of the first ten periods
(7 and 10) does the amount of time involved in crime differ from
the initial figure of 70 percent by more than five percent.
There are, then, only minor variations in subsequent periods
from the initial high rate of criminality in the first addiction
period.
Crime Pates During Successive Off Periods
A major finding concerning criminality in the off periods is
that it decreases in successive periods (Table 3). This is most
evident in the sharp decrease in the overall percent of time
that the addicts (or former addicts) engaged in crime from the
first to the fourth off period - a decrease from 22.4 percent
to 3.7 percent. This same trend is reflected in the five crime-
daymeasureswhichdecreasein successive periods. Thus, during
periods 2, 3 and 4, there was a decrease in crime-days in 13 of
the 15 instances. Furthermore, there is evidence of a complete,
or almost complete, cessation of crime after the fourth period.
INTERPRETATION AND CONCLUSION
In this follow-up study of a probability-based sample of
Baltimore heroin addicts, it was found that the 354 male addicts
maintained a high rate of criminality over their addiction
careers. Thus, they committed offenses some 255 days a year
while "on the street" and this high rate of criminality con-
timed during their years at risk. Indeed, the continuity and
stability of their frequent criminal behavior during their
periods of addiction was remarkable.
Five crime-day measures were employed to analyze criminality
within this sample over the risk years. It was found that
theft was the most common offense as it accounted for 38 percent
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of the total crime-days. Drug sales was second in overall fre-
quency as it accounted for 27 percent of the crime-days. The
"other crime" classification included 26 percent of the crime-
days. The remainder of their crime involved violent offenses
and con games; together these offenses accounted for ten percent
of the total crime. This pattern, or configuration, of crime
remained quite stable throughout their addiction periods.
While there is no support in the research findings for a matur-
ation hypothesis with respect to the association between crime
and opiate addiction, there was substantial support for the
thesis that drug dependence is a major contributory factor
leading to criminality among heroin addicts in the united States.
In this regard, the difference between crime rates in the first
addiction period and the first off period was striking (a mean
of 255 crime-days per year vs. 82 crime-days per year). The
comparable figure for the total number of crime-days during this
first addiction and first off period was 273,049 and 68,999 for
each of these two year periods.
The high crime-rates of the first addiction period continued
in subsequent addiction periods. Thus, the 354 males committed
well over 775,000 crimes during the nine-year risk period that
they were free in the community and 88 percent of these were
committed while they were addicted.
REFERENCES:
Ball, J.C., Levine, B.K., Demaree, R.G., and Neman, J.G. Pre-
treatment criminality of male and female drug abuse patients
in the United States. Addictive Diseases, 1(4):481-489, 1975.
Ball, J.C., Rosen, L., Flueck, J.A., and Nurco, D.N. Lifetime
criminality of heroin addicts in the United States. Journal
of Drug Issues, Summer:225-239, 1982.
Barton, W.I. Drug Abuse History and Criminality of Inmates of
Local Jails: Results of the 1978 LEAA Survey of Inmates of
Local Jails in the U.S. Washington, D.C., DEA,.1980a,
pp. 1-98. Drug histories and criminality: Survey of inmates
of State correctional facilities, January 1974. The Inter-
national Journal of Addictions, 15(2):233-258, 1980b.
Chaiken, J.M., and Chaiken, M.R. Varieties of Criminal Behavior.
Santa Monica, The Rand Corporation, 1982.
Chambers, C.D. Narcotic addiction and crime: an empirical
review. In: Inciardi, J.A. and Chambers, C.D., eds. Drugs
and the Criminal Justice System. Beverly Hills: Sage, 1974.
Chapter 5.
Clayton, R.R., and Voss, H.L. Young Men and Drugs in Manhattan:
A Causal Analysis. National Institute on Drug Abuse Research
Monograph 39. DHHS Rub. No. (ADM) 81-1167. Washington, D.C.:
supt. of Docs., U.S. Govt. Print. Off., 1981.
311
Gandossy, R.P., Williams, J.R., Cohen J., and Harwood, H.J.
Drugs and Crime. Washington: U.S. Government Printing Office,
1980.
Inciardi, J.A. Heroin use and street crime. Crime and
Delinquency, July:335-346, 1979.
McGlothlin, W.H., Anglin, M.D. and Wilson, B.D. Narcotic
addiction and crime. Criminology, 16(3):293-315, 1978.
O'Donnell, J.A. Narcotic addiction and crime. Social Problems,
13:374-385, 1966.
AUTHORS
John C. Hall, Ph.D.
Department of Psychiatry
Temple University School of Medicine
Philadelphia, Pennsylvania 19140
David N. Nurco, D.S.W.
Department of Psychiatry
University of Maryland School of Medicine
Baltimore, Maryland 21217
312
Depressive Symptoms in Drug
Abuse Treatment Clients:
Correlates, Treatment, and
Changes
Harold M. Ginzburg, Margaret Allison, and
Robert L. Hubbard
INTRODUCTION
An association between drug use and depression has been observed
in a number of studies (Robins 1974, Sutker 1971). These studies
indicate that higher levels of drug use are associated with in-
creases in depressive symptoms. In general, 30 to 50 percent of
clients in drug abuse treatment studies are diagnosed as at least
moderately depressed. These findings compare with estimates that
14-20 percent of the general population experience depressive
symptoms at any given time (Midanik 1981), and 4-7 percent of the
population may be diagnosable as having clinical depression
(Weissman et al. 1975-1976). Thus, it is, clear that depression
is a factor that must be considered in the treatment of drug
abuse.
The effects of drug abuse treatment on depression, however,
remain unclear. Woody and Blaine (1979) report that the high
levels of depression at intake decrease over time. However, they
also caution that suicide attempts are more common during with-
drawal phases of treatment. In a long-term study of drug abusers,
scores on depression scales decreased substantially regardless of
the type of substance. abuse or the duration of treatment (Dorus
and Senay 1980). It is apparent, then, that further research on
the nature, prevalence, and course of depressive symptoms among
clients in drug abuse treatment programs would be useful for a
variety of purposes.
This paper describes the depressive symptomatology found in
clients in drug abuse treatment programs in the Treatment Outcome
Prospective Study (TOPS). In addition, correlations between the
depressive symptoms and a number of demographic and outcome
variables are presented and discussed. Finally, changes in
symptom levels observed after three months in treatment are
reported.
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METHODOLOGY
Briefly, TOPS is a large scale, longitudinal, descriptive study
of the effects of drug abuse treatment programs. The research
tracks individuals who entered treatment during calendar years
1979, 1980, and 1981. Programs representing four major treatment
modalities were included in the TOPS study, i.e., outpatient
detoxification, methadone maintenance, residential, and outpatient
drug free programs. Nearly 12,000 clients in 59 clinics in 10
cities located throughout the United States voluntarily partici-
pated in the study. Clients were interviewed at the time they
entered treatment, at regular intervals while they remained in
treatment, and periodically after they left treatment.
The interviews collected a wide range of information including
demographic and background characteristics, drug and alcohol
consumption, drug-and alcohol-related problems, prior treatment
history for drug, alcohol or mental health problems, illegal
activities, and family and social relationships. A set of three
questions on depressive symptoms was also included in all of the
TOPS interviews. These items sought self-reports of (1) having
felt so depressed that one could not get out of bed in the morn-
ing, (2) having thought of suicide, or (3) having attempted
suicide.
The TOPS three-item scale was validated against the Beck Depres-
sion Inventory, the CES-D (a depression scale developed by the
National Institute of Mental Health, Center for Epidemiological
Studies) and Koss and Butcher's Critical Items derived from the
Minnesota Multiphasic Personality Inventory. Results of the
validation study indicate that the scale is sufficiently valid to
establish the internal validity of the depression data available
in the overall TOPS database.
CORRELATES OF DEPRESSIVE SYMPTOMS
The TOPS data indicate that, at intake, more clients entering
outpatient drug free (OPDF) or residential treatment programs
reported experiencing depressive symptoms during the year prior
to admission. Also, a substantially greater percentage of these
clients report having attempted suicide than clients entering
detoxification or methadone programs. Over 60 percent--roughly
three times the rate in the general population--of all clients
coming into TOPS drug abuse treatment programs state that they
have experienced one or more of these symptoms.
Client Characteristics
In each modality women are more likely to report signs of depres-
sion than men (table 1). Depressive symptoms are most common among
women entering residential, outpatient detoxification, and OPDF
programs. About 66 percent of women entering methadone programs
report depressive symptoms, compared to nearly 74 percent in the
other modalities. Among male clients, there appears to be a
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Table 1. Sex and Age by Depression Indicators During
the Year Before Admission to Treatment
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negative relationship between age and depression indicators.
Among female clients the relationship between age and depression
indicators is not so straightforward. Older women in methadone
programs are more likely to report depressive symptoms while, in
other modalities, it appears that younger women may be more
depressed. Overall, women under 21 are the most likely group to
report some sign of depression. These findings are quite similar
to those reported by Midanik (1981) based on a general population
sample.
The weekly drug use pattern of clients entering drug abuse treat-
ment programs was also correlated with the depression indicators.
Seven patterns have been identified on the basis of the TOPS
data. They are: (1) heroin and other narcotics; (2) heroin, not
other narcotics; (3) narcotics, not heroin; (4) multiple nonnar-
cotics; (5) single nonnarcotic; (6) alcohol and/or marijuana; and
(7) minimal drug use. It must be noted that membership in one of
these pattern groups does not preclude the use of other drugs on
a less than weekly basis.
It appears that heroin use, without the use of other narcotics,
is not particularly associated with suicidal thoughts or attempts
among clients in any of the treatment modalities. Similarly,
clients in the alcohol/marijuana and minimal use pattern groups
have relatively low rates of suicidal thoughts or attempts.
Those at highest risk of suicidal behaviors and ideation are
. clients in the multiple nonnarcotic and other narcotics groups.
Those in the single nonnarcotic group are at somewhat less risk
among all but residential clients. These are especially note-
worthy findings in view of the increasing numbers of polydrug
abusers entering treatment (Bray et al. 1982) and have obvious
implications for drug abuse treatment program planning.
In the TOPS interviews, clients were asked whether their drug
abuse had caused them any problems of a medical, psychological,
family, legal, educational, employment, or financial nature. As
might be expected-, those who said they had more such problems
were more likely to have experienced some sign of depression.
Also, there were more frequent reports of suicide attempts from
clients with more drug-related problems.
Not surprisingly, there is an unmistakable, positive relationship
between prior mental health, treatment and depression indicators
during the year before admission to drug abuse treatment, regard-
less of modality.
Ancillary Services
The data on which the following discussion is based were generated
in interviews with clients after they had been in treatment for
three months. Due to the short duration of detoxification treat-
ment, few ancillary services are provided in programs of that
modality. Therefore, they are not included in the discussion of
services received in relation to depressive symptoms.
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In methadone programs, there appears to be no relationship between
depressive symptoms experienced during the first three months in
treatment and the number of ancillary services received during
the first three months of treatment. Clients who received psycho-
logical services were less likely than those who did not receive
such services to say they had felt so depressed they couldn't get
out of bed (8 percent versus 22 percent), but were more likely to
say they had thought of or attempted suicide. The opposite was
true for those receiving or not receiving medical services.
In residential treatment programs, clients who received no ancil-
lary services were most likely to say they had no depressive
symptoms during their first three months in treatment. Those
receiving services for two or three types of problems (more than
half the clients) were most likely to report some sign of depres-
sion. In general, there was a slight tendency for those who had
received an ancillary service to be more likely to report some
symptom of depression. None of the TOPS clients in residential
treatment at three months reported suicide attempts during the
first three months of treatment; 9 percent reported suicidal
thoughts and 10 percent felt depressed.
Among OPDF clients there was little or no difference in the
levels of depression indicators reported by those receiving or
not receiving medical, family, or educational services. In
contrast, those receiving psychological services were more likely
to say they had been depressed or thought of suicide during their 
first three months in treatment. In nearly all cases, clients
who received service for a given type of problem were more likely
to say they had experienced some depressive symptoms during their
first three months in treatment. Presumably, this indicates that
those who are-more in need of treatment services are receiving
them.
CHANGES IN DEPRESSIVE SYMPTOMS
Given the frequency of reports' of depression indicators and the
potential effects of depression on treatment outcome and mental
health in general, reducing levels of depression should be an
important treatment goal. To examine the possible impact of
treatment, responses in the TOPS interview forms at intake and at
one month and three months in treatment were compared. Clients
in detoxification programs were not included in this analysis
because such programs are usually completed in less than one
month.
Data from the TOPS intake and intreatment interviews indicate
that there is a marked reduction in reports of depression indi-
cators after one month in treatment. In general, the rate drops
from about 60 percent at intake to an average of just over 30
percent at one month. Clients in residential programs show an
even greater decrease to about 20 percent reporting depressive
symptoms at one month. It is interesting to note that the rate
increases somewhat at three months and then falls slightly at six
months.
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A finding of reductions this large so soon after admission into
treatment may be partially explained by differences in the lengths
of the time periods being compared, i.e., the year before admis-
sion, the first month of treatment, and the first or second three-
month periods of treatment. On the other hand, it may suggest
that much of the depression reported at intake could be of a
transient situational type rather than a chronic mental health
problem. Nevertheless, there is a substantial percentage of
clients in all modalities who remain depressed. Early identifi-
cation and treatment of the 20-30 percent of clients who may
remain depressed for long periods could be important to the overall
effectiveness of the drug abuse treatment program.
To assess how depression indicators change during the first three
months in treatment as compared to the year prior to treatment
for various subgroups of clients, a change scoring scheme was
created. Based on the assumption of a hierarchy of severity (no
symptoms < felt depressed < thought of suicide < attempted sui-
cide), clients were categorized according to the most severe
symptom reported at admission and again after three months in
treatment. Clients who reported no depressive symptoms for either
time period were classified as "no problem" (NP). Those who re-
ported a less severe symptom at three months in treatment than
they did at admission were placed in the "reduced depression" (RO)
category. The "continued or increased depression" (CD) category
comprised those clients who remained in or moved'to the "felt
depressed" response group. Those who remained in or moved to
either the "thought about suicide" or "attempted suicide" response
groups were categorized in the "continued or increased suicidal
tendencies" (CS) group. The percentages of clients in each of the
categories are presented by modality in table 2.
Table 2. Changes in Depression Indicators Reported
for the Year Before Admission and First
Three Months in Treatment
Outpatient Outpatient
Methadone Residential Drug Free Overall
NP
CD
CS
RD
36.2% 38.9% 33.3% 36.3%
13.5
11.1
5.0 9.2
9.2 20.9
39.2 46.9
3 . 8
42.0
12.7
41.8
100.0 100.0 100.0 100.0
(n=658) (n=338) (n=264) (n=1260)
NP=no problem;. CD=cont'd or increased depression; CS=cont'd
or increased suicidal tendencies; RD=reduced depression
DISCUSSION
The findings reported in this paper have clear implications for
program planning and clinical case management in drug abuse
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treatment programs. Depressive symptoms are prevalent among
clients in drug abuse treatment, especially young women and those
who use two or more nonnarcotics on a weekly basis. Our findings
also indicate that depressive symptoms fade rapidly for many
clients but, at the same time, substantial proportions of clients
continue to express some degree of symptomatology.
Further research aimed at the early detection of those whose
symptoms are likely to persist would be of great benefit. Other
research questions, such as whether depressive symptoms are a
motivator for clients to seek treatment, how depression is related
to specific drug use patterns, and whether or how depression
might influence the effectiveness of drug abuse treatment are
also in need of further investigation.
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Striatal Dopamine Receptor
Function in Morphine-Tolerant
Dependent Rats: Influence of
Hypothalamic Peptides
Hemendra N. Bhargava
INTRODUCTION
Chronic administration of opiates to rodents is associated with changes
in the central dopaminergic systems. For instance, supersensitivity of
brain dopamine receptors develops in rodents following chronic
treatment with morphine (Lal 1975; Iwatsubo and Clouet 1975; Ritzmann
et al. 1979; Bhargava 1980, 1981a) or human ß-endorphin (Bhargava
1981b). Some studies, on the other hand, have been unable to
demonstrate the development of supersensitivity, and in some cases,
have observed subsensitivity of dopamine receptors after chronic
treatment with morphine (Kuschinsky 1975; Merali et al. 1975; Iversen
and Joyce 1978). Dopamine receptor function has been studied by using
3H-spiroperidol binding assays. In the rat, acute administration of
morphine did not alter striatal 3H-spiroperidol binding; implantation of
two morphine pellets increased the dissociation constant (Kd value), and
implantation of four morphine pellets reduced the number of binding
sites (Bmax value) and lowered the Kd value (Puri et al. 1978). Christie
and Overstreet (1979) have found higher Kd values for 3H-spiroperidol
binding in the striatum of morphine-withdrawn rats.
Because of the existence of conflicting reports on changes in dopamine
receptor system following chronic opiate administration, and also in an
effort to seek a possible relationship between the opiate tolerance-
dependence process and activity in the dopaminergic systems, the effect
of chronic treatment with morphine to rats on the striatal 3H-
spiroperidol binding has been examined. In addition, the effect of two
peptides, which have been shown to inhibit the development of tolerance
to and dependence on opiates (Bhargava 1980, 1981a, c, d; Bhargava et
al. 1980) on morphine-induced changes in 3H-spiroperidol binding has
been determined.
METHODS
Male Sprague-Dawley rats weighing about 250 g obtained from King
Animal Laboratories, Oregon, WI. were housed in rooms with controlled
temperature, humidity and light for 4 days before being used. The rats
were given food and water ad libitum.
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Cyclo(Leu-Gly) (CLG) was synthesized in these laboratories and its
purity checked by thin layer chromatographic analyses (Bhargava 1981c).
Melanotropin release inhibiting factor (MIF) was obtained from the
Abbott Laboratories, N. Chicago, Illinois, through the courtesy of Dr.
E.L. Woroch. The peptides were dissolved in distilled deionized water
and injected subcutaneously. 3H-Spiroperidol (specific activity 26.0
Ci/mmole) and d-butaclamol were obtained from New England Nuclear,
Boston, MA.
The rats were made tolerant to and dependent on morphine by s.c.
implantation of four morphine pellets (each containing 75 mg of
morphine free base) during a 3-day period using a schedule described
earlier (Bhargava 1977, 1978). Rats serving as controls were implanted
with four placebo pellets. The schedule of vehicle or peptides, and
morphine or placebo pellet treatment was similar to that described
previously (Bhargava 1981a, c). The dose of each peptide was 2
mg/kg/day. All the pellets were removed from the rats, under light
ether anesthesia. Twenty-four hours after the pellet removal, the rats
were decapitated, their striata removed, and frozen at -70°C until
assayed for 3H-spiroperidol binding.
Implantation of four morphine pellets during a 3-day period produces a
high degree of dependence (Bhargava 197.7) and a 6.5-fold tolerance to
the analgesic effect of morphine (Bhargava 1978). Brain and plasma of
morphine tolerant-dependent rats were shown to be devoid of morphine
at the time the animals were sacrificed (Bhargava 1978).
The binding of 3H-spiroperidol to rat striatal dopamine receptors was
carried out as described previously (Creese and Snyder 1979). Specific
binding of 3H-spiroperidol was defined as the difference in binding in the
absence and presence of 1 µM d-butaclamol. The concentration of
protein in the striatal homogenates was determined according to the
method of Lowry et al. (1951). The apparent dissociation constant (Kd)
and the maximal binding capacity (Bmax) were determined from the
Scatchard plots generated by least square regression analyses. Four rats
were used for each treatment group. The means of Bmax and Kd values
in different treatment groups were analyzed by one- way ANOVA
followed by the Schaffe’s 'S' test.
RESULTS
Chronic administration of morphine to rats resulted in an enhanced
affinity of 3H-spiroperidol binding to striatal dopamine receptors but the
number of binding sites did not change. Figure 1 shows the saturation
curves and the Scatchard plots of 3H-spiroperidol binding to striatal
membranes of rats implanted with placebo or morphine pellets. The
maximal number of binding sites (Bmax values) in morphine and placebo
pellet implanted rats were 141.5 ± 15.6 and 143.2 ± 9 fmoles of 3H-
spiroperidol bound per milligram of protein, respectively. Chronic
treatment with morphine decreased the apparent dissociation constant
(Kd value) to 49 pM from 111 pM found in placebo pellet-implanted rats.
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FIGURE 1
The saturation curves and Scatchard plots (insets) of 3H-spiroperidol
binding to striatal membranes of nontolerant (placebo pellets) and
morphine tolerant-dependent (morphine pellets) rats.
Analysis of variance indicated a significant interaction F(1,12) = 19.33,
P <0.001 . To seek a possible relationship between opiate tolerance-
dependence and dopamine receptor function, the effect of two peptides,
MIF and CLG, which have been shown to block the development of
tolerance to and physical dependence on morphine, on striatal 3H-
spiroperidol binding changes induced by chronic morphinization was
investigated. Multiple injections of either MIF or CLG to rats implanted
with placebo pellets had no effect on either the Bmax or the Kd values
of 3H-spiroperidol nor did they alter the Bmax values in rats implanted
with morphine pellets (Table 1). Both peptides, however, reversed the
changes in Kd values induced by chronic morphine administration, and
these values were similar to those found in the placebo + water treated
group (Table 1).
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TABLE 1
Effects of Pro-Leu-Gly-NH2 (MIF) and cyclo(Leu-Gly) (CLG) on
3H-spiroperidol binding constants in the striata of rats
treated chronically with morphine.
Treatmenta
3H-Spiroperidol binding parameters
Mean± S.E.M. (N = 4)
Bmax Kd
(fmoles/mg protein) (pM)
Vehicle + Placebo 143.2 ± 9.0
Vehicle + Morphine 141.5 ± 15.6
111.3 ± 11.2
49.3 ± 10.7b
MIF + Placebo 138.9 ± 5.7 106.3 ± 10.7
MIF + Morphine 124.0 ± 14.4 88.2 ± 9.6c
CLG + Placebo 144.3 ± 7.4 104.4 ± 10.3
CLG + Morphine 118.5 ± 19.0 87.4 ± 8.8C
a Rats were injected with vehicle (water) or the appropriate peptide
and then implanted subcutaneously with either 4 morphine or
placebo pellets as described in the text. The pellets were removed
72 hr after the first implantation. Twenty-four hours after the
pellet removal the animals were sacrificed, their striata removed
and frozen at -70°C until receptor binding studies were
undertaken.
b p < 0.05 vs vehicle + placebo group.
c p < 0.05 vs vehicle + morphine group.
DISCUSSION
As indicated in the introduction section, most studies indicate that the
development of tolerance to and dependence on opiates is associated
with the development of behavioral supersensitivity of brain dopamine
receptors. However, considerable disparity exists in the literature for
the biochemical evidence for dopamine supersensitivity using 3H-
spiroperidol binding assays. It is not clear whether this supersensitivity
results from the proliferation of dopamine receptors or from the changes
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in the affinity of the receptor ligands. It has been suggested that a high
degree of dependence decreases, whereas a low degree of dependence
increases, both the Kd and Bmax values for
3H-spiroperidol binding,
respectively (Puri et al. 1978). Christie and Overstreet (1979) found no
change in striatal 3H-spiroperidol in morphine-tolerant rats, but
observed an increase in Kd value in rats withdrawn from morphine. The
present studies indicate that development of morphine tolerance-
dependence process, which results in behavioral supersensitivity of brain
dopamine receptors, results from enhanced affinity of the ligands to the
receptors and not from the increased number of receptors. This
observation is consistent with the report of Cross et al. (1978) who found
a direct relationship between 3H-spiroperidol affinity and behavioral
supersensitivity to apomorphine.
MIF and CLG, which inhibit the development of tolerance to and
dependence on morphine, were found to block the morphine-induced
increased affinity of 3H-spiroperidol to striatal dopamine receptors. It
is thus possible that tolerance to and physical dependence on morphine
involves changes in the affinity of ligands to dopamine receptors, and it
may be one of the several mechanisms which may be involved in its
genesis.
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Drug Preference and Mood in
Humans: Mazindol and
Phenylpropanolamine
L. D. Chait, E. H. Uhlenhuth, and C. E. Johanson
ABSTRACT
Normal human volunteers participated in two drug preference studies.
In one study subjects (N=12) were allowed to self-administer either a
dose of mazindol (MAZ) (0.5, 1.0 or 2.0 mg) or placebo. In the other
s tudy  sub je c t s  (N=12 )  s e l f - admin i s te red  e i ther  a  dose  o f
phenylpropanolamine (PPA) (12.5, 25 or 50 mg) or placebo. In both
studies subjects were free to leave after drug ingestion and filled out
subjective report forms at the time of ingestion and 1, 3, and 6 hours later.
All three doses of MAZ were chosen less frequently than placebo (less
than 1 out of 5 choice occasions). Ratings of drug liking also were
less after MAZ than after placebo. The low dose of MAZ was most
frequently perceived to be a tranquilizer, whereas the high dose was
most often perceived to be a stimulant. Increases in ratings of Fatigue,
Anxiety and Confusion, and’ decreases in ratings of Elation and Positive
Mood were obtained on the Profile of Mood States (POMS) after MAZ.
Increases in ratings of “sedated” (visual analog scale - VAS) were also
obtained after MAZ, as were increases in scores on the PCAG and LSD
scales of the Addiction Research Center Inventor (ARCI). No significant
changes were observed on ratings of "hungry" (VAS) after MAZ.
No dose of PPA was chosen with a frequency differing significantly
from placebo (range 1.9 - 2.2 times out of 5 choice occasions). Ratings
of drug liking after PPA did not differ from those after placebo. The
low dose of PPA was most frequently perceived to be placebo, whereas
the high dose was most often perceived to be a stimulant. Increases
were obtained after PPA for ratings of Anxiety and Depression on the
POMS and for ratings of "anxious," "down," "high," and "stimulated" on
the VAS. No significant effects of PPA were obtained on the ARCI or
on ratings of "hungry."
The results demonstrate that, unlike d-amphetamine and diethylpropion,
MAZ and PPA are not preferred by subjects to placebo. In fact, MAZ
actually proved to be aversive compared to placebo. Most of the
subjective effects produced by the two drugs would generally be
considered unpleasant, which corresponds to the failure by the subjects
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to self-administer these two anorectics. These findings suggest that
PPA and MAZ are of low dependence potential.
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The Use of Phenobarbital in
Treating Abstinence in Newborns
Exposed In Utero to Psychoactive
Agents
Loretta P. Finnegan, Herman Michael, and Betty Leifer
Phenobarbital has been used extensively for neonatal abstinence as
it suppresses the major symptoms by a nonspecific central nervous
system depression. Two approaches to phenobarbital therapy are
currently in use. With both approaches, the initial dose and all
subsequent doses are determined by the severity of symptoms using
an abstinence scoring system. The titration approach provides the
infants with a total dose per body weight of 6-8-10 or 12 mg/kg per
day which is divided into 3 equal doses at 8-hour intervals. The
loading dose approach provides the infants with an initial dose of
20 mg/kg followed by maintenance doses sufficient to control the
symptoms. The study infants were born to women using narcotics in
combination with other illicit drugs during pregnancy. Of the 30
infants, 16 received the titration and 14 the loading dose regimen.
All were treated successfully with phenobarbital. The relative ef-
ficacy of the two treatment modalities was determined by recording
the number of hours necessary to achieve control of symptoms. Re-
sults revealed a statistically significant difference (p <.01) be-
tween the average time necessary to achieve control with the load-
ing dose method (33 hours) and the average time necessary with the
titration method (64 hours). These results suggest that although
both methods successfully manage the symptoms of neonatal absti-
nence, the loading dose methodology provides more rapid and effi-
cient control.
Copyright 1983, the International Pediatric Research Foundation,
Inc. Reprinted by permission, from Pediatric Research, 17:371,
1983.
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The Incidence of Violence in the
Lives of Pregnant Drug-Dependent
Women
Dianne O’Malley Regan, Betty Leifer, and
Loretta P. Finnegan
Several factors have been shown to be associated with the occur-
rence of child abuse. They include: 1) parental drug and/or
alcohol abuse, 2) extreme poverty, 3) chaotic life style, 4) abuse
experienced by the parents when they were children, and 5) violence
between the parents. Family Center (FC) is a multidisciplinary
outpatient program providing methadone maintenance along with com-
prehensive medical and psychosocial services to pregnant drug-de-
pendent women. Many of the women are poor and have experienced
much chaos in their lives. They may, therefore, be considered to
be at high risk for child abuse. To determine the levels of vio-
lence in the lives of these women compared to a control group of
women, a questionnaire was developed and administered to: 1) a
sample of 95 FC women, and 2) a matched sample of 69 non-drug-
abusing women enrolled in our prenatal clinic. Analysis of the
questionnaire responses showed that compared to control women,
FC patients have experienced, and continue to experience, signi-
ficantly more violence in their lives. Specifically, a greater
proportion of the drug-dependent women reported having been beaten
as children (27% vs. 14%, p <.05). Mothers were most often identi-
fied as the perpetrator of the beatings. Also, the experience of
having been beaten as an adult (usually by the husband or partner)
was reported by a significantly greater proportion of FC patients
than control, women (73% vs. 20%, p <.001). Finally, there was a
significantly difference between the proportion of patients in FC
(29%) and the proportion of those in the control group (6%) re-
porting the experience of childhood rape or sexual molestation
(p <.001). The high incidence of violent experience, both sexual
and non-sexual, among FC women appears particularly critical con-
sidering that this group may already be at risk for child abuse
according to other criteria. Evidence that abuse tends to be in-
tergenerationally transmitted underscores the need for early in-
tervention.
Copyright 1982, the International Pediatric Research Foundation,
Inc. Reprinted by permission, from Regan, D.O., Leifer, B., and
Finnegan, L.P. Generations at risk: Violence in the lives of
pregnant drug abusing women. Pediatric Research, 16:77, 1982.
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Cerebral Ventricular Changes in
Newborns Exposed to
Psychoactive Agents In Utero
Matthew Pasto, Leonard Graziani, Betty Leifer,
Sandra Tunis, Theresa Matteucci, and
Loretta P. Finnegan
In order to further evaluate the effects of psychoactive drugs
taken during gestation on the developing nervous system, ultra-
sound studies of the brain were obtained in drug-exposed infants
with neonatal abstinence and in a group of non-drug-exposed in-
fants at 24 and 72 hours, and 1, 2, and 6 months following birth.
The groups were comparable in birthweight, gestational age, Apgar
scores, sex, race, and socioeconomic status. Mothers of the drug
exposed infants had been maintained on methadone at an average
daily dose of 41 mg, and many used unknown quantities of heroin,
diazepam or amphetamines during gestation. Ultrasound examina-
tions at 24 and 72 hours and 1 month revealed the presence of
very small (slit-like) lateral ventricles in most of the drug-ex-
posed infants but in few of the controls [26 vs. 9 at 24 hours,
30 vs. 5 at 72 hours, (p <.OO1), and 25 vs. 5 at 1 month (p <.05)].
The 2-and 6-month images failed to reveal signficant differences
between the two groups of infants so that at 2 and 6 months, drug
exposed infants were just as likely as controls to have normal
lateral ventricles. The results suggest a relationship between
slit-like ventricles and the period of neonatal abstinence which
appears shortly after birth and is frequently manifested for as
long as 6 months. However, the pathogenesis of the abstinence
symptomatology was not defined by the current ultrasound studies.
Slit-like ventricles may be due to a lack of visualization of
fluid space within the ventricles, a diffuse compression of the
ventricles bilaterally, or to decreased production or increased
reabsorption of cerebrospinal fluid. Since increased intracranial
pressure may in part be responsible, fontanel pressure measurements
are being performed routinely on study and control infants. Fur-
thermore, on a select number of subjects, we obtained computerized
tomography (CT) examinations to determine whether the density of
the periventricular white matter was consistent with edema. Re-
sults of the pressure measurements to date show that brain pres-
sure is similar in drug-exposed and control infants. The CT exami-
nations have not revealed any localized or generalized cerebral
edema.
Copyright 1983, the International Pediatric Research Foundation,
Inc. Reprinted by permission, from Pediatric Research, 17:1678,
1983.
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Depression, Self-Concept, and
Violent Experience in Drug
Abusing Women and Their
Influence Upon Parenting
Effectiveness
Dianne O. Regan, Betty Leifer, and Loretta P. Finnegan
Perinatal management of drug-dependent women is a challenge to
health professionals due to the frequency with which the women ex-
perience psychiatric, psychological, and social difficulties. In
an effort to provide comprehensive services and outpatient metha-
done maintenance for the high-risk population of pregnant drug-de-
pendent women, Family Center was established. This investigation
was aimed at describing levels of depression and self-esteem among
women enrolled in Family Center, their experiences of violence,
and the possible relationship of each to parenting effectiveness.
To assess depression in a group of drug-free control women (n=26),
the Beck Depression Inventory was administered to both groups. Re-
sults revealed that the drug-dependent women showed significantly
more depression and that higher levels of depression were reported
by drug-dependent women whose children had been referred to a child
welfare agency. Additionally, levels of self-esteem in a group of
drug-dependent women (n=28) were measured with the Beck Self Con-
cept Test and compared with levels in a group of pregnant control
women (n=29). Results revealed that the Family Center women had
significantly lower self-esteem (p <.01); and for this group, self-
concept was negatively related to parity (p <.05). Finally, a
questionnaire on violence was developed and administered to drug-
dependent women (n=95) and controls (n=69) to identify the number
of past and present violent experiences. Significantly more of the
drug dependent women had been beaten as children (p <.05) and as
adults (p <.001). Also, significantly more Family Center women re-
ported that they had been raped as adults (p <.001) and/or sexu-
ally molested as children (p <.001).
The results of this study demonstrate that, in addition to having
problems directly associated with drug addiction, our sample of
drug-dependent women have certain psychological and social diffi-
culties compared to drug-free pregnant women. Because depression,
low self-esteem, and the experience of violence have all been
linked to problems in parenting, clinical intervention should ad-
dress these issues to assure the best possible outcome for the .
drug-dependent woman and her children.
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The Effects of RO15-1788, Alone
and in Combination With
Diazepam, on Ethanol-Induced
Loss of Righting Reflex in Rats
B. A. Regan and D. E. Clody
ABSTRACT
The depressant effects and motor impairments observed after
treatment with either benzodiazepines or ethanol are synergistic.
Although fatalities due to diazepam are rare, combining diazepam
with alcohol can increase the potential for toxic effects.
R015-1788, an imidazobenzodiazepine, is a novel and selective
inhibitor of benzodiazepine binding. In vivo, R015-1788 is
relatively devoid of intrinsic pharmacological activity, yet it
antagonizes many of the behavioral and pharmacological effects
typically induced by the benzodiazepines. These studies were
designed to determine the effects of R015-1788, alone and in
combination with diazepam, on ethanol-induced loss of righting
reflex in rats (see Figure 1 for structures).
Rats were treated with diazepam alone (4 mg/kg p.o.) or with
diazepam followed by R015-1788 (20 mg/kg p.o.) 45 minutes later.
Sixty minutes after diazepam, ethanol was administered, (3.2
g/kg i.p., the dose estimated to cause loss of righting reflex
in at least 70% of the rats, see Figure 2), and the rats were
then observed continuously for the incidence and duration of
loss of righting (rat remained in supine position on a hard
horizontal surface for at least 1 minute).
Diazepam alone caused a two-fold increase in the duration of
ethanol-induced loss of righting in rats; this effect was
reversed by the subsequent administration of R015-1788.
R015-1788 alone did not exert significant effects on righting
reflex. The results of this study, shown in Figure 3, suggest
that R015-1788 may be clinically useful in treating the
depressant effects observed after acute overdosage with a
combination of diazepam and ethanol.
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FIGURE 1
Ro15-1788 DIAZEPAM
FIGURE 2
INCIDENCE OF ETHANOL INDUCED LOSS OF RIGHTING REFLEX (LRR)
AND ACUTE LETHALITY IN RATS
1within 24hrs of treatment
2colculoted according to linear arc-sine transformation method of Finney
FIGURE 3
EFFECTS ON ETHANOL INDUCED LOSS OF RIGHTING REFLEX (LRR)
IN RATS
1 administered 60min prior to ethanol (3.2 g/kg i:p.)
2 administered 15 min prior lo ethanol
3 45min between treatments
4 statistically different from control (p < 0.05),
two-tailed Student’s t test
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Guanabenz Acetate: A New, Long-
Acting Alpha-Two Adrenergic
Agonist for Opioid Withdrawal
Forest S. Tennant, Jr., and Richard A. Rawson
ABSTRACT
Guanabenz Acetate (GA) is a new long-lasting alpha-two agonist.
We found that it effectively suppressed opioid withdrawal in the
majority of 47 opioid-dependent subjects. GA was usually given
in twice per day dosages and did not appear to have as many side
effects as clonidine. It may have greater acceptance among
heroin addicts than clonidine.
INTRODUCTION
Guanabenz acetate (GA) is a new, long-acting alpha-two agonist
with antihypertensive effects similar to clonidine hydro-
chloride. In addition, to its use in hypertension, clonidine
has proved to be an effective agent for opioid withdrawal.
Since clonidine is not an opioid and essentially has no abuse
potential, its development for opioid withdrawal represents a
significant clinical advance, and its use in opioid withdrawal
has rapidly spread in the United States and abroad. When
used in opioid withdrawal, however, clonidine may precipitate
severe hypotension, and its common side-effects of lethargy and
weakness have significantly limited its use, particularly in
outpatient settings.5-7 This study was undertaken to determine
if GA can suppress opioid withdrawal while possibly avoiding
some of clonidine's side effects.
METHODS
Forty-seven (47) subjects dependent upon the opioids, heroin
(N=41) or methadone (N=6), were admitted to this pilot study and
were administered GA. Heroin dependence was documented by a
self-reported history of a minimum of three intravenous injec-
tions per day for at least six months; urine containing mor-
phine; presence of fresh needle marks; and signs of opioid with-
drawal. Methadone-dependent persons were on a standard
methadone maintenance program; had a daily maintenance dose of
30 mg or less; and desired to withdraw to a drug-free state.
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Subjects were informed they had to attend the clinic daily and
would receive GA for a maximum of 14 days. The beginning dose
of GA was 4 mg administered twice per day for a 24-hour total of
8 mg. Maximum dosage allowed was 4 mg administered four times
per day for a 24-hour total of 16 mg.
On each day of attendance, subjects were assessed for withdrawal
symptoms, side-effects, and blood pressure. A daily opioid
withdrawal score was determined by assigning a numerical score
of 0 for absent, +1- for mild, +2 for moderate, and +3 for severe
to the following signs and symptoms: diaphoresis; rhinnorhea;
lacrimation; yawning; piloerection; myalgia/arthralgia; chills;
nausea/vomiting; insomnia; and anorexia. Each day, subjects
were asked if they were experiencing any of 38 side effects
including amnesia, blurred vision, constipation, delirium,
dizziness, drowsiness, dry mouth, dysphoria, edema, hallucina-
tions, headaches, lethargy, nocturia, numbness, photophobia,
polyuria, sedation, tremor, tinnitus, and weakness. In
addition, subjects were asked if they felt GA suppressed with-
drawal; produced euphoria or a "high"; if it had a narcotic
"feel," and if they had used heroin in the previous 24 hours.
Urine samples were collected every other day and analyzed for
the presence of morphine. Subjects were given the option to
discontinue GA at any time, or enter a standard methadone or
propoxyphene napsylate detoxification program.
RESULTS
Subjects were a very experienced group of opioid addicts as
indicated by demographic and drug use characteristics listed in
Table One. Forty (40) of 47 (85.1%) subjects returned for more
than one clinic visit, and 33 of 47 (70.2%) reported that GA
suppressed withdrawal (Table Two). Compared to a maximum of 30
possible points, withdrawal scores were very low. Mean scores
were as follows: Day one, 5.3; Day two, 7.7; Day three, 5.6; Day
five, 4.8. Only one (2.1%) subject reported that GA produced a
"high" or "felt" like a narcotic. Five (5; 10.6%) chose to take
GA for the maximum allowed time of 14 days. Mean retention was
5.0 days. Although 14 (29.8%) reported they ceased heroin use
during GA administration, only five (5; 10.6%) demonstrated
complete opibid withdrawal by producing a urine specimen devoid
of morphine.
The beginning dose of 4 mg given twice per day was satisfactory
for all but nine (9; 19.1%) subjects. Six (6; 12.8%) were given
4 mg three times per day for a total 24-hour dosage of 12 mg,
and three (3; 6.4%) subjects requested a 24-hour dose of 16 mg.
One methadone maintenance patient elected to stop GA and return
to methadone maintenance. The other five (5; 10.6%) dropped out
of treatment within five days following admission. Seven (7;
14.9%) of the subjects elected to switch to standard methadone
or propoxyphene napsylate detoxification during the study
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period. No subject reduced either systolic or diastolic blood
pressure by as much as 10 mm Hg during the study. Mean systolic
blood pressures were as follows:
Day One - 115.0 mm Hg Day Three - 120.0 mm Hg
Day Five - 117.2 mm Hg Day Ten - 112.4 mm Hg
Mean Diastolic blood pressures were:
Day One - 74.5 mm Hg Day Three - 75.4 mm Hg
Day Five - 76.0 mm Hg Day Ten - 73.2 mm Hg
The major reported side-effects were dry mouth, lethargy, and
weakness.
(Table Two)
DISCUSSION
Alpha-two agonists, including clonidine and lofexidine, appar-
ently block opioid withdrawal by suppressing the major noraden-
ergic nucleus, the locus coeruleus. The effects of electrical
or pharmacological activation of this nucleus produce changes
that resemble those of opiate withdrawal.4,9 Clonidine has been
shown in double-blind, placebo-controlled studies to suppress
withdrawal, so it, therefore, has proved to be an effective
opiate withdrawal agent.3-5
GA, a new, long-acting alpha-two agonist which has a longer half-
life than clonidine, appeared to have some effectiveness in treat-
ing opioid withdrawal. In this pilot study, 40 of 47 (85.2%)
stated that GA was effective in suppressing withdrawal symptoms.
Withdrawal scores were low in those subjects who remained in the
study. Several reports have shown that ineffective drug-depend-
ence treatments invariably result in failure of patients to return
to an outpatient setting, so the demonstration of return visits
should be regarded as a measure of patient acceptance.11,12
Subjects did not report that GA produces euphoria or feels like a
narcotic, so GA's abuse potential is probably negligible.
GA appears to have some clinical advantages over clonidine. It
has a half-life of 6 to 12 hours, and the majority of our
subjects (38, 80.9%) required only a dose of 4 mg twice'per day
(8 mg total in 24 hours) to adequately suppress withdrawal. In
outpatients, .1 to .2 mg of clonidine must usually be adminis-
tered four times per day to suppress opiate withdrawal, and this
dose frequently causes hypotension and a degree of lethargy and
weakness that causes many patients to shun treatment.5-7,10
have recently reported on over 200 opioid-dependent outpatients
we treated with clonidine.6,7 Approximately 40% developed such
severe lethargy that they refused to take clonidine at all, and
we have not succeeded in getting more than 5% of patients to
take clonidine for 14 days. In particular, we have not been
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successful in promoting acceptance of clonidine in heroin
addicts and have had to relegate its use almost entirely to
patients who wish to withdraw from methadone maintenance.6,7,10
The most common outpatient use we have found for clonidine is
for transition from methadone to naltrexone maintenance.10
Although the GA subjects reported here represent a relatively
small number of subjects treated on a non-blind basis, there was
lower incidence of lethargy and hypotension than that we have
observed with clonidine. GA also was accepted by heroin addicts
and many referred friends to the study. We have not observed
clonidine to be a detoxification agent which heroin addicts
prefer when methadone maintenance patients we attempted to
withdraw either returned to methadone or dropped out of the
study within five days. It is possible that clonidine and GA
may have subtle pharmacologic differences that make the former
more suitable for methadone and GA superior for heroin with-
drawal. Superiority of one compound over another and the
specific indications for each, however, must be determined by
studies in other settings as well as double-blind comparisons.
GA appeared, in this pilot study, to be a useful withdrawal
agent for some opioid-dependent persons. It appears equal or
superior to clonidine in that it can usually be given in twice
per day doses and has fewer side-effects. The theory that
alpha-two agonists effectively treat opiate withdrawal by nor-
adrenergic suppression is supported by data in this study.
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TABLE ONE
DEMOGRAPHIC AND DRUG USE CHARACTERISTICS
OF STUDY GROUP
N=47
Mean age (yrs) 29.5
Caucasian or Hispanic 47 (100%)
Females 12 (25.6%)
Total years heroin use (mean) 8.9
Number of previous treatment attempts (mean) 2.3
Heroin dependence on day of admission 41 (87.2%)
Methadone dependence on day of admission 6 (12.8%)
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TABLE TWO
ASSESSMENTS AND OUTCOMES OF GUANABENZ (GA) SUBJECTS
N=47
Number returned for one or more clinic visits
Number reported GA suppressed withdrawal
Number reported GA produces euphoria high
Number reported GA feels like a narcotic
Number completed 14 days
Mean number days in treatment
Number reported heroin cessation during
treatment
Number submitted morphine-negative urine
after admission
Number switched to methadone or propoxyphene
detoxification
Reported Side-Effects
Dry Mouth
Lethargy
Weakness
Drowsiness
Headache
Nocturia
Dizziness
Blurred vision
Constipation
Number had over 10 mm Hg drop in systolic
blood pressure
40 (85.1%)
33 (70.2%)
1 (2.1%)
1 (2.1%)
5 (10.6%)
5
14 (29.8%)
5 (10.6%)
7 (14.9%)
13 (27.7%)
13 (27.7%)
9 (19.1%)
8 (17.0%)
6 (12.8%)
5 (10.6%)
5 (10.6%)
3 (6.4%)
3 (6.4%)
3 (6.4%)
0 (0%)
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Opioids Alter Tumor Cell Growth
and Differentiation In Vitro
Ian S. Zagon and Patricia J. McLaughlin
INTRODUCTION
Heroin is an opioid that is best known for its analgesic and behav-
ioral properties (Jaffe and Martin 1980). Several investigators
have also demonstrated that perinatal exposure to heroin affects
somatic, as well as neural, growth in both humans (Wilson 1975;
Wilson et al. 1979, 1981) and laboratory-animals (Zagon and Mc-
Laughlin 1982). Heroin also appears to alter the growth of abnor-
mal neural tissues (Zagon and McLaughlin 1981). Mice inoculated
with neuroblastoma and receiving chronic treatment with heroin ex-
hibit retarded tumor development and prolonged survival; these
antitumor effects are not apparent when naloxone, a narcotic antag-
onist, is co-administered with heroin. These findings suggest that
opioids, most likely through an interaction at the opiate receptor
level, affect growth and development.
The present investigation was designed to explore the effect of
heroin on cellular events under in vitro conditions, thus eliminat-
ing any confounding influences (e.g., drug metabolism, endorphin
release, hormonal interaction) present in an intact biological
system. Cultures of murine neuroblastoma cells were subjected to
various dosages of heroin and cell proliferation (growth curves,
mitotic coefficients) and morphological differentiation (cell! pro-
cess lengths) were evaluated.
METHOD
Cell cultures. Murine tumor cells, S2OY neuroblastoma, cloned from
the A/Jax mouse Cl300 neuroblastoma, were obtained from Dr. M.
Nirenberg (NIH, Bethesda, MD); passage numbers 19-22 were utilized.
Cells were grown in Falcon plastic flasks (75 cm2) containing 15 ml
Dulbecco's medium with 10% donor calf serum and 0.225% Na2 CO3 in a
humidified atmosphere of 5% CO2/95% air at 37°C. Cells were seeded
at a density of 5x105 cells per flask. Drugs were added 36 hr
post-seeding; culture medium was changed every 24 hr thereafter.
Cultures were observed daily by phase microscopy.
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Drugs. Diacetylmorphine (heroin) was obtained from the National
Institute on Drug Abuse, Bethesda, MD, and naloxone was a gift from
Endo Laboratories, Garden City, NY. All drugs were prepared by
dissolution in-sterile water. Control cultures received comparable
volumes of sterile water.
Cell growth. Cells were harvested by rapping the culture flasks,
and centrifuging the homogenate in culture medium. Harvested cells
were counted with a hemacytometer at 400X magnification. Cell via-
bility was determined by the trypan blue exclusion test. For each
drug dosage at every time point monitored, 3 flasks were sampled.
Cells from each drug dosage were counted at 12, 24, 48, and 72 hr
after the addition of drug.
Mitotic index. Mitotic indices and assessment of differentiation
were conducted on cells grown on 22 mm round coverglasses in 60 x
15 mm plastic tissue culture dishes (Falcon); cells were seeded at
2x105 cells per dish. The coverglasses were fixed with 2 percent
glutaraldehyde in 0.07 M Sorenson's phosphate buffer and 3 percent
sucrose, stained with hematoxylin, inverted onto slides and mounted.
Forty-eight hours after addition of heroin, at least 1000 cells
were counted at 400X magnification from 4 or more coverglasses per
drug treatment, and the percentage of mitotic cells calculated.
Cell differentiation. The formation of cell processes that were
greater in length than the average cell diameter (40 µm) was con-
sidered indicative of "morphological differentiation" (Ishii et al
1978; Monard et al. 1973). Cells grown on coverglasses and fixed
as described above were stained with cresyl violet, inverted onto
slides, and mounted. At 48 hr post drug addition, the number of
cells having processes greater than or equal to 40 µm was determined
by light microscopy at 400X magnification; cells with multiple
processes were only scored once. Cells were counted from fields
selected in a random manner; at least 200 cells/coverglass from 3
or more coverglasses per drug treatment were examined.
Statistics. The number of live cells attached to the culture
flasks, as well as number of mitotic cells, were analyzed using
analysis of variance, with subsequent comparisons performed with
the Newman-Keuls test. Number of differentiated cells was analyzed
using analysis of variance.
RESULTS
Cell growth and differentiation. Fig. 1 shows the effects on growth
of neuroblastoma cells when heroin, at concentrations ranging from
10-2M to 10-8M, or sterile water, was added 36 hr after plating.
The addition of heroin to cell cultures resulted in a decrease in
the number of cells within 12 hr, with cultures receiving 10-2M,
10-4M, 10-6M, and 10-8M heroin having 87, 70, 73, and 48 percent,
respectively, fewer cells than control cultures at this time point.
Twenty-four hr after receiving drug, the number of cells in the
10-8M heroin cultures was comparable to controls, but a dose-re-
sponse reduction in cell number was observed for all other heroin-
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treated cultures. At 72 hr post-drug administration when the con-
trol and 10-8M heroin cultures were confluent, 10-6M, 10-4M, and
10-2M heroin cultures had 54, 56, and 99 percent, respectively,
fewer cells. Cytotoxicity, as evidenced by cell death, was only
noted in cultures given 10-2M heroin; fewer cells were observed in
these cultures at 48 hr and 72 hr post-drug administration than
recorded immediately prior to heroin treatment (i.e., at 36 hr).
FIGURE 1
The number of viable S20Y neuroblastoma cells
per culture flask plotted as a function of time.
Heroin in concentrations of 10-8M 1 0 - 6 M
10 - 4M 10
-2M o r
sterile water was added to cultures
36 hr after seeding. Significantly different
from controlsat p<0.05 (*) or p<0.01 (**)
The percentage of dividing cells in control and heroin-exposed
cultures is presented in Fig. 2a. At 48 hr after drug treatment,
a time of active cell proliferation in control cultures, cell cul-
tures exposed to 10-2M, 10-4M, and 10-6M heroin often had signifi-
cant reductions in the number of mitotic cells (mitotic indices
ranged from less than 1 to 14 percent). Cells treated with 10-8M
heroin were comparable to control cultures in mitotic coefficients
at 48 hr post-drug administration.
In general, heroin was observed to inhibit differentiation (Fig.
2b), with a subnormal number of differentiated cells noted in the
heroin-treated cultures. In contrast to the control cultures at
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48 hr in which 25 percent of the cells were differentiated, only
3-6 percent of the cells in the 10-2M and 10-8M heroin cultures
were differentiated. Cultures receiving 10-4M heroin had signifi-
cantly fewer differentiated cells than controls, whereas 10-6M
heroin cultures had a comparable number of differentiated cells
as control cultures.
FIGURE 2
The precentage of mitotic (a) and differ-
entiated (b) cells at 48 hr after addition
of heroin in cultures of S2OY neuroblastoma
cells. Heroin at concentrations of 10-8M
10-6M 10-4M and 10-2M or sterile water'
were added 36 hr after seeding. Significantly
different from controls at p<0.01 (*).
In order to determine if naloxone, an opiate antagonist, blocks
the effects of heroin on cell growth, 36-hr cultures of neuro-
blastoma were treated with solutions of either 10-4M  heroin, 10-4M
heroin and 10-4M naloxone, or sterile water. Cell cultures exposed
to heroin alone had fewer cells than were present in control cul-
tures at nearly all time points (Fig. 3). However, neuroblastoma
cell cultures exposed to both heroin and naloxone were comparable
to control cultures in growth.
DISCUSSION
The results of the present study confirm and extend previous
reports (e.g., Willson et al. 1976; Simon 1971; Corssen and Skora
1964; North-Root et al. 1976) that opiate treatment of neural and
non-neural cells and tissues maintained under in vitro conditions
alters growth processes. As evidenced by growth curves and mitotic
coefficients, heroin appears to exert an inhibitory effect on cell
division of S2OY neuroblastoma cells that is dose-response in nature.
At high drug dosages, cell death may even occur, since the number
of cells recorded at 48 hr and 72 hr after addition of 10-2M
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FIGURE 3
The number of viable S2OY neuroblastoma
cells per 75 cm culture flask plotted as a
function of time. The cells were grown
the presence of 10-4M heroin 10 - 4M
heroin and 10-4M naloxone (o-.-.-o), or
sterile water Drugs were added 36 hr
after seeding. Significantly different from
controls at p<.01 (*).
heroin decreased below pre-drug levels.
Although an inhibition of cell proliferation is often accompanied
by an increase in morphological differentiation (e.g., Prasad 1971;
Bear and Schneider 1976), this did not appear to be the case with
heroin. In the present investigation, heroin-exposed cultures that
were growth retarded usually contained significantly fewer differ-
entiated. cells relative to control cultures. Moreover, our results
show that cell differentiation may be a more sensitive indicator
of heroin's actions on cell function than growth inhibition, since
cultures of neuroblastoma cells exposed to dosages of heroin that
generally caused little growth retardation (i.e., 10-8M) were noted
to significantly alter activities related to morphological differ-
entiation.
The present study demonstrates that heroin's action in perturbing
cell division and differentiation may be related to certain speci-
fic features of opiates because concomitant administration of nal-
oxone, a well-known opiate antagonist, blocked heroin's effects.
Since the presumed locus of interaction between naloxone and nar-
cotic drugs is the opiate receptor, and narcotic receptors are
known to be present. in S2OY neuroblastoma cells (Klee and Nirenberg
1974), heroin's actions on cell activity appear to be mediated by
opiate receptors. These receptors could directly regulate differ-
ent physiological and biochemical processes related to cell function
(e.g., changes in ion concentrations, enzyme activity, or membrane
potential). Alternatively, the interaction of heroin with narcotic
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receptors may trigger another sequence of events important to
cellular integrity.
In an earlier study, we (Zagon and McLaughlin 1981) investigated
the effects of heroin on mice inoculated with neuroblastoma.
Daily SC injections of heroin, initiated 2 weeks prior to tumor
cell inoculation of 106 S2OY cells, were observed to prolong median
survival time by up to 50%, and to retard tumor growth. Furthermore
a number of animals receiving heroin did not develop tumors within
the post-inoculation period. Even when heroin treatment was init-
iated one week after tumor transplantation, a time when tumors were
sizeable, at least one dosage (i.e., 6 mg/kg) of heroin did prove
effective in retarding tumor growth and prolonging the lifespan
of neuroblastoma-bearing animals. Extrapolation of in vitro data
to in vivo studies suggests that heroin could be altering the
course of neuroblastoma in mice by inhibiting cell proliferation.
Finally, heroin has been found to alter normal growth mechanisms.
Children exposed to heroin in early life display a retardation in
growth, including being smaller in stature, lighter in weight, and
having smaller head circumferences. Laboratory studies in which
heroin was chronically administered to pregnant rats also provided
similar documentation of growth retardation (Zagon and McLaughlin
1982). The progeny of these heroin-treated mothers had lower
birthweights than controls, indicating intrauterine problems in
development. During the preweaning period (up to 21 days), these
offspring continued to be subnormal in body weight. Thus, from
these data as well as those mentioned earlier with our tumor
experiments, heroin exerts an extremely potent effect on the growth
of both normal and abnormal cells. Moreover, our data would suggest
that mechanisms underlying this effect bear a distinct relationship
to the opiate receptor.
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Annual Reports
A new format is being introduced this year to present the
evaluation data from the testing facilities of the Medical
College of Virginia (MCV) and the University of Michigan (UM).
After an overall review by Dr. Jacobson and brief introductory
presentations from each group, the data on individual compounds
has been combined into a single report. NIH numbers only are
used.
Certain data come only from one laboratory. Thus, the hotplate
and Nilsen data come from Dr. Jacobson's laboratory at the NIH,
while the rat infusion and other antinociceptive data come from
MCV. The guinea pig ileum, rat vas deferens, and binding data
come from UM. The monkey data is labeled separately as to its
origin.
We hope this new format will make these annual reports easier
to reference and more useful.
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Biological Evaluation of
Compounds for Their Dependence
Liability. VII. Drug Testing
Program of the Committee on
Problems of Drug Dependence,
Inc. (1983)
Arthur E. Jacobson
The Drug Testing Program of the Committee on Problems of Drug
Dependence (CPDD) has continued uninterrupted over its ca. 35 years
of existence, as an arm of the Committee directed towards the
determination of the potency of analgesics and discernment of their
dependence potential and abuse liability. The methodology which is
utilized, and the actual researchers and affiliated groups, have
changed somewhat over these three decades but the data which have
been obtained from this Program, published annually in one form or
other, stands as a basic framework of knowledge in the field. At
the present time, two university groups, as well as my laboratory at
the National Institutes of Health (NIH, NIADDK) are sponsored by the
CPDD for this effort. Funding, in large measure, comes from the
U.S. Government via the National Institute on Drug Abuse (ADAMHA), and
from NIH for my laboratory. Details of the procedures for
submission of samples from researchers, and of the in vivo and in
vitro assays, were described in my 1980 report (Jacobson 1981). The
work of the Drug Testing Program was expanded this year to include
three other groups of researchers, in order to examine stimulants
and depressants.
NEW TESTING PROGRAM - STIMULANTS AND DEPRESSANTS
In order to evaluate contemporary procedures which might be capable
of determining the dependence potential and abuse liability of
stimulants and depressants, three groups were chosen by the CPDD
which had been involved in research in these areas for some time and
had previously documented their procedures, These were groups under
the direction of Drs. J. Brady and N. Ator in the Department of
Psychiatry and Behavioral Sciences at the Johns Hopkins University
School of Medicine, Drs. C. R. Schuster and C. Johanson in the
Department of Psychiatry at the University of Chicago School of
Medicine, and Dr. C. Gorodetzky at the Addiction Research Center of
NIDA, in Lexington, Ky. Compounds were submitted to these groups in
the same manner as those submitted to the groups which test
analgesics, under a code number, with proof of purity (thin layer
chromatograph), molecular weight, and some solubility data. Their
preliminary reports were summarized at this Annual meeting by Dr. J.
Woods, and will be printed in this Annual Report. The CPDD has
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recommended that the work continue in 1984. Eventually, the
submission of samples to these groups will be handled through the
office of the Executive Secretary of the CPDD. The expansion of the
program to include samples submitted by researchers interested in
obtaining these data will be considered by the CPDD at the 1984
Annual Meeting, if the procedures prove to be useful for these
purposes. A joint meeting of the Stimulant/Depressant Testing
groups was held in April at the University of Chicago for a
discussion of the results which had been obtained. Dr. H. Sorer,
from NIDA, attended this meeting. Dr. Sorer’s involvement in the
Drug Testing Program has served to bring to the attention of NIDA
management the relationship between the CPDD's program and NIDA's
grants/contract programs in these biomedical areas.
PRECLINICAL DRUG TESTING PROGRAM ON ANALGESICS
The three involved groups, Drs. L. Harris, M. Aceto, and E. May in
the Department of Pharmacology of the Medical College of Virginia
(MCV), Drs. J. Woods, G. Winger, F. Medzihradsky, C. Smith, and J.
Katz in the Department of Pharmacology of the University of Michigan
(UM), School of Medicine, and myself at NIH, met with the NIDA
representative, Dr. H. Sorer, prior to both the interim and annual
meeting of the CPDD for general discussion of the program. A
jointly sponsored paper, on the pharmacology of C-homobenzomorphans,
is in the process of revision for the Japanese Journal of
Pharmacology. Another paper, on the pharmacology of various
peptides, is under consideration for publication by these groups in
1984. Two papers have previously appeared as the result of our
joint collaborative effort (Woods et al. 1983, Jacobson et al.
1982).
NEW FORMAT FOR ANNUAL REPORT FROM UM/MCV
Individual Annual Reports from MCV and UM will continue to be
distributed at the Annual Meeting of the CPDD. However, in order to
better utilize the data which have been obtained from MCV and UM, it
was decided to combine both reports into a single report for
publication in the Proceedings. Thus, rather than seeking data on
individual compounds in the separate reports, these data will be
more readily observed from their combination. Effort will be made
to identify the source of the data. All compounds will now be
identified through a single number, the NIH number assigned to the
compound, rather than through three separate numbering systems (i.e.
- UM, MCV and NIH numbers). Indexing of this combined report in the
Proceedings will be through the NIH number. The combined report
will, as well as aid the individual perusing this literature, save
considerable space in the printed volume, since antinociceptive data
need only be stated once for the compound, and only one molecular
structure will need to be listed rather than the duplication which
was necessary for separate reports.
The combined MCV/UM report will list compounds in, more-or-less,
random order. A more helpful ordering of them for medicinal
chemists would be by classical molecular structural types (e.g.-
morphinans, 4,5-epoxymorphinans, benzomorphans, pethidines, etc.).
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Tables 2 through 7 present the data of the combined MCV/UM annual
report in that classical framework. A highly abbreviated summary of
the biological data which have been obtained is included for each of
the compounds in the tables so that the reader can obtain an
impression of the characteristics of these compounds compared with
other members in that molecular class.
The Committee is indebted to the scientists at MCV and UM for the
continued excellence of their work and for their major contribution
to the field of analgesics represented by their Annual Report.
ORIGIN AND NUMBER OF SAMPLES SUBMITTED FOR EVALUATION -
The origin of the compounds examined by the Drug Testing Program has
been classified into seven sources in table 1. It can be seen in
that table that over 50% of the samples came from U.S. and foreign
universities. About 65% of the university samples were from the
U.S. The university samples combined with those from NIH constitute
over 75% of the total number of submissions this year. Quite
obviously, far fewer compounds are being sent by either U.S. or
foreign pharmaceutical industries this year and last year than
during. the previous three years. It is difficult to know whether
this trend will be reversed in the future, since annual fluctuation
in the percentage of submissions from each of the groups noted in
table 1 has been the norm, and is to be expected. However, the
major drop in the submission of samples from industrial sources seen
over the past four years may be a cause of future concern to the
program. The diminution of compounds sent to us by industry is only
partially reflected in the number of compounds sent to MCV/UM in
1982-1983 and is just fortuitously mirrored by the reports to the
CPDD from MCV/UM. The World Health Organization was responsible for
our examination of one compound this year.
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MOLECULAR CLASSES OF EXAMINED COMPOUNDS
The epoxymorphinans were the most numerous of the various types of
examined compounds. In table 2 and 3, the new compounds are shown
to be amides at C-14 (NIH 9915-9917), quaternary amines of specific
isomeric structure (NIH 9836-9837,9991-9995, C-6 substituted
oximes and hydrazines (NIH 10001, 10003-10005, 10008) , and a C-5
methyl substituted endoethanooripavine (NIH 10064). The p-tolyl
substituted N-ally1 group appeared to confer narcotic antagonist
activity on NIH 9916. A p-chlorophenyl substituted N-allyl (NIH
9917) did not have that effect. Among the quaternary amines, only
NIH 9994 appeared to have antinociceptive effect, as well as some
narcotic antagonist activity. Its stereoisomer, NIH 9991, had no
effect.
A limited nunber of morphinans, and only one homobenzomorphan, were
examined this year. The new morphinans, as shown in table 4, had
methoxy groups at C-4 (NIH 9959, 9997, and 10016), and an aromatic
unsubstituted 14-hydroxymorphinan (NIH 10007) was also examined.
The homobenzomorphan (NIH 9896) did not appear to act through opioid
receptors.
The benzomorphans are shown in table 5. Enantiomeric compounds with
disparate groups substituted on nitrogen were examined (NIH 10019,
10097-10098, 10167-10168). NIH 10168 was a fairly potent narcotic
antagonist.
In table 6, the hydroxy-substituted phenylmorphans (NIH 10006 &
10154) showed considerable stereospecificity. The more potent
isomer was morphine-like in SDS in monkeys.
The oxide-bridged decahydroisoquinoline in table 7 was one of the
most interesting compounds examined this year. Although
morphine-like in potency as an antinociceptive, it had little effect
in GPI and VD, and that effect in the tissue preparations was not
antagonizable. However, the compound binds to opioid receptors in
RBH with high affinity. It did not appear to be morphine-like in
SDS and was a potent narcotic antagonist.
ABBREVIATIONS USED IN TABLES 2 - 7
Antinociceptive assay (ED50, SC injection, mice) [Confidence limits
are listed in MCV/UM report]: HP = hot plate; N = Nilsen; PPQ =
phenylquinone; TF = tail flick; TFA = tail flick antagonism vs.
morphine.
I = inactive, without a reasonable dose-response relationship,
or insufficiently active for statistical analysis.
Receptor Binding Affinities:
RBH (EC50 by displacement of 0.5nM H-etorphine) = binding affinity,
without sodium, to rat cerebrum membrane preparations, in nM
(parenthesized nunber is ratio of +Na/-Na). The EC50 of morphine,
for comparison = 14.0 (1.69). NE = no effect.
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GPI = electrically stimulated guinea pig ilem EC50. E = x10
(parenthesized numbers are maximum percent inhibition at EC50);
[bracketed, letters: A = antagonized by 10-7M naltrexone; NA q not
antagonized by naltrexone; NE = no inhibition of twitch].
VD = electrically stimulated mouse vas deferens EC50 values. E =
x10 (parenthesized numbers are maximun percent inhibition at EC50);
[bracketed letters: A = antagonized by 10-8M naltrexone; NA = not
antagonized by naltrexone; NE = no inhibition of twitch; SA = slight
antagonism by naltrexone]
Data From Monkey Colonies:
SDS = single dose suppression: NS = no suppression; CS = complete
suppression; PS = partial suppression. (Parenthesized numbers =
dose range studied, in mg/kg) . Potency comparison with morphine [M]
may be stated, in brackets.
NW = studies in non-withdrawn monkeys: PW = precipitated
withdrawal at dose levels, in mg/kg, indicated in parenthesis &/or
comparison with naloxone [N], in brackets; NP = no precipitation; SP
= slight precipitation
Other Studies:
RI = rat infusion: NS = no suppression; CS = complete suppression;
PS = partial suppression. 
PPD = primary physical dependence.
SA = self-administration : NE = no effect; High = codeine-like; IN
= intermediate between saline and codeine; SE = slight effect.
Normal monkeys: M-like = morphine-like effect.
DD = drug discrimination.
The numbers used in the tables may be rounded. For precise values,
and details of the procedures, see the MCV/UM report in these
Proceedings.
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Evaluation of New Compounds
for Opioid Activity (1983)
James H. Woods, Gail D. Winger, Fedor Medzihradsky,
Charles B. Smith, and Jonathan L. Katz
The evaluation of new compounds by the programs at the Univer-
sity of Michigan and the Medical College of Virginia is coordi-
nated by Dr. Arthur E. Jacobson, Medicinal Chemistry Section,
NIADDK, National Institutes of Health, Bethesda, MD. The drugs,
which come originally from pharmaceutical companies, univer-
sities, and government laboratories, are submitted to Dr.
Jacobson, who performs the MOUSE ANALGESIA tests. Values
obtained in these tests for some representative opioid drugs are
given in Table I.
At the UM and MCV laboratories, drug samples arrive from Dr.
Jacobson with only the following information: (1) an identi-
fying NIH number, (2) molecular weight, (3) solubility informa-
tion and (4) a recommended starting dose. Only after the
evaluation is complete and the report submitted back to Dr.
Jacobson are the chemical structure and the mouse-analgesia data
released to the evaluating laboratory.
DEPENDENCE EVALUATION IN RHESUS MONKEYS
The single-dose suppression test (SDS) determines the ability of
a drug to suppress the signs of withdrawal in monkeys which have
been made dependent by the chronic administration of morphine (3
mg/kg every six hours). Compounds suspected of having morphine-
antagonist properties are tested for their ability to precipi-
tate the withdrawal syndrome in nonwithdrawn (NW) morphine-
dependent monkeys. Nondependent monkeys (Normals) are used to
determine whether the acute effects of the test drug are rever-
sible by nalorphine or naloxone. In a primary dependence study
(PDS), nondependent monkeys receive the test drug every six
hours for 30 days to determine whether withdrawal signs will
appear when the animals are challenged with an antagonist or
when drug administration is discontinued.
Details of these techniques have been presented in the ANNUAL
REPORT to the Committee in 1963 (Minutes of the 25th Meeting) by
Deneau and Seevers (1963) and by Villarreal (1973).
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SELF-ADMINISTRATION BY MONKEYS
Tests of self-administration determine the ability of the drug
to maintain responding in monkeys trained to self-inject
codeine. Each of at least three monkeys was studied with saline
as a negative control and a number of doses of the test compound
until a maximum rate of responding was obtained or until, in the
absence of evidence of a reinforcing effect, directly observable
changes in behavior were produced by the compound.
The schedule of intravenous drug delivery was a fixed-ratio 30;
when a light above a lever was illuminated, the 30th response
produced a five-second intravenous drug injection accompanied by
another light that was illuminated during drug delivery. After
each injection, a ten-minute timeout condition was in effect
during which responses had no scheduled consequence and neither
light was illuminated. Each of the two daily sessions consisted
of 13 injections or 130 minutes, whichever occurred first.
Other details of the procedure and initial findings with a
variety of narcotics are given in previous reports (Woods, 1977;
1980).
Doses of the drugs are typically described in terms of moles/kg/
injection (inj), to facilitate direct comparisons among drugs.
Duplicate observations of codeine (7.5 x 10-7 mol/kg/inj; 0.32
mg/kg/inj) and of saline were obtained for each monkey. A
saline substitution was conducted before and after the series of
observations on a test drug; the control rates of codeine-
reinforced responding were obtained by a random sampling of two
sessions between the drug-substitution sessions. These data are
represented in the following graphs with individual symbols for
each of the monkeys; each symbol is the mean of duplicate obser-
vations for a given dose in each monkey. There are two addi-
tional types of averaged data presented. The closed circles
indicate the averaged data for observations on the subset of
monkeys used to indicate the codeine and saline rates of
responding of 20 monkeys studied under the same conditions. The
brackets indicate ± 3 standard errors of the codeine mean, and +
3 standard errors of the saline mean for the group of 20
monkeys. In all cases, the rates of responding given are those
calculated during only the fixed-ratio portion of each session.
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
Details of the binding assay were described in the 1978 ANNUAL
REPORT (Swain et al., 1978). Briefly, aliquots of 3a membrane
preparation from rat cerebrum were incubated with 3H-etorphine
in the absence and presence of 150 mM NaCl, and in the presence
of different concentrations of the drug under investigation.
Stereospecific, i.e., opiate receptor related, interaction of
3H-etorphine was determined as the difference in binding ob-
tained in the presence of an appropriate excess of dextrorphan
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TABLE I
MOUSE ANALGESIA. Before submission to the The University of Michigan, all compounds are evaluated
for analgesic activity by Or. Arthur E. Jacobson. Shown below are comparative data (ED 50 mg/kg)
(95% Confidence Interval) from Hot Plate and Nilsend assays. umol/kg
HOT PLATE NILSEN
TABLE II Continued
and levorphanol, respectively. The potency of the drugs in
inhibiting the stereospecific binding of 3H-etorphine was
determined from log-probit plots of the data. It Should be
noted that since April 1982 the concentration of 3H-etorphine
in the binding assay was reduced from 3.0 nM to 0.5 nM, a con-
centration approaching the KD of the radiolabeled opiate. This
change was implemented in order to let the determined EC50
approximate the true Ki. of a given drug. However, due to the
different concentration of the radiolabeled ligand, the EC50s
determined since April 1982 are lower than those obtained
previously. For the purpose of reference, Table II contains
EC50 values of representative opiates determined in binding
assays using 0.5 nM 3H-etorphine.
INHIBITION OF TWITCH OF ISOLATED SMOOTH MUSCLE PREPARATIONS
In the past, submitted drugs have been evaluated on two smooth
muscle preparations, the details of which were described in the
1978 ANNUAL REPORT (Swain et al., 1978). Shown in the following
pages are the EC50's for the tested drug alone, for the drug in
the presence of naltrexone (a pure opioid antagonist which is
more effective against so-called "mu" agonists than against so-
called "kappa" agonists), and for the drug in the presence of UM
979 (an antagonist which appears to be more effective against
"kappa" than against "mu" drugs) (Smith, 1978). The maximum
depression of the electrically induced twitch in each of the
preparations is also indicated. The concentrations of both nal-
trexone and UM 979 used in tests of antagonism are always 10-7M
for the guinea-pig ileum and always 10-8M for the mouse vas
deferens. Recently, the drug evaluation procedure has been
modified. The guinea-pig ileal preparation has not proven to be
reliable and may give false positive results. Therefore, the
preparation is only used as a supplementary assay. Drugs are
still evaluated on the mouse vas deferens as described pre-
viously. There have been small additional modifications in pro-
cedure. First, naltrexone, 10-7M, is the only antagonist used.
Second, the ability of naltrexone, in an equimolar concentra-
tion, to reverse the inhibition of the twitch by active drugs
is assessed. Finally, the ability of each drug conducted to
reverse the inhibition of the twitch produced by a maximally
effective concentration of morphine is measured in order to
determine whether the unknown drug has antagonistic activity.
SUMMARY OF TESTS PERFORMED
The compounds which were evaluated at the University of Michigan
during the past year and the individual tests which were
performed are shown in Table III. Also shown are dates of
Annual Reports in which results are reported of earlier tests on
those compounds conducted at Michigan.
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TABLE II
EC50 of representative opiates in displacing
0.5 nM 3H-etorphine in a membrane preparation from rat cerebrum
Compound -NaCl
UM 911 14.6
Morphine 14.0
Dextrorphan 6180
UM 1071R 1.14
Ketazocine 10.7
Ethylketazocine 5.22
(-)SKF 10047 4.09
Etorphine 0.47
(-)Cyclazocine 0.85
Naltrexone 1.43
EC50 (M)
+NaCl
28.3
23.6
9820
1.55
14.1
6.60
3.93
0.37
0.53
0.63
+Na/-Na
1.94
1.69
1.59
1.36
1.32
1.26
0.96
0.79
0.63
0.44
NOTE: Binding data for these and other compounds, determined in
binding assays using 3.0 nM 3H-etorphine, are included in the
1978 and 1981 ANNUAL Reports.
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TABLE III
SUMMARY OF TESTS PERFORMED
Dependence Studies of New
Compounds in the Rhesus
Monkey, Rat, and Mouse (1983)
M. D. Aceto, L. S. Harris, and E. L. May
Technical Assistants
F. Tom Grove, R. F. Jones, and S. M. Tucker
All the test drugs except vasopressin, pentazocine, and the
dynorphin fragments were supplied by Dr. Arthur Jacobson, Medici-
nal Chemistry Section, NIADDK, under the auspices of the
Committee on Problems of Drug Dependence, Inc. The chemical
structures of the test compounds, excluding SKF 10,047 (-)-
Nicotine, vasopressin and the dynorphin fragments, were unknown
to us when they were originally submitted.
For the most part, the procedures described by Seevers and his
colleagues (1936, 1963) and Deneau (1956) regarding the facil-
ities and training of the monkeys were used and a brief des-
cription follows. The monkeys were injected with 3 mg/kg S.C.
of morphine sulfate every six hrs for at least 90 days before
being used. This dose schedule was reported by Seevers and
Deneau (1963) to produce maximal physical dependence.
Modified procedures for the precipitated withdrawal (PPt-W) and
single dose suppression (SDS) tests were reported by Aceto and
co-workers (1977 and 1978). The PPt-W test was initiated by
the injection of a test drug 2 1/2 hrs after an injection of
morphine and the animals were observed for signs of withdrawal.
The SDS test was started approximately 15 hrs after the last
dose of morphine at which time the animals were showing with-
drawal signs. The onset and duration of action of the test-drug
were noted. In both tests, a vehicle control and an appropriate
positive control (naloxone, 0.05 mg/kg or morphine sulfate,
3.0 mg/kg) along with three different treatments (doses) of a
test compound were studied. Usually, three or four groups per
compound were used. The observer was "blind" with regard to the
treatment given. A minimum two-week washout and recuperation period
between tests was allowed. In the primary physical dependence
(PPD) test, the animals of a group received the drug every four
to six hrs for 30-50 days. They were placed in abrupt withdrawal
and challenged with naloxone periodically and were observed for
signs of physical dependence. All potency estimates are rough
approximations only.
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The rat-infusion method was reported by Teiger (1974) and certain
modifications are indicated as follows. Semi-restrained male,
Sprague-Dawley rats were medicated by continuous infusion
through indwelling, intraperitoneal cannula for six days with the
drugs. Rats were anesthetized and each was fitted with a specially
prepared cannula which was passed subcutaneously from the nape of
the neck to the lateral side of the lower abdomen and then in-
serted in the peritoneal cavity. The cannula was anchored at
both ends with silk sutures and attached to a flow-through; swivel
mechanism which allowed the animal to move about in the cage and
eat and drink normally. The swivel was connected to a syringe which
was attached to a syringe pump. The animals received 7 to 10 ml
of solution every 24 hrs.
In the substitution for morphine (SM) test, the animals first
received morphine (50 mg/kg/24 hrs from days 3-6). Then, a test
drug was substituted for two days. The morphine controls received
an infusion of water. The animals were observed for changes in
bodyweight and for behavioral withdrawal signs for one-half hr
at 6,24,48,72 and/or 96 hrs after stopping the infusion of morphine.
In the primary physical dependence (PPD) study, the rats received
test compound for six days and then were placed in abrupt with-
drawal and observed as above.
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Table 1
Comparative Data-ED50 mg/kg S.C. (95% C.L.) of Selected
Standards in 3 Mouse Agonist-Antagonist Tests
Drug Tail-Flick Tail-Flick An- Phenylquinone
Test tagonism Test Test
Pentazocine 15% at 10.0 18 (12.4-26) 1.65 (1.0-2.5)
Cyclazocine 17% at l.Oa 0.03 (0.O2-.78) 0.011 (0.0046-
0.03)
Nalorphine None at 10.0 2.6 (0.69-9.75) 0.6 (0.25-1.44)
.HCL
Naloxone
.HCL
None at 10.0 0.035 (0.010-0.93) No Activity
Naltrexone None at 10.0 0.007 (0.002-0.02) No Activity
.HCL
Morphine 5.8 (5.7-5.9) - - - 0.23 (0.20-
Sulfate 0 . 2 5 )
aMice were ataxic at 3.0 and 10.0 mg/kg but no further increase
in reaction time was seen.
Three mouse tests were used in our laboratory at the Medical
College of Virginia to provide a preliminary estimate of the
potency and profile of activity of each test compound. The
tests were the tail-flick agonist (TF) and the morphine
antagonist (TF vs M) tests and the phenylquinone (PPQ) test
(Dewey et al., 1970; Dewey and Harris, 1971). Reference-
standard data for these tests are shown in table 1. In
addition, Dr. Jacobson provided us with estimated starting
doses. These doses were based on results obtained from the
mouse hot plate (HP) (Eddy and Leimbach, 1953; Jacobson and
May, 1965; Atwell and Jacobson, 1978) and Nilsen (N) (Parrine
et al., 1972) tests from his laboratory. Reference data for
these tests are shown in table 2.
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Table 2
Comparative Data (ED50 mg/kg s.c.) [95% S.E.] from the Hot Plate
and Nilsen Test
Naloxone .HCL and Naltrexone .HCL, no dose response.
Phenobarbital, Amobarbital, Valium, Oxazepam, Flurazepam,
Mepromate and Mescaline are inactive on the hot plate test.
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SUMMARY OF COMPOUNDS TESTEDa
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REPORT ON INDIVIDUAL COMPOUNDS
1983
NIH 7890. Naloxone hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 10.0
2) TF vs M - 0.035 (0.010 -
0.093
3) PPQ - No activity
4) HP - No dose-response
In this time course study, naloxone at 0.1 mg/kg produced 75%
antagonism of the ED80 of morphine sulfate in the tail-flick
test at 30 min, 60% antagonism at 60 min, and 15% antagonism at
120 min.
NIH 7958. 2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-
benzomorphan hydrochloride (Pentazocine).
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NIH 7958 (Con'd)
OBSERVATIONS IN THE MORPHINE DEPENDENT MONKEY (MCV)
MONKEY DATA # ANIMALS 4 3 7 5
(PPt-W) Doses (mg/kg s.c.) 7.5 7.5 5.0 2.5
3 9(Naloxone) 9(H2O)
1.25 0.05 1.0 ml/kg
Pentazocine is an unusual antagonist. The drug rarely preci-
piated the withdrawal signs rigid abdominal muscle and vocali-
zes when abdomen palpated. At 5.0, 7.5 and 10.0 mg/kg it pro-
duced ataxia and slowing which are not considered to be with-
drawal signs and at 10.0 it produced convulsions in 3/4 animals.
Pentobarbital was used to control the convulsions in 2 of the
animals. The withdrawal signs designated restless tremor,
drowsiness, retching, vomiting, salivation, avoids contact and
lying on side or abdomen were noted at the 2 higher doses. This
drug could be classified as a partial antagonist. It is about
50 times less active than naloxone.
NIH 9508. N-Cyclopropylmethyl-8 beta-ethyl-N-nordihydrocodei-
none hydrochloride.
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 16.8 (10.5 - 26.9)
Nilsen: 50% at 100
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DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS (UM)
Rates of responding maintained by NIH 9508 were only slightly
higher than those maintained by saline at doses of 7.44 x 10-9
and 7.44 x 10-8 mol/kg/inj). At doses of 2.48 x 10-8 and 7.44 x
10 mol/kg/injection, rates were no higher than those maintained
by saline.
NIH 9625. 1-[(2-alpha,6-alpha,llS)-(±)-1-(1,2,3,4,5,6-Hexa-
hydro-8-hydroxy-3,6,ll-trimethyl-2,6-methano-3-benzazocin-11-
yl]-6-methyl-3-heptanone methanesulfonate.
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 1.1 (0.8 - 1.3)
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone 1.94 x 1O-8 M 93.0
After naltrexone 2.60 x 1O-7 M 92.7
NIH 9625, 3 x 10-5 M, did not antagonize an equimolar concen-
tration of morphine. A maximally effective concentration of
NIH 9625, 10-6 M, was reversed by an equimolar concentration
of naltrexone.
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PRIMARY DEPENDENCE STUDY IN RHESUS MONKEYS (UM)
In studies in withdrawn morphine-dependent monkeys conducted at
The Medical College of Virginia, this drug neither suppressed
nor exacerbated withdrawal. A primary dependence study was
terminated prematurely as subjects were unconscious after in-
jections (See CPDD Proceedings 1980, 81). The present study
initially increased dose very slowly in an attempt to allow
more tolerance to develop to the sedative effects of the drug.
Subjects. Three rhesus monkeys weighing from 4.4. to 5.5 kg
were used. Each monkey lost about 1.0 kg over the 32 days of
chronic drug administration.
Dosage Schedule. The drug was dissolved in water.
Day Dose (mg/kg/6 hr, s.c.)
1 1.0
2 3.0
5 5.6
12 10.0
23 17.0
35 abrupt withdrawal
Subjects were tested for precipitation of withdrawal with nalor-
phine on days 15 and 29, and with naloxone on days 18 and 32.
Acute Effects. There were no obvious effects of 1.0 mg/kg.
with the increase in dose to 3.0 mg/kg, there was some pupil
dilation, scratching, and decreases in activity and eating.
Chronic Effects. Apparent tolerance developed to effects at 3.0
mg/kg by the third day so the dose was increased to 5.6 mg/kg
with little increase in effects. Since the subjects were losing
weight, that dose was maintained until the 12th day of the study
when it was increased to 10.0 mg/kg. At this dose one monkey
(FQ-35) was observed to assume peculiar postures with little
muscle tone but could be aroused by observers. All three mon-
keys lost weight at this dose. Additionally, abscesses devel-
oped at injection sites. At 17.0 mg/kg a second monkey showed
a loss of muscle tone and was lying on the cage floor. This
subject also could be aroused by observers. On the fifth day
at 17.0 mg/kg, monkey FQ-35 was found dead one hour after an
observation indicating no obvious effects.
Dependence. Nalorphine. administered on days 15 and 30 produced
very mild, if any, signs of withdrawal. Naloxone had greater
effects than nalorphine. Subjects were observed to be lying on
their sides, vocalizing, and restless after naloxone administra-
tion on day 33. With the abrupt discontinuation of drug admin-
istration, only very mild signs of withdrawal were observed in
the two surviving monkeys.
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NIH 9733. (-)-Nicotine di-l-tartrate.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - 5.2 (2.7 - 10.0)
2) TF vs M - 1.6 (0.03 - 15.0)
3) PPQ - 1.3 (0.5 - 5.2)
4) HP - 2.2 (1.6 - 3.0)
5) N - 19.6 (13.6 - 28.1)
PRIMARY DEPENDENCE STUDY IN RHESUS MONKEYS (MCV).
This primary physical dependence study in 5 non-tolerant rhesus
monkeys was recently completed in which (-)nicotine-di-l-tar-
trate was administered chronically for 48 days. The treatment
regimen included 6 injections per day on weekdays at 6:00 a.m.,
9:00 a.m., noon, 3:00 p.m., 6:00 p.m. and midnight. The start-
ing dose was 0.35 mg/kg SC (as base). This dose was gradually
escalated with occasional reductions or adjustments, so that
the animals received 4.9 mg/kg SC per injection by day 44.
Effects were dose-related and when the dose of 3.5 mg/kg was
reached, the animals exhibited salivation, lying on side abdo-
men, fighting, vocalizing, restlessness, drowsiness, wet-dog
shakes, scratching, retching, coughing and vomiting. Convul-
sions were also seen. In spite of the severe effects produced
by the chronic administration of nicotine, the animals contin-
ued to gain body weight throughout the study. A certain degree
of tolerance developed which was quickly lost if the dose was
reduced or when the animals were placed in abrupt withdrawal at
15 and 30 days; at the end of the study, few signs were observed.
Naloxone (2.0 mg/kg s.c.) did not precipitate withdrawal signs.
The animals appeared worse after nicotine administration than
when the drug was withdrawn. In fact, the injection of nicotine
elicited many signs designated as withdrawal signs. We realize
that many mechanisms could account for these signs. Obviously,
more studies are required to determine the significance of these
results.
NIH 9836. N-Allylmorphinium bromide.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0 and 30.0
2) TF vs M - Inactive at 1.0 and
30.0
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3) PPQ - 14% at 1.0 and 30.0
4) HP - 0% at 20.0, 40% at 50.0
and 40% at 100.0
5) N - 0% at 20.0, 50.0, 100.0
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone 6.35 x 1O-7 M 49.6
After naltrexone 8.24 x 1O-8 M 3 7 . 3
Naltrexone, 3 x 10-5 M, caused a very slight reversal of the
inhibition of the twitch caused by an equimolar concentration
of morphine.
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
NIH 9836 failed to produce any effect in withdrawn monkeys
(5.6 - 17 mg/kg) or in nonwithdrawn monkeys (5.6 mg/kg).
NIH 9837. N-Methylnalorphinium iodide.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0 and 30.0
2) TF vs M - Inactive at 1.0 and
30.0
3) PPQ - 30% at 1.0 and 38% at
30.0
4) HP - 10% at 20.0, 10% at 50.0
and 20% at 100.0
5) N - 0% at 20.0, 50.0 and 100.0
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone 7.10 x 1O-9 M 30.5
After naltrexone 8.10 x 1O-8 M 35.5
Naltrexone, in an equimolar concentration, reversed the inhibi-
tion produced by a maximally effective concentration of NIH 9837.
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NIH 9837, in an equimolar concentration, reversed the inhibition
produced by a maximally effective concentration of morphine, 3 x
1O-5 M.
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
NIH 9837 failed to affect either withdrawn (5.6 - 10 mg/kg) or
nonwithdrawn monkeys (5.6 mg/kg). Drug supply depleted.
NIH 9652. 3-Cyclopropylmethyl-2,3,4,4a 5,6,7,7a octahydro-
1H-benzo[4,5]furyl[3,2-e] isoquinoline-9-01.
TF - 26% at 10.0; 21% at 50.0
2) TF vs M - 0.08 (0.02 - 0.41)
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
3) PPQ - 0.004 (0.001 - 0.10)
4) HP - 1.0 (0.65 - 1.6)
5) N- 1.7 (1.2 - 2.5)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
NIH 9652. was not studied in the binding assay due to solubility
limitations.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
In concentrations which ranged from 10-9 M to 3 x 10-4 M, this
drug caused only a slight inhibition of the twitch, which was
completely antagonized by naltrexone and UM 979. In all pre-
parations, this drug-increased the magnitude of the twitch at
concentrations of 10-4 M and greater.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50
High Affinity
Maximum Response
Drug alone 3.47 x 1O-7 M 53.6
After naltrexone 8.63 x 1O-8 M 42.9
After UM 979 1.17 x 1O-8 M 53.3
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Low Affinity
Drug alone 2.58 x 1O-5 M 70.1
After naltrexone 4.48 x 1O-4 M 63.4
After UM 979 5.20 x 1O-5 M 73.3
NIH 9652 had a biphasic inhibitory action upon the vas deferens.
Both naltrexone and UM 979 slightly antagonized the low affinity,
but not the high affinity action of the drug.
COMMENT
Due to the limited solubility of NIH 9652, it was studied using
DMSO as solvent for the smooth muscle preparations. Other com-
pounds have not been studied under these conditions.
OBSERVATIONS IN THE MORPHINE-DEPENDENT MONKEY (MCV)
MONKEY DATA 1 ,  2 ,  1 ,  2 ,  3 ,
A. (SDS)
# ANIMALS
Doses (mg/kg s.c.) 36.0 18.0 12.0 9.0 6.0
1 ,  2 ,  2 , 5(Vehicle), 4(Morphine)
4.5 3.0 1.5 1.0 m l / k g  3 . 0
In the dose range tested, the compound did not substitute for
morphine.
MONKEY DATA # ANIMALS 1 ,  2 ,  2 ,  2 ,  1 ,
(PPt-W) Doses (mg/kg s.c.) 36.0 18.0 9.0 4.5 2.25
1 ,  1 ,  1 ,  2 , 3 ,  4 ,  3 ,  1 ,
1.125 0.56 0.28 0.14 0.035 0.00875 0.0022 0.0005
8(H2O + Lactic Acid), 8(Naloxone)
1.0 ml/kg 0.05
Results: NIH 9652 precipitated withdrawal in the dose range
0.00875-36.0 mg/kg. At the 2 higher doses convulsions were
seen which were terminated by giving morphine (2 x 2.0 mg/kg)
and pentobarbital S.C. (20 mg). Some mild withdrawal signs
were seen at 0.00219 mg/kg. The drug appears to be more po-
tent than naloxone by one order of magnitude. Its duration
of action is at least 2½ hrs.
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NIH 9873. 3-(2-Ethyl-4,6-dimethyl-2-morpholinyl)phenol.
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate 2.1 (1.6-2.8)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 59.1 nM in absence of 150 mM NaCl
EC50 of 54.6 nM in presence of 150 mM NaCl
Sodium response ratio = 0.92
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
EC50 Maximum Response
Drug alone 2.94 x 1O-7 M 59.8
Both naltrexone and U M 979 abolished all responses to NIH 9873.
Concentrations of 10-4 M and higher caused increases in magni-
tude of twitch.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
After UM 979
SUMMARY
EC50 Maximum Response
9.49 x 1O-8 M 57.3
7.21 x 1O-7 M 42.0
1.72 x 1O-6 M 39.4
Though somewhat less potent, NIH 9873 appears to be morphine-
like upon both smooth-muscle preparations. The binding results
also indicate the compound is less potent than morphine with a
smaller sodium-response ratio.
NIH 9892. (+)-2-Butyl-5-(m-hydroxyphenyl)morphan hydrochloride.
MOUSE DATA ED50 (95% C.L.)
(mg/kg s.c.)
1) 12.2 (5.2 - 28.8
2) TF vs M - Inactive at 1.0
and 30.0
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3) PPQ - 0.7 (0.2 - 1.8)
4) HP - 2.6 (2.1 - 3.4)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 221 nM in absence of 150 mM NaCl
EC50 of 224 nM in presence of 150 mM NaCl
Sodium response ratio = 1.01
OBSERVATIONS OF THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
NIH 9892 precipitated a withdrawal syndrome in the monkey with
a potency 1/300 that of naloxone but with a comparable time
course.
NIH 9893. (+)-5-(m-Hydroxyphenyl)-2-pentylmorphan hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - 2.2 (0.8 - 6.5)
2) TF vs M - (0% at 1.0, 10.0
and 30.0
3) PPQ - 0.2 (0.1 - 0.7)
4) HP - 1.8 (1.6 - 2.7)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 51.6 nM in absence of 150 mM NaCl
EC50 of 41.7 nM in presence of 150 mM NaCl
Sodium response ratio = 0.87
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
EC50 Maximum Response
Drug alone
After naltrexone
After UM 979
6.56 x 1O-7 M 86.9
7.67 x 10-6 M 78.8
4.84 x 10-6 M 83.3
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INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
EC50 Maximum Response
6.56 x 1O-8 M
5.22 x 10-8 M
35.5
26.5
After UM 979 2.96 x 1O-8 M 18.3
At 10-4 M there was a contraction of the baseline.
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
NIH 9893 precipitated a withdrawal syndrome with a potency of
0.016 that of naloxone with a comparable time course.
SUMMARY
NIH 9893 appears to have a morphine-like activity upon the guinea
pig ileal preparation but not upon the vas deferens. Its actions
in the monkey indicate significant antagonist activity.
NIH 9896. (-)-4-Allyl-1-methyl-10-hydroxy-2,3,4,5,6,7-hexa-
hydro-1,6-methano-1H-4-benzazonine.
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: insufficient activity
at 50 mg/kg
Nilsen: inactive at 5.0 mg/kg
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BIINDING
NIH 9896 failed to displace significantly tritiated etorphine
up to a concentration of 2 x 10-6 M.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
At no concentration did this drug inhibit the twitch of this
preparation. Concentrations of 10-6 M and greater caused in-
creases in the magnitude of the twitch, and concentrations of
10-5 M and greater caused a baseline contraction of the pre-
paration. Neither naltrexone nor UM 979 altered these re-
sponses.
INHIBITION OF TWTICH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
NIH 9896 did not inhibit the twitch of this ption at any
concentration studied.
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SUMMARY
In the receptor binding assay and upon both the guinea pig ileum
and the mouse vas deferens, NIH 9886 appears to be devoid of
opiate-like activity.
NIH 9915. 14-ß-3-(4-Chlorphenyl)propionylaminomorphinone.
MOUSE DATA-ED50 (95% C.L.)
1) TF - 0.3 (0.1 - 0.6)
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 0.2 (0.1 - 0.3)
4) HP - 0.3 (0.2 - 0.4)
OBSERVATIONS IN THE MORPHINE-DEPENDENT MONKEY (MCV)
MONKEY DATA # ANIMALS 3 ,  3 ,  3 ,
(SDS) Doses (mg/kg s.c.) 0.25 0.5 1.0
3 (Vehicle dil HCl + H20 or DMSO) 3(Morphine)
0.25 or 1.0 ml/kg 3.0
At the highest dose, the drug substituted completely for mor-
phine. The onset of action was ½-l hr and the duration was >
2½ hr. At the intermediate dose, the drug substituted partially
for morphine and completely suppressed the withdrawal sign retch-
ing. Its potency is estimated as 2 times that of morphine.
NIH 9916. 14-ß-(4-Methylcinnamoyl)aminomorphi none.
MOUSE DATA-ED 5 0
(mg/kg s.c.)
(95% C.L.)
1) TF - 6% at 1.0, 10% at 10.0
and 35% at 30.0
2) TF vs M - 1.3 (0.2 - 6.9)
3) PPQ - 1.0 (0.3 - 3.0)
4) HP - 40% at 10.0 and 50.0,
20% at 20.0 and 70% at 100.0
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DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
NIH 9916 was not studied due to solubility problems.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
At no concentration did NIH 9916 cause an inhibition of the
twitch of this preparation.
For studies on the
solved in dimethyl
EC50 Maximum Response
6.37 x 1O-9 M 64.1
3.62 x 1O-8 M 61.4
3.15 x 1O-8 M 42.9
smooth-muscle preparations NIH 9916 was dis-
sulfoxide at a concentration of 10-3 M.
Drug alone
After naltrexone
After UM 979
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
SUMMARY
NIH 9916 appears to have opiate activity upon the mouse vas de-
ferens, but is devoid of activity upon the guinea pig ileal pre-
paration. This pattern of response is extremely rare; and, in
part may be due to conditions associated with the use of DMSO.
OBSERVATIONS IN THE MORPHINE-DEPENDENT MONKEY (MCV)
MONKEY DATA # ANIMALS 2 ,  3 ,  3 ,
(SDS) Doses (mg/kg s.c.) 10.0 20.0 40.0
3 (DMSO) , 3 (Morphine)
1.0 ml/1g 3.0
The compound did not substitute for morphine at any of the
doses tested. However, it did reduce the incidence of retching
and vomiting at all doses. The supply was exhausted.
NIH 9917. 14-ß-(4-Chlorocinnamoyl)aminomorphinone.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - 0.5 (0.1 - 1.7)
2) TF vs M - Inactive at 1.0
and 30.0
389
NIH 9917 (Cont'd)
3) PPQ - Solvent (DMSO) active
in this test
4) HP - 0.95 (0.7 - 1.3)
OBSERVATIONS IN THE MORPHINE-DEPENDENT MONKEY (MCV)
3 (DMSO) 3 (Morphine)
1.0 ml/kg 3.0
MONKEY DATA # ANIMALS 2 ,  2 ,  3 ,  1 ,
(SDS) Doses (mg/kg s.c.) 0.25 0.5 1.0 2.0
NIH 9917 substituted completely for morphine at the 2 higher
doses. The onset was prompt and the duration of action was
longer than that of morphine. At the highest dose, duration
of action was approximately 5 hours. Its potency is about 6
times morphine.
NIH 9930. Naltrexone hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg.s.c.)
1) TF - None at 10.0
2) TF vs M - 0.007 (0.002 -
0.021)
3) PPQ - No activity
In this time-course study, naltrexone at 0.2 mg/kg produced 95%
antagonism of the ED80 of morphine sulfate on the tail-flick test
at 30 min., 81% antagonism at 60 min., and was inactive at 2 hr.
In previous reports naltrexone is also numbered as NIH 8503.
NIH 9940. ±-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-4-
phenyl-2-naphthylamine hydrochloride.
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 60% at 100
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
NIH 9940, failed to displace tritiated etorphine significantly
up to a concentration of 6 x 10-6 M.
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INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
At no concentration did NIH 9940 cause an inhibition of the
twitch either in control preparations or in the presence of
naltrexone. Concentrations of NIH 9940 of 3 x 10-6 M to 3 x
10-5 M caused large increases in the magnitude of the twitch.
OBSERVATIONS IN MORPHINE-DEPENDENT RHESUS MONKEYS (UM)
At 5.6 and 10 mg/kg, NIH 9940 had no apparent effects in with-
drawn monkeys. At 17 mg/kg, the drug induced convulsions in
one monkey and significant tremors in another.
NIH 9955. (±)-2,9
chloride.
Dimethyl-5-(m-hydroxyphenyl)morphan hydro-
3) PPQ - a. 19% at 1.0 and 28%
at 30.0
b. 17% at 1.0, 20% at
10.0 and 17% at 30.0
4) HP - 10.0 (6.0 - 16.8)
5) N - 40% at 100
TF vs M - 5.0 (2.0 - 12.8)
MOUSE DATA-ED50(95% C.L.)
(mg/kg s.c.)
1) TF-Inactive at 1.0 and 30.0
NIH 9962. trans-4-Bromo-N-methyl-N-[2(1-pyrrolidinyl)cyclo-
hexyl]benzamide.
MOUSE DATA-ED50 (95% C.L.)
(MG/KG s.c.) 
1) TF - 3.7 (1.4 - 9.2)
2) TF vs M - Inactive at 1.0
and 30
3) PPQ - 6.8 (3.7 - 12.8)
4) HP - 5.7 (4.1 - 8.0)
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DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 2435 nM in absence of 150 mM NaCl
EC50 of 4767 nM in presence of 150 mM NaCl
Sodium response ratio = 1.96
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
Drug alone
After naltrexone
After UM 979
EC50 Maximum Response
1.27 x 1O-7 M 84.7
7.62 x 1O-6 M 67.6
2.35 x 1O-6 M 80.3
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone 4.2    x 1O-7 M 89.0
After naltrexone 4.02 x 1O-6 M 67.6
After UM 979 2.35 x 1O-6 M 80.3
OBSERVATIONS IN MORPHINE-DEPENDENT AND NORMAL RHESUS MONKEYS
(UM)
NIH 9962 failed to precipitate more severe withdrawal signs in
the morphine-dependent monkey, and also failed to suppress the
withdrawal syndrome. Rather, it produced signs of intoxication
similar to those of kappa agonists.
OBSERVATIONS IN THE MORPHINE-DEPENDENT MONKEY (MCV)
MONKEY DATA
(SDS)
# ANIMALS
Doses (mg/kg s.c.) 12.0 9.0 6.0 3.0
 2 ,  2 ,  4 ,  2 ,
4(Morphine)4(dilHcl + H2O)
1.0 ml/kg 3.0
NIH 9962 suppressed some withdrawal signs at all doses. Thus,
it substituted partially. Retching was the withdrawal sign that
was suppressed the most. At 9.0 and 12.0 mg/kg the drug substi-
tuted completely for morphine in 2/3 of the animals. The action
was slightly delayed and of brief duration, i.e., 1 hr. Tremors
were observed in some monkeys at the three higher doses.
MONKEY DATA # ANIMALS
Normal Monkeys Doses (mg/kg s.c.)
NIH 9962 was given to normal non tolerant rhesus monkeys at
doses of 12.0, 6.0 and 3.0 mg/kg s.c. respectively. Ataxia,
lying on side, slowing, drowsiness, sagging (body) and scratch-
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ing were the main effects noted. These effects developed
promptly and began waning after 1 hr. Drowsiness persisted
for 2½ hr. In another group of normal monkeys, 3 were given
12.0, 9.0 and 6.0 mg/kg S.C. respectively. One-half hr later
they were challenged with 0.5 mg/kg S.C. of naloxone. The
observed signs designated lying on side, ataxia, slowing,
restlessness, drowsiness, sagging, and scratching quickly sub-
sided. It appears that NIH 9962 produces many signs reminis-
cent of those seen after appropriate doses of morphine. How-
ever, the drug does not have a complete morphine-like profile.
DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS (UM)
GRAND AVERAGE
AVERAGE
NIH 9962 750
334
484
MOL/KG/INJECTION
NIH 9962 maintained self-injection responding at high rates in
one of three monkeys; in the two monkeys in which the drug
maintained lower rates, the rates of responding were marginally
above those of saline.
NIH 9962 produced drug-appropriate responding at 1.0 mg/kg in
one monkey and 3.2 mg/kg in another; each trained to discrimi-
nate ethylketazocine from saline.
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SUMMARY
NIH 9962 produced a novel spectrum of activity in the various
preparations. Though somewhat less potent than morphine in the
smooth-muscle preparations, its actions were reversed by both
antagonists, a pattern of effects indicative of morphine-like
compounds. Unlike morphine, it produced baseline contractures
in both preparations at high concentrations.
The drug was markedly less potent than morphine in the binding
assay. However, its in vivo activity is markedly different from
morphine; in both the observational and drug discrimination stu-
dies NIH 9962 resembled ethylketazocine. The drug was consider-
ably less potent than ethylketazocine in producing these actions.
The actions of NIH 9962 were reversed by naloxone in the observa-
tional studies, suggesting that its actions are narcotic related.
In the drug self-injection studies, two of three monkeys main-
tained rates only marginally above saline; this is consistent
with findings on other ethylketazocine'like agents. The third
monkey, however, self-injected the drug at high rates. NIH 9962
should be studied in another set of monkeys to add evidence for
the resolution of these findings. Thus, these data suggest that
in the smooth muscle preparations the compound is morphine-like,
but the behavioral data in the rhesus monkey suggest an ethyl-
ketazocine-like action. The drug should also be studied in
monkeys trained to discriminate morphine-like agents from saline.
NIH 9971. (-)-2,9
chloride
Dimethyl-5-( m-hydroxyphenyl)morphan hydro-
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0 and 30.0
2) TF vs M - Inactive at 1.0 and
30.0
3) PPQ - 3.1 (1.1 - 9.3) 2.96
(0.91 - 9.61)
4) HP - 10.0 (7.2 - 13.9)
5) N - 25% at 50
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NIH 9972. (+)-2,9 Dimethyl-5-(m-hydroxyphenyl)morphan hydro-
chloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0 and 30.0
2) TF vs M - 4.5 (1.7 - 11.8)
3) PPQ - a. 8% at 1.0 and 3% at
30.0
b. 0% at 1.0, 9% at 10.0
and 0% at 30.0
4) HP - Inactive
5) N- Inactive
NIH 9991. N-Cyclopropylmethylmorphinium iodide.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0 and 30.0
2)
3)
4)
TF vs M - Inactive at 1.0
and 30.0
PPQ - 30% at 1.0, 4% at 30.0
HP - 20% at 20.0, 10% at 50.0
and 100.0
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
7.79 x 1O-8 M 53.2
7.35 x 1O-8 M 49.0
Drug alone
After naltrexone
After UM 979
A very high concentration of naltrexone, 3 x 10-4 M, caused a
very slight reversal of the inhibition produced by an equimolar
concentration of NIH 9991. NIH 9991, 3 x 10-5 M, caused a very
slight reversal of the effects of an equimolar concentration of
morphine upon this preparation.
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NIH 9991 (Cont'd)
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
At 5.6 and 10 mg/kg, NIH 9991 was without effect in withdrawn
monkeys. Depletion of drug supply precluded full evaluation of
in vivo activity.
NIH 9992. N-Methyl-N-ethylnormorphinium iodide.
MOUSE DATA-ED5O (95% C.L.)
(mg/kg s.c.)
1) TF - 1% at 1.0 and 12% at 30.0
2) TF vs M - Inactive at 1.0 and
30.0
3) PPQ - 17% at 1.0, 40% at 10.0,
55% at 30.0 and 55% at 50.0
4) HP - 0% at 20.0 and 50.0
NIH 9993. N-Ethylmorphinium iodide.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0 and 30.0
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 0% at 1.0, 29% at 30.0
4) HP - 0% at 20.0 and 100.0
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone 4.89 x 1O-8 M 56.0
After naltrexone 4.5  x 1O-8 M 38.5
NIH 9993, in a concentration of 10-5 M, did not reverse the in-
hibition produced by an equimolar concentration of morphine.
Naltrexone, 3 x 10-5 M, caused a very slight reversal of the
inhibition produced by an equimolar concentration of NIH 9993.
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NIH 9993 (Cont'd)
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
At 5.6 and 10 mg/kg, NIH 9993 was without activity in withdrawn
monkey. Depletion of drug supply prevented full characteriza-
tion of effects.
NIH 9994. N-Methyl-N-cyclopropylnormorphinium iodide.
NIH 9995. N-Methylmorphinium iodide
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - 3% at 1.0 and 20% at 30.0
2) TF vs M - 26% at 5.0, 3% at
10.0, 40% at 30.0
and 82% at 60.0
3) PPQ - 11.9 (2.9 - 47.9)
4) HP - 30% at 50.0
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0 and 30.0
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 2% at 1.0, 15% at 30.0
4) HP - 0% at 20.0, 50.0 and
100.0
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERNS
Drug alone
After naltrexone
EC50 Maximum Response
2.77 x 1O-7 M 55.1
6.08 x 1O-8 M 46.9
Naltrexone, 3 x 10-5 M, produced a very minute reversal of the
inhibition produced by an equimolar concentration of NIH 9995.
NIH 9995, 10-5 M, caused no reversal of the effects of an equi-
molar concentration of morphine upon this preparation.
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NIH 9995 (Cont'd)
OBSERVATIONS IN MORPHINE DEPENDENT RHESUS MONKEYS (UM)
NIH 9995 was without significant effect in withdrawn monkeys
at 5.6 and 10 mg/kg. Depletion of drug supply precluded full
characterization of effects.
NIH 9996. (-)-1-[N-(Cyclopropylmethyl)morphinan-3-yl]ethanone
D-tartrate.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - 1.3 (0.6 - 2.6)
2) TF vs M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.6 - (0.3 - 1.0)
4) HP - 1.3 (1.0 - 1.8)
5) N- 0.13 (0.06 - 0.30)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 22.4 nM in absence of 150 mM NaCl
EC50 of 26.8 nM in presence of 150 mM NaCl
Sodium response ratio = 1.20
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
EC50 Maximum Response
Drug alone 3.00 x 1O-7 M 45.4
After naltrexone 3.70 x 1O-6 M 53.6
After UM 979 completely blocked
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
After UM 979
EC50 Maximum Response
4.66 x 1O-8 M 96.9
4.69 x 1O-8 M 97.5
3.53 x 1O-8 M 97.2
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NIH 9996 (Cont'd)
OBSERVATIONS IN THE MORPHINE-DEPENDENT MONKEY (MCV)
MONKEY DATA # ANIMALS
(SDS) Doses (mg/kg s.c.) 2.0 1.0 0.5 0.25 0.125
1 ,  4 ,  3 ,  4 ,  1
5 (Morphine), 5(H20)
3.0 1.0 ml/kg
This compound abolished many withdrawal signs such as retching,
vomiting, rigid abdominal muscles, vocalization when abdomen
palpated, etc. However, tremor, slowing, drowsiness and body
sag were seen at the higher doses. The drug substituted par-
tially for morphine. Partial substitution does not necessarily
indicate that the drug is morphine-like.
DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS (UM)
GRAND AVERAGE
A V E R A G E
1608
NIH 9996 6 7 5
1 1 5
NIH 9996 maintained intermediate rates of drug self-injection,
the highest rate at a dose of 0.01 mg/kg/inj.
SUMMARY
The findings on the smooth muscle preparations reported for NIH
9996 resemble a number of other compounds we have examined, in-
cluding compounds such as baclofen. However, NIH 9996 has an
affinity comparable to morphine, unlike baclofen, in the binding
assay. Thus, NIH 9996 has a very interesting spectrum of action
in these preparations. Unlike baclofen, NIH 9996 maintains drug
self-injection responding. The potent antinociceptive activity
and the ability of the drug to substitute partially for morphine
in the dependent monkey also point to opioid-like activity for
the drug.
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NIH 9997. (-)-14-Hydroxy-4-methoxy-N-methylmorphinan.
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.89 (0.65 - 1.24)
Nilsen: 2.2 (1.7 - 3.0)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 281 nM in absence of 150 mM NaCl
EC50 of 347 nM in presence of 150 mM NaCl
Sodium response ratio = 1.23
INHIBITION OF TWTICH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
Drug alone
After naltrexone
After UM 979
INHIBITION OF TWITCH OF
Drug alone
After naltrexone
After UM 979
SUMMARY
EC50 Maximum Response
2.33 x 1O-7 M 62.2
2.12 x 1O-7 M 45.2
blocked
ELECTRICALLY DRIVEN MOUSE VAS DEFERNS
EC50 Maximum Response
8.68 x 1O-9 M 48.9
9.97 x 1O-9 M 27.0
6.77 x 1O-9 M 61.5
NIH 9997 was less potent on each preparation than morphine. Its
actions, however, on the smooth muscle preparations were not
morphine-like.
NIH 10,001. 6-Desoxy-6,6-hydrazinaloxone.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0 and 30.0
2) TF vs M - 0.06 (0.04 - 0.1)
3) PPQ - Inactive at 1.0 and 30.0
4) HP - 20% at 20.0, 0% at 50.0
and 100.0
5 ) N - Inactive
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NIH 10,001 (Cont'd)
TF vs M - Time Course Study
0.15 mg/kg AD80 oof NIH 10,001)
Time % Antagonism
30 min 77%
1 hr 44%
2 hr 44%
4 hr 14%
NIH 10,003. 6-Desoxy-6,6-hydrazinaltrexone.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0 and 30.0
2) TF vs M - 0.02 (0.01 - 0.03)
3) PPQ - Inactive at 10.0 and
30.0
4) HP - 20% at 50
5) N - Inactive at 100.0
1 hr
2 hr
4 hr
TF vs M - Time Course Study
0.09 mg/kg (AD80 of NIH 10,003
TIME
30 min
% Antagonism
93%
51%
0%
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 2.34 nM in absence of 150 mM NaCl
EC50 of 0.77 nM in presence of 150 mM NacL
Sodium response ratio = 0.33
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
Drug alone
After naltrexone
After UM 979
EC50 Maximum Response
1.09 x 1O-7 M 94.6
1.07 x 10-7 M 94.9
9.46 x 1O-8 M 89.6
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NIH 10,003 (Cont'd)
INHIBITON OF TWITCH
Drug alone
After naltrexone
After UM 979
SUMMARY
OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
4.74 x 10-6 M 94.3
1.63 x 1O-5 M 97.1
8.61 x 1O-6 M 75.5
NIH 10,003 is a very potent compound in the binding assay compar-
able to naltrexone with a lower sodium response ratio. Its in-
hibitory action upon the smooth muscle preparations was obtained
at 10-7 M and higher suggesting that NIH 10,003 will be a potent
naltrexone-like antagonist over a broad range of concentrations.
At higher concentrations, the drug has a non-opiate component of
inhibitory action in the guinea pig ileum and may have a narcotic
component of inhibitory action in the mouse vas deferens.
This interestino compound should be studied more extensivelv in
comparison to other naltrexone-like compounds
(NIH 9752), NIH 10,003].
NIH 10,004. 6-Desoxy-6-isonitrosonaltrexone.
[e.g., WIN 44,441
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0 and 30.0
2) TF vs M - 0.08 (0.03- 0.2)
3) PPQ - Inactive at 1.0 and
30.0
4) HP - 20% at 20.0, 50.0 and
100.0
5) N - Inactive at 100.0
TF vs M - Time Course Study
0.3 mg/kg (AD80 of NIH 10,004)
Time
30 min
% Antagonism
91%
1 hr 70%
2 hr 68%
4 hr 11%
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NIH 10,004 (Cont'd)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 1.96 nM in absence of 150 mM NaCl
EC50 of 0.90 nM in presence of 150 mM NaGl
Sodium response ratio = 0.46
INHIBITION OF TWTICH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
EC50 Maximum Response
Drug alone 1.40 x 1O-5 M 97.4
After naltrexone 1.18 x 1O-5 M 100
After UM 979 7.35 x 1O-6 M 83.2
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
After UM 979
EC50 Maximum Response
2.88 x 1O-5 M 75.9
In all preparations, NIH 10,004 caused a marked contraction of
the vas deferens at a concentration of 3 x 10-4. Naltrexone
markedly reduced and UM 970 completely abolished the response
to the drug at 10-4 M.
SUMMARY
NIH 10,004 resembles naltrexone in the binding assay, yet its
agonist actions on the smooth muscle preparations were not ob-
served until concentrations on the order of 10-5 M were reached.
This suggested that NIH 10,004 will be a potent antagonist in
vivo as it was in the mouse. The inhibitory actions of NIH
10,004 upon the guinea pig ileum were more efficacious than
morphine and were not reversed by either antagonist, suggesting
that the drug has a non-narcotic component of action at high
concentrations. Upon the mouse vas deferens, NIH 10,004 has a
narcotic component of action since its inhibitory effects were
reversed by both antagonists.
Obviously, this interesting compound should be studied in com-
parison to other naltrexone-like compounds [e.g. WIN 44,441
(NIH 9752) and NIH 10,003].
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NIH 10,005. 6-Desoxy-6,6-hydrazioxymorphine.
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.56
Nilsen: 0.45
(0.40 - 0.77)
(0.31 - 0.65)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 13.5 nM in absence of 150 mM NaCl
EC50 of 19.5 nM in presence of 150 mM NaCl
Sodium response ratio = 1.45
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
EC50 Maximum Response
Drug alone 4.49 x 1O-9 M 79.1
After naltrexone 3.53 x 10-6 M 55.6
After UM 979 3.81 x 10-7 M 39.5
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERNS
Drug alone
After naltrexone
After UM 979
SUMMARY
EC50 Maximum Response
4.58 x 1O-8 M 96.6
9.37 x 10-7 M 92.4
2.29 x 10-7 M 97.1
NIH 10,005 has significant opiate-like activity upon each of the
preparations. It was as potent as or slightly more potent than
morphine in the various assays.
NIH 10,006. 9 Hydroxy-5-(m-hydroxyphenyl)-2-methylmorphan
hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - 3.5 (2.5 - 5.0)
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 0.2 (0.07 - 0.4)
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NIH 10,006 (Cont'd)
4) HP - 1.9 (1.5 - 2.6)
5) N - 2.7 (2.2 - 3.2)
OBSERVATIONS IN THE MORPHINE-DEPENDENT MONKEY (MCV)
MONKEY DATA # ANIMALS 1 ,  3 ,  4 , 3 ,  1 ,
(SDS) Doses (mg/kg s.c.) 16.0 8.0 4.0 1.0 0.25
5(H2O) , 5(Morphine)
1.0 ml/kg 3.0
This compound substituted completely for morphine in 2/3 at 1.0
mg/kg, 2/4 monkeys at 4.0 mg/kg and 2/3 monkeys at 8.0 mg/kg.
The monkey receiving the highest dose did not require morphine
at the noon injection. Drug supply was exhausted. Potency is
about that of morphine.
NIH 10,007. (-)-14-Hydroxy-N-methylmorphinan.
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 3.6 (2.7 - 4.8)
Nilsen: 4.2 (3.0 - 6.0)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 661 nM in absence of 150 mM NaCl
EC50 of 503 nM in presence of 150 mM NaCl
Sodium response ratio = 0.76
INHIBITION OF TWITCH OF ELECTRICALLY
EC50
DRIVEN GUINEA PIG ILEUM
Maximum Response
Drug alone 4.16 x 10-7 M 74.2
After naltrexone 7.28 x 1O-5 M 70.6
After UM 979 1.35 x 1O-6 M 39.3
SUMMARY
In the binding assay, NIH 10,007 was considerably less potent
than morphine and the sodium response ratio was much lower. The
inhibitory responses in the smooth muscle preparations produced
by NIH 10,007 were antagonized by both antagonists, a pattern of
results like that expected from a morphine-like drug. The con-
tractures observed in both preparations at high concentrations
are uncharacteristic of morphine.
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NIH 10,008. 6-Desoxy-6-isonitroso-oxymorphone.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - 0.7 (0.3 - 1.7)
2) TF vs M - Inactive at 1.0
and 30.0
3) PPQ - 0.05 (0.01 - 0.2)
4) HP - 0.8 (0.7 - 1.0)
5) N- 2.0 (1.4 - 2.9)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 5.95 nM in absence of 150 mM NaCl
EC50 of 6.91 nM in presence of 150 mM NaCl
Sodium response ratio = 1.16
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
Drug alone
After naltrexone
After UM 979
EC50 Maximum Response
5.22 x 1O-9 M 73.8
1.63 x 1O-6 M 95.7
8.05 x 1O-8 M 100
SUMMARY
In both the binding assay and the guinea pig ileum NIH 10,008
was more potent than morphine; in addition the drug appears to
be morphine-like in its actions upon the guinea pig ileum as
demonstrated by its interactions with antagonists. The failure
of UM 979 to antagonize NIH 10,008 upon the mouse vas deferens
suggests that this is a very pure "mu" agonist upon this pre-
paration.
OBSERVATION IN THE MORPHINE-DEPENDENT MONKEY (MCV)
MONKEY DATA # ANIMALS 3 ,  3 , 2 ,
(SDS) Doses (mg/kg s.c.) 2.0 0.5 0.125
3(Morphine), 3(H2O)
3.0 1.0 ml/kg
At the highest dose, NIH 10,008 substituted completely for mor-
phine. The drug acted promptly and had a long duration of
action. Morphine was not required at the noon injection pe-
riod. The drug is slightly more potent than morphine.
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NIH 10,016. (-)-N-Allyl-3,4-dimethoxymorphinan-6-one.
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 10.6 (8.0 - 14.1)
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone 1.23 x 1O-7 M 36.0
After naltrexone 1.64 x 1O-7 M 24.8
Naltrexone, in an equimolar concentration, reversed the inhibi-
tion produced by a maximally effective concentration of NIH
10,016. NIH 10,016, in an equimolar concentration reversed the
inhibition produced by a maximally effective concentration of
morphine sulfate.
NIH 10,016 is much less potent and efficacious than morphine.
It appears to have both agonistic and antagonistic properties
upon this preparation.
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
NIH 10,016 produced a prompt severe withdrawal syndrome at 1.0
mg/kg in nonwithdrawn monkeys. Depletion of drug supply pre-
cluded a determination of relative potency.
NIH 10,019. (+)-5, 9 Dimethyl-2'-hydroxy-2-propynyl-6,7-
benzomorphan hydrobromide.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg. s.c.)
1) TF - Inactive at 1.0 and 30.0
2) TF vs M - Inactive at 1.0 and
3.0
3) PPQ - Inactive at 1.0 and 30.0
4) HP - 10% at 20.0 and 50.0,
20% at 100.0
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NIH 10,019 (Cont'd)
OBSERVATIONS IN THE MORPHINE-DEPENDENT MONKEY (MCV)
MONKEY DATA # ANIMALS 1 ,  2 ,  2 ,  1 ,
(SDS) Doses (mg/kg s.c.) 10.0 5.0 2.5 1.25
2(H2O) 2(Morphine)
1 ml/kg 3.0
At the 2 higher doses, severe ataxia was noted in one monkey
and the other appeared catatonic. These effects lasted for
about 30 minutes. The drug substituted partially and briefly
for morphine. Partial substitution does not necessarily indi-
cate that a compound is morphine-like. More work is recom-
mended. Drug supply was exhausted.
NIH 10,064. 5-Methylbuprenorphine.
1 ) TF - Inactive at 1.0, 15.0
and 30.0
2) TF vs M- 0% at 1.0, 4l% at
10.0 and 62% at 30.0
3 ) PPQ - 10% at 20, toxic at 50.0
(convulsions)
4) HP - Toxic at 20 (convulsions)
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
NIH 10,097. (-)-5,9 Dimethyl-2'-hydroxy-2-(4-methylpentyl)-
6, 7-benzomorphan hydrobromide.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - 20.6 (9.9 - 42.4)
2) TF vs M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.9 (0.3 - 3.1)
4) HP - 3.1 (2.4 - 4.1)
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NIH 10,097 (Cont'd)
OBSERVATIONS IN THE MORPHINE-DEPENDENT MONKEY (MCV)
MONKEY DATA # ANIMALS 3, 3, 2,
(SDS) Doses (mg/kg s.c. 3.0 1.5 0.75
3(Morphine), 3(H2O)
3.0 1.0 ml/kg
At the 2 higher doses, NIH 10,097 substituted completely for
morphine in 3/3 monkeys at 3.0 mg/kg and 2/3 at 1.5 mg/kg.
The onset was prompt and the duration short (approximately 90
min). The drug is approximately equipotent with morphine.
NIH 10,098. (+)-5,9 Dimethyl-2'-hydroxy-2-(4-methylpentyl)-
6, 7-benzomorphan hydrobromide.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 16.3 (5.7 - 45.8)
4) HP - 70% at 100.0 convulsions
OBSERVATIONS IN THE MORPHINE-DEPENDENT MONKEY (MCV)
MONKEY DATA #  A N I M A L S 2 , 2 , 1 ,
A. (SDS) Doses (mg/kg s.c.) 12.0 6.0 3.0
2(Alcohol, Tween 80 and H2O) 2(Morphine)
1.0 ml/kg 3.0
In the dose range of 3.0 - 12.0 mg/kg, NIH 10,098 did not sub-
stitute for morphine in dependent monkeys.
MONKEY DATA # ANIMALS 2 ,  2 ,  3 ,
B. (PPt-W) Doses mg/kg s.c.) 18.0 12.0 6.0
3(Naloxone), 3(Alcohol + Tween 80 + H2O)
0.05 1.0 ml/kg
The compound elicited some withdrawal signs but never produced
a full withdrawal syndrome. At the 2 higher doses, 2 monkeys
developed convulsions which were terminated with pentobarbital
injections.
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NIH 10,122.* Codeine phosphate.
MOUSE DATA-ED50 (95% C.L.)
(mG/kg s.c.)
1) TF - 14.5 (8.1 - 2.0)
2) TF vs M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 1.1 (0.5- 2.5)
4) HP- 9.3 (6.7 - 12.8)
5) N - 9.2 96.4 - 13.0)
INHIBTION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
NIH 10,122 produced a bfphasic dose-response relationship. The
first phase of-inhibition occurred between concentrations of
10-10 M and 10-6 M. The second phase of inhibition occured in
concentrations between 3 x 10-6 M and 3 x 10-4 M.
First Phase of Inhibition
EC50 Maximum Response
Drug alone 2.05 x 1O-9 M 43.1
After naltrexone 2.28 x 10-8,M 37.5
Second Phase of Inhibition
EC50 Maximum Response
Drug alone 4.19 x 1O-4 M 86.2
After naltrexone 6.12 x 1O-5 M 49.2
OBSERVATIONS IN THE MORPHINE-DEPENDENT MONKEY (MCV)
MONKEY DATA # ANIMALS
(SDS) Doses (mg/kg s.c.) 8.0 4.0 1.0 0.25 
3 ,  4 ,  2 ,  1 ,
4(Morphine), 4(H20)
3.0 1.0 ml/kg
NIH 10,122 substituted completely for morphine at the 2 higher
doses. The onset of action was delayed for about 30 min and
the duration was about 1½ hr at the highest dose and 1 hr at
the next active dose. The drug is slightly less potent than
morphine.
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NIH 10,122 (Cont'd)
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
NIH 10,122 completely reversed the withdrawal syndrome at 18
mg/kg. This is in substantial agreement with historical con-
trols.
*NIH 10,122 (Codeine) has previously been numbered NIH 00002.
NIH 10,123*. Levorphanol tartrate.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - 0.1 (0.04 - 0.2)
2) TF vs M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.05 (0.1 - 0.2)
4) HP - 0.21 (0.16 - 0.28)
5) N - 0.25 (0.17 - 0.35)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 3.37 nM in absence of 150 mM NaCl
EC50 of 4.73 nM in presence of 150 mM NaCl
Sodium response ratio = 1.27
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone 1.48 x 10-7 M 80.2
After naltrexone 3.43 x 10-6 M 83.4
After UM 979
MONKEY DATA
(SDS)
# ANIMALS 1 ,  3 ,  3 ,  3 , 1 ,
Doses (mg/kg s.c.) 1.6 0.8 0.4 0.1 0.025
4(H2O), 4(Morphine)
1.0 ml/kg 3.0
NIH 10,123 substituted completely for morphine at 1.6 and 0.8
mg/kg. The drug acted promptly and the duration of action was
similar to morphine. The drug is about 3 x as potent as mor-
phine.
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NIH 10,123* (Cont'd)
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY
UM 1410 completely suppressed the withdrawal syndrome at 1.0
mg/kg. This is in substantial agreement with historical con-
trols.
*NIH 10,123 (Levorphanol) has previously been numbered NIH 4590.
NIH 10,124.* Nalorphine hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - 12% at 1.0, 19% at 10.0,
12% at 30.0
2) TF vs M - 0.5 (0.1 - 1.7)
3) PPQ - 3% at 1.0, 49% at 3.0,
43% at 10.0 and 60% at 30.0
4) HP - 13.8 (9.0 - 21.3)
5) N - 27.0 (18.5 - 39.5)
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 8.10 nM in absence of 150 mM NaCl
EC50 of 5.43 nM in presence of 150 mM NaCl
Sodium response ratio = 0.67
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
After UM 979
EC50 Maximum Response
1.36 x 1O-7 M 47.7
8.88 x 1O-7 M 54.7
In the presence of morphine (3 x 10-5 M) a maximally effective
concentration of morphine, an equimolar concentration of NIH
10,124 caused a partial reversal of the inhibition produced by
morphine, which indicates that the drug has antagonistic activity.
In summary, NIH 10,124 is a partial agonist. It is approximately
l/10 as potent as morphine and less efficacious.
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NIH 10,124 (Cont'd)
OBSERVATIONS IN THE MORPHINE-DEPENDENT MONKEY (MCV)
MONKEY DATA # ANIMALS 2 ,  2 ,  1 ,
A. (SDS) Doses (mg/kg s.c.) 0.2 0.05 0.0125
2(Morphine), 2(H20)
3.0 1.0 ml/kg
The compound did not substitute for morphine. It appeared to
exacerbate withdrawal at the 2 higher doses. Vomiting was
noted at the highest dose.
MONKEY DATA
B. (PPt-W)
# ANIMALS 3 ,  3 ,  2 ,
Doses (mg/kg s.c.) 0.4 0.1 0.025
3(H2O) , 3(Naloxone)
1.0 ml/kg 0.05
At the 2 higher doses, NIH 10,124 precipitated withdrawal in
all the monkeys. The results were dose-related. Onset of ac-
tion was prompt and the duration about 1½ to 2 hr. The drug
is approximately 1/8 as potent as naloxone.
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
NIH 10,124 precipitated an intermediate grade of withdrawal at
0.1 mg/kg in nonwithdrawn monkeys. This is in substantial
agreement with historical controls.
*NIH 10,124 (Nalorphine) has previously been numbered NIH 2105.
NIH 10,154. 9ß-Hydroxy-5-(m-hydroxyphenyl)-2-methylmorphan
mandelate.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - 1% at 1.0, 9% at 10.0,
31% at 30.0 and 46% at 60.0
2) TF vs M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 8.6 (4.2 - 17.6)
4) HP - 30% at 100.0
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NIH 10,154 (Cont'd)
OBSERVATIONS IN MORPHINE-DEPENDENT MONKEYS - (MCV)
MONKEY DATA
(SDS)
# ANIMALS 2 ,  3 ,  3 ,
Doses (mg/kg s.c.) 18.0 12.0 6.0
3(Morphine), 3(H2O)
3.0 1.0 ml/kg
At-doses ranging from 3.0 to 18.0 mg/kg the drug did not sub-
stitute for morphine. The drug appeared to suppress retching
and wet-dog shakes at all doses. Drug supply was exhausted.
NIH 10,165. Ethylketocyclazocine methanesulfonate.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.) 
1)
2)
AD50 for naloxone vs NIH 10,165 in TF - 0.1 (0.04 - 0.25)
AD50 for naloxone vs NIH 10,165 in PPQ - 0.02 (0.04 - 1.6)
PPQ - 0.04 (0.02 - 0.1)
HP - 0.09 (0.07 - 0.12)
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Drug alone
After naltrexone
3)
4)
TF - 0.4 (0.1 - 1.0)
TF vs M - Inactive at 1.0,
10.0 and 30.0
EC50 Maximum Response
1.16  x 10-8 M 94.7
1.51 x 10-7 M 94.7
NIH 10,165 in an equimolar concentration did not reverse the
inhibition produced by a maximally effective concentration of
morphine, 3 x 10-5 M; this concentration of NIH 10,165 added to
the suppression of the twitch produced by morphine.
OBSERVATIONS IN THE MORPHINE-DEPENDENT MONKEY (MCV)
MONKEY DATA # ANIMALS 4 ,  7 ,  4 ,  2 ,
A. (SDS) Doses (mg/kg s.c.) 0.1 0.025 0.006 0.001
7 ( H 2 O ) , 7(Morphine)
1.0 ml/kg 3.0
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NIH 10,165 (Cont'd)
A. In a preliminary SDS study, one monkey received 0.25 mg/kg.
Within 5 min., the animal showed severe ataxia, tremors,
salivation, appeared depressed and became prostrate. Nalox-
one, (2 doses of 0.08 mg/kg) 5 min apart reversed all the
signs except salivation. In the full SDS study, the drug
substituted partially for morphine in all monkeys at the
highest dose, and in reducing-the incidence of retching,
vomiting, and vocalization when abdomen palpated. Relaxed
abdominal muscles were also noted. In two monkeys re-
ceiving the 0.006 dose, the drug appeared to substitute
completely for morphine for about 30 min. Interestingly,
the drug also produced a number of dose-related signs,
designated jaw and body sag, slowing, ptosis, ataxia,
tremors, salivation, and prostration in one animal.
B. Special Study in Normal Non-Addicted Monkeys. Two monkeys
were given 0.28 mg/kg of NIH 10,165. In one monkey, with-
in 5 min., the animal was prostrate and stopped breathing.
Naloxone (0.075) mg/kg ip and 0.075 mg/kg S.C. 5 and 15 min
later revived the animal. The other monkey showed the signs
ataxia, tremors, jaw and body sag, slowing, and was almost
prostrate. Naloxone 0.5 mg/kg reversed the syndrome.
OBSERVATIONS IN THE MORPHINE-DEPENDENT RHESUS MONKEY (UM)
In partially withdrawn monkeys, NIH 10,165 (0.03 mg/kg) produced
ataxia and sedation. At 0.1 mg/kg it increased the ataxia and
produced pupil dilation. At higher doses, these effects were
increased and ptosis and tremor were evident; however, signs of
withdrawal were not altered otherwise.
Naloxone (0.2 mg/kg) reversed substantially the effects of 0.1
mg/kg NIH 10,165 in normal monkeys.
*NIH 10,165 (Ethylketocyclazocine) has previously been numbered
NIH 8848.
This is in substantial agreement with historical controls.
Larger doses of naloxone were used earlier.
NIH 10,167. (+)-2-(3-Chloro-2-propenyl)-5,9 dimethyl-2'-
hydroxy-6,7,-benzomorphan hydrobromide.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs M - 23.9 (17.6 - 32.6)
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NIH 10,167 (Cont'd)
3) PPQ - 0% at 3.0, 0% at 10.0,
and 55% at 30.0
4) HP - 30% at 50.0
OBSERVATIONS IN THE MORPHINE-DEPENDENT MONKEY (MCV)
MONKEY DATA # ANIMALS 3 ,  3 ,  1 ,
A. (SDS) Doses (mg/kg s.c.) 4.0 1.0 0.25
3(Morphine), 3(H2O)
3.0 1.0 ml/kg
The drug did not substitute for morphine. At the highest dose,
jaw sag, ataxia and slowing were observed. Some slowing was
also observed at the intermediate dose.
MONKEY DOSE # ANIMALS 1 ,  2 ,  2 ,  1 ,
B. (PPt-W) Doses (mg/kg s.c.) 12.0 8.0 4.0 1.0
2(Naloxone), 2(H20)
0.05 1.0 ml/kg
The drug did not precipitate withdrawal. It did produce a num-
ber of signs including slowing, ataxia, and tremors. One monkey
receiving the 8.0 mg/kg dose showed all these signs and in ad-
dition fell off the perch and seemed unable to move. Two doses
of 0.05 mg/kg of naloxone helped reverse the syndrome consider-
ably. This type of activity resembles that produced by sigma
agonists and PCP.
NIH 10,168. (-)-2-(3-Chloro-2-propenyl)-5,9 dimethyl-2'-
hydroxy-6,7-benzomorphan hydrobromide.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs M - 0.004 (0.002 -
0.008)
3) PPQ - 1.7 (0.5 - 5.9)
4) HP - 20% at 20 mg/kg
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NIH 10,168 (Cont'd)
OBSERVATIONS IN THE MORPHINE-DEPENDENT MONKEY (MCV)
MONKEY DATA # ANIMALS 2 , 2 , 2(Morphine),
A. (SDS) Doses (mg/kg s.c.) 0.5 0.125  3.0
2(H2O)
1.0 ml/kg
In the dose range tested, NIH 10,168 did not substitute for
morphine. It seemed to exacerbate withdrawal.
MONKEY DATA # ANIMALS 1 ,  2 ,  2 ,  2 ,
B. (PPt-W) Doses (mg/kg s.c.) 1.0 0.25 0.06 0.015
2 ,
0.002
2(Naloxone), 2(H2O)
0.05 1.0 ml/kg
NIH 10,168 precipitated withdrawal at all the doses tested ex-
cept the lowest dose. The drug acts promptly and its duration
of action is similar to that of the reference compound naloxone.
It is approximately 3 x more potent than naloxone.
NIH 10,207. Alfentanil hydrochloride.
MOUSE DATA-ED50 (95% C.L.)
(mg/kg s.c.)
1) TF - 1.6 (1.0 - 2.5) 1.5
3) PPQ - 0.1 (0.05 - 0.2) 2.8
4) HP - 0.04 (0.03 - 0.05)
2) TF vs M - Inactive at 1.2,
10.0 and 30.0
NALOXONE AD50 vs NIH 10,207 in TF = 0.3 (0.1 - 0.6) 3.7
NALOXONE AD50 vs NIH 10,207 in PPQ 0 0.2 (0.1 - 0.5) 3.5
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 of 133 nM in absence of 150 mM NaCl
EC50 of 290 nM in presence of 150 mM NaCl
Sodium response ratio = 2.18
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NIH 10,207 (Cont'd)
INHIBITION OF TWITCH OF ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
EC50 Maximum Response
Drug alone 9.49 x 10-7 M 75.7
After naltrexone 1.07 x 1O-5 M 33.7
After UM 979
OBSERVATIONS IN THE MORPHINE-DEPENDENT MONEKY (MCV)
MONKEY DATA # ANIMALS 3 ,  1 ,  2 ,
(SDS) Doses (mg/kg s.c.) 0.2 0.05 0.0125
3(Morphine), 3(H2O)
3.0 1.0 ml/kg
NIH 10,207 substituted completely for morphine in all the ani-
mals at the highest dose. The action was rapid and duration
short (approx. 1 hr.). Scratching was also noted in these
animals. At the peak effect the drug is 10-15 times more
potent than morphine.
DRUG SELF-ADMINISTRATION IN RHESUS MONKEYS (UM)
GRAND AVERAGE
AVERAGE
NIH 10207
1392
A L F E N T A N I L
DD8
334
COMMENT
Alfentanil maintained extraordinarily high rates of drug self-
injection responding. One other narcotic test compound has
maintained higher rates of responding in the rhesus monkey than
codeine. (It, too, was a fentanyl analogue). Alfentanil also
maintained rates of responding over a broad range of doses with
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NIH 10,207 (Cont'd)
marked individual differences among monkeys in sensitivity to
the compound. Alfentanil was 10 times more potent than morphine
in terms of the maximal rate-maintaining dose (see attached
figure).
Drug discrimination in rhesus monkeys. Alfentanil produced com-
plete drug-appropriate responding in rhesus monkeys trained to
discriminate codeine from saline. It was 30-100 times as potent
as morphine in producing this effect. It has a rapid onset and
brief duration of discriminative effect in the monkey.
This is a potent morphine-like compound in each of the assays
described above. It may have been less active in the binding
assay due to the use of etorphine as the tritiated ligand.The
in vivo assays in primates suggest a potency range of 10-100
times that of morphine with a significantly shorter duration of
action. This latter property in addition to its rapid onset may
contribute to its capacity to maintain high rates of drug self-
injection responding.
NIH 10,303. Dynorphin-(1-13): H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-
iLE-aRG-Pro-Lys-Leu-Lys-OH.
OBSERVATIONS IN MORPHINE-DEPENDENT MONKEYS (MCV)
MONKEY DATA # ANIMALS 3 ,  5 ,  5 ,  3 ,
(SDS) Bose (mg/kg i.v.) 0.5 0.25 0.125 0.062
6(Saline)
2.0 ml
Dynorphin-(1-13) at 0.5, 0.25 and 0.125 mg/kg i.v. suppressed
withdrawal signs in a dose-related manner within 30 min. The
effects were
NIH 10,304.
OBSERVATIONS IN MORPHINE-DEPENDENT MONKEYS (MCV)
MONKEY DATA 4, 4, 3(Saline),
(SDS)
waning at 90 min.
Dynorphin (1-10) amide.
# ANIMALS
Dose (mg/kg i.v.) 0.5 0.25 2.0 ml
3(Morphine)
3.0
Dynorphin-(1-10) amide suppressed withdrawal signs at 0.5 mg/kg
i.v.
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NIH 10,306. Dynorphin-(1-6).
OBSERVATIONS IN MORPHINE-DEPENDENT MONKEYS (MCV)
MONKEY DATA # ANIMALS 4, 4, 3(Saline)
(SDS) Dose (mg/kg i.v.) 0 . 5 0.25 2.0 ml
3(Morphine)
3.0
Dynorphin (1-6) did not suppress withdrawal signs at 0.25 or
0.5 mg/kg i.v.
NIH 10,307. Neo-Endorphin.
OBSERVATIONS IN MORPHINE-DEPENDENT MONKEY (MCV)
MONKEY DATA # ANIMALS
(SDS)
4 , 4 , 3(Saline),
Dose (mg/kg i.v.) 0.5 0.25 2.0 ml
3(Morphine)
3.0
Neo-Endorphin did not suppress withdrawal signs at either
0.25 or 0.5 mg/kg i.v.
NIH 10,308. Vasopressin tannate (Pitressin).
OBSERVATIONS IN MORPHINE-DEPENDENT MONKEYS (MCV)
MONKEY DATA
A. (SDS)
# ANIMALS 4 , 4 , 3 ( H 2 O ) ,
Dose (s.c.) 20 units 10 units 1.0 ml/kg
3(Morphine)
3.0
Pitressin did not substitute for morphine. This substance may
have produced more retching than the control animals at approx-
imately 3 units/kg.
MONKEY DATA # ANIMALS 2 , 3 , 4  ,
B. (PPt-W) Dose (s.c.) 80 units 40 units 20 units
2(H2O) , 2(Naloxone)
1.0 ml/kg 0.05
In doses up to approximately 25 units/kg pitressin did not pre-
cipitate withdrawal in these dependent monkeys.
ACKNOWLEDGMENT: This study was supported by National Institute on
Drug Abuse contract #271-81-3830, Dr. Heinz Sorer, project officer.
AUTHORS' AFFILIATION: Medical College of Virginia, Department of
Pharmacology and Toxicology, Virginia Commonwealth University,
Richmond, Virginia 23298
420
Subject Index
Abstinence
morphine abstinence syndrome: cholinergic mechanisms in the
ventral periaqueductal gray of the dog, 143-149
treatment modalities in neonates, 282-288, 329
Addiction
perinatal addiction: effects of maternal narcotic and non-
narcotic substance abuse on the fetus and neonate, 220-226
Agonists
behavioral interactions of opioid agonists with serotonergic
systems in the rat, 179-184
differential tolerance and cross-tolerance to chronic treat-
ment with mu and kappa opioid agonists in the rat, 121-127
discriminative and analgesic effects of irreversible and re-
versible narcotic agonists, 136-142
interaction between mu, kappa and sigma agonists in the cat:
antitussive studies, 80-82
steric theory of opioid agonists, antagonists, agonist-anta-
gonists and partial agonists, 16-23
D-Ala2-D-Leu5-enkephalin (DADL)
binding competition experiments in human brain, 6
effects of ethanol on binding, 7
Alcohol
effect of chronic alcohol self-administration on luteinizing
hormone in monkeys, 159
self-administration in female primates: effects on reproduc-
tive function, 156-162
social control as an explanation of sex differences in its
use among adolescents, 296-304
Alcoholics
stimulus control of drinking, 47-58
Alfentanil hydrochloride (NIH 10,207, MCV 4374)
biological evaluation for dependence liability, 359
depression of smooth muscle twitch, 418
displacement of stereospecific 3H-etorphine binding, 417
mouse analgesia, 417
self-administration in monkeys, 418-419
(-)-N-Allyl-3,4-dimethoxymorphinan-6-one (NIH 10,016, MCV 4318,
UM 1383)
biological evaluation for dependence liability, 358
dependence studies in monkeys, 407
depression of smooth muscle twitch, 407
mouse analgesia, 407
(-)-4-Allyl-1-methyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1,6-
methano-1H-4-benzazonine (NIH 9896, MCV 4236, UM 1291)
biological evaluation for dependence liability, 358
depression of smooth muscle twitch, 387
displacement of stereospecific 3H-etorphine binding, 387
mouse analgesia, 387
421
N-Allylmorphinium bromide (NIH 9836, MCV 4277, UM 1342)
biological evaluation for dependence liability, 357
dependence studies in monkeys, 382
depression of smooth muscle twitch, 382
mouse analgesia, 381
N-Allylnormetazocine (SKF-10,047)
binding in the guinea-pig brain, 67-68
disruption of operant behavior in the rat, 180-182
effect on bombesin-induced scratching in rats, 116
N,N-bis-Allyl-Tyr-Gly-Gly-(CH2S)-Phe-Leu-Oh (ICI 154, 129)
effect on bombesin-induced scratching in rats, 116
Amobarbital
mouse analgesia, 364, 371
reinforcing properties and sensory/motor toxicity in baboons,
97
d-Amphetamine
discriminative stimulus properties of, 150-155
Analgesia
effect of pentazocine-tripelennamine combination in the rat,
67
Antagonists
behavioral interactions of opioid antagonists with seroton-
ergic systems in the rat, 179-184
steric theory of opioid agonists, antagonists, agonist anta-
gonists and partial agonists, 16-23
Antihistamines
interactions with opioids, 66-68
Antitussives
effect of optical isomers of opiates in the cat, 77-84
Aspirin
oral aspirin compared to oral fenoprofen and intramuscular
morphine in cancer patients with postoperative pain, 205-211
side effects in cancer patients, 207
Azidomorphine
effect on bombesin-induced scratching in rats, 116
Behavior therapy
use in conjunction with naltrexone to treat opiate addicts,
289-295
Benzodiazepines
behavioral and subjective effects in humans, 98-99
drug discriminative and physiological dependence, 163-164
Benzomorphans
an in vivo pharmacological analysis of binding sites in
rats, 114-120
Bombesin
scratching behavior in rats, 114
Bremazocine
effect on bombesin-induced scratching in rats, 116
trans-4-Bromo-N-methyl-N-[2(1-pyrrolidinyl)cyclohexyl]benzamide
(NIH 9962, MCV 4290, UM 1345)
biological evaluation for dependence liability, 359
dependence studies in monkeys, 392-393
depression of smooth muscle twitch, 392
displacement of stereospecific 3H-etorphine binding, 392
422
mouse analgesia, 391
self-administration in monkeys, 393
Buprenorphine
discriminative effects in pigeons, 138-139
effect on bombesin-induced scratching in rats, 116
mouse analgesia, 137-138
relative reinforcing properties in monkeys, 172-178
substitution for methadone in opioid-dependence treatment,
72-73
substitution in heroin-dependent patients, 73-74
use in opioid-dependence treatment, 72-74
(+)-2-Butyl-5-(m-hydroxyphenyl)morphan hydrochloride (NIH 9892,
MCV 4262, UM 1306)
biological evaluation for dependence liability, 359
dependence studies in monkeys, 386
displacement of stereospecific 3H-etorphine binding, 386
mouse analgesia, 385-386
l-(n-Butyl)-1-phenylcyclohexylamine (NNBPCA)
self-administration in baboons, 92-94
Caffeine
environmental studies in humans, 100-105
Carbachol
effect of microinjections in the periaqueductal gray of the
dog, 145
Cell growth
heroin effects on, 344-350
Cerebral ventricular changes
in newborns exposed to psychoactive agents in utero, 331
2-Chloroadenosine (2-CA)
effect on rota-rod performance in mice, 89
suppression of withdrawal contracture in guinea-pig ileum, 87
suppression of withdrawal effects in morphine-dependent
mice, 89
14-ß-(4-Chlorocinnamoyl)aminomorphinone (NIH 9917, MCV 4257)
biological evaluation for dependence liability, 357
dependence studies in monkeys, 390
mouse analgesia, 389-390
(-)-2-(3-Chloro-2-propenyl)-5,9 -dimethyl-2'-hydroxy-6,7-benzomor-
phan (NIH 10,168, MCV 4360)
biological evaluation for dependence liability, 358
dependence studies in monkeys, 417
mouse analgesia, 416
(+)-2-(3-Chloro-2-propenyl)-5,9 dimethyl-2'-hydroxy-6,7-benzomor-
phan (NIH 10,167, MCV 4359)
biological evaluation for dependence liability, 358
dependence studies in monkeys, 416
mouse analgesia, 415-416
14-ß-3-(4-Chlorphenyl)propionylaminomorphinone (NIH 9915, MCV 4255)
biological evaluation for dependence liability, 357
dependence studies in monkeys, 388
mouse analgesia, 388
Chlorpromazine hydrochloride
mouse analgesia, 364, 371
423
Cholinergics
morphine abstinence syndrome: cholinergic mechanisms in the
ventral periaqueductal gray of the dog, 143-149
Cigarettes
social control as an explanation of sex differences in its
use among adolescents, 296-304
ultradian consummatory cycles and smoking, 233-238
Clonidine
bioassay of subjective effects associated with drug with-
drawal in animals, 185-194
self-administration by methadone detoxification patients,
192-198
Cocaine
adverse effects of cocaine abuse, 247-254
discriminative stimulus properties of, 150-155
self-administration in baboons, 92-94
(-)-Codeine (NIH 0002, NIH 10,122, MCV 4125, MCV 4334, UM 1409)
antitussive potency in the cat, 79-80
biological evaluation for dependence liability, 357
dependence studies in monkeys, 410-411
depression of smooth muscle twitch, 410
effect on bombesin-induced scratching in rats, 116
inhibition of (-)-3H-codeine binding in the guinea-pig
medulla, 83
mouse analgesia, 363, 371, 410
(+)-Codeine
antitussive potentcy in the cat, 79-80
inhibition of (-)-3H-codeine bindings in the guinea-pig
medulla, 83
Conditioning
conditioned, tolerance effects, 38-42
opioid conditioning, 36-37
withdrawal-like effects, 36-39
Consummatory cycles
in non-smokers, smokers and ex-smokers, 235
Criminality
association with heroin addiction, 305-312
(+)-Cyclazocine (NIH 7981)
disruption of operant behavior in the rat, 180-181
effect on bombesin-induced scratching in rats, 116
mouse analgesia, 364, 370-371
(-)-Cyclazocine
antitussive potency in the cat, 79-80
displacement of stereospecific 3H-etorphine binding, 366
inhibition of (-)-3H-codeine binding in the guinea-pig
medulla, 83
(+)-Cyclazocine
antitussive potency in the cat, 79-80
inhibition of (-)-3H-codeine binding in the guinea-pig
medulla, 83
N6-Cyclohexyladenosine (CHA)
effect on rota-rod performance in mice, 89
suppression of withdrawal contracture in guinea-pig ileum, 88
424
suppression of withdrawal effects in morphine-dependent
mice, 89
Cyclo(Leu-Gly)
reversal of change in 3H-spiroperidol binding induced by
chronic morphine administration, 320-326
N-Cyclopropylmethyl-8ß-ethyl-N-nordihydrocodeinone hydrochloride
(NIH 9508, MCV 4142, UM 1325)
biological evaluation for dependence liability, 357
mouse analgesia, 378
self-administration in monkeys, 379
(-)-1-[N-(Cyclopropylmethyl)morphinan-3-yl]ethanone D-tartrate
(NIH 9996, MCV 4306, UM 1367)
biological evaluation for dependence liability, 358
dependence studies in monkeys, 399
depression of smooth muscle twitch, 398
displacement of stereospecific 3H-etorphine binding, 398
mouse analgesia, 398
self-administration in monkeys, 399
N-Cyclopropylmethylmorphinium iodide (NIH 9991, MCV 4300, UM 1348)
biological evaluation for dependence liability, 357
dependence studies in monkeys, 396
depression of smooth muscle twitch, 395
mouse analgesia, 395
3-Cyclopropylmethyl-2,3,4,4a ,5,6,7,7a octahydro-1H-benzo[4,5]
furyl[3,2-e]isoquinoline-9-0l (NIH 9652, MCV 4179, UM 1235)
biological evaluation for dependence liability, 359
dependence studies in monkeys, 384
depression of smooth muscle twitch, 383
displacement of stereospeicific 3H-etorphine binding, 383
mouse analgesia, 383
DADL
See D-Ala2-D-Leu5-enkephalin
Dependence
benzodiazepines: drug discrimination and physiological
dependence, 163-164
bioassay of subjective effects associated with drug with-
drawal in animals, 185-194
clinical evaluation of mecamylamine for withdrawal from
nicotine dependence, 239-246
incidence of violence in pregnant addicts, 330-331
measurement and extinction of conditioned withdawal-like
responses in opiate-dependent patients, 212-219
opioid dependence: treatment with buprenorphine, 72-74
relationship of the endogenous opioid system to drug
dependence, 11-12
stimulus control of drinking in alcoholics, 47-58
Depressants
abuse liability, evaluation project, 59-62
reinforcinq properties and sensory/motor toxicity in
baboons, 97-98
Depression
in drug abusing women, 332
Depressive symptoms
in drug abuse treatment clients, 313-319
425
6-Desoxy-6,6-hydrazinaloxone (NIH 10,001, MCV 4308)
biological evaluation for dependence liability, 357
mouse analgesia, 400-401
6-Desoxy-6,6-hydrazinaltrexone (NIH 10,003, MCV 4310, UM 1372)
biological evaluation for dependence liability, 357
depression of smooth muscle twitch, 401-402
displacement of stereospecific 3H-etorphine binding, 401
mouse analgesia, 401
6-Desoxy-6,6-hydrazioxymorphone (NIH 10,005, MCV 4312, UM 1374)
biological evaluation for dependence liability, 357
depression of smooth muscle twitch, 404
displacement of stereospecific 3H-etorphine binding, 404
mouse analgesia, 404
6-Desoxy-6-isonitrosonaltrexone (NIH 10,004, MCV 4311, UM 1373)
biological evaluation for dependence liability, 357
depression of smooth muscle twitch, 403
displacement of stereospecific 3H-etorphine binding, 403
mouse analgesia, 402
6-Desoxy-6-isonitrosooxymorphone (NIH 10,008, MCV 4314, UM 1377)
biological evaluation for dependence liability, 357
depression of smooth muscle twitch, 406
displacement of stereospecific 3H-etorphine binding, 406
mouse analgesia, 406
Detoxification
effects of methadone dose versus time in treatment, 269-274
methadone detoxification patients self-administration of
clonidine and oxazepam, 192-198
Dextromethorphan
antitussive potency in the cat, 79-80
inhibition of (-)-3H-codeine binding in the guinea-pig
medulla, 83
Dextrorphan
displacement of stereospecific 3H-etorphine binding, 366
effect on bombesin-induced scratching in rats, 116
Diazepam
behavioral and subjective effects in humans, 98-99
bioassay of subjective effects associated with drug with-
drawal in animals, 185-194
in combination with diazepam, effect on ethanol-induced
loss-of-righting reflex in rats, 333-337
mouse analgesia, 364, 371
reinforcing properties and sensory/motor toxicity in
baboons, 97
sensory/motor effects of chronic administration in baboons,
94-96
subjective effects of, 230
treatment of neonatal abstinence, 282-288
Dihydromorphine (NIH 0123)
effects of ethanol on binding, 7
mouse analgesia, 364
Dihydromorphinone hydrochloride
mouse analgesia, 371
426
2,5-Dimethoxy-4-methylamphetamine (DOM)
effect on FR-40 behavioral response pattern in the rat,
180-181
(+)-5,9 Dimethyl-2'-hydroxy-2-(4-methylpentyl)-6,7-benzomorphan
hydrobromide (NIH 10,097, MCV 4332)
biological evaluation for dependence liability, 358
dependence studies in monkeys, 409
mouse analgesia, 408
(+)-5,9 Dimethyl-2'-hydroxy-2-(4-methylpentyl)-6,7-benzomorphan
hydrobromide (NIH 10,098, MCV 4333)
biological evaluation for dependence liability, 358
dependence studies in monkeys, 409
mouse analaesia. 409
(±)-2,9 Dimethyl-5-( m-hydroxyphenyl)morphan hydrochloride (NIH
9955, MCV 4275)
-biological evaluation for dependence liability, 359
mouse analgesia, 391
(-)-2,9 Dimethyl-5-( m-hydroxyphenyl)morphan hydrochloride (NIH
9971. MCV 4293)
'biological evaluation for dependence liability, 359
mouse anaalesia. 394
(+)-2,9 Dimethyl-5-( m-hydroxyphenyl)morphan hydrochloride (NIH
9972, MCV 4294)
'biological evaluation for dependence liability, 359
mouse analgesia, 395
(+)-5,9 Dimethyl-2'-hydroxy-2-propynyl-6,,7-benzomorphan hydro-
bromide (NIH 10,019, MCV 4321)
biological evaluation for dependence liability, 358
dependence studies in monkeys, 408
mouse analgesia, 407
±-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-4-phenyl-2-
naphthylamine hydrochloride (NIH 9940, MCV 4282, UM 1326)
biological evaluation for dependence liability, 359
dependence studies in monkeys, 391
depression of smooth muscle twitch, 391
displacement of stereospecific 3H-etorphine binding, 390
mouse analgesia, 390
DOM
See 2, 35-Dimethoxy-4-methylamphetamine
Dopamine receptor
involvement in development of morphine tolerance, 320-326
Drug Abuse
abuse liability and toxicity assessment, 92-108
adverse effects of cocaine abuse, 247-254
depression, self-concept and violent experience in drug
abusing women, 332
methadone plasma levels and persistent drug abuse in high
dose maintenance patients, 262-268
perinatal addiction: effects of maternal narcotic and non-
narcotic substance abuse on the fetus and neonate, 220-226
Drug use
depressive symptoms in treatment of, 313-319
Dynorphin-(1-6) (NIH 10,.306, MCV 4356)
dependence studies in monkeys, 420
427
Dynorphin (1-10) amide (NIH 10,304, MCV 4354)
dependence studies in monkeys, 419
Dynorphin-(1-13) (NIH 10,303, MCV 4353)
dependence studies in monkeys, 419
Endogenous opioids
relationship to drug dependence, 11-12
ß-Endorphin
effect on bombesin-induced scratching in rats, 116
Ethanol
in combination with R015-1788 and diazepam, 333-337
3-(2-Ethyl-4,6-dimethyl-2-morpholinyl)phenol (NIH 9873, MCV 4229,
UM 1294).
biological evaluation for dependence liability, 359
depression of smooth muscle twitch, 385
displacement of stereospecific 3H-etorphine binding, 385
mouse analgesia, 385
Ethylketocyclazocine methanesulfonate (NIH 10,165, MCV 4348)
biological evaluation for dependence liability, 358
cortical EEG and associated power spectra in non-tolerant
and tolerant states in-the rat, 124-125
dependence evaluation for dependence liability, 358
depression of smooth muscle twitch, 414
displacement of stereospecific 3H-etorphine binding, 366
disruption of operant behavior in the rat, 180-182
mouse analgesia, 414
effect on bombesin-induced scratching in rats, 116
N-Ethylmorphinium iodide (NIH 9993, MCV 4302, UM 1349)
biological evaluation for dependence liability, 357
dependence studies in monkeys, 397
depression, of smooth muscle twitch, 396
mouse analgesia, 396
Etorphine
displacement of stereospecific 3H-etorphine binding, 366
Fencamfamine
reinforcing properties of, 65-66
Fenoprofen
analgesic effect in cancer patients, 206
oral fenoprofen compared to intramuscular morphine and oral
aspirin in cancer patients with post operative pain, 205-211
side effects, in cancer patients, 207
Flurazepam
mouse analgesia, 364, 371
Guanabenz acetate
suppression of withdrawal in opioid-dependent subjects,
338-343
Heroin
alteration in tumor cell growth and differentiation in vitro,
344-350
effect on bombesin-induced scratching in rats, 116
perinatal addiction: effects on the fetus and neonate,
220-226
relative reinforcing properties in monkeys, 172-178
use of buprenorphine in heroin-dependent patients, 73-74
withdrawal symptoms suppressed by guanabenz acetate, 338-343
428
Heroin addiction
association with criminality, 305-312
1-[(2 6 llS)-(+)-1-(1,2,3,4,5,6-Hexahydro-8-hydroxy-3,6,11-
trimethyl-2,6-methano-3-benzazocin-ll-yl]-6-methyl-3-heptanone
methanesulfonate (NIH 9625, MCV 4176, UM 1401)
biological evaluation for dependence liability, 358
dependence studies in monkeys, 380
depression of smooth muscle twitch, 379
mouse analgesia, 379
2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)6,7-benzomorphan
hydrochloride (pentazocine, NIH 7958, MCV 4268, UM 381)
biological evaluation for dependence liability, 358 .
dependence studies in monkeys, 578
mouse analgesia, 364, 370-371
9 Hydroxy-5-( m-hydroxyphenyl)-2-methylmorphan hydrochloride
(NIH 10,006, MCV 4307)
biological evaluation for dependence liability, 359
dependence studies in monkeys, 405
mouse analgesia, 404-405
9ß-Hydroxy-5-(m-hydroxyphenyl)-2-methylmorphan mandelate
(NIH 10,154, MCV 4344)
biological evaluation for dependence liability, 359
dependence studies in monkeys, 414
mouse analgesia, 413
(-)-14-Hydroxy-4-methoxy-N-methylmorphinan (NIH 9997, UM 1368)
biological evaluation for dependence liability, 358
depression of smooth muscle twitch, 400
displacement of stereospecific 3H-etorphine binding, 400
mouse analgesia, 400
(-)-14-Hydroxy-N-methylmorphinan (NIH 10,007, MCV 4313, UM 1376)
biological evaluation for dependence liability, 358
depression of smooth muscle twitch, 405
displacement of stereospecific 3H-etorphine binding, 405
mouse analgesia, 405
5-(m-Hydroxyphenyl)morphans
pharmacological and biochemical properties of, 111
(+)-5-(m-Hydroxyphenyl)-2-pentylmorphan hydrochloride (NIH 9893,
MCV 4263, UM 1307)
biological evaluation for dependence liability, 359
dependence studies in monkeys, 387
depression of smooth muscle twitch, 386-387
displacement of stereospecific 3H-etorphine binding, 386
mouse analgesia, 386
ICI 154, 129
See: N,N-bis-Allyl-Tyr-Gly-Gly-(Ch2S)-Phe-Leu-OH
Ketamine
reinforcing properties and sensory/motor toxicity in
baboons, 97
self-administration in baboons, 92-94
Ketazocine
displacement of stereospecific 3H-etorphine binding, 366
(±)-Ketocyclazocine
antitussive potency in the cat, 79-80
429
inhibition of (-)-3H-codeine binding in the guinea-pig
medulla, 83
Levomethorphan
antitussive potency
inhibition of (-)-3H-codeine binding in the guinea-pig
in the cat, 79-80
medulla, 83
Levorphanol tartrate (NIH 4590, NIH 10,123, MCV 4335, UM 510,
UM 1410)
biological evaluation for dependence liability, 358
dependence studies in monkeys, 411-412
depression of smooth muscle twitch, 411
displacement of stereospecific 3H-etorphine binding, 411
effect on bombesin-induced scratching in rats, 116
mouse analgesia, 363, 371, 411
Lorazepam
behavioral and subjective effects in humans, 98-99
drug preference in humans, 227-232
subjective effects of, 230
LSD
See: Lysergic acid diethylamide
Luteinizing hormone (LH)
effect of chronic alcohol self-administration in monkeys, 159
Lysergic acid diethylamide (LSD)
effect on FR-40 behavioral response pattern in the rat,
180-181
Marijuana
abuse potential of marihuana cigarette smoking, 71-72
clinical validity study, 63-65
effect and tolerance: subchronic self-administration in
women, 199-204
environmental studies in humans, 100-105
social control as an explanation of sex differences in its
use among adolescents, 296-304
Mazindol
MCV 4002 (NIH 8503, NIH 9930, UM 792, UM 1312)
MCV
MCV
drug perference and mood in humans, 327-328
See Naltrexone hydrochlodride
4125 (NIH 0002, NIH 10,122, MCV 4334, UM 1409)
See Codeine phosphate
4142 (NIH 9508, UM 1325)
See N-Cyclopropylmethyl-8ß-ethyl-N-nordihydrocodeinone
hydrochloride
4176 (NIH 9625, UM 1401)
See 1-[(2 6 llS)-(±)-1-(1,2,3,4,5,6-Hexahydro-8-hydroxy-
3,6,ll-trimethyl-2,6-methano-3-benzazocin-ll-yl)]-6-methyl-
3-heptanone methanesulfonate
4179 (NIH 9652, UM 1235)
See 3-Cyclopropylemthyl-2,3,4,,4a 5,6,7,7a octahydro-lH-
benzo[4,5]furyl[3,2-e]isoquinoline-9-ol
4229 (NIH 9873, UM 1294)
See 3-(2-Ethyl-4,6-dimethyl-2-morpholinyl)phenol
4236 (NIH 9896, UM 1291) 
See (-)-4-Allyl-l-methyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1,
6-methano-1H-4-benzazonine
MCV
MCV
MCV
MCV
430
MCV 4255 (NIH 9915)
See 14ß-3-(4-Chlorphenyl)propionylaminomorphinone
MCV 4256 (NIH 9916, UM 1317)
See 14ß-(4-Methylcinnamoyl)aminomorphinone
MCV 4257 (NIH 9917)
See 14ß-(4-Chlorocinnamoyl)aminomorphinone
MCV 4261 (NIH 7890, UM 426)
See Naloxone hydrochloride
MCV 4262 (NIH 9892, UM 1306)
See (+)-2-Butyl-5-(m-hydroxyphenyl)morphan hydrochloride
MCV 4263 (NIH 9893, UM 1307)
See (+)-5-(m-Hydroxyphenyl)-2-pentylmorphan hydrochloride
MCV 4268 (pentazocine, NIH 7958, UM 381)
See 2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl),6,7-benzo-
morphan hydrochloride
MCV 4275 (NIH 9955)
See (+)-2,9 Dimethyl-5-(m-hydroxyphenyl)morphan hydro-
chloride
MCV 4277 (NIH 9836, UM 1342)
See N-Allylmorphinium bromide
MCV 4278 (NIH 9837, UM 1343)
See N-Methylnalorphinium iodide
MCV 4282 (NIH 9940, UM 1326)
See ±-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-4-
phenyl-2-naphthylamine hydrochloride
MCV 4290 (NIH 9962, UM 1345)
See trans-4-Bromo-N-methyl-N-[2(1-pyrrolidinyl)cyclohexyl]
benzamide
MCV 4293 (NIH 9971)
See (-)-2,9 Dimethyl-5-(m-hydroxyphenyl)morphan hydro-
chloride
MCV 4294 (NIH 9972)
See (+)-2,9 Dimethyl-5-( m-hydroxyphenyl)morphan hydro-
chloride
MCV 4300 (NIH 9991, UM 1348) l
See N-Cyclopropylmethylmorphinium iodide
MCV 4302 (NIH 9993, UM 1349)
See N-Ethylmorphinium iodide
MCV 4303 (NIH 9994)
See N-Methyl-N-cyclopropylnormorphinium iodide
MCV 4304 (NIH 9995, UM 1350)
See N-Methylmorphinium iodide
MCV 4305 (UM 1340)
See NIH 9959
MCV 4306 (NIH 9996, UM 1367)
See (-)-1-[N-(Cyclopropylmethyl)morphinan-3-yl]ethanone
D-tartrate
MCV 4307 (NIH 10,006)
See 9 Hydroxy-5-(m-hydroxyphenyl)-2-methylmorphan hydro-
chloride
MCV 4308 (NIH 10,001)
See 6-Desoxy-6,6-hydrazinaloxone
MCV 4310 (NIH 10,003, UM 1372)
See 6-Desoxy-6,6-hydrazinaltrexone
431
MCV 4311 (NIH 10,004, UM 1373)
See 6-Desoxy-6-isonitrosonaltrexone
MCV 4312 (NIH 10,005, UM 1374)
See 6-Desoxy-6,6-hydrazioxymorphone
MCV 4313 (NIH 10,007, UM 1376)
See (-)-14-Hydroxy-N-methylmorphinan
MCV 4314 (NIH 10,008, UM 1377)
See 6-Desoxy-6-isonitrosooxymorphone
MCV 4318 (NIH 10,016, UM 1383)
See (-)-N-Allyl-3,4-dimethoxymorphinan-6-one
MCV 4321 (NIH 10,019)
See (+)-5,9 Dimethyl-2'-hydroxy-2-propynyl-6,7-benzo-
morphan hydrobromide
MCV 4331 (NIH 10,064)
See 5-Methylbuprenorphine
MCV 4332 (NIH 10,097)
See (-)-5,9 Dimethyl-2'-hydroxy-2-(4-methylpentyl)-6,7-
benzomorphan hydrobromide
MCV 4333 (NIH 10,098)
See (+)-5,9 Dimethyl-2'-hydroxy-2-(4-methylpentyl)-6,7-
benzomorphan hydrobromide
MCV 4334 (NIH 0002, NIH 10,122, MCV 4125, UM 1409)
See Codeine phosphate
MCV 4335 (NIH 4590, NIH l0,123 UM 510, UM 1410)
See Levorphanol tartrate
MCV 4336 (NIH 2105, NIH l0,124 UM 1411)
See Nalorphine hydrochloride
MCV 4344 (NIH 10,154)
See 9ß-Hydroxy-5-(m-hydroxyphenyl)-2-methylmorphan
mandelate
MCV 4348 (NIH 10,165)
See Ethylketocyclazocine methanesulfonate
MCV 4353 (NIH 10,303)
See Dynorphin-(1-13)
MCV 4354 (NIH 10,304
See Dynorphin (1-10) amide
MCV 4356 (NIH 10,306)
See Dynorphin-(1-16)
MCV 4357 (NIH 10,307)
See -Neo-endorphin
 MCV 4358 (Pitressin, NIH 10,308)
See Vasopressin tannate
MCV 4359 (NIH 10,167)
See (+)-2-(3-Chloro-2-propenyl)-5,9 dimethyl-2'-hydroxy-6,
7-benzomorphan hydrobromide
MCV 4360 (NIH 10,168)
See (-)-2-(3-Chloro-2-propenyl)-5,9 dimethyl-2'-hydroxy-6,
7-benzomorphan hydrobromide
MCV 4374 (NIH 10,207)
See Alfentanil hydrochloride
Mecamylamine
clinical evaluation of mecamylamine for withdrawal from
nicotine dependence, 239-246
effects on cigarette smoking, 74-75
432
Melanotropin-release-inhibiting factor
reversal of changes in 3H-spiroperidol binding induced
by chronic morphine administration, 320-326
Meperidine (NIH 5221)
effect on bombesin-induced scratching in rats, 116
mouse analgesia, 363, 371
Meprobamate
mouse analgesia, 364, 371
Mescaline
mouse analgesia, 364, 371
(-)-Metazocine hydrobromide (NIH 7569)
mouse analgesia, 363, 371
Metergoline
effect on N-allylnormetazocine-induced disruption of operant
behavior in the rat, 180-182
effect on ethylketocyclazocine-induced disruption of operant
behavior in the rat, 180-182
interaction with quipazine and cyclazocine on the operant
behavior in the rat, 180-181
Methadone
analgesia and concentrations in rat brain and plasma:
dose-response effects, 131
analgesia and concentrations in rat brain and plasma:
time-response effect, 130
antitussive potency, in the cat, 79-80
cerebral ventricular changes in neonates exposed to methadone
in utero: 331
correlation between brain and Dlasma concentrations and
analgesia in the rat, 132
detoxification: effects of methadone dose versus time in
treatment, 269-274
effect on bombesin-induced scratching in rats, 116
inhibition of (-)-3H-codeine binding in the guinea-pig
medulla, 83
high-performance liquid chromatogram of rat brain extract
after administration of 14C-methadone, 130
perinatal addiction: effects on the fetus'and neonate,
220-226
phenobarbital-induced decrease in methadone plasma
levels and withdrawal syndrome in a methadone maintenance
patient, 132-134
plasma concentrations in methadone maintenance patients, 132
plasma levels and persistent drug abuse in high dose main-
tenance patients, 262-268
relationship of plasma level and pharmacological activity of,
128-135
relative reinforcing properties in monkeys, 172-178
self-administration of clonidine and oxazepam by methadone
detoxification patients, 192-198
use of buprenorphine in methadone maintenance patients, 72-73
withdrawal symptoms suppressed by guanabenz acetate, 338-343
(+)-Methadone
antitussive potency in the cat, 79-80
433
inhibition of (-)-3H-codiene binding in the guinea pig
medulla, 83
Metkephamid
effect on bombesin-induced scratching in rats, 116
d-Methylamphetamine
reinforcing properties and sensory motor toxicity in
baboons, 97
Methylatropine
antagonism of response produced by microinjections of
carbachol in the periaqueductal gray of the dog, 145
interaction with naloxone in the morphine-dependent dog, 146
5-Methylbuprenorphine (NIH 10,064, MCV 4331)
biological evaluation for dependence liability, 357
mouse analgesia., 408
14-ß-(4-Methylcinnamoyl)aminomorphinone (NIH 9916, MCV 4256,
UM 1317)
biological evaluation for dependence liability, 357
dependence studies in monkeys, 389
depression of smooth muscle twitch, 389
displacement of stereospecific 3H-etorphine binding, 389
mouse analgesia, 388
N-Methyl-N-cyclopropylnormorphinium iodide (NIH 9994, MCV 4303)
biological evaluation for dependence liability, 357
mouse analgesia, 397
N-Methyl-N-ethylnormorphinium iodide (NIH 9992, MCV 4301)
biological evaluation for dependence liability, 357
mouse analgesia, 396
N-Methylmorphinium iodide (NIH 9995, MCV 4304, UM 1350)
biological evaluation for dependence liability, 357
dependence studies in monkeys, 398
depression of smooth muscle twitch, 397
mouse analgesia, 397
N-Methylnalorphinium iodide (NIH 9837, MCV 4278, UM 1343)
biological evaluation for dependence liability, 352
dependence studies in monkeys, 383
depression of smooth muscle twitch, 382
mouse analgesia, 382
N-Methyl-1-phenylcyclohexylamine (NMPCA)
self-administration in baboons, 92-94
Morphine (NIH 0001, NIH 9929)
abstinence syndrome: cholinergic mechanisms in the ventral
periaqueductal gray of the dog, 143-149
Morphine
analgesic effect in cancer patients, 206
antitussive potency in the cat, 79-80
brain reinforcement systems: concurrent self-administration
of food, water and morphine in the rat, 165-171
discriminative effects in pigeons, 138-139
displacement of stereospecific 3H-etorphine binding, 366
EEG and behavioral responses in non-tolerant and tolerant
states in the rat, 123-125
effect on bombesin-induced scratching in rats, 116
effects on responses as a function of nociceptive stimuli in
men, 27-31
434
inhibition of (-)-3H-codeine binding in the guinea-pig
medulla, 83
intramuscualr morphine compared to oral fenoprofen and oral
aspirin in cancer patients with post operative pain, 205-211
involvement of striatal dopamine receptors in tolerance,
320-326
mouse analgesia, 137-138, 363, 370-371
side effects in cancer patients, 207
suppression of withdrawal effects by adenosine analogs, 85-91
(+)-Morphine
antitussive potency in the cat, 79-80
inhibition of (-)-3H-codeine binding in the guinea-pig
medulla, 83
Nalbuphive
effect on bombesin-induced scratching in rats, 116
Nalorphine hydrochloride (NIH 2105, NIH 10,124, MCV 4336, UM 1411)
biological evaluation for dependence liability, 357
dependence studies in monkeys, 413
depression of smooth muscle twitch, 412
displacement of stereospecific 3H-etorphine binding, 412
effect on bombesin-induced scratching in rats, 116
mouse analgesia, 364, 370-371, 412
Naloxone hydrochloride (NIH 7890, MCV 4261, UM 426)
binding competition experiments in human brain regions, 6
biological evaluation for dependence liability, 357
effect on N-allylnormetazocine-induced disruption of operant
behavior in the rat, 180-182
effect on bombesin-induced scratching in rats, 116
effect on ethylketocyclazocine-induced disruption of operant
behavior in the rat, 180-182
effect on the antitussive potencies of d- and l-opiates in
the cat, 81
interaction with methylatropine in the morphine-dependent
dog, 146
mouse analgesia, 364, 370-371, 377
potentiation of the disruptive effect of LSD and DOM in the
rat, 180-181
Naltrexone hydrochloride (NIH 8503, NIH 9930, MCV 4002, UM 792,
UM 1312)
abstinence treatment for opiate addicts, 275-281
biological evaluation for dependence liability, 357
displacement of stereospecific 3H-etorphine binding, 366
effects of ethanol on binding, 7
effect on the discriminative effects of morphine, oxymorpha-
zone and buprenorphine, 139-140
mouse analgesia, 364, 370-371, 390
use in conjunction with behavior therapy to treat opiate
addicts, 289-295
Nathan B. Eddy Memorial Award Lecuture
recent studies on opioid receptors: heterogeneity and
isolation, 5-13
Neonatal abstinence
cerebral ventricular changes during, 331
435
treatment with paregonic, phenobarbital and diazepam, 282-288
treatment with phenobarbital, 329
Neonates
perinatal addiction: effects of maternal narcotic and non-
narcotic substance abuse on the fetus and neonate, 220-226
-Neo-endorphin (NIH 10,307, MCV 4357)
dependence studies in monkeys, 420
(-)-Nicotine di-l-tartrate (NIH 9733)
dependence studies in monkeys, 381
mouse analgesia, 381
Nicotine
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
clinical evaluation of mecamylamine for withdrawal from
nicotine dependence, 239-246
EEG correlates of nicotine-induced euphoria, 75
effect of nicotine chewing gum on cigarette smoking, 74-75
environment studies in humans, 100-105
001 (NIH 9929)
See
0002
See
0123
See
2105
See
4590
See
5221
See
7569
See
7890
See
7958
Morphine sulfate
(NIH 10,122, MCV 4125, MCV 4334, UM 1409)
Codeine phosphate
Dihydromorphine hydrochloride
(NIH 10,124, MCV 4336, UM 1411)
Nalorphine hydrochloride
(NIH 10,123, MCV 4335, UM 510, UM 1410)
Levorphanol tartrate
Meperidine hydrochloride
See
Metazocine hydrobromide
(MCV 4261, UM 426)
Naloxone hydrochloride
(pentazocine, MCV 4268, UM 381)
2'-Hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-
benzomorphan hydrochloride
7981
See Cyclazocine
8503 (NIH 9930, MCV 4002, UM 792, UM 1312)
See Naltrexone hydrochloride
8848 (UM 975)
biological evaluation for dependence liability, 358
9508 (MCV 4142, UM 1325)
See N-Cyclopropylmethyl-8ß-ethyl-N-nordihydrocodeinone
hydrochloride
9625 (MCV 4176, UM 1401)
See 1-[(2 6 llS)-(±)-1-(1,2,3,4,5,6-Hexahydro-8-hydroxy-3,
6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)]-6-methyl-3-
heptanone methanesulfonate
9652 (MCV 4179, UM 1235)
See 3-Cyclopropylmethyl-2,3,4,4a 5,6,7,7a octahydro-1H-
benzo[4,5]furyl[3,2-e]isoquinoline-9-ol
9733
See (-)-Nicotine di-l-tartrate
436
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
9991
See
9 3 7
See
9993
See
9994
See
9995
See
9996
See
D-tartrate
(MCV 4300, UM 1348)
N-Cyclopropylmethylmorphinium iodide
(MCV 4301)
N-Methyl-N-ethylnormorphinium iodide
(MCV 4302, UM 1349)
N-Ethylmorphinium iodide
(MCV 4303)
N-Methyl-N-cyclopropylnormorphinium iodide
(MCV 4304, UM 1350)
N-Methylmorphinium iodide
(MCV 4306, UM 1367)
(-)-l-[N-(Cyclopropylmethyl)morphinan-3-yl]ethanone
9836
See
9837
See
9837
See
9892
See
9893
See
9896
(MCV 4277, UM 1342)
N-Allylmorphinium bromide
(MCV 4278, UM 1343)
N-Methylnalorphinium iodide
(MCV 4229, UM 1294)
3-(2-Ethyl-4,6-dimethyl-2-morpholinyl)phenol
(MCV 4262, UM 1306)
(+)-2-Butyl-5-( m-hydroxyphenyl)morphan hydrochloride
(MCV 4263. UM 1307)
(+)-5-(m-Hydroxyphenyl)-2-pentylmorphan hydrochloride
(MCV 4236, UM 1291)
(-)-4-Allyl-1-methyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1,See
6-methano-1H-4-benzazonine
9915 (MCV 4255)
See 14ß-3-(4-Chlorphenyl)propionylaminomorphinone
9916 (MCV 4256, UM 1317)
See 14ß-(4-Methylcinnamoyl)aminomorphinone
NIH 9917 (MCV 4257)
See 14ß-(4-Chlorocinnamoyl)aminomorphinone
9929 (NIH 0001)
See Morphine sulfate
9930 (NIH 8503, MCV 4002, UM 792, UM 1312)
See Naltrexone hydrochloride
9940 (MCV 4282, UM 1326)
See (+)-trans-N,N-Dimethyl-1,2,3,4-tetrahydro-4-methyl-4-
phenyl-2-naphthylamine hydrochloride
9955 (MCV 4275)
See (±)-2,9 Dimethyl-5-( m-hydroxyphenyl)morphan hydro-
chloride
9959 (MCV 4305, UM 1340)
biological evaluation for dependence liability, 358
9962 (MCV 4290, UM 1345)
See trans-4-Bromo-N-methyl-N-[2(1-pyrrolidinyl)cyclo-
hexyl]benzamide
9971 (MCV 4293)
See (-)-2,9 Dimethyl-5-( m-hydroxyphenyl)morphan hydro-
chloride
9972 (MCV 4294)
See (+)-2,9 Dimethyl-5-(m-hydroxyphenyl)morphan hydro-
chloride
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NIH 9997 (UM 1368)
See (-)-14-Hydroxy-4-methoxy-N-methylmorphinan
NIH 10,001 (MCV 4308)
See 6-Desoxy-6,6-hydrazinaloxone
NIH 10,003 (MCV 4310, UM 1372)
See 6-Desoxy-6,6-hydrazinaltrexone
NIH 10,004 (MCV 4311, UM 1373)
See 6-Desoxy-6-isonitrosonaltrexone
NIH 10,005 (MCV 4312, UM 1374)
See 6-Desoxy-6,6-hydrazioxymorphone
NIH 10,006 (MCV 4307)
See 9 Hydroxy-5-( m-hydroxyphenyl)-2-methylmorphan
hydrochloride
NIH 10,007 (MCV 4313, UM 1376)
See (-)-14-Hydroxy-N-methylmorphinan
NIH 10,008 (MCV 4314, UM 1377)
See 6-Desoxy-6-isonitrosooxymorphone
NIH 10,016 (MCV 4318, UM 1383)
See (-)-N-Allyl-3,4-dimethoxymorphinan-6-one
NIH 10,019 (MCV 4321)
See (+)-5,9 Dimethyl-2'-hydroxy-2-propynyl-6,7-
benzomorphan hydrobromide
NIH 10,064 (MCV 4331)
See 5-Methylbuprenorphine
NIH 10,097 (MCV 4332)
See (-)-5,9 Dimethyl-Z'-hydroxy-2-(4-methylpentyl)-6,7-
benzomorphan hydrobromide
NIH 10,098 (MCV 4333)
See (+)-5,9 Dimethyl-2'-hydroxy-2-(4-methylpentyl)-6,7-
benzomorphan hydrobromide
NIH 10,122 (NIH 0002, MCV 4125, MCV 4334, UM 1409)
See Codeine phosphate
NIH 10,123 (MCV 4590, MCV 4335, UM 510, UM 1410)
See Levorphanol tartrate
NIH 10,124 (NIH 2105, MCV 4336, UM 1411)
See Nalorphine hydrochloride
NIH 10,154 (MCV 4344)
See 9ß-Hydroxy-5-(m-hydroxyphenyl)-2-methylmorphan
fidelate
NIH 10,165 (MCV 4348)
See Ethylketocyclazocine methanesulfonate
NIH 10,167 (MCV 4359)
See (+)-2-(3-Chloro-2-propenyl)-5,9 dimethyl-2'-hydroxy-6,
7-benzomorphan hydrobromide
NIH 10,168 (MCV 4360)
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GPO Stock #017-024-01097-9 $5.50 NTIS PB #82-147372 $19
40 ADOLESCENT MARIJUANA ABUSERS AND THEIR FAMILIES. Herbert
Hendin, M.D., Ann Pollinger, Ph.D., Richard Ulman, Ph.D., and
Arthur Carr, Pn.D. A psychodynamic study of adolescents
involved in heavy marijuana use, to determine what inter-
action Detween family and adolescent gives rise to drug abuse.
GPO Stock #017-024-01098-7 $4.50 NTIS PB #82-133117 $13
41 PROBLEMS OF DRUG DEPENDENCE, 1981: PROCEEDINGS OF THE 43R0
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. A broad review of
current research. Includes treatment issues; chemistry and
pharmacology of abused drugs; efficacy and dependence liability
of new compounds.
Not available from GPO NTIS PB #82-190760 $41.50
42 THE ANALYSIS OF CANNABINOIOS IN BIOLOGICAL FLUIDS. Richard L.
Hawks, Ph.D., ed. Presents varied approaches to sensitive,
reliable, and accessible auantitative assays for the chemical
constituents of marijuana, for basic researchers in biomedical
and forensic science.
GPO Stock #017-024-01151-7 $5 NTIS PB #83-136044 $16
453
43 PROBLEMS OF DRUG DEPENDENCE, 1982: PROCEEDINGS OF THE 44TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. A collection of
papers which together record a year’s advances in drug abuse
research; also includes reports on tests of new compounds for
efficacy and dependence liability.
GPO Stock #017-024-01162-2 $8.50 NTIS PB 83-252-692 $40
45 CONTEMPORARY RESEARCH IN PAIN AND ANALGESIA, 1983. Roger M.
Brown, Ph.D.; Theodore M. Pinkert, M.D., J.O.; and Jacqueline P.
Ludford, M.S., eds. A RAUS Review Report on the anatomy,
physiology, and neurochemistry of pain and its management.
GPO Stock #017-024-01191-6 $2.75 NTIS PB to be assigned
47 PREVENTING ADOLESCENT DRUG ABUSE: INTERVENTION STRATEGIES.
Thomas J. Glynn, Ph.D.; Carl G. Leukefeld, D.S.W.; and
Jacqueline P. Ludford, M.S., eas. A RAUS Review Report on a
variety of approaches to prevention of adolescent drug abuse, how
they can be applied, their chances for success, and needed future
research.
Not available from GPO NTIS PB to be assigned
48 MEASUREMENT IN THE ANALYSIS AND TREATMENT OF SMOKING
BEHAVIOR. John Grabowski, Ph.D., and Catherine S. Bell, M.S.,
eds. Based upon a meeting cosponsored by NIDA and the National
Cancer Institute to delineate necessary and sufficient measures
for analysis of smoking oehavior in research and treatment
settings.
GPO Stock #017-024-01181-9 $4.50
IN PRESS
NTIS PB 84-145-184 $14.50
46 BEHAVIORAL INTERVENTION TECHNIQUES IN DRUG ABUSE TREATMENT.
John Grabowski, Ph.D.; Maxine L. Stitzer, Ph.D., and Jack E.
Henningfield, Ph.D., eds. Reports on a variety of behavioral
contingency management procedures used in research/treatment
environments.
IN PREPARATION
44 MARIJUANA EFFECTS ON THE ENDOCRINE AND REPRODUCTIVE SYSTEMS.
Moniaue C. Braude, Ph.D., and Jacqueline P. Ludford, M.S., eds.
A RAUS Review Report of animal studies and preclinical and
clinical studies of effects of cannabinoids on human endocrine
and reproductive functions.
49 PROBLEMS OF DRUG DEPENDENCE, 1983: PROCEEDINGS OF THE 44TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. A collection of
papers which together record a year’s advances in drug abuse
research; also includes reports on tests of new compounds for
efficacy and dependence liability.
454
50 COCAINE: PHARMACOLOGY, EFFECTS, AND TREATMNT OF ABUSE. John
Grabowski, Ph.D., ed. Content ranges from an introductory
overview through neuropharmacology, pharmacology, animal and
human behavioral pharmacology, patterns of use in the natural
environment of cocaine users, treatment, through commentary on
societal perceptions of use.
DRUG ABUSE TREATMENT EVALUATION: STRATEGIES, PROGRESS, AND
PROSPECTS. Frank M. Tims, Ph.D., ed. A state-of-the-art review
of drug abuse treatment evaluation, identifying research needs,
promising approaches, and emerging issues.
MECHANISMS OF TOLERANCE AND DEPENDENCE. 'Charles Wm. Sharp,
Ph.D., ea. Review of Basic knowledge concerning the mechanism of
action of opiates and other drugs in producing tolerance and/or
dependence.
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